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Abstract 
 
The genetic contribution to the aetiology of psychiatric illness is well-established; however, 
few variants that alter the encoded protein have been irrefutably identified as causative, 
leading to the hypothesis that variants affecting gene regulation may play a pathogenic role. 
This thesis focuses on two genes, Neuregulin 1 (NRG1) and Disrupted in Schizophrenia 1 
(DISC1), for which there is strong genetic evidence for involvement in psychiatric illness, as 
well as evidence for altered expression in patients.  
 
Association analysis was carried out to assess the involvement of six intronic NRG1 single 
nucleotide polymorphisms (SNPs) in schizophrenia and bipolar disorder in two independent 
samples from the Scottish (Scottish 2; n = 307 control subjects, 303 schizophrenic patients, 
and 239 bipolar disorder patients  and German populations (n = 397 control subjects, 396 
schizophrenic patients, and 400 bipolar disorder patients). These SNPs form two haplotypes, 
one encompassing the 5’ and promoter region of the gene and the other located at the 3’ end 
of the gene, that were previously associated with schizophrenia and bipolar disorder in a 
Scottish sample (Scottish 1). The location of these haplotypes, together with the prior 
evidence for altered NRG1 expression in schizophrenia, suggested the potential involvement 
of regulatory variants. On combining the Scottish 1 and Scottish 2 samples (combined n = 
765 control subjects, 682 schizophrenic patients and 601 bipolar disorder patients), a two-
SNP haplotype spanning both coding and non-coding regions in the 3’ region was associated 
with schizophrenia (p = 0.0037, OR=1.3, 95% CI: 1.1-1.6) and the combined schizophrenia 
and bipolar disorder case group (p = 0.0080, OR=1.2, 95% CI: 1.1-1.5), with both these 
associations remaining significant after permutation analysis (p = 0.022 and p =  0.044, 
respectively). 
 
To further understanding of how DISC1, a leading candidate gene for schizophrenia that has 
also been implicated in other psychiatric disorders, is regulated the previously 
uncharacterised promoter region was assessed both bioinformatically and in vitro using the 
dual luciferase reporter assay. The region was found to lack canonical promoter motifs but to 
contain a CpG island, consistent with DISC1’s ubiquitous pattern of expression. A region 
located 300bp to -177bp relative to the transcription start site (TSS) was identified as 
contributing positively to DISC1 promoter activity, whilst a region -982bp to -301bp relative 
to the TSS was found to confer a repressive effect. FOXP2, a transcription factor which is 
mutated in a rare speech and language disorder and implicated in autism pathogenesis, was 
found to repress transcription from the DISC1 promoter. Two pathogenic FOXP2 point 
  xxv 
mutations reduced this transcriptional repression. Preliminary evidence for a bi-directional 
regulatory relationship between DISC1 and FOXP2 was observed: a mouse model of 
schizophrenia that carries a Disc1 L100P amino acid substitution and shows altered 
developmental Disc1 expression was also found to show altered developmental expression of 
Foxp2. 
 
These results further understanding of two genes whose altered expression might contribute 
to the pathogenesis of psychiatric illness.  
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Chapter 1: Introduction 
 
1.1 Overview of psychiatric illness 
 
Millions of people worldwide are affected by psychiatric illness: in their 2001 report, the 
World Health Organisation (WHO, 2001) reported neuropsychiatric conditions to have a 
point prevalence of 10% in adults
1
. When considering 12 month prevalence, the percentage 
affected rises to approximately 38% in Europe
2
 and 30% in the USA
3
 (Kessler et al., 1994; 
Wittchen et al., 2011). A recent report on the financial consequences of brain disorders 
concluded that these conditions cost Europe almost €800 billion each year (Gustavsson et al., 
2011). Mood and psychotic disorders alone were estimated to account for €209.4 billion of 
this expenditure. For comparison, Europe’s expenditure on cancer is thought to lie in the 
range €150 - €250 billion (Gustavsson et al., 2011). This thesis will focus on two of the most 
severe psychiatric conditions: schizophrenia and bipolar disorder. 
 
Schizophrenia is characterised by a constellation of positive, negative, and cognitive 
symptoms (van Os and Kapur, 2009). Positive symptoms are symptoms that are not usually 
experienced by individuals without the disorder. These include hallucinations, delusions, 
thought disorder, and disorders of movement. Negative symptoms, on the other hand, 
represent a loss of normal function and include social withdrawal, blunted affect, poverty of 
speech, and a lack of motivation. Abnormalities in cognitive function, which include deficits 
in working memory, long-term memory, and executive function, are considered a core 
component of the disorder as they are present before the onset of the positive and negative 
symptoms, before the onset of antipsychotic treatment, and are also seen in the unaffected 
relatives of patients (Barch and Ceaser, 2012; Callicott et al., 2003; Saykin et al., 1994; Snitz 
et al., 2006). Furthermore, deficits in cognitive function have been shown to be a good 
predictor of functional outcome (Green et al., 2000; Silver et al., 2003). Given the centrality 
of cognitive dysfunction to the schizophrenia phenotype, it is surprising that the Diagnostic 
                                                     
1
 The conditions considered were unipolar depression, bipolar disorder, and schizophrenia, epilepsy, 
alcohol and selected drug use disorders, Alzheimer’s and other dementias, post-traumatic stress 
disorder, obsessive and compulsive disorder, panic disorder, and primary insomnia. 
2
 The conditions considered were alcohol and drug dependence, psychotic disorder, major depressive 
disorder, bipolar disorder, anxiety disorders, somatoform disorders, eating disorders, personality 
disorders, childhood and adolescent disorders, mental retardation, sleep disorders, and dementia. 
3
 The conditions considered were major depressive disorder, mania, dsythymia, panic disorder, social 
phobia, agoraphobia, generalised anxiety disorder, alcohol and drug dependence, antisocial 
personality disorder, and nonaffective psychosis, which comprises schizophrenia, schizophreniform 
disorder, schizoaffective disorder, delusional disorder and atypical psychosis. 
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and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV) (APA, 1994) does not 
include cognitive deficits amongst the criteria for schizophrenia. It has been suggested that 
the inclusion of cognitive impairment in the diagnostic criteria for schizophrenia in the 
forthcoming DSM-V would improve prognosis and treatment outcomes (Keefe and Fenton, 
2007). 
 
Several subtypes of schizophrenia are recognised by the DSM-IV, including paranoid type, 
disorganised type, and catatonic type. It has been argued that these subtypes fail to capture 
the true heterogeneity of schizophrenia and that they have low diagnostic stability; it has, 
therefore been proposed that schizophrenia subtypes should not be included in the DSM-V 
(American Psychiatric Association (APA) DSM-V Development 
http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=411#).  Instead, 
it is proposed that the DSM-V should use psychopathological dimensions (American 
Psychiatric Association DSM-V Development); this suggestion is consistent with the 
findings of (Cuesta et al., 2007) who found no evidence for taxa within psychosis based on 
the severity of positive, negative, and disorganisation symptoms. 
 
Patients with bipolar affective disorder experience repeated episodes of mania and 
depression. Symptoms of mania include elated mood, without an obvious cause, rapid 
speech, increased energy, and disordered thoughts. Depressive episodes are characterised by 
feelings of hopelessness, low self-esteem, decreased energy, and insomnia. In common with 
schizophrenia, the DSM-IV recognises different subtypes of bipolar disorder. These include 
bipolar I disorder, characterised by at least one manic or mixed (comprising both manic and 
major depressive symptoms) episode, bipolar II disorder, which includes at least one major 
depressive episode and at least one hypomanic episode, and cyclothymia, a milder form of 
bipolar disorder, which is characterised by a fluctuating mood that comprises episodes of 
hypomania and episodes of depression that do not meet the diagnostic criteria for a major 
depressive episode. 
 
The precise estimation of the lifetime prevalence of these disorders is complicated by 
variation between samples, which is, at least in part, attributable to the heterogeneity of the 
disorders. From a review of studies carried out between 1965 and 2002, Saha et al. (2005) 
reported the lifetime prevalence of schizophrenia to be between 0.3 and 2%, with an average 
of approximately 0.7%. The majority of patients are diagnosed with schizophrenia in their 
late adolescence or early twenties, and there are several reports of earlier onset in males than 
Chapter 1: Introduction 
  4 
females (Angermeyer and Kuhn, 1988), although a recent meta-analysis has revealed this 
gender difference to be only about 1.5 years, smaller than previously believed (Eranti et al., 
2012). There is a lack of consensus regarding the proportion of males to females affected by 
the disorder: initial studies concluded that the risk of developing schizophrenia was equal for 
males and females (Wyatt et al., 1988), while subsequent studies have indicated a higher 
prevalence of the disorder amongst males (Aleman et al., 2003; McGrath, 2005). Bipolar 
disorder occurs with similar lifetime prevalence to schizophrenia, with recent findings from 
the World Mental Health Survey Initiative indicating that bipolar I disorder has a lifetime 
prevalence of 0.6% and bipolar II disorder has a lifetime prevalence of 0.4% (Merikangas et 
al., 2011). Gender differences have been reported in the presentation of bipolar disorder: 
while approximately equal numbers of men and women are affected by the disorder (Gold, 
1998), women have been reported as experiencing depression, mixed episodes, and rapid 
cycling more often than men, as well as having a later age of onset (Robb et al., 1998).   
 
The accuracy of estimates of the prevalence of both schizophrenia and bipolar disorder is 
limited by the lack of definitive biomarkers for psychiatric illness. Moreover, as the 
symptoms of schizophrenia and bipolar disorder are heterogeneous and overlapping, debate 
exists over the extent to which these disorders should be considered separate entities. The 
distinction of schizophrenia and bipolar disorder as separate clinical conditions can be traced 
back to Emil Kraepelin (1919) who described two conditions, crystallised dementia praecox, 
now referred to as schizophrenia, and manic depressive illness, now known as bipolar 
disorder. Craddock and Owen (2005; 2007) question the validity of this traditional diagnostic 
distinction by highlighting several genes implicated in both disorders. They predict that 
advances in genetic epidemiology mark “The beginning of the end for the Kraepelinian 
dichotomy”. Crow (2008), in contrast, highlights the fact that the beginning of the downfall 
of the Kraepelinian dichotomy started with Kraepelin himself, who stated that “It is 
becoming increasingly clear that we cannot distinguish satisfactorily between these two 
illnesses and this brings home the suspicion that our formulation of the problem may be 
incorrect.”, (Kraepelin, 1920). 
 
1.2 Evidence for a genetic basis to schizophrenia and bipolar disorder 
 
A genetic contribution to the aetiology of psychiatric illness has been demonstrated by 
family, twin and adoption studies (Cardno and Gottesman, 2000; Ingraham and Kety, 2000; 
Lichtenstein et al., 2009; McGuffin, 2004; Sullivan et al., 2003; Sullivan et al., 2000).  For 
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schizophrenia, the concordance rate between monozygotic twins is higher than between 
dizygotic twins: in a review of the literature, Cardno and Gottesman (2000) report 
concordance rates of 41-65% in monozygotic twins and concordance rates of 0-28% in 
dizygotic twins. The heritability of schizophrenia was estimated as being approximately 80-
85% (Cardno and Gottesman, 2000). First degree relatives of patients with schizophrenia 
have an increased risk of developing schizophrenia of approximately 10-fold compared to 
other members of the population (Lichtenstein et al., 2009), and adoption studies have found 
that adopted children’s risk of developing schizophrenia is related to the affected status of 
their biological but not adoptive parents (Ingraham and Kety, 2000). 
 
Compared with schizophrenia, fewer studies have been carried out to ascertain the genetic 
contribution to bipolar disorder; however, those that have been performed suggest a strong 
genetic basis. In a twin study in which the diagnostic groups of bipolar I disorder and bipolar 
II disorder were considered together, McGuffin et al. (2003) reported concordance rates of 
40% for monozygotic twins and 5.4% for dizygotic twins, which resulted in a heritability 
estimate of 85%. Similar concordance rates were observed in a study in which only bipolar I 
disorder was considered: in this study, the concordance rate for monozygotic twins was 43% 
for monozygotic twins and 6% for dizygotic twins, resulting in a heritability estimate of 93% 
(Kieseppa et al., 2004). Consistent with the genetic contribution suggested by twin studies, 
the first degree relatives of patients with bipolar disorder have an elevated risk of bipolar 
disorder of approximately seven-fold compared to the general population (Lichtenstein et al., 
2009). Only two adoption studies have been carried out in which the modern definition of 
bipolar disorder was used: both of these studies found evidence suggestive of a genetic basis 
to the disorder; however, for both studies, the sample size was relatively small (Mendlewicz 
and Rainer, 1977; Wender et al., 1986). Moreover, both studies used definitions of illness 
that extended beyond bipolar disorder: Mendlewicz and Rainer (1977) identified parents as 
“ill” when they were diagnosed with bipolar disorder, unipolar disorder, schizoaffective 
disorder, or cyclothymia, and Wender et al. (1986) considered both probands and parents as 
affected when they were diagnosed with either bipolar disorder or unipolar disorder.  
 
The use of broad diagnostic categories by both Mendlewicz and Rainer (1977) and Wender 
et al. (1986) hints at an observation that has important consequences when considering the 
genetic basis of psychiatric illness. This observation is that psychiatric illnesses do not 
“breed true”: close relatives of individuals diagnosed with one disorder are themselves not 
only at greater risk of developing the same disorder but other psychiatric disorders too. 
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Relatives of patients with bipolar disorder are at an elevated risk of unipolar disorder 
compared to relatives of control subjects (Merikangas et al., 2002), and in a twin study in 
which the probands were diagnosed with bipolar disorder, McGuffin et al. (2003) found that 
the inclusion of co-twins with either bipolar disorder or unipolar disorder resulted in an 
increase in the heritability estimate compared to when co-twins with only bipolar disorder 
were considered.  
 
While the co-aggregation of affective disorders in families has been recognised for several 
years, the evidence for the co-aggregation of schizophrenia and bipolar disorder has been 
more contentious. This debate has clear implications for the diagnostic distinction between 
schizophrenia and bipolar disorder. Early studies suggesting that schizophrenia and bipolar 
disorder do breed true supported their diagnostic distinction (Berrettini, 2003); however a 
recent study, the largest family study of schizophrenia and bipolar disorder to date, has 
challenged this assertion. Lichtenstein et al. (2009) found the first degree relatives of 
probands diagnosed with either schizophrenia or bipolar disorder to have an increased risk of 
developing either disorder. This observation is in keeping with Cardno et al.’s (2002) finding 
from the study of twins diagnosed with schizophrenia, schizoaffective disorder, or manic 
disorder that the genetic contribution to the three disorders is correlated and that there are 
both disorder-specific and common genetic contributions. The existence of a shared genetic 
component is further corroborated by the findings of the International Schizophrenia 
Consortium who have demonstrated that polygenic risk alleles identified in a schizophrenic 
sample are associated with risk for bipolar disorder in two independent samples (Purcell et 
al., 2009). 
 
1.3 The role of non-genetic factors in the aetiology of schizophrenia and 
bipolar disorder 
 
The observations that (i) monozygotic twins show less than perfect concordance for 
schizophrenia and bipolar disorder and (ii) concordance rates for dizygotic twins are less 
than half the monozygotic rate hint at the involvement of additional non-genetic influences. 
Furthermore, the risks to offspring of both the affected and unaffected twins from a pair of 
monozygotic twins who are discordant for schizophrenia are almost equally elevated 
(Kringlen and Cramer, 1989). Epidemiological studies have identified several environmental 
factors conferring risk for schizophrenia and bipolar disorder. For schizophrenia, prenatal 
stress, such as bereavement or famine, obstetric complications, infection, winter births, and 
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being born into an urban environment have all been shown to increase the risk of developing 
the disorder (Sullivan, 2005). There is strong evidence that gestational exposure to infection 
increases risk for schizophrenia. Longitudinal study of a birth cohort has found an increased 
incidence of schizophrenia amongst the offspring of mothers who had experienced the 
influenza virus, herpes simplex virus type 2, or had elevated levels of toxoplasma gondi 
during pregnancy (Babulas et al., 2006; Brown et al., 2004). Consistent with these findings, 
mothers whose offspring developed schizophrenia were found to have elevated levels of the 
pro-inflammatory cytokine interleukin-8 during the second and early third trimester of 
pregnancy (Brown et al., 2005). The role of maternal infection is supported by the study of 
rodent models: prenatal immune challenge is associated with cognitive, behavioural and 
pharmacological abnormalities relevant to schizophrenia in the adult offspring (Meyer and 
Feldon, 2009). Moreover, mice expressing a dominant negative form of human Disrupted in 
Schizophrenia 1(DISC1), a leading candidate gene for schizophrenia, who are injected 
neonatally with poly I:C, which promotes the production of pro-inflammatory cytokines, 
show synergistic deficits in memory function (Ibi et al., 2010), which are characteristic of the 
cognitive defects observed in schizophrenia. Additionally, mice expressing a mutant 
truncated form of human DISC1 who were subjected to prenatal exposure to poly I:C, 
displayed a postnatal phenotype that recapitulated many features of psychiatric disorders 
including depressive-like behaviour, anxiety, abnormal social interaction, attenuated 
serotonin neurotransmission, decreased amygdala volume, reduced granule cell dendritic 
spine density in the hippocampus and changes in gene expression (Abazyan et al., 2011). 
 
Environmental variables are also known to influence the onset of bipolar disorder. Several 
studies have reported an increased incidence of stressful life events prior to the onset of 
individual episodes. (Alloy et al., 2005) and Etain et al. (2008) concluded from a review of 
the literature that childhood trauma is a risk factor for the onset and clinical expression of 
bipolar disorder. Investigation of the role of maternal infection in the pathogenesis of bipolar 
disorder has been less extensive than for schizophrenia; however, based on a limited number 
of studies, it appears that maternal infection does not confer risk for bipolar disorder 
(Mortensen et al., 2011; Mortensen et al., 2003; Stober et al., 1997). 
 
One mechanism by which environmental influences might exert a pathogenic effect is via an 
effect at the epigenetic level. Epigenetic mechanisms that can effect gene expression have 
been found to be influenced by environmental factors such as diet, drugs and stress (Oh and 
Petronis, 2008). In a genome-wide analysis of blood DNA methylation in monozygotic twins 
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discordant for either schizophrenia or bipolar disorder, several loci were found to be 
differentially methylated between affected and unaffected twin pairs (Dempster et al., 2011). 
Moreover, pathway analysis of the dysregulated genes revealed enrichment for pathways 
previously implicated in psychiatric illness and neurodevelopment, thus highlighting the 
potential of this approach to extend our understanding of pathogenic mechanisms.  
 
It is important to note that epigenetic differences between monozygotic twins do not 
necessarily reflect the actions of environmental influences: it is possible that they reflect the 
influence of stochastic variables. It has been suggested that differences in gene expression 
levels, which are known to randomly fluctuate (Kaern et al., 2005), might be crystallised 
during embryogenesis by epigenetic chromatin modifications and clonally inherited 
(Mitchell, 2007). Furthermore, in addition to the epigenetically mediated influence of 
random variation, it is possible that stochastic events might also impact on other processes 
involved in brain development and thus risk for schizophrenia (Mitchell, 2007; Woolf, 
1997). 
 
1.4 Pathological hallmarks of schizophrenia and bipolar disorder 
 
Whilst no physiological or pharmacological hallmark of schizophrenia or bipolar disorder 
occurs with the required specificity to qualify as a diagnostic marker, several abnormalities 
have been replicated in enough studies to provide useful insights into the aetiology of these 
disorders. Several abnormalities are common to both conditions, while others are more 
specific in their appearance. Taken together, the identified abnormalities suggest a strong 
neurodevelopmental basis to schizophrenia (Fatemi and Folsom, 2009) and the involvement 
of neurodevelopmental factors in bipolar disorder (Sanches et al., 2008). 
 
1.4.1 Structural abnormalities 
 
Brain imaging has permitted huge advances in our understanding of the state of the brain in 
schizophrenia and bipolar disorder in the living patient, avoiding many confounds associated 
with the study of post-mortem brains. Magnetic resonance imaging (MRI) studies of both 
conditions have been numerous and not always unanimous in their findings. Meta-analyses 
have, however, supported the existence of several structural abnormalities. In schizophrenia, 
meta-analyses have supported the existence of volumetric reductions in the hippocampus, 
thalamus, amygdala, and anterior cingulate cortex and a volumetric increase in the size of the 
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ventricles, particularly the lateral ventricles (Baiano et al., 2007; Baiano et al., 2008; Konick 
and Friedman, 2001; Nelson et al., 1998; Wright et al., 2000). A reduction in the area of the 
corpus callosum has also been identified (Arnone et al., 2008). A meta-analysis of bipolar 
disorder MRI studies revealed reductions in whole brain volume and an increase in the 
volume of the lateral ventricles and globus pallidus (Arnone et al., 2009). An increased 
incidence of white matter hyperintensities (WMHs), areas of high intensity visible on certain 
types of MRI scan, is a well-established finding in patients with bipolar disorder (Mahon et 
al., 2010). The relevance of WMHs to the pathophysiology of bipolar disorder remains 
unknown: WMHs can be caused by ischemia, gliosis, edema, and demyelination, and it is 
unclear which cause contributes to the presence of WMHs in bipolar disorder (Mahon et al., 
2010). It has been suggested that WMHs disrupt brain tissue and thus neuronal connectivity 
(Schloesser et al., 2008). Further supporting the role of aberrant connectivity in both bipolar 
disorder and schizophrenia, abnormalities in white matter, which consists mostly of 
myelinated axons and glial cells, have been detected in both conditions (Heng et al., 2010; 
Thomason and Thompson, 2011). As the myelination of axons is necessary for the efficient 
transmission of action potentials, white matter abnormalities suggest reduced connectivity. 
Indeed, Harrison and Weinberger (2005) have termed schizophrenia a “disorder of 
connectivity”. Importantly, some of these changes have been detected in first-episode 
patients and those genetically at high-risk of developing schizophrenia or bipolar disorder, 
indicating that they are not simply a result of drug treatment of disease progression (Jung et 
al., 2010; Sprooten et al., 2011a; Vita et al., 2009; Vita et al., 2006). 
  
1.4.2 Abnormalities found in the post-mortem brain 
 
Post-mortem studies offer the advantage over imaging studies of permitting a more detailed 
examination of abnormalities at the cellular level; however, they are, of course, subject to the 
possible confounds of long-term medication, circumstances surrounding death, and post-
mortem factors. At a macroscopic level, a decrease in brain weight has been observed in 
several studies of schizophrenic patients (Brown et al., 1986; Bruton et al., 1990; 
Pakkenberg, 1987) consistent with the volumetric reductions reported by MRI studies.  
 
Post-mortem studies also support the notion that white matter abnormalities contribute to the 
pathogenesis of schizophrenia and bipolar disorder.  In the post-mortem brains of patients 
with schizophrenia, several studies have found subcortical white matter neurons to be 
increased in density and spatial distribution (Connor et al., 2011). An increase in white 
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matter neuron density has been reported in bipolar disorder too (Connor et al., 2009). This 
increase in density may result, in part, from altered neuronal migration: several studies have 
identified aberrantly positioned neurons in schizophrenia (Arnold et al., 1991; Falkai et al., 
2000; Jakob and Beckmann, 1994; Kovalenko et al., 2003). Several other cytoarchitectural 
abnormalities have been identified in both schizophrenia and bipolar disorder. In the 
prefrontal cortex (PFC) of schizophrenic patients, pyramidal neurons have been found to be 
more densely packed, and it is thought that this difference arises from a reduction in neuropil 
and soma size (Rajkowska et al., 1998; Selemon and Goldman-Rakic, 1999). Abnormalities 
in GABAergic interneurons have also been detected in both schizophrenia and bipolar 
disorder (Benes and Berretta, 2001; Fatemi et al., 2005; Marin, 2012; Wang et al., 2011a; 
Woo et al., 2004). In both schizophrenia and bipolar disorder, a reduction in the expression 
of GAD67, the rate limiting enzyme in GABA synthesis has been observed (Akbarian et al., 
1995; Guidotti et al., 2000; Hashimoto et al., 2003; Thompson Ray et al., 2011). GABAergic 
interneurons are involved in the inhibition of pyramidal neurons, which is necessary for the 
maintenance of normal gamma oscillations, the bursts of coordinated firing thought to play 
an important role in cognition (Bartos et al., 2007). Abnormal gamma oscillations have been 
detected in schizophrenic patients performing tests of working memory (Haenschel et al., 
2009; Uhlhaas and Singer, 2010) and in patients with bipolar disorder during an implicit 
emotional task (Liu et al., 2012). Both schizophrenia and bipolar disorder are associated with 
aberrant myelination. The number of oligodendroglial cells, the glial cell type responsible for 
myelination in the central nervous system (CNS), is reduced in various brain regions in 
patients with schizophrenia or bipolar disorder (Uranova et al., 2004; Vostrikov et al., 2007), 
and down-regulation of myelin-related genes has been detected in both conditions (Hakak et 
al., 2001; Matthews et al., 2012; Tkachev et al., 2003). Deficits in myelination may 
contribute to the reduced connectivity mentioned in section 1.4.1. 
 
1.4.3 Abnormalities in neurotransmitter systems 
 
Multiple lines of evidence suggest that aberrant neurotransmission plays a fundamental role 
in the pathogenesis of both schizophrenia and bipolar disorder. In addition to the GABAergic 
deficits described in section 1.4.2, abnormalities have also been detected in glutamate, 
dopamine, and acetylcholine function, leading to difficulties in determining the primary 
pathology. As might be expected, given the observed abnormalities in neurotransmission, 
deficits in synaptic plasticity have been observed in both schizophrenia and bipolar disorder. 
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The dopamine hypothesis was one of the first theories of the aetiology of schizophrenia. In 
its initial incarnation, the dopamine hypothesis proposed hyperdopaminergia as playing a 
causal role in schizophrenia (Howes and Kapur, 2009). This conclusion was based on the 
discoveries that (i) the clinical effectiveness of antipsychotics equated with their affinity for 
dopamine D2 receptors where they exert an antagonistic effect and (ii) the symptoms of 
schizophrenia could be induced or exacerbated by amphetamine, which increases synaptic 
concentrations of dopamine and other monoamines (Lieberman et al., 1987; Matthysse, 
1973; Seeman and Lee, 1975; Snyder, 1976). The discovery that there is an increase in the 
density of striatal dopamine D2 receptors in schizophrenic patients appeared to support the 
hypothesis of hyperdopaminergia (Seeman, 1992); however, these studies were unable to 
rule out the contribution of long-term antipsychotic use. Interestingly, subsequent studies 
using positron emission tomography (PET) or single-photon emission computed tomography 
(SPECT) have demonstrated an increase in dopamine synthesis and amphetamine-induced 
dopamine release in drug-free patients with schizophrenia (Laruelle et al., 1996; Lindstrom 
et al., 1999). Moreover, it has been shown that patients with treatment-resistant 
schizophrenia do not show the same increase in dopamine synthesis observed in patients 
whose symptoms are ameliorated by antipsychotics, suggesting differences in the underlying 
pathology and/or effects of antipsychotic medication (Demjaha et al., 2012). 
 
The original dopamine hypothesis was limited by its ability to account only for the positive 
symptoms of schizophrenia; it provided no explanation for either the negative or cognitive 
aspects of the disorder. To remedy this deficit, the hypothesis was extended such that it 
described a hyperactive mesolimbic dopamine system, underlying the positive symptoms, 
and a hypoactive mesocortical dopamine system, underlying the cognitive symptoms (Davis 
et al., 1991; Weinberger, 1987). Hypoactivity of the mesocortical dopamine system was 
suggested by the discovery that dopamine D1 receptor availability is increased in 
schizophrenic patients, with this increase correlating positively with working memory 
impairments (Abi-Dargham et al., 2002).   
 
Dopamine dysregulation has also been proposed to play a role in bipolar disorder (Berk et 
al., 2007). It is thought that during manic episodes there is an excess of dopaminergic 
signaling, while episodes of depression are characterised by reduced dopamine signaling. In 
support of this hypothesis, episodes of hypomania can be induced in patients with bipolar 
disorder by administering the dopamine precursor L-Dopa (Murphy et al., 1971) and 
dopamine agonists have been shown to be effective in alleviating depression in patients with 
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bipolar disorder (Berk et al., 2007). In common with schizophrenia, an increase in dopamine 
D2 receptor density has been reported in bipolar disorder patients, with increased density 
correlating positively with the severity of psychotic symptoms (Pearlson et al., 1995). 
 
Subsequent to the dopamine hypothesis, a glutamate hypothesis of schizophrenia, which 
proposes glutamate hypofunction as a pathogenic mechanism, was proposed (Olney and 
Farber, 1995). Suggestive evidence for glutamate hypofunction came from the observation 
that the concentration of glutamate in the cerebrospinal fluid of patients with schizophrenia 
is reduced (Kim et al., 1980) and further support came from the finding that low doses of 
NMDA receptor antagonists, such as ketamine and phencyclidine, can mimic the symptoms 
of schizophrenia when administered to healthy individuals (Adler et al., 1999; Javitt and 
Zukin, 1991; Krystal et al., 1994). Importantly, the symptoms elicited by these drugs are 
reminiscent of the negative and cognitive symptoms of schizophrenia, as well as the positive 
symptoms, thus suggesting that glutamatergic hypofunction might have greater explanatory 
power than the dopamine hypothesis. Studies of glutamate receptor expression in the post-
mortem brains of schizophrenic patients have provided support for the notion of 
glutamatergic hypofunction with a decrease in the expression of certain subclasses of 
glutamate receptor being reported by several studies (Meador-Woodruff and Healy, 2000). It 
is important to note that the dopamine and glutamate hypotheses of schizophrenia do not 
represent competing theories of schizophrenia, evidence for dysfunction in both 
neurotransmitter systems can be reconciled by circuit-based models. Lisman et al. (2008) 
describe a model whereby glutamatergic hypofunction results in a reduction in the activity of 
fast-spiking interneurons resulting in the disinhibition of pyramidal cells, which can produce 
hyperdopaminergia, particularly in the hippocampus. Moreover, glutamatergic neurons 
synapse directly onto mesocortical dopaminergic neurons in the ventral tegmental area, 
regulating their activity such that glutamatergic hypofunction would result in a decrease in 
the activity of mesocortical dopamine neurons (Takahata and Moghaddam, 2000; Westerink 
et al., 1998). 
 
Abnormal glutamate function also appears to play a role in bipolar disorder. There is 
evidence for an increase in glutamatergic neurotransmission in patients with bipolar disorder 
(Eastwood and Harrison, 2010) and Lamotrigine, which reduces cortical glutamate, has been 
found to have mood-stabilising and antidepressant effects (Muzina et al., 2005). Similarly, 
the mood stabiliser lithium has been found to protect neurons in primary cultures from 
glutamate-induced excitotoxicity (Chuang et al., 2002). Perhaps paradoxically, decreased 
Chapter 1: Introduction 
  13 
expression of certain glutamatergic receptors has been detected in the post-mortem brains of 
patients with bipolar disorder (Beneyto et al., 2007; Nudmamud-Thanoi and Reynolds, 2004; 
Scarr et al., 2003); however, it is possible that this decrease represents a compensatory 
mechanism or medication effect.  
 
Recently, interest has grown in the contribution of cholinergic dysfunction to schizophrenia. 
Compared to the general population, there is an increased incidence of cigarette smoking 
amongst patients with schizophrenia and it has been suggested that this might represent an 
attempt to compensate for deficits in nicotinic acetylcholine function (Aubin et al., 2012). A 
decrease in acetylcholine receptor expression has been reported in schizophrenic patients 
(Deng and Huang, 2005; Perl et al., 2003; Scarr et al., 2009) and the expression of nicotinic 
acetylcholine receptors (nAChRs) has been shown to be differentially modulated by smoking 
in schizophrenic smokers (Mexal et al., 2010). Interestingly, agonists of α7 nAChRs have 
been shown to alleviate cognitive deficits associated with schizophrenia and reverse the 
effects of phencyclidine (AhnAllen, 2012). This finding is of great interest given the lack of 
efficacy of many currently available antipsychotics in the amelioration of cognitive 
dysfunction (Money et al., 2010). Cholinergic abnormalities are also implicated in bipolar 
disorder: hippocampal α7 nAChRs have been found to be decreased in the post-mortem 
brains of patients with bipolar disorder (Thomsen et al., 2011). In common with 
schizophrenia, the incidence of cigarette smoking is increased amongst individuals with 
bipolar disorder (Heffner et al., 2011). 
 
Other neurotransmitter systems identified as functioning abnormally in schizophrenia and 
bipolar disorder include the serotonergic system. The atypical antipsychotics clozapine and 
risperidone are believed to act, in part, via their antagonistic effects on serotonin receptors 
(Kapur and Remington, 1996) and selective serotonin reuptake inhibitors are often used to 
treat the depressive symptoms of bipolar disorder (Shastry, 2005). Furthermore, serotonin 
receptor expression has been reported to be abnormal in both schizophrenic and bipolar 
disorder patients (Castensson et al., 2003; Eastwood et al., 2001; Lopez-Figueroa et al., 
2004). 
 
Deficits in synaptic plasticity are believed to play a key role in both schizophrenia and 
bipolar disorder. Aberrant expression of several synapse-related genes has been detected for 
both disorders (Lopez de Lara et al., 2010; Maycox et al., 2009; Mirnics et al., 2000; Ryan et 
al., 2006), and mood stabilisers, antidepressants and antipsychotics are believed to exert their 
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therapeutic effects, at least in part, via an effect on synaptic function (D'Sa and Duman, 
2002; Konradi and Heckers, 2001; Shaldubina et al., 2001). Moreover, abnormalities in 
synaptic plasticity have been detected in several animal models of schizophrenia and 
depression (Pittenger and Duman, 2008; Yin et al., 2011) and, in recent years, direct 
evidence has been obtained for abnormal plasticity in schizophrenic patients (Frantseva et 
al., 2008; Hasan et al., 2011). 
 
Taken together, since the formulation of the dopamine and glutamate hypotheses of 
schizophrenia, subsequent evidence suggests a widespread disruption of normal 
neurotransmitter, and thus synaptic, function in both schizophrenia and bipolar disorder. 
Improved understanding of the inter-relationship between different neurotransmitter systems, 
and identification of relevant functional schizophrenia/bipolar disorder-associated genetic 
variants, will aid in establishing the primary pathology. 
 
1.5 The genetic architecture of schizophrenia and bipolar disorder 
 
Despite the clear evidence for a genetic contribution to the risk of developing schizophrenia 
or bipolar disorder, the underlying genetic architecture of the two conditions remains poorly 
understood. Two contrasting models have dominated the debate: the common disease-
common variant (CDCV) model and the multiple rare variants model. The CDCV model 
proposes that, within an individual, multiple common variants in different genes, each of 
small effect size, confer susceptibility for the disorder (i.e. the disorder is polygenic). To 
apply the CDCV model to conditions which are binary in nature (i.e. an individual has the 
disorder or does not have it), a liability threshold has been invoked: the underlying 
distribution of liability for the disorder is assumed to be continuous but only those 
individuals who pass a minimum burden of common variants actually get the disease 
(Falconer, 1989). In contrast, the multiple rare variants model posits that the majority of the 
variance for complex diseases is due to the actions of rare variants (typically with a minor 
allele frequency of less than 1%). These variants may occur in different genes in different 
individuals, making the disorder genetically heterogeneous. A mixed model in which other 
loci in the genetic background act in a polygenic fashion together with environmental factors 
to modify the expressivity of rare alleles provides an alternative to either the CDCV or rare 
variant models interpreted in the most narrow of senses. Indeed, this model is congruent with 
experimental findings that have indicated that genetic background effects are common and 
can have a substantial effect on phenotype (Nadeau, 2001; Shao et al., 2008). 
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For various reasons the CDCV model has dominated the field of psychiatric genetics; 
however, in recent years, the premises of this hypothesis have been called into question and 
the plausibility of other hypotheses considered (McClellan et al., 2007; Mitchell, 2012; 
Mitchell and Porteous, 2011). An argument often used in favour of the polygenic CDCV 
model of schizophrenia and bipolar disorder is that neither disorder segregates in a manner 
consistent with classical Mendelian inheritance (Gottesman and Shields, 1967). The 
recurrence risk to relatives of schizophrenic patients decreases more quickly than would be 
expected if the disorder was caused by a single gene acting with a dominant mode of 
inheritance (Gottesman and Shields, 1967; Risch, 1990). The involvement of multiple 
common variants of small effect has also been used as an explanation for the fairly constant 
prevalence of schizophrenia over time despite the decrease in fertility associated with this 
disorder (Gottesman and Shields, 1967). Risch et al. (1990) have argued that should different 
rare alleles play a causal role in different families, one would expect the clinical presentation 
of the disorder to be distinct between families. Moreover, it has been argued that if these 
disorders were caused by rare variants of large effect, the variants involved would have been 
detected by genetic linkage studies (Risch, 1990). This latter argument can easily be refuted 
on the basis that many genetic linkage studies have been carried out across multiple 
unrelated families: risk alleles would have to be sufficiently common to contribute to disease 
pathogenesis in enough of the families studied to be detected using this approach. 
 
Further doubt has been cast over the CDCV hypothesis of schizophrenia and bipolar disorder 
by recent findings that question many of the assumptions on which the acceptance of this 
hypothesis was based. One such assumption was that the rate of de novo mutations was too 
low to replenish highly penetrant deleterious alleles, which would be eliminated by purifying 
selection (Gottesman and Shields, 1967). A hint that this assumption was incorrect came 
from the observation that an increased incidence of both schizophrenia and bipolar disorder 
is associated with advanced paternal age (Frans et al., 2008; Matheson et al., 2011). Paternal 
age is associated with an increase in de novo germline mutations (Kong et al., 2012) and an 
increase in the incidence of hereditary disorders (Glaser and Jabs, 2004). The advent of 
whole-genome sequencing and its application to family pedigrees has facilitated direct 
assessment of the rate of spontaneous mutations and their contribution to disease. Based on 
the sequencing of a family quartet, (Roach et al., 2010) have estimated that there will be 
approximately 70 new mutations in each diploid genome. Following whole-genome 
sequencing in 78 parent-offspring trios, Kong et al. (2012) have predicted that de novo 
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mutations occur at a rate of roughly 2 per a year, when their data is fitted with a linear 
model, or double every 16.5 years under an exponential model. Under both models, paternal 
age explains at least 94% of the variation in the occurrence of de novo mutations. 
Furthermore, an increase in the rate of spontaneous mutations with predicted deleterious 
consequences has been identified in individuals with schizophrenia (Awadalla et al., 2010). 
Further supporting the role of spontaneous mutations in the pathogenesis in schizophrenia is 
the discovery that de novo copy number variants (CNVs) are associated with the disorder 
(Kirov et al., 2012; Malhotra et al., 2011; Xu et al., 2008). The involvement of CNVs in the 
pathogenesis of schizophrenia and bipolar disorder will be discussed further in section 
1.6.2.2. De novo mutations may also represent a causal factor for bipolar disorder as the 
condition has been associated with an increase in somatic gene conversion and deletion 
(Ross, 2011), processes that occur when highly homologous but non-allelic regions of the 
genome exchange genetic information in a unidirectional fashion.  
 
The involvement of de novo mutations in schizophrenia and bipolar disorder could also 
account for some instances of non-Mendelian inheritance. Furthermore, de novo pathogenic 
variants could, at least in part, explain the observed recurrence risks amongst relatives of 
schizophrenic patients. In fact, Mitchell and Porteous (2011) have demonstrated that the 
observed familial recurrence risks for schizophrenia are compatible with a mixed model in 
which varying proportions of cases of schizophrenia are attributable to dominant, recessive, 
or de novo modes of inheritance. 
 
Risch’s (1990) argument that distinct genetic causes of a disorder should be reflected by 
distinct phenotypic presentation is now outdated. Accumulating evidence highlights the fact 
that individual mutations are associated with a broad range of psychiatric conditions 
(reviewed in Mitchell and Porteous, 2011). An example of such a mutation, which will be 
discussed further in section 1.7.4.2, is a balanced translocation affecting the gene Disrupted 
in Schizophrenia 1 (DISC1) (Millar et al., 2000b). This translocation was identified in a 
family with a high incidence of psychiatric illness; translocation carriers are variously 
affected by a wide range of psychiatric conditions including major depressive disorder, 
schizophrenia, and bipolar disorder (St Clair et al., 1990). 
 
As alluded to previously, a mixed model, in which both common and rare variants confer 
susceptibility offers a compromise between the polarised CDCV and rare variant models. In 
a recent publication (Lee et al., 2012) used mathematical modelling to estimate the 
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proportion of variance in liability to schizophrenia attributable to SNPs of different minor 
allele frequencies. This analysis indicated that SNPs across the range of minor allele 
frequencies considered explained some proportion of the total variance. It is important to 
note that the genotypes of the SNPs in this study were ascertained by whole-genome 
genotyping chips and, therefore, rare variants would have been under-represented in this 
analysis. Indeed, a model that incorporated all SNPs (both genotyped and imputed) could 
only account for 23% of the variance in liability to schizophrenia. Nevertheless, these 
findings highlight the need to consider variants spanning the entire spectrum of allelic 
frequencies. 
 
Taken together, the evidence calls for a re-evaluation of our understanding of the genetic 
architecture of schizophrenia and bipolar disorder. Ascertaining the genetic architecture of 
schizophrenia and bipolar disorder is more than a matter of academic debate: several 
methods are available for the detection of disease-associated variables, with the choice of 
method depending on the nature of the variant to be detected. These methods will be 
introduced in section 1.6. Until the underlying architecture of a condition is understood, it 
has been argued that “the genetic variants related to human disease that have been identified 
to date primarily reflect the methods used to detect them” (Campbell and Manolio, 2007). 
 
1.6 Methods for the identification of genes involved in schizophrenia and 
bipolar disorder 
 
Several methods for the identification of genetic variants involved in hereditary disorders 
exist. These will be introduced below, together with some examples of schizophrenia and 
bipolar disorder candidate genes that have been identified through their application. 
 
1.6.1 Linkage analysis 
 
Linkage analysis involves the comparison of closely related individuals to identify regions of 
the genome that segregate with a given phenotype. As genetic loci that are located in close 
proximity are less likely to be separated during meiotic recombination, they tend to be 
inherited together more often than distally located loci. Thus, by studying the segregation of 
genotyped markers with the phenotype of interest, the genomic region harbouring the causal 
variant can be narrowed down. The resolution of linkage analysis is usually fairly low: it is 
able to identify phenotype-associated chromosomal regions, which may span several 
megabases of DNA. Linkage analysis is most applicable for the detection of genomic regions 
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containing causal variants that are highly penetrant and of large effect; the method lacks 




Several linkage studies have been carried out for both schizophrenia and bipolar disorder, 
which have between them implicated much of the genome. In a review of the literature, 
Harrison and Weinberger (2005) highlight four regions (6p22-24, 8p21-22, 1q21-22, 
10q25.3-26.3) as having attained genome-wide significance for linkage to schizophrenia but 
point out that each of these regions has been studied in other studies in which significant 
linkage was not observed.  In a meta-analysis of 32 independent genome-wide linkage 
studies of schizophrenia, Ng et al. (2009) detected genome-wide linkage to chromosome 2q 
and suggestive evidence for linkage to chromosome 5q and, in European subjects only, 
chromosome 8p. Interestingly, Neuregulin 1 (NRG1), a well-supported schizophrenia 
candidate gene (section 1.7.4.1), is located within the linked region on chromosome 8p. 
Another gene in this region, PPP3CC, which encodes the calcineurin gamma subunit, has 
also been implicated in schizophrenia by association studies (Gerber et al., 2003; Horiuchi et 
al., 2007; Kyogoku et al., 2011; Liu et al., 2007) and the finding of altered expression in the 
brains of schizophrenic patients (Eastwood et al., 2005). On chromosome 2q, zinc-finger 
protein 804A (ZNF804A), which has been implicated in schizophrenia by genome-wide 
association studies (GWAS) (O'Donovan et al., 2008) and candidate gene  association 
studies (Riley et al., 2010; Steinberg et al., 2011), and a meta-analysis of association studies 
(Williams et al., 2011), is located within a nominally significant region, rather than the 
region that showed genome-wide significance. 
 
1.6.1.2 Bipolar disorder 
 
In a recent review of whole-genome linkage studies for bipolar disorder, Alsabban et al. 
(2011) highlight a lack of congruence between the approximately 20 individual studies and 
combined analyses of these studies that had been carried out at that time. A large scale meta-
analyses had failed to identify any linkage peaks at the level of genome-wide significance 
(Segurado et al., 2003), whilst a mega-analysis reported significant linkage to chromosome 
6q for bipolar disorder 1 and 8q for bipolar disorder 1 and bipolar disorder 2 (McQueen et 
al., 2005). Similarly, in a review of linkage studies of bipolar disorder performed until 
December 2007, Serretti and Mandelli (2008) report the existence of linkage peaks on almost 
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every single chromosome. Some peaks have received support from multiple studies (e.g. 
4p16.1, 6q21 and 11p15.5); however, the majority have been identified only by single 
studies. A few linkage peaks span genomic regions containing genes implicated by 
association studies, such as dopamine receptor D4 (DRD4) and the serotonin transporter 
gene SLC6A4. 
 
1.6.1.3 Conclusions from linkage studies 
 
Interpretations of the lack of consistency between individual linkage studies have varied. 
Some, such as Alsabban et al. (2011), have concluded that the lack of consistent major “hits” 
indicates that single-gene forms of the disorder in question (in this case, bipolar disorder) are 
exceedingly rare, if not non-existent. However, as mentioned in section 1.5, if many cases of 
schizophrenia and bipolar disorder are attributable to the effects of single mutations that are 
so rare that they only play a causal role in a small number of individuals, then the act of 
combining several unrelated families in a single linkage sample is likely to render the results 
of linkage analysis essentially meaningless. 
 
1.6.2 Association analysis 
 
Association analysis presents an alternative approach to linkage analysis, which is 
complimentary in terms of the kind of variants it can detect. A large number of cases 
selected for a phenotype of interest and controls (without the phenotype of interest) are 
genotyped for a set of markers and a comparison carried out to detect those variants that 
occur statistically significantly more frequently in the case group compared to the control 
group. Sometimes, the genotyped markers may contain the causal variant; however, more 
often, it will be the case that they are in linkage disequilibrium (LD) with the casual variant. 
LD describes the phenomenon whereby the rate at which markers at two or more genetic loci 
co-occur deviates from that expected based on random recombination during meiosis. The 
existence of regions of high LD can be exploited in the search for disease-associated variants 
by the use of “haplotype-tag” SNPs (Johnson et al., 2001). These are SNPs that capture the 
genetic variation within haplotype blocks (regions in which just a few common haplotypes 
are observed) in a non-redundant fashion. Association analysis has higher resolution than 
linkage analysis and is capable of detecting variants of smaller effect size. Prior to the 
availability of affordable high-throughput genotyping methods, association analysis would 
typically either be carried out to study genes implicated by linkage analysis (positional 
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candidates) or to investigate genes of interest based on  their known functions (functional 
candidates). Nowadays, the advent of such methods has resulted in an increase in the number 
of GWASs being performed. These operate on the same principles as standard association 
analysis, except, instead of assessing association to a few markers, association is assessed to 
markers covering the entire genome. GWASs offer the advantage of, in theory, providing an 
unbiased method for identifying variants involved in the disease pathogenesis; however, as is 
true for all association analyses, their validity depends on both the genetic architecture of the 





Numerous association studies have been performed for both schizophrenia and bipolar 
disorder, implicating many genes, of which a few have received replicated support. For 
schizophrenia, at the time of Sun et al.’s (2008) pre-GWAS era survey of association studies, 
over 500 genes had been tested for association with schizophrenia in more than 2000 
association studies. In a review of the schizophrenia association study literature, Harrison 
and Weinberger (2005) identify the best supported schizophrenia candidate genes based on 
association and linkage data, as well as functional plausibility and evidence for altered 
expression in schizophrenia. Based on the evidence from association studies alone, 
dystrobrevin binding protein 1 (DTNBP1) and NRG1 are the best supported genes; however, 
when considering the other lines of evidence, catechol-O-methyl transferase (COMT) 
became one of the best supported candidate genes due to its functional plausibility. COMT 
degrades catecholamines, such as dopamine, adrenaline and noradrenaline, by catalysing 
their methylation. As abnormalities in dopamine function are believed to play a key role in 
the pathogenesis of schizophrenia (Howes and Kapur, 2009), altered COMT function is a 
plausible aetiological factor. A SNP in exon four of the COMT gene results in an amino acid 
substitution from valine (val) to methionine (met); the amino acid change affects the stability 
of COMT, such that the val form has significantly higher enzyme activity than met-COMT 
(Lachman et al., 1996). Several association studies have been carried out to assess the 
involvement of this amino acid change in schizophrenia with mixed results. Of those studies 
detecting a positive association, val-COMT has been associated with schizophrenia more 
frequently than met-COMT (Harrison and Weinberger, 2005). This finding was surprising: 
the classic dopamine hypothesis of schizophrenia, which postulates an increase in dopamine 
transmission at dopamine D2 receptors, would have predicted association to the lower 
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activity (i.e. higher dopamine) met-COMT. Subsequent studies have, to some extent, 
resolved this paradox by showing that COMT is particularly involved in the regulation of 
dopamine levels in the PFC (Weinberger et al., 2001), a region in which dopaminergic 
hypofunction has been detected in the brains of schizophrenic patients (Howes and Kapur, 
2009). Indeed, the val158met polymorphism has been found to be associated with various 
aspects of prefrontal cognitive function relevant to schizophrenia (Bilder et al., 2002; Egan et 
al., 2001; Malhotra et al., 2002). Nevertheless, despite the strong biological plausibility of 
variation in COMT as a causal factor in schizophrenia, the most recent meta-analysis of 
COMT association studies found no evidence for the association of COMT SNPs, including 
the val158met polymorphism, and haplotypes with schizophrenia (Okochi et al., 2009). 
 
Small-scale association studies investigating particular functional and positional candidate 
genes have now been largely superseded by GWASs. In a recent mega-analysis carried out 
by the Schizophrenia Psychiatric GWAS Consortium, samples of European ancestry were 
combined from 17 previous studies to give 9,394 cases and 12,462 controls and association 
assessed for a large number of SNPs across the genome (Ripke et al., 2011). Associations 
attaining genome-wide significance were observed for 136 SNPs, with the majority of these 
mapping to a region within chromosome 6p21.32-6p22.1 where the major histocompatibility 
complex (MHC) is located. Other significantly associated SNPs were located in regions 
harbouring genes implicated in schizophrenia such as transcription factor 4 (TCF4) and 
neurogranin (NRGN). Genetic variation in TCF4 has been associated with schizophrenia in 
an independent sample (Li et al., 2010), associated with sensorimotor gating in both 
schizophrenic patients and healthy controls (Quednow et al., 2012) and associated with 
cognitive performance, negative symptoms and age-of-onset in patients with psychosis 
spectrum disorders (Wirgenes et al., 2012). Reduced NRGN expression has been identified 
in the prefrontal cortex of schizophrenic patients (Broadbelt et al., 2006), genetic variation in 
the gene has been associated with schizophrenia in males (Ruano et al., 2008), and 
sequencing has identified rare variants present only in cases with schizophrenia (Shen et al., 
2012). 
 
An independent replication sample (8,442 cases and 21,397 controls) was assessed for a 
subset of the SNPs showing the strongest evidence for association in Ripke et al.’s (2011) 
initial sample. In this sample, a high level of agreement was observed with the results 
obtained in the initial sample. Combined analysis of the initial sample and the replication 
sample identified genome-wide significant association to seven loci, five of which were 
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novel (1p21.3, 2q32.3, 8p23.2, 8q21.3 and 10q24.32-q24.33), with the remaining two loci, 
located at 6p21.32-p22.1 and 18q21.2, containing the MHC and TCF4, respectively.  
 
1.6.2.2 Bipolar disorder 
 
A recent meta-analysis (i.e. the pooled analysis of published results) of bipolar disorder 
association studies failed to identify any variants attaining the threshold for significance 
following correction for multiple testing (Seifuddin et al., 2012). Four genes were found to 
contain variants that attained nominal significance (p ≤ 0.05), including BDNF, which 
encodes brain derived neurotrophic factor. BDNF is a strong functional candidate for bipolar 
disorder: in rats, its expression shows a long-term reduction in response to neonatal stress 
(Russo-Neustadt et al., 2001), which is believed to play a role in the pathogenesis of bipolar 
disorder, and is increased following treatment with the mood-stabilising drugs lithium and 
valproate (Einat et al., 2003). Moreover, variants in BDNF have been implicated in bipolar 
disorder by several independent association studies (Serretti and Mandelli, 2008). Other 
genes receiving replicated support for association with bipolar disorder (in the pre-GWAS 
era) include DAOA, DISC1, DRD4, DTNBP1, NRG1, SLC6A3, SLC6A4, and TPH2 (Serretti 
and Mandelli, 2008). 
 
Several GWASs have been performed for bipolar disorder. Studies yielding genome-wide 
significant association are summarised in table 1.1. In a recent mega-analysis (i.e. the pooled 
analysis of raw data) carried out by The Psychiatric GWAS Consortium, variants within two 
genes, CACNA1C (encoding the α (1C) subunit of the voltage-dependent L-type calcium 
channel) and ODZ4 (encoding Odz4/Ten-m4), attained genome-wide significance (Sklar et 
al., 2011). This mega-analysis represented the largest case-control association study of 
bipolar disorder carried out to date, including subjects of American, Canadian, and European 
ancestry who had previously been analysed in smaller GWASs. Seifuddin et al. (2012) 
carried out a comparison of their meta-analysis results for bipolar disorder association 
studies with the findings of the mega-analysis. Of the four genes identified by Seifuddin et 
al. (2012) as containing nominally significantly associated variants, none were implicated by 
Sklar et al.’s (2011) mega-analysis. 
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A test/replication study design was employed. 550,000 
SNPs were assessed for association in the initial sample 
(NIMH sample) using pooled DNA: 461 unrelated BPD 1 
cases, 563 controls. SNPs meeting replication-testing 
criteria were assessed for association in the second 
sample (German sample): 772 BPD 1 patients and 876 
control individuals. Both samples were of European 
ancestry. 
DGKH  The strongest 
association was to a 
marker within the first 






372,193 SNPs were assessed for association in a case-
control group comprising 1,461 cases with BPD 1 and 
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1,769,948 SNPs were assessed in 4,387 cases (81.2% 
BPD 1, 15.6% BPD 2, 2.21% SAB, and 0.935% manic 
disorder) and 6,209 controls. The sample included two 
previously assessed samples, the STEP-UCL sample 
(Sklar et al., 2008) and the WTCCC sample (WTCCC, 
2007) and a third novel sample. Subjects were of 
European and American ancestry. 
ANK3 Association was 
detected to an imputed 
intronic SNP within 





A test/replication study design was employed. 511,978 
SNPs were assessed for association in the initial GWAS 
sample of 682 cases (99.6% BPD 1, 0.29% BPD 2, and 
0.15% SAB) and 1,300 controls. The most significant 48 
SNPs were assessed for association in a replication 
sample of 1729 cases (81.50% BPD 1, 10.99% BPD 2, 
and 7.51% SAB) and 2313 controls.  Further evidence 
for replication was sought in a second replication 
sample comprising 6,030 cases (85.14% BPD 1, 9.04% 
BPD 2, 3.78% SAB, 1.97% BPD-NOS, and 0.0663% 
manic disorder) and 31,748 controls. Subjects were of 
European ancestry. 
NCAN Significant association 
to an exonic SNP in the 
NCAN gene was 
identified in meta-
analyses of (i) the initial 
GWAS sample and the 
first replication sample 
(p = 3.02 × 10
−8
) and (ii) 
the initial GWAS sample 
and both replication 






Mega-analysis of previously reported GWAS samples 
(WTCCC, 2007; Ferreira et al., 2007; Sklar et al., 2008; 
8; Scott et al., 2009; Smith et al., 2009; Djurovic et al., 
2010; Cichon et al., 2012). Employed a test/replication 
design. The primary GWAS sample comprised 7,481 
cases (84.1% BPD 1, 11.0% BPD 2, 3.52% SAB and 
1.40% other BPD diagnoses) and 9,250 controls. 
2,542,952 SNPs were assessed for association. 
Replication analysis was carried out for 34 SNPs 
showing association in the primary GWAS sample. 
Association to these SNPs was assessed in 4,496 cases 
(for the 4,111 cases for whom sub-type diagnoses 
were available: 81.6% BPD 1, 15.1% BPD 2, 1.92% SAB, 
and 1.39% BPD-NOS) and 42,422 controls. Subjects 
were of European, American and Canadian ancestry. 
ODZ4 and 
CACNA1C,  
Meta-analysis of the 
primary GWAS sample 
and the replication 
sample identified 
intronic SNPs in 
CACNA1C (p = 1.52 x 10
-
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Table 1.1. Summary of positive bipolar disorder genome-wide association study (GWAS) findings. 
Only those studies in which association attained the threshold for genome-wide significance of p ≤ 5 x 
10
-8
 are mentioned. For each GWAS, details of the study such as study design, numbers of cases and 
controls, the number of single nucleotide polymorphisms (SNPs) assessed, and the ancestry of the 
subjects are provided. Genes containing associated SNPs are indicated together with further details 
about the association. Abbreviations not already specified: BPD 1 = bipolar 1 disorder; BPD 2 = 
bipolar 2 disorder; BPD-NOS = bipolar disorder not otherwise specified; NIMH = National Institute 
of Mental Health; SAB = schizoaffective disorder, bipolar type. 
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1.6.2.3 Conclusions from association analyses 
 
Taken together, association studies of schizophrenia and bipolar disorder have implicated 
several variants, each predicted to confer a small increase in risk (odds ratios have typically 
been around 1.1 (Ripke et al., 2011). At the outset, it was widely expected that GWASs 
would reveal much of the genetic variation responsible for the heritable component of 
psychiatric disorders such as schizophrenia and bipolar disorder. More recently, it has, 
however, become apparent that, collectively, the associated variants can only explain a small 
percentage of the heritable variance: in recent studies, the variance explained has ranged 
from 3-6% (Purcell et al., 2009; Ripke et al., 2011; Ruderfer et al., 2011). This discovery has 
led to the notion of “missing heritability” and, subsequently, several theories as to where the 
missing heritability might be found. One approach to the missing heritability problem has 
been to consider marginally significant variants (i.e. those failing to meet the threshold for 
genome-wide significance but attaining a more liberal threshold, such as p ≤ 0.5) with the 
hope that this might improve the amount of variance accounted for. Two strategies employed 
in the analysis of marginally associated variants are polygenic analysis and pathway analysis. 
 
Purcell et al. (2009) have used a polygenic approach in the analysis of schizophrenia GWAS 
data. SNPs with p-values falling below a significance threshold (e.g. p ≤ 0.1 or p ≤ 0.5) in a 
discovery sample comprising schizophrenic patients and controls were used to calculate 
polygenic scores for each individual in a target sample, which also included schizophrenic 
patients and controls. To assess whether the polygenic score reflected schizophrenia risk, 
Purcell et al. (2009) assessed whether the cases in the target sample had a higher mean score 
than controls. Score alleles identified in the discovery sample were found to be significantly 
enriched amongst cases in the target sample, although they only explained around 3% of the 
variance. As the set of variants contributing to the polygenic score was likely to contain 
several false positives, Purcell et al. (2009) hypothesised that the amount of variation 
explained if only the true risk alleles were considered would be higher than 3%. To estimate 
the percentage of the variation explained by the true risk alleles a series of simulations were 
performed. These converged on an estimate of 34%; however, to reach this figure, 
assumptions were made about the genetic architecture of schizophrenia (such as the 
existence of a liability threshold), that may render the estimate invalid. Nevertheless, Purcell 
et al.’s (2009) demonstration that relaxing the significance threshold for the inclusion of 
SNPs in the polygene score resulted in an increase in the enrichment of score alleles in the 
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target sample cases suggests that the study of marginally significant p-values may yield 
useful insights. 
 
The rationale behind pathway analysis of marginally associated variants is that by taking into 
account prior knowledge about the way genes operate in a biological context, the 
identification of true risk variants can be facilitated, even when these variants fail to attain 
genome-wide significance in single-marker tests of association (Wang et al., 2011a). Jia et 
al. (2010) applied pathway analysis to a schizophrenia case-control GWAS dataset and 
identified several pathways, including glutamate metabolism and the TGF-beta signalling 
pathway, as being overrepresented. Highlighting the potential for this approach to 
complement traditional GWAS analysis, several genes in the significantly overrepresented 
pathways had not been implicated by single-marker tests of association. By identifying 
biological pathways containing multiple implicated genes, this approach has the potential to 
offer insight, and thus generate testable hypotheses, regarding genetic interactions that may 
play an important role in disease pathogenesis. 
 
The extent to which strategies designed to reveal the “hidden heritability” present in GWAS 
data will account for missing heritability in the context of psychiatric genetics remains to be 
seen. In light of the uncertainty surrounding the underlying genetic architecture of 
psychiatric conditions, discussed in section 1.5, it is, however, a viable prospect that the 
missing heritability problems stems, at least in part, from a mismatch between the type of 
variants best detected by GWAS and the nature of the risk variants involved in psychiatric 
illness. 
 
The design and interpretation of GWASs has traditionally been predicated on the CDCV 
hypothesis. The majority of variants detected by GWAS chips are common variants (e.g., the 
Omni family of microarrays from Illumina can detect variants with minor allele frequencies 
greater than 2.5-5%, depending on the specific array; 
http://www.illumina.com/documents/products/brochures/brochure_omni_microarrays.pdf)  
and, while the genotyped SNPs are not themselves expected to be causal, association to a 
given marker has generally been interpreted as a reflection of the actions of another as-of-yet 
unidentified common variant with which the marker is in LD with. This line of reasoning has 
led some to interpret the results emerging from GWASs as supporting a polygenic CDCV 
genetic architecture (Purcell et al., 2009). Under this model, the failure of GWASs to 
account for anything more than a small proportion of the total heritable component of a 
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given disorder might be attributable to action of many common variants each conferring an 
increase in risk so infinitesimally small that they are not detectable using currently studied 
sample sizes. While this explanation receives some support from the analysis of marginally 
significant variants discussed above, a strong case has been made for the reconsideration of 
the involvement of rare variants (Dickson et al., 2010; Goldstein, 2009; Mitchell, 2012). 
 
One possibility is that, due to the imperfect LD between the genotyped variant and the causal 
variant, the effect size of the causal variant is underestimated. Rare variants, which are likely 
to have evolved on a particular haplotype background, but, which, by definition will only co-
occur with the genotyped variant in a small number of individuals, are likely to be most 
affected. Moreover, as rare variants may have developed on multiple haplotypes at any given 
locus, it is possible that their effects will cancel out when assessed in a large sample 
genotyped only for common variants. Furthermore, as a given rare variant is only likely to 
play a causal role in a very small number of cases within a sample, even though within these 
cases it may account for a large proportion of the genetic component of the disease, at the 
level of the whole sample, its estimated effect size will be diluted. 
 
The issue of phenotypic heterogeneity is highly pertinent to the study of psychiatric disorders 
and has consequences for the interpretation of the missing heritability problem. The 
diagnostic categories of schizophrenia and bipolar disorder are broad (even when 
considering bipolar disorder 1 and 2 separately) and can result in patients diagnosed with the 
same disorder sharing few symptoms. In light of this phenotypic heterogeneity there is no 
reason to assume that schizophrenia or bipolar disorder represent unitary conditions in terms 
of their underlying aetiology. If schizophrenia and bipolar disorder are not unitary 
conditions, association analysis of cases selected purely by diagnostic status will produce 
results that are meaningless. A valid assessment of the extent of the missing heritability 
problem can only be made in the absence of the confounding effect of phenotypic 
heterogeneity; as such, it appears likely that the extent of the missing heritability problem for 
psychiatric conditions remains unknown. Moreover, the issue of phenotypic heterogeneity is 
relevant to arguments regarding the likely contribution of rare and common variants: if 
conditions such as schizophrenia comprise a sub-set of conditions that are individually rare, 
the theoretical basis of the CDCV hypothesis is thrown into question. 
 
It is important to note that rare and common variants do not represent mutually exclusive 
mechanisms for genetic susceptibility. Indeed, as mentioned in section 1.4, it seems probable 
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that genetic background will play an important role in determining the effect of a given 
mutation. It has been suggested that genetic background may act in a polygenic fashion to 
modify the expressivity of rare variants (Mitchell and Porteous, 2011). As such, certain 
genetic backgrounds might render an individual less capable of overcoming the deleterious 
effects of a rare mutation than others. Under this model, some associated variants may 
represent modifiers of disease risk rather than directly causal variants.  
 
As more genetic linkage and association studies for schizophrenia and bipolar disorder have 
been performed it has become increasingly apparent that efforts to detect causal variants are 
hampered by a lack of understanding of what kind of variants should be sought. Ultimately, 
if an unbiased exploration of the genetic basis of schizophrenia and bipolar disorder is to be 
achieved, it is likely that re-sequencing of large numbers of affected individuals will be 
necessary. Moreover to uncover the full-spectrum of regulatory and structural variants, 
whole genome-sequencing, rather than exome sequencing must be performed. 
 
1.6.3 Cytogenetic studies 
 
The detection of chromosomal abnormalities, such as translocations, deletions, or inversions, 
using cytogenetic methods has proven to be a useful approach in the search for genes 
involved in schizophrenia and bipolar disorder. One advantage to this approach is that, in 
contrast to association and linkage studies, cytogenetic methods permit the location of the 
variant to be accurately identified. Perhaps the best known gene implicated in the 
pathogenesis of psychiatric illness by a gross cytogenetic abnormality is the DISC1 gene. 
DISC1 was detected by virtue of its presence at the breakpoint of a balanced translocation, 
which segregates with various psychiatric diagnoses including schizophrenia, bipolar 
disorder, and major depressive disorder, in a large family (St Clair et al., 1990; Millar et al., 
2000). The contribution of variation in the DISC1 gene to psychiatric illness will be 
discussed further in section 1.7.4.2.2. Other candidate genes for schizophrenia and/or bipolar 
disorder implicated by their disruption by a chromosomal abnormality include ABCA13 
(encoding ATP-binding cassette subfamily A member 13) (Knight et al., 2009), GRIK4 
(encoding glutamate receptor, ionotropic, kainite 4) (Pickard et al., 2006), NPAS3 (encoding 
neuronal PAS domain protein 3) (Kamnasaran et al., 2003; Pickard et al., 2005), and PDE4B 
(encoding phophodiesterase 4B) (Millar et al., 2005). The discovery that cytogenetic lesions 
in several genes appear to play a causal role in schizophrenia and bipolar disorder supports 
the role of rare variants in these conditions (Mitchell and Porteous, 2011).  
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1.7 Dysregulation of gene expression as a pathogenic mechanism for 
psychiatric illness 
 
The role of altered gene expression in the pathogenesis of psychiatric illness is an area that 
has received increasing attention in recent years. In part, this interest has been fuelled by the 
relative paucity of risk variants with an effect on the encoded protein uncovered by 
approaches such as association and linkage analysis (Bray, 2008) and the fact that many of 
the most significant associations detected by GWAS are to variants located in non-coding 
regions (Duan et al., 2010). While it is possible that some non-coding and synonymous 
variants are in linkage disequilibrium with variants affecting the encoded protein, it is likely 
that at least some variants will confer risk via an effect on gene expression. Such variants 
might have an effect at the RNA level by altering transcription, stability or splicing or at the 
protein level via an effect on translation or stability; the ultimate outcome for any such 
variant would be to alter the level of the encoded protein. In relation to the rare vs. common 
variant hypotheses of the genetic architecture of psychiatric illness, one possible contribution 
of regulatory variants to disease pathogenesis might be in determining the degree to which a 
deleterious gene product is expressed. 
 
1.7.1 Evidence for gene expression abnormalities in schizophrenia and 
bipolar disorder 
 
Studies of gene expression in patients with schizophrenia have identified changes at multiple 
loci involved in processes such as synaptic function (Maycox et al., 2009; Mirnics et al., 
2000; Vawter et al., 2006), mitochondrial and metabolic function (Altar et al., 2005; 
Prabakaran et al., 2004), myelination (Hakak et al., 2001; Sugai et al., 2004; Tkachev et al., 
2003) and inflammation (Saetre et al., 2007). There is also evidence of altered gene 
expression in bipolar disorder, with aberrantly expressed genes contributing to pathways that 
overlap with those identified for schizophrenia. These include synaptic function (Cruceanu et 
al., 2012; Lopez de Lara et al., 2010; Ryan et al., 2006) and mitochondrial function (Lopez 
de Lara et al., 2010). Moreover, gene expression studies support the idea that there are 
pathogenic mechanisms common to schizophrenia and bipolar disorder: several genes have 
been found to be dysregulated in both conditions (Shao et al., 2008; Thomsen et al., 2011), 
and a study by Pedrosa et al. (2010) in which chromatin immunoprecipitation followed by 
microarray analysis (ChIP-chip) was performed to identify the transcriptional targets of β-
catenin identified several genes with known involvement in schizophrenia and bipolar 
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disorder. Additionally, the discovery that glutamate receptor expression is abnormal in both 
bipolar disorder and schizophrenia (Beneyto et al., 2007; Woo et al., 2007; Woo et al., 2004) 
supports the role of glutamatergic dysfunction, a well-established pathophysiological 
mechanism for schizophrenia (Kantrowitz and Javitt, 2012), in the aetiology of bipolar 
disorder. As these studies did not select patients on the basis of genotype, it is likely that they 
reflect the combined influence of cis- and trans-acting effects, including environmental 
influences, converging on common molecular pathways. 
 
Several well supported candidate genes for schizophrenia have been found to show 
dysregulated expression in at least some samples. These include DTNBP1 (Talbot et al., 
2004; Tang et al., 2009; Weickert et al., 2008; Weickert et al., 2004), G72 (DAOA) 
(Korostishevsky et al., 2004), RGS4 (Bowden et al., 2007; Erdely et al., 2006; Mirnics et al., 
2001), NRG1 (Hashimoto et al., 2004; Law et al., 2006; Nicodemus et al., 2009) and DISC1 
(Maeda et al., 2006; Nakata et al., 2009; Sawamura et al., 2005). The evidence implicating 
altered NRG1 and DISC1 expression in psychiatric illness will be discussed further in 
sections 1.7.4.1.5 and 1.7.4.2.5.  
 
In addition to the evidence implicating dysregulated gene expression in the pathogenesis of 
schizophrenia and bipolar disorder, a study by Mar et al. (2011) highlights another manner in 
which abnormalities in gene expression might manifest. Using neural stem cells derived 
from patients with schizophrenia, Mar et al. (2011) performed genome-wide transcriptional 
profiling and assessed variance in gene expression. Compared to control subjects, patients 
with schizophrenia showed a marked reduction in gene expression variance, suggesting that 
gene regulation is more tightly constrained. Mar et al. (2011) suggest that overly constrained 
biological pathways would be less able to adapt to environmental stressors and, therefore, 
might precipitate a pathological state. Although replication of these findings would be 
necessary in order to draw firm conclusions, it seems that the study of gene expression 
variance might yield clues into the aetiology of psychiatric illness that would be missed by 
the traditional approach of simply studying differences in mean expression levels.  
 
1.7.2 Genetic mechanisms contributing to dysregulated gene expression in 
psychiatric illness 
 
As suggested above, there are several mechanisms by which abnormalities in gene 
expression might occur. Changes in gene expression can be brought about by the actions of 
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cis-acting regulatory variants located in the transcribed sequence, promoter region, or in 
distal regulatory elements located on the same chromosome, variation in trans-acting factors, 
such as proteins involved in transcriptional regulation or protein degradation, and copy 
number variation.  
 
1.7.2.1 Cis- and trans-acting factors 
 
Evidence for the role of cis-acting variants has come from studies in which disease-
associated polymorphisms located in, or in linkage disequilibrium with, regulatory regions 
have been shown to be associated with gene expression level. Several variants in the NRG1 
gene have been shown to be associated with both schizophrenia and either endogenous gene 
expression level or transcriptional activity using the in vitro luciferase reporter assay (Law et 
al., 2006; Nicodemus et al., 2009; Pedrosa et al., 2009; Tan et al., 2007). Likewise, a 
schizophrenia-associated variant in the promoter region of the alpha7 neuronal nicotinic 
acetylcholine receptor subunit gene (CHRNA7) has been shown to result in decreased 
promoter activity in the luciferase reporter assay (Leonard et al., 2002). 
 
If alterations in gene expression level mediated by cis-acting regulatory variants contribute 
to the pathogenesis of psychiatric illness, then there is no reason why changes in gene 
expression resulting from trans-acting factors should not also play a role. Using the 
expression level of the schizophrenia susceptibility gene DTNBP1 as a quantitative trait, 
(Bray et al., 2008) performed genome-wide linkage analysis to detect genes involved in the 
regulation of DTNBP1 expression, which might, therefore, also contribute to disease 
susceptibility. This approach highlighted the role of both cis- and trans-acting factors in the 
regulation of DTNBP1 expression. Intriguingly, a linkage peak was observed in a region of 
chromosome 8p that encompasses NRG1, highlighting the possibility of a functional link 
between the two genes.  
 
One trans-acting regulatory mechanism that has been the focus of increasing attention in 
recent years is microRNA (miRNA) mediated regulation. miRNAs are short (~22 
nucleotide) single-stranded DNA molecules that mediate post-transcriptional regulation of 
gene expression by binding to partially complementary binding sites located at the 3’ ends of 
mRNAs. In the vast majority of cases miRNA-mediated regulation results in repression of 
gene expression; however, there have been reports of miRNA-mediated increases in gene 
expression via upregulation of translation under some circumstances (Vasudevan et al., 
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2007). miRNAs repress gene expression by two predominant mechanisms: destabilising the 
mRNA transcript or blocking translation initiation (Huntzinger and Izaurralde, 2011). 
miRNAs biogenesis involves several steps. In animals, miRNAs are initially transcribed as 
long primary miRNAs, which are then cut into hairpin-shaped pre-miRNAs of ~70 
nucleotides by the nuclear RNase III Drosha (Lee et al., 2003). The pre-miRNA is exported 
out of the nucleus and cleaved by the cytoplasmic RNase III Dicer to form ~22 nucleotide 
miRNA duplexes (Bernstein et al., 2001). One strand of the duplex is then usually degraded 
and the remaining strand becomes the mature miRNA; although, in some cases, both strands 
are expressed at a high level (Guo and Lu, 2010). 
 
There is now substantial evidence for the aberrant expression of miRNAs in both 
schizophrenia and bipolar disorder (Beveridge and Cairns, 2012; Forero et al., 2010). Genes 
encoding proteins involved in miRNA biogenesis, including Drosha and Dicer, have also 
been found to show increased mRNA expression in schizophrenia (Beveridge and Cairns, 
2012). Furthermore, in a recent genome-wide association study, a variant within the primary 
transcript of miR-137 was identified as being associated with schizophrenia and four other 
variants attaining genome-wide significance were located in genes identified as predicted 
targets of miR-137 (Ripke et al., 2011). These genes have subsequently been confirmed, in 
vitro, as miR-137 targets (Kwon et al., 2011). miRNAs have been shown to play an 
important role in brain development and in structural plasticity (Forero et al., 2010), 
processes that, when disrupted, are known to contribute to the pathogenesis of schizophrenia 
(Harrison and Weinberger, 2005). Several miRNAs found to be disregulated in 
schizophrenia are known to regulate genes that have been implicated in the disorder, either 
by association of variants or gene expression analysis (Beveridge et al., 2010; Miller et al., 
2012). One such example is miR-195, which shows increased expression in the brains of 
patients with schizophrenia (Beveridge et al., 2010), and has been found to regulate several 
genes relevant to schizophrenia, including BDNF (Mellios et al., 2008), RELN (Beveridge et 
al., 2010), and GRIN3 (Beveridge et al., 2010). Interestingly, miRNAs have shown some 
promise as peripheral blood biomarkers: Lai et al. (2011) identified a seven-marker miRNA 
peripheral blood expression signature that could differentiate between patients with 
schizophrenia and controls with an area under the curve of receiver operating characteristics 
of 93%.  
 
The potential pathogenic role of epigenetically mediated regulation of gene expression has 
already been alluded to in the context of monozygotic twins who are discordant for 
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psychiatric illness (section 1.3). Several studies have detected differences in epigenetic 
modifications in patients with schizophrenia or bipolar disorder; however, there are 
inconsistencies between individual studies (Gavin and Akbarian, 2012). DNA methylation of 
CpG islands within promoter regions is generally thought to mediate transcriptional 
inhibition (Klose and Bird, 2006). Increases in the expression of enzymes required for DNA 
methylation have been detected in the post-mortem brains of patients with schizophrenia 
(Guidotti et al., 2007; Veldic et al., 2004; Veldic et al., 2005), suggesting decreased gene 
expression via increased methylation as a pathogenic mechanism. The expression of both 
RELN and GAD67, genes expressed from CpG-island containing promoters, has been 
consistently found to be down-regulated in the post-mortem brains of patients with 
schizophrenia (Akbarian et al., 1995; Fatemi et al., 2005; Guidotti et al., 2000; Hashimoto et 
al., 2008), and both genes have also been shown to be down-regulated in the post-mortem 
brains of patients with bipolar disorder (Guidotti et al., 2000). In the post-mortem brains of 
patients with schizophrenia increased methylation of the RELN promoter has been reported 
(Abdolmaleky et al., 2005; Grayson et al., 2005) and GAD-67 expression has been found to 
correlate negatively with levels of the DNA methyltransferase DNMT1 (Veldic et al., 2005). 
Findings regarding the hypermethylation of the RELN promoter in schizophrenia have not 
been unanimous (Mill et al., 2008; Tochigi et al., 2008); however, such between-study 
variation is not surprising when considering an aetiologically heterogeneous disorder. 
 
In addition to DNA methylation, epigenetic regulation of gene expression can occur via 
modification of histone proteins. DNA is organised into chromatin by wrapping around 
octamers of histone proteins to form nucleosomes. Covalent posttranslational modifications 
of histone proteins, such as acetylation, methylation, or phosphorylation, alter chromatin 
structure or function by changing the charge of the nucleosome and/or affecting the 
recruitment of non-histone proteins (Kouzarides, 2007). These modifications alter the 
interaction of the DNA sequence with molecules involved in transcription and, therefore, 
regulate gene expression (Berger, 2007). Histone acetylation promotes an open chromatin 
structure, which is accessible to the transcriptional machinery (Gorisch et al., 2005). The 
level of histone acetylation is maintained by the opposing actions of histone acetyltransferase 
(HAT) and histone deacetyltransferase (HDAC) enzymes (Bannister and Kouzarides, 2011). 
 
In schizophrenia post-mortem brain samples, HDAC1 levels have been found to be elevated 
(Benes et al., 2008; Sharma et al., 2008), with HDAC1 level correlating negatively with 
GAD67 expression (Sharma et al., 2008). In keeping with these findings, reduced levels of 
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acetylated histone 3 have been detected in the peripheral blood mononuclear cells of patients 
with schizophrenia (Gavin et al., 2008). In contrast to acetylation, dimethylation of lysine 9 
on histone 3 is a repressive histone mark. Levels of this mark have been found to be 
increased in patients with schizophrenia (Gavin et al., 2009). Based on these findings, it has 
been suggested that schizophrenia is characterised by a restrictive chromatin state, which 
results in reduced transcription and expression of certain genes (Gavin et al., 2009). 
 
The role of aberrant epigenetic modification in bipolar disorder has been less well studied; 
however, a genome-wide epigenomic screen of patients with bipolar disorder and 
schizophrenia identified several loci showing altered methylation, some of which were 
common to both conditions (Mill et al., 2008). Altered expression of HDACs has also been 
reported in bipolar disorder (Hobara et al., 2010). Interestingly, the action of the mood 
stabilising drug valproate has been linked to HDAC inhibition (Phiel et al., 2001). Moreover, 
in a mouse model of hypermethylation, the antipsychotics clozapine and sulpiride have been 
found to demethylate hypermethylated RELN and GAD67 promoters, with the action of both 
drugs being potentiated by valproate (Dong et al., 2008). These findings support the 
hypothesis that altered epigenetic regulation of gene expression might contribute to the 
pathogenesis of schizophrenia and bipolar disorder; however, they also highlight the 
importance of considering treatment effects when studying gene expression in medicated 
patients. 
 
1.7.2.2 Copy number variation 
 
In 2004, two studies demonstrated that submicroscopic (< 500kb) variations in DNA in copy 
number (CNVs) are common in normal human genomes (Iafrate et al., 2004; Sebat et al., 
2004). Studies in rodents have shown that gene dosage differences resulting from CNVs 
show a weak but significant positive correlation with gene expression (Guryev et al., 2008; 
Henrichsen et al., 2009). Furthermore, differences in gene expression have been identified in 
genomic regions in the vicinity of CNVs: Stranger et al. (2007) found that while CNVs 
account for 18% of the variation in gene expression in human lymphoblastoid cell lines, 
more than half of the associations involved genes mapping outside of CNVs.  This suggests 
that some gene expression changes associated with CNVs will result from disruption of cis- 
or trans-regulatory regions and/or alterations to the chromatin structure. 
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Accumulating evidence implicates rare CNVs in the pathogenesis of both schizophrenia and 
bipolar disorder (Malhotra and Sebat, 2012). Association studies have repeatedly identified 
an enrichment of CNVs in cases compared to controls (Buizer-Voskamp et al., 2011; ISC, 
2008; Kirov et al., 2009; Walsh et al., 2008). Family studies have highlighted a high 
prevalence of de novo CNVs in schizophrenia; however, their contribution to sporadic 
compared to familial cases requires further clarification (Kirov et al., 2012; Malhotra et al., 
2011; Xu et al., 2008). The genes affected by CNVs in patients have been found to 
contribute to functions known to be abnormal in schizophrenia, such as neurodevelopment 
and synaptic activity (Walsh et al., 2008; Malhotra et al., 2011). 
 
In bipolar disorder, findings from association studies looking at the incidence of CNVs have 
been equivocal: two studies have reported an increased burden of CNVs in cases compared 
to controls (Priebe et al., 2011; Zhang et al., 2009), whilst two other studies failed to find any 
evidence for the involvement of CNVs (Grozeva et al., 2010; McQuillin et al., 2011), 
although McQuillin et al. (2011) do report the discovery of some rare CNVs found to occur 
only in cases. In common with schizophrenia, de novo CNVs appear to occur more 
frequently amongst patients with bipolar disorder, although, they have not been associated 
with sporadic incidences of the condition, as might be hypothesised (Malhotra et al., 2011). 
There is some evidence to suggest that de novo (Malhotra et al., 2011) and inherited CNVs 
(Zhang et al., 2009a; Priebe et al., 2012) might promote an earlier age of onset; however, 
evidence for the involvement of inherited CNVs in age of onset has not been replicated in 
some studies (Grozeva et al., 2010; McQuillin et al., 2011).  
 
1.7.3 Issues surrounding the assessment of gene expression in psychiatric 
illness 
 
The most fundamental issue surrounding the study of the contribution of gene expression to 
the pathogenesis of psychiatric illness is the ability to measure gene expression in a 
biologically relevant tissue. Clearly, when studying disorders such as bipolar disorder or 
schizophrenia, the tissue of choice would be the brain; however, for obvious reasons 
obtaining brain tissue from sufficient numbers of cases and controls is often impossible. 
Moreover, the use of post-mortem brain tissue is affected by several potential confounds that 
can be difficult to control for given the naturalistic nature of post-mortem studies. One such 
confound is the cause of death and the related issue of the state of the subject immediately 
prior to death. A reduction in brain pH has been observed following a prolonged agonal state 
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(Harrison and Kleinman, 2000) and altered brain pH has been shown to affect post-mortem 
gene expression levels (Harrison et al., 1995; Mexal et al., 2006; Tomita et al., 2004; Vawter 
et al., 2006). Time and season of death are also likely to affect gene expression and should 
be considered when using post-mortem brain tissue (Lewis, 2002). The evidence for the 
effect of post-mortem interval (PMI; the time between death and freezing of the tissue) on 
gene expression is not conclusive: some studies have detected an effect on gene expression 
(Birdsill et al., 2011), although this effect appears to be far less widespread than that of brain 
pH (Harrison et al., 1995); others have failed to detect a correlation between PMI and gene 
expression (Tomita et al., 2004).  
 
Several studies have investigated the validity of using peripheral tissues, such as the blood, 
as a proxy for ascertaining gene expression in the brain. Sullivan et al. (2006) compared the 
expression levels of around 33,000 genes in the blood and the central nervous system and 
found a moderate positive correlation of 0.5 between the two. In a study that assessed a 
larger sample for the expression of a smaller number of genes in the blood and three brain 
regions, small but significant correlations were observed between expression levels in the 
blood and the brain(r = 0.24-0.32); however, it should be noted that different platforms were 
used to measure blood and brain expression, potentially reducing the correlation between the 
tissue types (Cai et al., 2010). Moreover, when genes were considered as co-expression 
modules, 67% of genes in the cortex were part of a conserved gene expression module. 
Analysis of miRNA expression provides further support for the use of the blood as a 
surrogate for brain tissue in studies of gene expression: Liang et al. (2007) performed cluster 
analysis to assess miRNA co-expression in several different tissues and found the brain and 
peripheral blood mononuclear cells (together with thymus, adrenal gland, and testes) to form 
a unique cluster. Clearly, blood gene expression levels must be interpreted with caution 
when extrapolating to the brain. In support of the use of blood expression levels in the 
context of psychiatric illness, it is interesting to note that some schizophrenia-associated 
expression changes observed in the brain have been recapitulated in the blood (Glatt et al., 
2005). Additionally, in patients with bipolar disorder or schizophrenia, BDNF has been 
found to show reduced expression in the hippocampus and prefrontal cortex (Thompson Ray 
et al., 2011; Weickert et al., 2003) and reduced serum expression, even in antipsychotic-
naive schizophrenia patients (Grillo et al., 2007; Jindal et al., 2010). Further investigation of 
the comparability of blood and brain gene expression, ideally using a within-subject design, 
would be beneficial, as would further assessment of the effects of antipsychotics and mood-
stabilising drugs on the relationship between blood- and brain-based gene expression. 
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1.7.4 NRG1 and DISC1: two leading candidate genes for psychiatric illness 
susceptibility 
 
As the work carried out in this thesis centres around NRG1 and DISC1, two of the best-
supported candidate genes for schizophrenia, which have also both been implicated in 




1.7.4.1.1 The NRG1 gene and its isoforms 
 
The NRG1 gene is located at chromosome 8p12-8p21. It is a large (~1.3Mb) gene, 
containing several transcription start sites and alternative splice sites that give rise to at least 
31 isoforms (Mei and Xiong, 2008). All isoforms contain a core epidermal growth factor 
(EGF)-like domain (EGFc); however further sources of variability give rise to the distinct 
isoforms. These isoforms are classified into six types based on their 5’ exon usage (Falls, 
2003; Harrison and Law, 2006) (figure 1.1).  Types IV-VI were identified more recently than 
types I-III (Steinthorsdottir et al., 2004) and less is known about their biological functions. 
Isoform-specific variation results from alternative splicing, resulting in different types of 
EGF domain: differential exon retention results in either EGFα or EGFβ, with the β variant 
predominating in the brain and being a more potent receptor activator than the α variant. 
After the EGF domain, most NRG1 isoforms contain a C-terminal transmembrane domain 
(TMc), which is sometimes preceded by a type 1 or type 4 stalk but can occur without a stalk 
(TMc-containing isoforms without a stalk are known as “2” isoforms). Some NRG1 isoforms 
contain a type 3 stalk: these isoforms are truncated prior to the TMc domain and are 
synthesised as soluble isoforms. All TMc-containing isoforms contain a carboxy-terminal 
region, which can take three forms (a, b, or c) depending on exon usage. NRG1 types I, II, 
IV, and V contain an immunoglobulin (Ig) domain and are sometimes referred to as Ig-
NRG1s; NRG1 type III contains a cysteine rich domain (CRD), and is sometimes referred to 
as CRD-NRG1.The CRD domain contains an additional N-terminal transmembrane domain 
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1.7.4.1.2 NRG1 processing and signalling 
 
NRG1 proteins interact with ErbB receptor tyrosine kinases, binding to ErbB3 and ErbB4 
receptors via the EGF-like domain. NRG1 binding of ErbB receptors promotes ErbB 
dimerisation and autophosphorylation of tyrosine residues within the cytoplasmic domain of 
the receptor. This creates docking sites for various proteins, such as Grb2, Shc, and the 
regulatory subunit of phosphoinositide-3-kinase (PI3-kinase), that are involved in the 
activation of downstream signalling pathways. NRG1-ErbB4 signalling serves to mediate a 
variety of functions, including cell proliferation, migration, differentiation, adhesion, and 
apoptosis  (Yarden and Sliwkowski, 2001). In the nervous system, NRG1 signalling has been 
implicated in synaptic formation, transmission, and plasticity (Mei and Xiong, 2008). Taken 
together, the cellular functions in which NRG1 is involved render NRG1 a strong functional 




EGF-like Stalk Cytoplasmic tail 
Figure 1.1. Types of Neuregulin 1 (NRG1). NRG1 isoforms can be classified into six types (I-
VI) based on alternative 5’ exon usage (type-specific sequences). Variation also arises from the 
existence of multiple epidermal growth factor (EGF)-like domain types, the type of stalk (1, 2, 
3,or 4) preceding the C-terminal transmembrane domain (TMc), and alternative splicing of the C-
terminal domain (a, b, and c). Types I, II, IV, and V have an immunoglobulin (Ig)-like domain 
between the N-terminal domain and the EGF domain. Some isoforms additionally contain a 
spacer (S) domain. All NRG1 types contain the core EGF domain (EGFc), with alternative exon 
retention resulting in the inclusion of α, β and γ variants. Type III NRG1 has a cysteine rich 
domain (CRD) in its N-terminal region, which includes an additional transmembrane domain 
(TMn). * indicates a stop codon. Adapted from Mei and Xiong, 2008. 
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With the exception of the glial growth factor isoform (GGF2), which is synthesised as a 
soluble fragment, NRG1 isoforms are synthesised as transmembrane proteins. The Ig-
NRG1s are single-pass transmembrane proteins that undergo activity-dependent proteolytic 
cleavage between the EGF and TMc domains to release a soluble N-terminal fragment, 
which contains the EGF and Ig domains (Harrison and Law, 2006). The soluble N-terminal 
fragment activates ErbB receptors via both paracrine and autocrine signalling (Falls et al., 
2003). 
 
In contrast to the Ig-NRG1s, type III NRG1 (CRD-NRG1) contain two transmembrane 
domains, and are thus synthesised as two-pass transmembrane proteins. Proteolytic cleavage 
of type III NRG1s creates a transmembrane N-terminal fragment (Wang et al., 2001). This 
fragment engages with ErbB receptors in a juxtacrine fashion, a process which is required for 
the regulation of the myelination of axons in the peripheral nervous system by Schwann cells 
(Taveggia et al., 2005). In addition to participating in canonical forward signalling, the 
interaction of type III NRG1 with ErbB receptors also elicits back signalling: the 
intracellular domain of NRG1 is released following proteolysis and translocates to the 
nucleus where it regulates gene expression, including the repression of pro-apoptotic genes 
(Bao et al., 2003). Neuronal depolarisation can also stimulate NRG1 back signalling (Bao et 
al., 2003). In addition to its effects on cell survival, NRG1 back signalling has been shown to 
regulate the expression of postsynaptic density protein-95 (PSD-95; Bao et al., 2004) and α7 
nicotinic acetylcholine receptors (nAChRs) via activation of the PI3K pathway (Hancock et 
al., 2008; Zhong et al., 2008), and regulate axon pathfinding of sensory neurons (Hancock et 
al., 2011). 
 
1.7.4.1.3 NRG1 as a functional candidate for schizophrenia and bipolar disorder 
 
Many of the known functions of NRG1 mirror functions known to be abnormal in 
schizophrenia and bipolar disorder. As might be expected for a gene with so many isoforms, 
the functions of NRG1 are diverse and are essential for the normal functioning of many 
organs including the brain. The necessity of NRG1 for normal development was revealed by 
the discovery that pan-Nrg1 knockout (KO) mice (binding of all Nrg1 isoforms with ErbB 
receptors was prohibited by disruption of the EGF-like domain) die at embryonic day (E) 
10.5 due to a defect in cardiogenesis (Meyer and Birchmeier, 1995). Here, those functions of 
NRG1 relevant to our understanding of the pathophysiology of schizophrenia and bipolar 
disorder will be considered. 
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As mentioned in section 1.4, white matter abnormalities, which may be caused by aberrant 
myelination and/or neuronal migration, are a well-established finding in the brains of 
schizophrenic and bipolar disorder patients. NRG1 signalling through ErbB receptors has 
been implicated in both processes. In the CNS, axon myelination is performed by 
oligodendrocytes. NRG1 has been linked to many aspects of oligodendrocyte function, 
including proliferation, survival, maturation, and migration (Fernandez et al., 2000; Ortega et 
al., 2012; Sussman et al., 2005; Vartanian et al., 1999); however, it should be noted that 
normal myelination has been reported both in conditional null mutant mice that lack Nrg1 
expression in projection neurons from various developmental stages and mice lacking 
oligodendrial expression of ErbB3 and ErbB4, receptors necessary for Nrg1 signalling 
(Brinkmann et al., 2008). Nevertheless, a role for NRG1 signalling in CNS myelination, in 
humans at least, is suggested by imaging studies showing an association between NRG1 
variants previously associated with risk of psychosis and white matter density and integrity 
(McIntosh et al., 2008; Sprooten et al., 2009).  
 
NRG1 has been implicated in neuronal migration by the finding that NRG1-ERBB signalling 
promotes radial glia formation and facilitates the movement of neurons along radial glia, a 
process that is essential for normal cortical development (Anton et al., 1997; Rio et al., 
1997). Interestingly, in the context of the abnormalities in GABAergic interneurons observed 
in the brains of schizophrenic and bipolar disorder patients (see section 1.4.2), Nrg1 
signalling via ErbB4 receptors has recently been show to play a role in the guidance of 
migrating GABAergic interneurons from the ganglionic eminence to their cortical targets (Li 
et al., 2012). Sei et al. (2007) have demonstrated the potential involvement of aberrant 
NRG1 signalling in the neurodevelopmental abnormalities observed in the brains of 
schizophrenic patients: in an in vitro system, in which NRG1 is used to induce the migration 
of B lymphoblasts, cells from schizophrenic patients were found to show decreased NRG1-
induced migration. 
 
A role for Nrg1-ErbB4 signalling in axon guidance, another process key to 
neurodevelopment, has been demonstrated by López-Bendito et al. (2006). Following the 
tangential migration of a population of GABAergic interneurons from the lateral ganglionic 
eminence to the medial ganglionic eminence, a permissive corridor is created through which 
thalamocortical axons navigate through the telencephalon. The permissive nature of this 
corridor has been shown to rely, in part, on the interaction of CRD-Nrg1, expressed by cells 
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lining the corridor, and diffusible Ig-Nrg1, released from the pallium, with ErbB4 receptors 
expressed by thalamic neurons. These two isoforms of Nrg1 appear to contribute to axon 
pathfinding and outgrowth, respectively. A subsequent study has shown CRD-Nrg1 to 
regulate the pathfinding of sensory neurons in both the spinal cord and periphery (Hancock 
et al., 2011). 
 
NRG1 has also been implicated in the regulation of several neurotransmitter systems that 
have been shown to function abnormally in schizophrenia and bipolar disorder. NRG1 
appears to play a key role in regulating neurotransmitter receptor expression: to date, there is 
evidence to suggest that NRG1 is involved in regulating the expression of NMDA, GABAA, 
and ACh receptors (Liu et al., 2001b; Okada and Corfas, 2004; Ozaki et al., 1997; Rieff et 
al., 1999). Furthering support for the notion that aberrant NRG1 signalling might contribute 
to the GABAergic deficits observed in schizophrenia and bipolar disorder, Abe et al. (2011) 
have demonstrated that Nrg1 regulates the expression and sensitivity of AMPA receptors in 
GABAergic interneurons, thus affecting their firing rate.  
 
Studies demonstrating the role of NRG1 in regulating synaptic plasticity extend support for 
NRG1’s functional candidacy. NRG1 has been shown to regulate LTP in the hippocampus 
(Kwon et al., 2008) and an impairment in LTP observed in heterozygous Nrg1 mutant mice 
can be rescued by exogenous Nrg1 (Bjarnadottir et al., 2007). 
 
1.7.4.1.4 Overview of genetic studies implicating variation in NRG1 in 
schizophrenia and bipolar disorder 
 
Several linkage studies have implicated the chromosomal locus, 8p21.1-22, where NRG1 is 
situated in schizophrenia, although support for the involvement of this region has not been 
unanimous (reviewed in Harrison and Law, 2006). However, as mentioned previously 
(section 1.6.1.1), the existence of a risk variant within the chromosome 8p region, at least in 
individuals of European ancestry, has been supported by a meta-analysis of 32 independent 
genome-wide linkage studies of schizophrenia (Ng et al., 2009).  
 
The first evidence for association of variants in NRG1 with schizophrenia came from a study 
carried out by (Stefansson et al., 2002), who identified a haplotype (HapICE) at the 5’ end of 
the gene that doubled the risk of schizophrenia. Subsequent studies have replicated this 
finding (Stefansson et al., 2003; Williams et al., 2003) and others have reported association 
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to other markers or haplotypes either nearby to or overlapping HapICE (Corvin et al., 2004; 
Georgieva et al., 2008; Hall et al., 2004; Kim et al., 2006; Lachman et al., 2006; Prata et al., 
2009; Tang et al., 2004; Thomson et al., 2007; Yang et al., 2003; Zhao et al., 2004). While 
the majority of association studies have focussed on markers at the 5’ end of the gene, others 
that have considered SNPs further downstream have reported association to 3’ haplotypes 
(Petryshen et al., 2005; Thomson et al., 2007; Yang et al., 2003). However, it should be 
noted that the evidence is not unequivocal, with some association studies failing to identify 
any risk variants within NRG1 (Ingason et al., 2006; Jonsson et al., 2009; Moon et al., 2011). 
Although the association of NRG1 variants with bipolar disorder has been less well studied, 
positive association findings suggest that certain NRG1 variants may also be risk factors for 
bipolar disorder (Green et al., 2005; Prata et al., 2009; Thomson et al., 2007). 
 
1.7.4.1.5 Evidence implicating altered NRG1 expression in the pathophysiology of 
schizophrenia and bipolar disorder 
 
As mentioned above (section 1.7.4.1.5), several association studies have been carried out 
implicating variation in NRG1 in the pathophysiology of schizophrenia and accumulating 
evidence suggests that NRG1 variants may also confer risk for bipolar disorder. The vast 
majority of the associated variants do not have an effect on the encoded protein, suggesting 
that they may confer risk via altered gene regulation. It is, of course, possible that some non-
coding variants are in linkage disequilibrium with coding variants; however, this is unlikely 
to always be the case. Indeed, NRG1 SNPs associated with schizophrenia have been shown 
to be associated with altered NRG1 expression (Law et al., 2006; Nicodemus et al., 2009). 
Moreover, some studies have detected increased levels of NRG1 in the brains of patients 
with schizophrenia (Hashimoto et al., 2004; Law et al., 2006), while Parlapani et al. (2010) 
found decreased expression of NRG1 type 1 but increased expression of NRG1 type 2 in the 
post-mortem brains of elderly schizophrenic patients. In a recent study, Marballi et al.(2012) 
assessed the expression of full-length NRG1 and NRG1 cleavage products in the post-
mortem brains of patients with schizophrenia or bipolar disorder. No differences were 
observed in the amount of full-length NRG1 in either group; however, an increase in the 
NRG1 N-terminal cleavage product was detected in the schizophrenic patients and the 
hippocampal expression of a 50kDa product was decreased in both groups. Consistent with 
the potential role of altered NRG1-ERBB signalling in schizophrenia, antipsychotics have 
been found to down-regulate NRG1-ERBB signalling (Pan et al., 2011).  
 
Chapter 1: Introduction 
  43 
 
1.7.4.1.6 Background to the NRG1 association study carried out in this thesis 
 
In this thesis, the analyses described in chapter 2 are based on a study carried out by 
Thomson et al. (2007). Here, Thomson et al.’s (2007) study will be described briefly to 
provide the background to the work presented in chapter 2. 
 
Thomson et al. (2007) analysed the association of haplotype-tagging SNPs across the entire 
NRG1 gene in a sample of patients with schizophrenia or bipolar disorder and healthy 
controls drawn from the Scottish population. Significant associations were detected to 
haplotypes in two regions (defined by linkage disequilibrium) of the NRG1 gene: region A, 
located at the 5’ end of the gene, which overlaps with the NRG1 promoter region and extends 
into the first intron, and region B, which spans a largely intronic region but also overlaps 
with the sensory and motor neuron-derived factor (SMDF) and heregulin alpha (HRGα) 
isoforms, and the 3’ exons of all other isoforms.  
 
Given the evidence presented in section 1.7.4.1.5 for the likely involvement of altered NRG1 
expression in schizophrenia, a plausible hypothesis is that the associated haplotypes 
identified by Thomson et al. (2007) reflect the involvement of regulatory variants.  In this 
thesis, an attempt will be made to replicate Thomson et al.’s (2007) findings for the two most 
significant haplotypes in regions A and B in two new case-control samples, comprising 
schizophrenic patients, bipolar disorder patients and healthy controls. It was hypothesised 
that this analysis might aid in the identification of a region containing regulatory variants 




1.7.4.2.1 Initial discovery of the DISC1 gene 
 
The DISC1 gene was first identified at the breakpoint of a balanced chromosomal 
translocation t(1;11) (q42.1;14.3) that segregates with psychiatric illness in a large Scottish 
family (StClair et al., 1990; Millar et al., 2000). Of the 87 family members assessed for the 
translocation, 37 were found to be carriers (Blackwood et al., 2001). In the most recent 
description of the family, 29 translocation carriers underwent psychiatric assessment and of 
these individuals, 18 were diagnosed with major mental illness (schizophrenia (7 cases), 
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bipolar disorder (1 case), or recurrent major depression (10 cases)) and an additional three 
individuals were diagnosed with anxiety, alcoholism, and minor depression, respectively. Of 
the thirty-eight non-carriers who underwent psychiatric assessment, none were diagnosed 
with a major psychiatric illness, whilst three were diagnosed with minor depression, one with 
alcoholism, and one with adolescent conduct disorder. Linkage analysis resulted in a 
logarithm of odds (LOD) score of 7.1 for the segregation of the translocation with the broad 
diagnosis of major mental illness, which included schizophrenia, bipolar disorder, and 
recurrent major depression, and a LOD score of 3.6 for the narrow diagnosis of 
schizophrenia (Blackwood et al., 2001). In addition to disrupting DISC1, the translocation 
disrupts a non-coding RNA gene located antisense to DISC1 called DISC2 (Millar et al., 
2000), and, transcripts resulting from a gene on chromosome 11, thought to be a non-coding 
RNA gene, have also been identified that would also be disrupted by the translocation (Zhou 
et al., 2008). Analysis of lymphoblastoid cell lines derived from carriers of the t(1;11) 
translocation has revealed that the translocation results in the formation of fusion transcripts, 
which, if expressed as proteins, have been demonstrated to have a deleterious effect on 
mitochondrial function (Eykelenboom et al., 2012).  
  
While not all carriers of the translocation were diagnosed with a psychiatric condition, there 
is evidence to suggest the existence of functional brain deficits even in diagnosis-free 
carriers. The P300 is an event related potential (ERP) thought to reflect the speed and 
efficiency of information processing. It is typically found to occur with reduced amplitude 
and increased latency in patients with schizophrenia (Bramon et al., 2004). Blackwood et al. 
(2001) found carriers of the translocation to have deficits in their P300 ERP characteristic of 
schizophrenia, with deficits existing in translocation carriers without any psychiatric 
diagnosis. While it should be noted that this study considered only 12 translocation carriers, 
of which only 3 were not diagnosed with a psychiatric condition, these results are consistent 
with other studies that have identified abnormal P300 ERPs in the relatives of patients with 
schizophrenia (Bramon et al., 2005). Moreover, Shaikh et al. (2011) have reported an 
association between DISC1 variants and P300 amplitude and latency in a sample that 
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1.7.4.2.2 Overview of genetic studies implicating variation in DISC1 in 
schizophrenia and bipolar disorder 
 
Following the identification of DISC1, genetic linkage and association studies have 
identified variation in DISC1 as playing a more general role in conferring risk for psychiatric 
illness. Positive association and linkage studies have provided further support for the role of 
variation in DISC1 in schizophrenia, bipolar disorder, and recurrent major depression, and 
extended the range of DISC1-associated conditions to include autism and Asperger’s 
syndrome (Bradshaw and Porteous, 2012; Chubb et al., 2008). Moreover, variation in DISC1 
has been associated with aspects of cognitive function, including cognitive ageing (Burdick 
et al., 2005; Carless et al., 2011; Palo et al., 2007; Thomson et al., 2005); these results are 
highly pertinent in the context of the cognitive deficits central to the schizophrenia 
phenotype (Barch and Ceaser, 2012). While the accumulating evidence presents a strong 
case for the pathogenic role of certain DISC1 variants, it is important to note that not all 
association studies have been positive (Arai et al., 2007; Devon et al., 2001; Hotta et al., 
2011; Kockelkorn et al., 2004; Sanders et al., 2008; Zhang et al., 2005). Genome-wide 
association studies (GWASs) have not identified significant association between variants 
within the DISC1 gene and schizophrenia (Athanasiu et al., 2010; Need et al., 2009; 
O'Donovan et al., 2008; Ripke et al., 2011; Sullivan et al., 2008), although Sullivan et al. 
(2008) identified several single nucleotide polymorphisms (SNPs) that showed a trend for 
association but did not remain significant after correction for multiple testing. GWAS 
findings from bipolar disorder samples echo those from schizophrenia: in the largest GWAS 
carried out for bipolar disorder to date, Sklar et al. (2011) did not detect association to any 
variants within the DISC1 gene. The failure to detect association to DISC1 by GWAS, 
however, does not negate the evidence supporting DISC1’s involvement in psychiatric 
illness arising from other methods: allelic heterogeneity may render DISC1 risk variants too 
individually rare to be detected by GWAS and phenotypic heterogeneity might make the 
grouping together of affected individuals as a unitary case group invalid. 
 
1.7.4.2.3 Structure of the DISC1 gene and the encoded protein 
 
In recent years it has become apparent that the DISC1 gene gives rise to a huge variety of 
transcripts through alternative splicing: Nakata et al. (Nakata et al., 2009) have identified 
more than 50 DISC1 splice variants in the brain, some of which arise from splicing to the 
upstream gene TSNAX. Excluding those transcripts that use the TSNAX transcription start 
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site (TSS), all of the DISC1 transcripts have been shown to share the same TSS. The gene 



















Understanding of the structure of encoded protein remains relatively poor. The full-length 
transcript encodes a protein 854 amino acids in length, which is believed to comprise an N-
terminal “head” domain and an alpha helical coiled-coil containing C-terminal tail (Chubb et 
al., 2008; Soares et al., 2011) (figure 1.2). Traditionally, the N-terminal head domain has 
been thought to be formed of, approximately, the first 350 amino acids, and the C-terminal 
coiled-coil domain to comprise amino acids ~350-854. The N-terminal head domain has 
often been referred to as “globular” (Chubb et al., 2008); however, a recent study by Soares 
et al. (2011) suggests that this region may be predominantly disorganised and suggests a 
revised definition of the N-terminal region such that it is considered to include amino acids 
1-326. The N-terminal domain shows little homology with known protein structures, 
containing only two recognisable motifs: a nuclear localisation signal (Ma et al., 2002) and 
serine-phenylalanine-rich motif (Taylor et al., 2003). The alpha helical coiled-coil C-
terminal domain, in contrast, shows greater conservation amongst orthologs (Millar et al., 
2000; Ma et al., 2002; Taylor et al., 2003). 
 
 
Figure 1.2.  Schematic of the DISC1 structure. The DISC1 secondary structure has been predicted 
to comprise a predominantly disordered N-terminal region and an alpha helical coiled-coil 
containing C-terminal tail (Chubb et al., 2008). The N-terminal head domain contains  only two 
conserved regions, which encode a nuclear localisation signal (NLS) and serine-phenylalanine- 
(SF) rich motif. Mapped secondary structure is indicated as follows: alpha helices are indicated in 
pink, coiled-coil helices are indicated in dark green, and ambiguous helices are indicated in light 
green. Yellow horizontal lines indicate predicted disordered regions. Known and putative 
phosphorylation sites are indicated by brown triangles and the location of the t(1;11) translocation 
breakpoint is indicated by a vertical dashed line. Numbers below the schematic indicate amino 
acid numbers and the thirteen exons encoding full-length DISC1 are shown above the schematic. 
Figure taken from Soares et al. (2011).  
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1.7.4.2.4 DISC1: interactors, functions, and their relationship to schizophrenia and 
bipolar disorder 
 
The discovery that DISC1 interacts with a large number of proteins has led to the idea that 
DISC1 acts as a molecular “hub” (Camargo et al., 2007). Understanding of the functions of 
DISC1 has, therefore, largely been shaped through the identification and investigation of its 
interactors. 
 
In 2007, Camargo et al. carried out a yeast two hybrid screen to identify interactors of 
DISC1. This resulted in the identification of 289 interactors, several of which were already 
known, in screens with the full-length protein. Analysis of the functions of the identified 
interactors revealed enrichment for proteins involved in synaptic function and 
dendritic/axonal morphology. Subsequent studies have confirmed several of the interactors 
identified by Camargo et al. (2007) and supported the idea that DISC1 plays a key role at the 
synapse and in neurodevelopment. 
 
Many of DISC1’s interactors are involved in microtubule function: DISC1 is known to 
interact with several microtubule-associated proteins, such as nuclear distribution protein 
nudE1 (NDE1), NDE-like 1 (NDEL1), lissencephaly protein 1 (LIS1), microtubule-
interacting protein associated with TRAF3 (MIPT3), microtubule-associated protein 1A 
(MAP1A), and dynactin (Brandon and Sawa, 2011). Further supporting DISC1’s role in 
microtubule function, DISC1 has been shown to localise to the centrosome, where 
microtubules are organised (Morris et al., 2003). A recent study demonstrated that the 
phosphorylation of DISC1 underlies the developmental switch from neuronal proliferation to 
neuronal migration (Ishizuka et al., 2011). Unphosphorylated DISC1 interacts with GSK3β 
to regulate the canonical Wnt signalling pathway, a process that supports the proliferation of 
mitotic progenitor cells. Upon phosphorylation at serine 710, DISC1 recruits Bardet-Biedl 
syndrome proteins to the centromere, a process required for migration. Thus, altered DISC1 
function could contribute to the cell migration abnormalities observed in schizophrenia and 
bipolar disorder via disruption of microtubule function. Consistent with notion, studies in 
animal models have revealed mutant versions of DISC1 to result in aberrant cell migration 
(Kamiya et al., 2005; Young-Pearse et al., 2010). Knockdown of Disc1 has also been 
reported to affect migration: knockdown of Disc1 in newly generated cells in the adult 
hippocampus has been shown to result in over-extended migration (Duan et al., 2007; 
Enomoto et al., 2009; Kim et al., 2009). Recently, Steinecke et al. (2012) showed, in mice, 
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that knockdown of Disc1 in the medial ganglionic eminence, either ex utero or in utero, 
resulted in a reduction in the number of interneurons that reached their target destinations. 
This finding highlights a mechanism by which altered DISC1 function might contribute to 
GABAergic interneuron abnormalities observed in schizophrenia and bipolar disorder. 
 
As well as the Disc1 knockdown-induced deficits in neuronal migration, abnormalities in 
neuronal morphology have also been reported following knockdown. Duan et al. (2007) 
found neurons expressing a short hairpin construct used to knockdown Disc1 expression to 
have enlarged soma and enhanced dendritic outgrowth. In migrating interneurons, Steinecke 
et al. (2012) found Disc1 knockdown to result in an increase in the length of the leading 
process and a reduced number of side branches. Further supporting a role for DISC1 in the 
regulation of cell morphology, mice carrying mutant versions of Disc1 in which point 
mutations have resulted in amino acid substitutions (L100P and Q31L) have been shown to 
have a decrease in dendritic length in the frontal cortex (Lee et al., 2011). These findings 
highlight the possibility that the reduction in neuropil seen in the brains of a proportion of 
schizophrenic patients might result, in some cases, from aberrant DISC1 function. 
 
Evidence is emerging to suggest that, in common with NRG1, DISC1 is involved in axon 
myelination. In zebrafish in which disc1 has been knocked down, oligodendrocyte 
development is impaired (Wood et al., 2009). Consistent with this finding, mice expressing 
an inducible C-terminal truncated version of DISC1, which is expressed predominantly in the 
forebrain, show premature oligodendrocyte differentiation and increased proliferation of 
oligodendrocyte progenitors (Katsel et al., 2011). Moreover, expression of the mutated 
protein affected the expression of Nrg1 and the Nrg1 receptors ErbB3 and ErbB4, suggesting 
that some of Disc1’s effects on oligodendrocytes might be mediated through altered Nrg1 
signalling. In humans, a DISC1 variant previously associated with schizophrenia was found 
to affect white matter integrity, suggesting that DISC1 variants that alter white matter 
development might confer risk for schizophrenia (Sprooten et al., 2011b). 
 
Together with DISC1’s involvement in dendritic outgrowth and myelination, studies 
showing that DISC1 plays a key role at the synapse highlight DISC1 as playing a central role 
in neuronal connectivity. DISC1 is known to be expressed at the synapse, particularly at 
excitatory synapses, in the human brain (Kirkpatrick et al., 2006) and subcellular 
fractionation has indicated that DISC1 is enriched in the post-synaptic density (Hayashi-
Takagi et al., 2010). Consistent with its synaptic location, many of DISC1’s protein 
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interactors are synaptic proteins, including Kalirin-7, PSD-95 (Hayashi-Takagi et al., 2010) 
and TNIK (Wang et al., 2011b). Wang et al. (2011) have shown DISC1 binding of TNIK to 
result in a reduction in TNIK activity. Inhibition of TNIK activity was found to result in a 
decrease in the expression of several post-synaptic proteins, including PSD-95 and the 
GluR1 AMPA receptor subunit, as well as decreasing AMPA receptor-mediated miniature 
excitatory post-synaptic currents (mEPSCs). Consistent with these findings, in neuronal 
cultures in which DISC1 has been knocked down, increases in the surface expression of 
GluR1 and the frequency of mEPSCs have been observed (Hayashi-Takagi et al., 2010). 
These findings suggest that DISC1 plays a key role, at least in part via its interaction with 
TNIK, in regulating synaptic formation and strength. Moreover, abnormalities in 
glutamatergic neurotransmission are believed to be central to the pathophysiology of 
schizophrenia, indicating a mechanism by which altered DISC1 function might play a causal 
role. 
 
In addition to DISC1’s role in regulating glutamatergic neurotransmission, there is evidence 
for the involvement of DISC1 in the function of two other neurotransmitter systems 
implicated in schizophrenia and bipolar disorder: the dopamine and GABA systems. Mice 
carrying L100P mutant Disc1 have been found to have enhanced dopamine function: these 
mice show an enhanced response to amphetamine, have an increase in the number of striatal 
dopamine receptors, and show behavioural abnormalities that are ameliorated by the 
dopamine D2 receptor antagonist haloperidol (Lipina et al., 2010). Further evidence for 
DISC1’s role in dopamine function comes from the finding that mice in which Disc1 was 
knocked down transiently in the pre- or peri-natal stages show abnormalities in postnatal 
mesocortical dopaminergic maturation (Niwa et al., 2010). Niwa et al. (2010) also detected a 
reduction in parvalbumin, a marker of fast-spiking GABAergic interneurons following Disc1 
knockdown. Similarly, mice expressing a dominant negative C-terminal truncated form of 
DISC1 have been shown to have reduced parvalbumin reactivity in the PFC (Hikida et al., 
2007). 
 
The interaction of DISC1 with GSK3β was mentioned previously in the context of the role of 
DISC1 in neuronal proliferation and migration. As GSK3β is a key target of lithium (Klein 
and Melton, 1996) and is involved in several neurodevelopmental processes (Hur and Zhou, 
2010) this interaction has been the subject of much interest. In zebrafish, Disc1 has been 
shown to regulate both canonical, β-catenin-mediated, and non-canonical Wnt signalling 
during embryogenesis (De Rienzo et al., 2011) and Singh et al. (2011) have demonstrated 
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that  DISC1 polymorphisms can disrupt Wnt/GSK3β signalling and cortical development 
(Singh et al., 2011). It should, however, be noted that two of the polymorphisms assessed by 
Singh et al. (2011) were common variants, suggesting the possibility for functional 
compensation in the majority of individuals. GSK3β binding sites on DISC1 overlap with 
binding sites for the enzyme phosphodiesterase 4B (PDE4B) (Mao et al., 2009; Murdoch et 
al., 2007). As phosphodiesterases are the only enzymes involved in the hydrolysis of cyclic 
adenosine 3',5'-monophosphate (cAMP) , a second messenger involved in learning, memory 
and mood (Benito and Barco, 2010), they are of great relevance to schizophrenia and bipolar 
disorder, as well as other psychiatric disorders. Indeed, PDE4B polymorphisms and altered 
expression have been associated with schizophrenia (Fatemi et al., 2008b; Guan et al., 2012; 
Numata et al., 2008) and a translocation affecting the gene has been identified in an 
individual with schizophrenia and a relative with a psychotic illness (Millar et al., 2005). 
Recent evidence supports the existence of functional convergence between GSK3β and 
PDE4B: Carlyle et al. (2011) demonstrated the coordinated modulation of cAMP signalling 
by DISC1, GSK3β and PDE4B, and Lipina et al. (2012) have shown combined subthreshold 
doses of rolipram (a PDE4 inhibitor) and TDZD-8 (a GSK3 inhibitor) to be effective in 
ameliorating behavioural abnormalities in the L100P Disc1 mouse model. 
 
1.7.4.2.5 Evidence for the role of altered DISC1 expression in schizophrenia and 
bipolar disorder 
 
Initial evidence for the role of altered DISC1 expression in the pathogenesis of psychiatric 
disorders came from the study of lymphoblastoid cell lines derived from carriers of the 
t(1;11) translocation. An observed reduction in DISC1 protein expression of 50% in these 
cell lines highlighted reduced DISC1 expression as a risk factor for the onset of illness in 
translocation carriers (Millar et al., 2005). The findings from subsequent studies 
investigating the role of DISC1 expression in psychiatric illness have, however, been 
equivocal. Some studies (Maeda et al., 2006; Nakata et al., 2009; Sawamura et al., 2005) 
have identified altered DISC1 expression in individuals diagnosed with psychiatric illnesses, 
whereas others (Dean et al., 2007; Rastogi et al., 2009) have not identified any such 
differences. One study (Lipska et al., 2006) reported no change in DISC1 mRNA expression 
in the dorsolateral prefrontal cortex or the hippocampus in patients with schizophrenia, but 
identified a modest (~20%) but significant increase in hippocampal DISC1 protein 
expression in patients. Furthermore, this study reported a positive correlation between 
DISC1 mRNA and protein expression in the hippocampus. Factors such as differences in the 
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brain regions assessed, differences in the DISC1 transcripts quantified, and phenotypic 
heterogeneity might have contributed to the lack of consensus between these studies. 
Moreover, if altered DISC1 expression is a risk factor for psychiatric illness, it is likely that 
it will not (i) always result in the onset of psychiatric illness or (ii) be present in affected 
individuals diagnosed, thus reducing statistical power to detect a significant association. 
Furthermore, it is important to note that the demonstration of altered mRNA expression does 
not necessarily indicate a change in protein expression. These issues are discussed further in 
section 3.5. 
 
Whilst not a direct assessment of gene expression, the presence of copy number variation in 
a region is at least suggestive of altered expression of the affected genes. Two studies have 
reported the presence of CNVs involving the DISC1 locus in individuals diagnosed with 
autism spectrum disorders: Williams et al. (2009) reported the case of a boy with autism 
spectrum disorder who was found to have a deletion involving DISC1, DISC2, and TSNAX, 
the gene located immediately 5’ of DISC1, and Crepel et al. (2010) identified a 
microduplication involving seven genes, including DISC1, in two brothers with autism and 
mild mental retardation. In a genome-wide association analysis of CNVs with schizophrenia, 
Glessner et al. (2010) identified an association between large CNVs (≥100kb) affecting 
DISC1 and schizophrenia. The key question, however, when discussing CNVs in relation to 
gene expression is to what extent do changes at the DNA level resulting from CNVs result in 
altered gene expression? Assessment of the relationship between CNVs and gene expression 
in cell lines from individuals in the HapMap project revealed that CNVs could account for 
almost 18% of the variation in mRNA expression (Stranger et al., 2007). The relationship 
between CNVs and protein expression may, however, be less direct: a study in cancer cells 
revealed that in most cases there is no correspondence between gene copy number and the 
level of protein expression, although the protein expression of some oncogenes and tumour 
suppressor genes was found to be affected by gene copy number (Geiger et al., 2010). In 
light of these findings, it would be of interest to investigate the relationship between CNVs 




To summarise, psychiatric disorders, such as schizophrenia and bipolar disorder, are severe 
conditions, often poorly treated by currently available medications, which represent a 
considerable economic burden. While a genetic basis for both schizophrenia and bipolar 
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disorder is well-established, and several candidate genes have been identified by classical 
genetic techniques, few causative variants have been uncovered. The frequent implication of 
variants in non-coding regions of the genome by association studies, observations of altered 
gene expression in affected individuals and the growing evidence for the aberrant function of 
mechanisms involved in the regulation of gene expression, such as miRNA-mediated 
regulation, in affected individuals suggest the investigation of gene expression to be a 
worthwhile endeavour in furthering understanding of the aetiology of these conditions. 
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1.9 Aims of this thesis 
 
The aims of this thesis were as follows: 
 
1. To assess association of six intronic SNPs previously found to form two three-SNP 
haplotypes associated with either schizophrenia or schizophrenia and bipolar 
disorder (Thomson et al., 2007) in two novel case-control samples and to perform 
combined analyses of the new samples with the original sample assessed in 
Thomson et al. (2007). 
 
2. To use a combination of bioinformatics and information available in the published 
literature to define a candidate promoter region for DISC1 and to design a series of 
nested promoter fragments for assessment in the dual luciferase assay. 
 
3. To determine the transcriptional activity of the DISC1 promoter fragments and, on 
the basis, of this information to design further fragment(s) for empirical assessment. 
 
4. To use publicly available data to identify transcription factors potentially involved in 
the regulation of DISC1 expression and to experimentally assess their effects on 
DISC1 promoter activity using the dual luciferase assay. 



















Association analysis of Neuregulin 1 candidate 
regions in schizophrenia and bipolar disorder 
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Neuregulin 1 (NRG1) is one of the best supported candidate susceptibility genes for 
schizophrenia. Evidence for its involvement in the disorder comes both from genetic linkage 
and association studies (see section 1.7.4.1.4) and from the known functions of NRG1, which 
mirror many aspects of schizophrenia (see section 1.7.4.1.3). In 2007, (Thomson et al., 2007) 
carried out association analysis to assess the role of variation in the NRG1 gene in conferring 
risk for schizophrenia and bipolar disorder in a sample from the Scottish population. Prior to 
this study, one study had identified NRG1 as a susceptibility gene for bipolar disorder (Green 
et al., 2005), thus adding NRG1 to a growing list of genes implicated in both schizophrenia 
and bipolar disorder (Owen et al., 2007). 
 
In order to assess the role of NRG1 in schizophrenia and bipolar disorder, Thomson et al. 
(2007) analysed the association of haplotype-tagging SNPs across the entire NRG1 gene in a 
sample of patients with schizophrenia and bipolar disorder and healthy controls drawn from 
the Scottish population. This represented the first study to select markers systematically, 
based on linkage disequilibrium (LD) across the whole of NRG1, thus permitting an 
unbiased assessment of the existence and location of susceptibility variants. Thomson et al. 
(2007) selected haplotype-tagging SNPs to tag haplotypes of greater than 10% frequency in 
the HapMap Data Release 7 using data from the CEPH trios of Utah residents with ancestry 
from northern and western Europe (CEU).  
 
Using a Nyholt-adjusted preliminary significance threshold of p = 0.0016, Thomson et al. 
(2007) identified haplotypes that showed significant association with schizophrenia and/or 
bipolar disorder in two regions of the NRG1 gene (figure 2.1). The first region, region A, 
was located at the 5’ end of the gene, overlapping the majority of SNPs and haplotypes 
identified as being associated with schizophrenia in previous studies, including HapICE, the 
NRG1 haplotype identified as being associated with schizophrenia in the first association 
study to identify variation in NRG1 as a risk factor for schizophrenia (Stefansson et al., 
2002). The second region, region B, was located at the less well studied 3’ end of the gene.  
 




Region A was found to contain multiple haplotypes that were nominally associated with 
schizophrenia and/or bipolar disorder. The most significant of these, which shall be 
henceforth referred to as “the region A haplotype”, was a three-SNP haplotype that was 
associated with schizophrenia in both global  (pg = 0.0043) and individual (pi = 0.00032) 
tests of haplotype association. This haplotype was not associated with bipolar disorder (pg = 
0.40, pi = 0.084), and association in the combined case group fell just short of the Nyholt-
adjusted significance threshold (pg = 0.0080, pi = 0.0017). This haplotype comprised SNPs 
rs1503491, rs553950, and rs327329 (T-T-T), and was present with an estimated frequency of 
1.3% in schizophrenia, and was not predicted to occur in individuals with bipolar disorder or 
control individuals. Following correction for multiple testing by permutation analysis, this 
haplotype no longer showed significant association to schizophrenia. 
 
Region B harboured the most significant haplotype in Thomson et al.’s (2007) study. This 
haplotype was significantly associated with schizophrenia (pg = 0.0078, pi = 0.00014), 
nominally associated with bipolar disorder (pg = 0.13, pi = 0.0022), and showed the most 
significant association in the combined case group (pg = 0.0034, pi = 0.000062). Association 
to this haplotype survived permutation correction in both the schizophrenia and the 
combined case group (pi = 0.024 and pi = 0.016).  
 


























Figure 2.1. Schematic showing the most significant individual haplotype p-values from previous association studies of NRG1 and 
schizophrenia and/or bipolar disorder. The significance of each haplotype is indicated by its location on the y-axis and the genomic 
position of the haplotype, according to NCBI build 36, is indicated by position on the x-axis. Vertical lines indicate the boundaries of 
regions A and B defined by LD blocks. All SNPs and microsatellites are within chromosome 8p12. This figure has been published 
previously in Walker et al. (2010). 
 




The region A haplotype spans a region in intron 1, and the 5’ boundary of region A, defined 
by LD, extends into the putative NRG1 promoter region. Region B also spans a largely 
intronic region, although it does contain the coding sequence of the sensory and motor 
neuron-derived factor (SMDF) isoform, and the 3’ exons of all other isoforms. As discussed 
in the introduction (section 1.7.4.1.5), there is evidence that the dysregulation of NRG1 
expression might play a pathogenic role in schizophrenia: association studies have identified 
a paucity of SNPs with an effect on the encoded protein; altered NRG1 expression has been 
identified in the post-mortem brains of patients with schizophrenia; and some schizophrenia 
associated variants show association with NRG1 expression level (Harrison and Law, 2006). 
In this context, it was hypothesised that the region A and region B haplotypes might confer 
risk via a variant that has an effect on NRG1 expression by altering transcription, translation, 
splicing, or RNA and/or protein stability.  
 




The aims of this chapter were to confirm whether a variant contained within, or in LD with, 
(i) the region A and (ii) the region B haplotypes confers susceptibility to (i) schizophrenia, 
(ii) bipolar disorder, or (iii) the combined schizophrenia and bipolar disorder case group with 
a view to determining whether haplotypes showing replicated association might confer 
susceptibility to schizophrenia and/or bipolar disorder by tagging variants that disrupt NRG1 
regulatory mechanisms. This was achieved by assessing association in two independent case-
control samples from the Scottish (n = 307 control subjects, 303 schizophrenic patients, and 
239 bipolar disorder patients) and German populations (n = 397 control subjects, 396 
schizophrenic patients, and 400 bipolar disorder patients). In addition, association was 
assessed in combined samples comprising (i) the Scottish sample assessed by Thomson et al. 
(2007), and the novel Scottish sample analysed in this chapter (n = 765 control subjects, 682 
schizophrenic patients and 601 bipolar disorder patients), and (ii) the two Scottish samples 
and the German sample (n = 1162 control subjects, 1078 schizophrenic patients and 1001 
bipolar disorder patients). The analysis of the combined samples was carried out in order to 
assess association in a larger sample, which would, in theory, have greater power to detect 
common variants of small effect size. 
  




2.3 Materials and methods 
 
2.3.1.1 Scottish case-control sample (Scottish 2) 
 
Individuals with bipolar disorder or schizophrenia (table 2.1), according to Diagnostic and 
Statistical Manual of Mental Disorders (4th Edition) (DSM–IV) and/or International 
Classification of Diseases 10th edition (ICD-10) criteria were recruited from inpatient and 
outpatient services at psychiatric hospitals in South East and South Central Scotland, 
including the Royal Edinburgh Hospital, and the Ravenscraig Hospital, near Inverclyde. 
Diagnoses were reached by consensus between two psychiatrists (Professor Douglas 
Blackwood and Dr. Walter Muir) and were based on performance on the Schedule for
 
Affective Disorder and Schizophrenia - Lifetime version (SADS-L) or the Structured 
Clinical Interview for DSM-IV (SCID), interviews, and a detailed review of medical case 
notes.  
 
Control subjects  were recruited from the same population, with the majority (>80%) being 
recruited through the Scottish National Blood Transfusion Service, which only accepts 
unmedicated individuals who do not have a chronic illness. The remaining control subjects 
were recruited from hospital staff or the general population, and were screened to exclude 
individuals currently taking medication, or with a family history of psychiatric illness.  
 
2.3.1.2 German case-control sample 
 
The German case-control sample (table 2.1) was obtained through collaboration with Dr. 
Sven Cichon and colleagues (Department of Genomics, Life and Brain Center, University of 
Bonn, Germany). Individuals with a lifetime diagnosis of bipolar disorder 1 or 
schizophrenia, according to DSM-IV criteria, were recruited from consecutive admissions to 
the inpatient unit of the Department of Psychiatry and Psychotherapy of the University of 
Bonn and of the Central Institute of Mental Health in Mannheim. Final diagnoses were 
reached using a consensus best estimate procedure (Leckman et al., 1982), based on medical 
records, family history, and information obtained through a structured clinical interview for 
and Statistical Manual of Mental Disorders (3rd Edition, Revised) (DSM-III-R) (SCID-1) 
(Spitzer et al., 1992).   




Control subjects were recruited from the Bonn region of Germany by Dr. Marcella Rietschel. 




















2.3.1.3 Combined samples 
 
Two combined sample sets were created: firstly, the Scottish 1 sample was combined with 
the Scottish 2 sample to create a combined Scottish dataset (Merged Scottish); and secondly, 
the two Scottish samples were combined with the German sample (Merged All). The 
statistical program SPSS 14.0 was used to combine the datasets.  
 
2.3.2 Selection of SNPs 
 
SNPs were selected for replication analysis on the basis that they had previously been found 
to form the two three-SNP haplotypes showing the most significant association with 
schizophrenia and/or bipolar disorder in a Scottish sample (Thomson et al., 2007). This 
sample shall henceforth be referred to as the Scottish 1 sample.  
 
Sample Control  SCZ  BPD  Total 
Scottish 1 458* 386  368  1212 
Scottish 2 307  303  239  849 
German 397  396  400  1193  
Merged Scottish** 765  682  601  2048  
Merged All 1162  1078 1001 3241  
 
Table 2.1. Numbers of participants in the Scottish 1, Scottish 2, and German case-control 
samples, and in the two combined samples, Merged Scottish (Scottish 1 and Scottish 2) and 
Merged All (Scottish 1, Scottish 2, and German). The number of control subjects, subjects 
diagnosed with schizophrenia (SCZ) and subjects diagnosed with bipolar disorder (BPD) in each 
study is shown, together with the total. *corrected from Thomson et al. (2007), ** the Merged 
Scottish totals for schizophrenia (SCZ) and bipolar disorder (BPD) are not equal to the sum of the 
Scottish 1 and Scottish 2 samples as 13 subjects from the Scottish 1 sample were excluded from 
the merged analyses due to a subsequent change in their diagnostic status. 
 




These six SNPs were initially selected for genotyping in the Scottish 1 population as they are 
haplotype-tagging SNPs; that is, together with the other 34 SNPs genotyped by Thomson et 
al. (2007), they efficiently capture genetic variation across the NRG1 locus. Thomson et al. 
(2007) defined the LD structure of NRG1 using HapMap Data Release 7 using data from the 
CEPH trios of Utah residents with ancestry from northern and western Europe (CEU). 
Haplotypes were defined using the solid spine of LD algorithm (D'>0.8) and adjacent blocks 
were joined where the multiallelic D' exceeded 0.85. Haplotype-tagging SNPs (MAF > 10%) 
were then selected using Haploview. Of the six SNPs genotyped in the present study, the 
three region A SNPs are located in haplotype blocks two and three, and the three region B 

























Block 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
SNP 1-6 7-9 10-11 12 13 14-16 17-31 32 33-35 36-37 NT NT 38-39 40 
 
Figure 2.2. LD map of the NRG1 locus. A. The region chr8: 31,52, 000–32,854,000 (hg17) was 
downloaded from HapMap into Haploview (CEPH trios from Utah with western or northern 
European ancestry (CEU), Data Release 16c, June 2005) and the LD map generated from 409 
SNPs of >10% minor allele frequency. LD was calculated by Haploview version 2.5 using solid 
spine of LD>0.8 and adjacent blocks were joined where the multiallelic D'>0.8, resulting in a 
total of 14 haplotype blocks across the NRG1 locus. B. Table indicating the haplotype block 
location of the 40 haplotype-tagging SNPs genotyped by Thomson et al. (2007). These SNPs 
were selected to tag haplotypes of greater than 10% frequency in the HapMap data release 7). The 
SNPs genotyped in the present study are located in haplotype blocks two and three (region A 
SNPs) and nine and ten (region B SNPs). Figure adapted from Thomson et al. (2007). 
A 
B 




2.3.3 Genotyping and quality control 
 
2.3.3.1 Scottish 2 sample 
 
Genotyping was performed at the Genetics Core of the Wellcome Trust Clinical Research 
Facility, at the Western General Hospital, Edinburgh, using the Illumina BeadArray™ 
platform. Probes and primers were designed by Illumina. In addition to the individuals in the 
Scottish 2 sample, some individuals who had previously been genotyped as part of the 
Scottish 1 sample were included in this genotyping set. As the initial genotyping of the 
Scottish 1 sample was carried out using either the Illumina BeadArray™ platform or 
TaqMan assays on an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems), this 
provided an opportunity to assess the replicability of genotyping on two different occasions 
using partially overlapping methods. Andrea Christoforou (AC) used the Illumina 
BeadStudio software to make genotype calls, discarding data points with a GenCall score of 
less than 0.25. AC then clustered the SNPs, excluding samples with a genotype call rate of 
less than 80%. SNPs with a locus success rate of less than 90% and samples with a 
genotyping success rate less than 90% were excluded from the analysis. AC then reformatted 
the genotype data for input into Dr. Naomi Wray’s Fortran program BasicAS (Basic 
Association Study; Wray, unpublished), such that it included sample ID, gender, diagnosis, 
and genotype.  
 
After AC had formatted the data for input to BasicAS, I identified individuals who had 
previously been genotyped as part of the Scottish 1 sample, checked for discrepancies in 
their gender, genotype, and diagnostic data and when no discrepancies were identified 
removed duplicated samples from the dataset. No discrepancies were identified for either 
gender or genotype; however where diagnostic status had changed from schizophrenia to 
bipolar disorder, or vice versa, individuals were included in the Scottish 2 sample using their 
most recent information, and excluded from the Scottish 1 sample on forming the combined 
(Merged Scottish and Merged All) samples. When diagnostic status was either uncertain or 
had changed to unipolar depression, individuals were not included in the Scottish 2 sample, 
and were excluded from the Scottish 1 sample when the combined samples were formed. I 
then used BasicAS to perform a test of Hardy-Weinberg Equlibrium (HWE), as described 
below (section 2.3.4.1). 
 
 




2.3.3.2 German sample 
 
The three region B SNPs were genotyped in the German sample in 1202 unrelated 
individuals using the high-throughput Illumina BeadArray™ platform at the Department of 
Genomics, Life, and Brain Centre at the University of Bonn, Germany. Initial quality control 
measures were implemented at the University of Bonn by Drs. Sven Cichon (SC), Axel 
Hillmer (AH), and Per Hoffman (PH): genotypes between duplicate samples included in the 
dataset were compared to assess the consistency of genotype calls; samples with a genotype 
call rate of less than or equal to 50% were excluded (nine samples); and SNPs that failed to 
genotype were removed (five SNPs). None of the three region B SNPs were affected by 
these measures. AC reformatted the data, using Progeny (www.progenygenetics.com), for 
entry into BasicAS. I then used BasicAS to assess HWE, as described below (section 2.3.4.1). 
 
2.3.4 Statistical analysis 
 
Assessments of HWE and the single-marker analysis were performed using BasicAS. 
BasicAS was also used to create linkage format files to be used as input for the haplotype 
analysis program Cocaphase version 2.4 (Dudbridge, 2003) (www.mrc-
bsu.cam.ac.uk/personal/frank/software/unphased). 
 
2.3.4.1 Assessment of Hardy Weinberg Equilibrium 
 
To assess whether genotype frequencies at any of the six markers deviated from HWE in 
control individuals, a χ
2
 test of independence with one degree of freedom was implemented 
in BasicAS. Deviation from HWE was considered to have occurred when p ≤ 0.01.  
 




 test of independence, as implemented in BasicAs was used to test for allele frequency 
differences between control individuals in each of the three samples. To account for the 
testing of multiple markers, p-values were subjected to permutation analysis, and the 








2.3.4.3 Single-marker analysis 
  
Differences in allele and genotype frequencies between cases and controls were assessed 
using the χ
2
 test of independence with one and two degrees of freedom, respectively, as 
implemented in BasicAS. Odds ratios (ORs) and their 95% confidence intervals (CI) were 
calculated in Microsoft Excel. The significance of ORs was assessed using the Z-statistic.  
 
2.3.4.4 Haplotype analysis  
 
Haplotype frequency estimation and comparisons between cases and controls were carried 
out using Cocaphase 2.404 (Dudbridge, 2003). Haplotypes were assessed in both global and 
individual tests of haplotype frequency. The global test assesses the significance of the 
overall difference in haplotype frequencies between cases and controls at a given haplotype 
locus, whereas the individual test compares the case-control frequencies of a particular 
haplotype compared to a reference haplotype at that locus. To avoid the potential 
confounding effects of rare haplotypes, haplotypes with a frequency of less than or equal to 
1% in both the cases and controls were grouped together for the global test of significance. 
 
ORs and 95% CIs were calculated using the most common haplotype in the control sample 
as the reference. When the most common haplotype was the haplotype of interest, the second 
most common haplotype was used as the reference haplotype. 
 
2.3.4.5 Multiple testing correction 
 
In the separate analyses of the Scottish 2 and German samples, associations directly 
replicating those identified in the analysis of the Scottish 1 sample (Thomson et al., 2007) 
were accepted as significant when p ≤ 0.05, due to the a priori evidence for the involvement 
of these SNPs. Novel associations attaining nominal significance (p ≤ 0.05) were corrected 
by permutation analysis. In the merged analyses, all nominally significant associations were 
corrected by permutation analysis, as the merged samples were considered to be novel 
samples. 
 
As permutation analysis is a resampling-based method, it maintains the correlation structure 
present in a dataset. This is important when correcting for multiple testing in a dataset that 
contains non-independent variables, such as SNPs in linkage disequilibrium (LD). For such 




data, the use of methods that assume independence, such as the Bonferroni correction, would 
be overly conservative, resulting in inflation of the type II error rate (Nyholt, 2004). 
 
Permutation analysis was performed using Cocaphase version 2.404 (Dudbridge, 2003). The 
case-control status of individuals was randomly shuffled and the test statistic re-calculated 
under these new conditions. This re-shuffling process was performed 1000 times, creating a 
random distribution of the test-statistic from the null hypothesis of no association between 
case-control status and genotype. Churchill and Doerge (1994) recommend the use of at least 
1000 permutations for an alpha level of 0.05. 
 
As Cocaphase only corrects for the most significant result within a certain window (i.e. 
single-marker, two-SNP haplotype, or three-SNP haplotype), an application developed by 
Omer Jilani (OJ) was used to correct for other significant results in a given window. This 
application compiles the 1000 permuted p-values produced by Cocaphase and these are used 
to produce a distribution to which empirically obtained p-values are compared and corrected. 
Corrections were made at two levels: the single-test level (pst) and the experiment-wise level 
(pew). The single-test level corrects for multiple comparisons within a particular subgroup 
(e.g. the schizophrenic group in the German sample) and region, at the single-marker or x-
SNP haplotype (i.e. two-SNP or three-SNP) level. The experiment-wise level combines p-
values across diagnostic groups (schizophrenia, bipolar disorder, and the combined case 
group), and single-marker and haplotype tests to give a regionally corrected p-value within 
each sample. This was achieved by permuting each test individually and then selecting the 
best p-value from each of the 1000 permutations across all tests to create a new distribution 
of 1000 permuted p-values. No correction was made for the use of both allelic and genotypic 
tests, as these tests are highly correlated and should not, therefore, greatly increase the 
number of independent tests performed. 
 
2.3.5 Imputation of the missing three-SNP region B haplotype  
 
As genotyping of one of the region B SNPs, rs2919390, was unsuccessful in the Scottish 2 
sample, the ability of the two-SNP region B haplotype to predict the three-SNP region B 
haplotype was assessed in the Scottish 1 sample. Genotype data was uploaded to Haploview 
v4.2, which uses the expectation-maximisation algorithm to estimate haplotypes from 
unphased genotype data. Haplotypes were defined using the “custom” option for defining 






 between the associated two-SNP region B haplotype (GC) and the 
associated three-SNP region B haplotype (AGC) was calculated by treating each haplotype 
as an “allele” and using the following formula for multi-allelic r
2
, where hij is the observed 
frequency of a two loci haplotype comprising allele i (haplotype GC), which has frequency 




   
(    (      ))
 
























Six intronic SNPs were selected for replication analysis. These SNPs formed the two three-
SNP haplotypes that were found to show the most significant association with schizophrenia 
and/or bipolar disorder in the Scottish 1 sample. Three SNPs formed the 5’, region A, 
haplotype and three formed the 3’, region B, haplotype (figure 2.3). All six SNPs were 
genotyped in the Scottish 2 sample, whereas only the three region B SNPs were genotyped in 















SNP name Alleles  Location 
(chr. 8) 
Genotyping success rate (%) 
Scottish 2 German 
 
A 
1 rs1503491 C/T 31642106 99.88 N/A 
2 rs553950 G/T 31791362 100.0 N/A 
3 rs327329 C/T 31853498 100.0 N/A 
 
B 
4 rs2919390 A/G 32526955 N/A* 99.33 
5 rs6988339 C/T 32545916 99.76 99.83 
6 rs3757930 C/T 32589118 99.76 99.66 
 
Table 2.2. Details of the three region A and three region B SNPs selected for replication in the 
Scottish 2 sample and the German sample (region B only). SNPs are listed together with their rs 
numbers and their genomic coordinates (UCSC human genome browser, hg 19). N/A = not 
available. *data discarded due to poor GenCall score (< 0.25).  
 
 
Figure 2.3. Schematic showing the location of the three region A and three region B SNPs 
selected for replication analysis (UCSC human genome browser, hg 19). All six SNPs were 
genotyped in the Scottish 2 sample; only the three region B SNPs were genotyped in the German 
sample. The locations of the six SNPs assessed in this study relative to the NRG1 gene (chr 8: 
31496911-32622558) are indicated by red crosses. Regions A (chr 8: 31469479-31991227) and B 
(32499740-32624387) are delimited by the boundaries of linkage disequilibrium blocks (dashed 
blue lines). 
 
Region A Region B 




2.4.2 Genotyping and quality control 
 
2.4.2.1 Scottish 2 sample 
 
The six SNPs (table 2.2) were genotyped in the Scottish sample using the Illumina 
BeadArray™ platform at the Genetics Core of the Wellcome Trust Clinical Research 
Facility, as described in section 2.3.3.1. Following the quality control measures described in 
section 2.3.3 (performed by AC), one of the region B SNPs (rs2919390) was excluded from 
the dataset due to a poor GenCall score. This left five SNPs to be included in the analyses, 
three in region A, and two in region B.  
 
At this point, I received the data for the five SNPs. The dataset contained genotype 
information from both new individuals (n = 847) and individuals previously genotyped as 
part of the Scottish 1 dataset (n = 842). I searched for samples duplicated from the Scottish 1 
sample and checked that the gender, genotype, and diagnostic information for these 
individuals was consistent with the information obtained on initial genotyping of the Scottish 
1 sample in 2004. If an exact match was detected, the sample was removed from the current 
dataset.  Mismatches were detected for thirteen duplicated samples; in all cases, the 
mismatch was for diagnostic status. These individuals were excluded from the merged 
analyses. 
 
Markers in control individuals were examined for deviation from Hardy-Weinberg 
Equilibrium (HWE) using the χ
2
 test of independence, as implemented in BasicAS. It is 
assumed that in a large population, under conditions of random mating, and free from the 
influence of selection, mutation, or migration, genotype frequencies for individual markers 
will be in HWE (Sham, 1998). Deviations from HWE can be indicative of inaccurate 
genotyping (Hosking et al., 2004). None of the five markers genotyped in the Scottish 2 



























2.4.2.2 German sample 
 
The three region B SNPs were genotyped in the German sample using the high-throughput 
Illumina BeadArray platform at the Department of Genomics, Life, and Brain Centre at the 
University of Bonn, Germany, as described in section 2.3.3.2. All three SNPs survived the 
quality control measures implemented SC, AH, and PH, described in section 2.3.3.2. 
 
At this point, I received the data for these three SNPs. Deviations from HWE were assessed 
in the control sample using the χ
2
 test of independence, as implemented in BasicAs. None of 









Marker (region) Genotype HWE p-value 
11 (%) 12 (%) 22 (%) 
rs1503491 (A) 161 (52.4) 125 (40.7) 21 (6.8) 0.622 
rs553950 (A) 244 (79.5) 61 (19.9) 2 (0.7) 0.385 
rs327329 (A) 19 (6.2) 133 (43.3) 155 (50.5) 0.172 
rs6988339 (B) 102 (33.3) 149 (48.7) 55 (18.0) 0.964 
rs3757930 (B) 158 (51.5) 122 (39.7) 27 (8.8) 0.620 
 
Table 2.3.  Assessment of Hardy-Weinberg Equilibrium in control individuals of the Scottish 2 
sample. Hardy-Weinberg Equilibrium (HWE) was assessed for each of the five genotyped 
markers using the 
2
 test of independence, as implemented in BasicAS. For each marker, the 
number and percentage of control individuals identified as carrying each genotype are shown, 
together with the associated p-value. Genotypes are indicated using a “1” to refer to the allele 
that occurs first alphabetically and a “2” to represent the allele that occurs second.  Deviation 
from HWE was defined as p ≤ 0.05. 
 



















2.4.2.3 Comparison of control groups 
 
As the individual case-control datasets were to be combined for the merged analyses, it was 
important to assess whether there were differences between the two datasets. Therefore, 
allele frequency differences between the control subjects of each sample were assessed using 
the χ
2
 test of independence in BasicAS (table 2.5). The two sets of Scottish controls (Scottish 
1 and Scottish 2) were found to differ significantly on two SNPs: a region A SNP, rs553950, 
(uncorrected p = 0.029), and a region B SNP, rs6988339, (uncorrected p = 0.011). However, 
neither of these differences remained significant after correction for multiple testing by 










Marker (region) Genotype HWE p-value 
11 (%) 12 (%) 22 (%) 
rs2919390 (B) 139 (35.0) 182 (45.8) 76 (19.1) 0.236 
rs6988339 (B) 152 (38.4) 187 (47.2) 57 (14.4) 0.966 
rs3757930 (B) 199 (50.1) 155 (39.0) 43 (10.8) 0.402 
 
Table 2.4. Assessment of Hardy-Weinberg Equilibrium in the control individuals of the German 
sample. Hardy-Weinberg Equilibrium (HWE) was assessed for each of the three genotyped 
markers using the 
2
 test of independence, as implemented in BasicAS. For each marker, the 
number and percentage of control individuals identified as carrying each genotype are shown, 
together with the associated p-value. Genotypes are indicated using a “1” to refer to the allele 
that occurs first alphabetically and a “2” to represent the allele that occurs second.  Deviation 
from HWE was defined as p ≤ 0.05. 
 





























To further compare the two Scottish samples, the correlation between the allele frequencies 
for each marker was calculated (figure 2.4). This revealed a high level of correlation (r
2
 = 
0.98). Based on these findings, the merged analyses were performed, although the potential 








Allele frequency (%) Uncorrected p-value 
(corrected p – value) 
Scottish 1 vs. Scottish 2 Scottish 1 Scottish 2  
rs1503491 (A) 669 (74.2) 447 (72.8) 0.553 
rs553950 (A) 841 (92.6) 549 (89.4) 0.029 (0.129) 
rs327329 (A) 236 (26.5) 171 (27.9) 0.550 
rs6988339 (B) 580 (64.2) 353 (57.7) 0.011 (0.053) 
rs3757930 (B) 625 (69.4) 438 (71.3) 0.430 
Scottish 1 vs. German Scottish 1 German  
rs2919390 (B) 489 (54.5) 460 (57.9) 0.150 
rs6988339 (B) 580 (64.2) 491 (62.0) 0.357 
rs3757930 (B) 625 (69.4) 553 (69.6) 0.928 
Scottish 2 vs. German Scottish 2 German  
rs6988339 (B) 353 (57.7) 491 (62.0) 0.101 
rs3757930 (B) 438 (71.3) 553 (69.6) 0.491 
 
Table 2.5. Comparison of controls groups. The allele frequencies of the control groups of each 
sample were compared to assess the existence of systematic differences between the samples. 
Comparisons were carried out using the χ
2
 test of independence in BasicAS. For each 
comparison, the list of markers assessed is listed, together with the number and percentage of 
individuals in each sample carrying the allele that occurs first alphabetically. Uncorrected p-values 
for each comparison are shown. Where an uncorrected p-value attained the threshold for nominal 
significance (p ≤ 0.05), correction for multiple testing was performed by permutation analysis and 
a corrected p-value is shown in parentheses. 

























2.4.3 Association analyses 
 
Association analyses were performed to assess the association of the three region A SNPs 
and the region B SNPs with schizophrenia, bipolar disorder, and the combined case group 
(schizophrenia and bipolar disorder).  Single-marker and haplotype analyses were carried 
out, with the two regions being analysed separately. Both regions were assessed in the 
Scottish 2 and the Merged Scottish samples, whereas only region B was assessed in the 
German and Merged All samples. 
 
2.4.3.1 Single-marker analysis 
 
Differences in allele and genotype frequencies between cases and controls were assessed 
using the χ
2
 test of independence, as implemented in BasicAS. The results of this analysis are 
 
Figure 2.4. Correlation between the allele frequencies of the control individuals in the Scottish 
1 and Scottish 2 samples. The correlation between allele frequencies for the five genotyped 
markers was assessed by calculation of the coefficient of determination, R
2
, which is displayed 
above. Allele frequencies for the Scottish 1 sample are displayed as percentages on the y-axis 
and allele frequencies for the Scottish 2 sample are displayed as percentages on the x-axis. For 
each marker, the displayed allele frequency relates to the allele appearing first alphabetically. 




displayed in table 2.6. The results of the single-marker analysis for the Scottish 1 sample, 
which has been analysed previously (Thomson et al., 2007), are shown for comparison. 
  








Allele frequency p-value Genotype frequency p-value HWE p-
value 
Group Allele 1 (%) Allele 2 (%) 11 (%) 12 (%) 22 (%) 
rs1503491 (A) C T  CC CT TT   
Scottish 1         
BPD 518 (71.5) 206 (28.5) 0.237 183 (50.6) 152 (42.0) 27 (7.5) 0.486 0.551 
SCZ 578 (75.3) 190 (24.7) 0.609 220 (57.3) 138 (35.9) 26 (6.8) 0.612 0.494 
BPD+SCZ 1097 (73.5) 395 (26.5) 0.702 403 (54.0) 290 (38.9) 53 (7.1) 0.836 0.933 
Controls 669 (74.2) 233 (25.8)  246 (54.5) 177 (39.2) 28 (6.2)  0.607 
         
Scottish 2         
BPD 353 (74.2) 123 (25.8) 0.615 131 (55.0) 91 (38.2) 16 (6.7) 0.827 0.970 
SCZ 440  (72.6) 126 (27.4) 0.939 162 (53.5) 116 (38.3)  25 (8.3) 0.719 0.513 
BPD+SCZ 793 (73.3) 289 (26.7) 0.827 293 (54.2) 207 (38.3) 41 (7.6) 0.758 0.597 
Controls 447 (72.8) 167 (27.2)  161 (52.4) 125 (40.7) 21 (6.8)  0.622 
         
Merged 
Scottish  
        
BPD 861 (72.5) 327 (27.5) 0.507 310 (52.2) 241 (40.6) 43 (7.2) 0.787 0.680 
SCZ 1005(73.9) 355 (26.1) 0.790 376 (55.3) 253 (37.2) 51 (7.5) 0.505 0.353 
BPD+SCZ 1865 (73.2) 683 (26.8) 0.864 686 (53.8) 494 (38.8) 94 (7.4) 0.703 0.697 
Controls 1116 (73.6) 400 (26.4)  407 (53.7) 302 (39.8) 49 (6.5)  0.481 
         
rs553950 (A) G T  GG GT TT   
Scottish 1         
BPD 650 (89.5) 76 (10.5) 0.028 291 (80.2) 68 (18.7) 4 (1.1) 0.023 0.990 
SCZ 688 (89.6) 80 (10.4) 0.028 311 (81.0) 66 (17.2) 7 (1.8) 0.009 0.121 
BPD+SCZ 1339 (89.6) 155 (10.4) 0.012 602 (80.6) 134 (17.9) 11 (1.5) 0.012 0.264 
Controls 841 (92.6) 67 (7.4)  387 (85.2) 67 (14.8) 0 (0.0)  0.204 
         
Scottish 2         
BPD 428 (89.5) 50 (10.5) 0.946 191 (79.9) 46 (19.2) 2 (0.8) 0.955 0.671 
SCZ 542 (89.4) 64 (10.6) 0.989 244 (80.5) 54 (17.8) 5(1.7) 0.430 0.324 
BPD+SCZ 970 (89.5) 114 (10.5) 0.964 435 (80.3) 100 (18.5) 7(1.3) 0.612 0.646 
Controls 549 (89.4) 65 (10.6)  244 (79.5) 61 (19.9) 2 (0.7)  0.385 
         
Merged 
Scottish 
        
BPD 1067 (89.5) 128 (10.5) 0.109  477 (80.0) 113 (19.0) 6 (1.0) 0.114 0.809 
SCZ 1217 (89.5) 143 (10.5) 0.093 549 (80.7) 119 (17.5) 12 (1.8) 0.013 0.068 
BPD+SCZ 2284 (89.5) 268 (10.5) 0.058 1026 
(80.4) 
232 (18.2) 18 (1.4) 0.026 0.242 
Controls 1390 (91.3) 132 (8.7)  631 (82.9) 128 (16.8) 2 (0.3)  0.088 
         
rs327329 (A) C T  CC CT TT   
Scottish 1         
BPD 198 (26.9) 538 (73.1) 0.840 20 (5.4) 184 (41.3) 236 (51.6) 0.881 0.077 
SCZ 191 (24.8) 579 (75.2) 0.442 30 (7.8) 131 (34.0) 224 (58.2) 0.079 0.085 
BPD+SCZ 389 (25.8) 1117 (74.2) 0.735 50 (6.6) 289 (38.4) 414 (55.0) 0.578 0.964 
Controls 236 (26.5) 656 (73.5)  26 (5.8) 184 (41.3) 236 (52.9)  0.204 
         
Scottish 2         
BPD 133 (27.8) 345 (72.2) 0.583 16 (6.7) 94 (39.3) 129 (54.0) 0.643 0.840 
SCZ 169 (27.9) 437 (72.1) 0.988 24 (7.9) 121 (39.9) 158 (52.1) 0.562 0.901 
BPD+SCZ 295 (27.2) 793 (72.8) 0.778 40 (7.4) 215 (39.7) 287 (53.0) 0.531 0.976 
Controls 171 (27.9) 443 (72.1)  19 (6.2) 133 (43.3) 155 (50.5)  0.172 
         
Merged 
Scottish 
        
BPD 321 (26.7) 881 (73.3) 0.852 36 (6.0) 249 (41.4) 316 (52.6) 0.969 0.153 
SCZ 357 (26.2) 1005 (73.8) 0.561 54 (7.9) 247 (36.3) 380 (55.8) 0.048 0.124 
BPD+SCZ 677 (26.4) 1887 (73.6) 0.645 90 (7.0) 496 (38.7) 696 (54.3) 0.265 0.899 
Controls 407 (27.0) 1099 (73.0)  45 (6.0) 317 (42.1) 391 (51.9)  0.065 
 
Table 2.6. Results of the single-marker association analysis. See page 74 for legend. 






































p-value Genotype frequency p-value HWE p-
value 
Group Allele 1 (%) Allele 2 (%) 11 (%) 12 (%) 22 (%) 
rs2919390 (B) A C  AA AC CC   
Scottish 1         
BPD 428 (58.8) 300 (41.2) 0.079 130 (35.7) 168 (46.2) 66 (18.1) 0.189 0.365 
SCZ 463 (60.8) 299 (39.2) 0.010 143 (37.5) 177 (46.5) 61 (16.0) 0.036 0.615 
BPD+SCZ 891 (59.8) 599 (40.2) 0.010 273 (36.6) 345 (46.3) 127 (17.0) 0.037 0.315 
Controls 489 (54.5) 409 (45.5)  134 (29.8) 221 (49.2) 94 (20.9)  0.870 
         
German         
BPD 495 (62.3) 299 (37.7) 0.073 154 (38.8) 187 (47.1) 56 (14.1) 0.145 0.949 
SCZ 451 (57.7) 331 (42.3) 0.916 124 (31.7) 203 (51.9) 64 (16.4) 0.225 0.210 
BPD+SCZ 476 (60.0) 318 (40.0) 0.328 278 (35.3) 390 (49.5) 120 (15.2) 0.204 0.379 
Controls 460 (57.9) 334 (42.1)  139 (35.0) 182 (45.8) 76 (19.1)  0.236 
         
rs6988339 (B) A G  AA AG GG   
Scottish 1         
BPD 433 (59.0) 301 (41.0) 0.032 132 (36.0) 169 (46.0) 66 (18.0) 0.113 0.355 
SCZ 448 (58.0) 324 (42.0) 0.010 133 (34.5) 182 (47.2) 71 (18.4) 0.041 0.529 
BPD+SCZ 881 (58.5) 625 (41.5) 0.006 265 (35.2) 351 (46.6) 137 (18.2) 0.026 0.272 
Controls 580 (64.2) 324 (35.8)  191 (42.3) 198 (43.8) 63 (13.9)  0.312 
         
Scottish 2         
BPD 297 (62.1) 181 (37.9) 0.137 90 (37.7) 117 (49.0) 32 (13.4) 0.289 0.533 
SCZ 338 (56.0) 266 (46.0) 0.545 97 (32.1) 144 (47.7) 61 (20.2) 0.781 0.571 
BPD+SCZ 635 (58.7) 447 (41.3) 0.686 187 (34.6) 261 (48.2) 93 (17.2) 0.921 0.906 
Controls 353 (57.7) 259 (42.3)  102 (33.3) 149 (48.7) 55 (18.0)  0.964 
         
German         
BPD 469 (58.8) 229 (41.2) 0.189 141 (35.3) 187 (46.9) 57 (17.8) 0.380 0.511 
SCZ 508 (64.1) 284 (35.9) 0.376 165 (41.7) 178 (44.9) 53 (13.4) 0.637 0.649 
BPD+SCZ 976 (61.4) 614 (38.6) 0.795 306 (38.5) 365 (45.9) 124 (15.6) 0.839 0.382 
Controls 491 (62.0) 301 (38.0)  152 (38.4) 187 (47.2) 57 (14.4)  0.966 
         
Merged 
Scottish 
        
BPD 725 (60.4) 475 (39.6) 0.550 221 (36.8) 283 (47.2) 96 (16.0) 0.790 0.734 
SCZ 782 (57.4) 580 (42.6) 0.024 229 (33.6) 324 (47.6) 128 (18.8) 0.085 0.480 
BPD+SCZ 1506 (58.8) 1056 (41.2) 0.087 450 (35.1) 607 (47.4) 224 (17.5) 0.231 0.434 
Controls 932 (61.5) 584 (38.5)  293 (38.7) 347 (45.8) 118 (15.6)  0.365 
         
Merged All         
BPD 1195 (59.8) 803 (40.2) 0.194 362 (36.2) 470 (47.0) 167 (16.7) 0.438 0.491 
SCZ 1290 (59.9) 864 (40.1) 0.216 394 (36.6) 502 (46.6) 181 (16.8) 0.464 0.328 
BPD+SCZ 2483 (59.8) 1669 (40.2) 0.140 756 (36.4) 972 (46.8) 348 (16.8) 0.344 0.237 
Controls 1424 (61.7) 884 (38.3)  445 (38.6) 534 (46.3) 175 (15.2)  0.477 
 
Table 2.6. Results of the single-marker association analysis (continued). See next page for legend. 









































p-value Genotype frequency p-value HWE p-
value 
Group Allele 1 (%) Allele 2 (%)  11 (%) 12 (%) 22 (%) 
rs3757930 (B) C T  CC CT TT   
Scottish 1         
BPD 533 (72.6) 201 (27.4) 0.160 193 (52.6) 147 (40.1) 27 (7.4) 0.332 0.891 
SCZ 558 (72.3) 214 (27.7) 0.204 197 (51.0) 164 (42.5) 24 (6.5) 0.186 0.236 
BPD+SCZ 1090 (72.4) 416 (27.6) 0.115 390 (51.8) 311 (41.3) 52 (6.9) 0.148 0.344 
Controls 625 (69.4) 275 (30.6)  220 (48.9) 185 (41.1) 45 (10.0)  0.507 
         
Scottish 2         
BPD 347 (72.9)  129 (27.1) 0.568 124 (52.1) 99 (41.6) 15 (6.3) 0.547 0.416 
SCZ 437 (72.4)  167 (27.6) 0.694 158 (52.3) 121 (40.1) 23 (7.6) 0.868 0.980 
BPD+SCZ 784 (72.6) 296 (27.4) 0.579 282 (52.2) 220 (40.7) 38 (7.0) 0.651 0.579 
Controls 438 (71.3) 176 (28.7)  158 (51.5) 122 (39.7) 27 (8.8)  0.620 
         
German         
BPD 537 (67.5) 259 (32.5) 0.348 176 (44.2) 185 (46.5) 37 (9.3) 0.105 0.241 
SCZ 523 (66.4) 265 (33.6) 0.162 173 (43.9) 177 (44.9) 44 (11.2) 0.194 0.900 
BPD+SCZ 1060 (66.9) 524 (33.1) 0.179 349 (44.1) 362 (45.7) 81 (10.2) 0.086 0.362 
Controls 553 (69.6) 241 (30.4)  199 (50.1) 155 (39.0) 43 (10.8)  0.966 
         
Merged 
Scottish 
        
BPD 870 (72.6) 328 (27.4) 0.168 313 (52.3) 244 (40.7) 42 (7.0) 0.242 0.551 
SCZ 987 (72.5) 375 (27.5) 0.168 353 (51.8) 282 (41.4) 46 (6.8) 0.162 0.303 
BPD+SCZ 1859 (72.6) 701 (27.4) 0.105 666 (52.0) 526 (41.1) 88 (6.9) 0.098 0.247 
Controls 1063 (70.2) 451 (29.8)  378 (49.9) 307 (40.6) 72 (9.5)  0.402 
         
Merged All         
BPD 1408 (70.6) 586 (29.4) 0.697 489 (49.0) 429 (43.0) 79 (7.9) 0.155 0.259 
SCZ 1511 (70.3) 639 (29.7) 0.849 526 (48.9) 459 (42.7) 90 (8.4) 0.270 0.469 
BPD+SCZ 2917 (70.4) 1227 (29.6) 0.738 1015 
(49.0) 
888 (42.9) 169 (8.2) 0.115 0.193 
Controls 1616 (70.0) 692 (30.0)  577 (50.0) 462 (40.0) 115 (10.0)  0.114 
 
Table 2.6. Results of the single-marker association analysis (continued). The association 
between intronic NRG1 single nucleotide polymorphisms (SNPs) and bipolar disorder (BPD), 
schizophrenia (SCZ), and bipolar disorder and schizophrenia (BPD+SCZ) was assessed in case-
control samples from Scotland (Scottish 2) and Germany. Association had previously been 
reported in the Scottish 1 sample (Thomson et al., 2007) and the results of this analysis are 
shown here for comparison. In addition to the single case-control samples, two combined 
samples were analysed, these were: (i) the Merged Scottish sample, which comprised the 
Scottish 1 and the Scottish 2 samples; and (ii) the Merged All sample, which comprised the 
Scottish 1, Scottish 2, and German samples. The SNPs analysed here were previously found to 
form two three-SNP haplotypes in the Scottish 1 sample: one haplotype located at the 5’ end of 
the gene (region A) and the other located at the 3’ end of the gene (region B). Five SNPs were 
analysed in the Scottish 2 sample, as one region B SNP (rs2919390) did not genotype 
successfully. Only the three region B SNPs were assessed in the German sample. Results are 
shown for allelic and genotypic tests of association. For both tests, p-values attaining the 
nominal significance level of p ≤ 0.05 are highlighted in yellow. P-values are also displayed for 
the test of Hardy-Weinberg Equilibrium.  
 




2.4.3.1.1 Scottish 2 and German case-control samples 
 
No individual SNP or genotype was found to be associated with bipolar disorder, 
schizophrenia, or the combined case group in either the Scottish 2 or the German samples. 
 
2.4.3.1.2 Merged Scottish case-control sample 
 
Association was observed to three SNPs in the Merged Scottish sample, which comprises the 
Scottish 1 and the Scottish 2 samples, in the allelic or the genotypic tests of association (table 
2.6).  
 
The region B SNP rs6988339, was nominally associated with schizophrenia (uncorrected p = 
0.024); however, this association did not withstand correction for multiple testing (corrected 
pst = 0.059). The G allele was more prevalent in the schizophrenia group than the control 
group, conferring an increase in disease risk (ORG/A = 1.18, 95% CI: 1.10-1.37, table 2.7). 
Only a trend towards significance was observed for this allele at the genotype level (p < 0.1).  
This finding is consistent with the association to this SNP observed in the Scottish 1 sample 
(Thomson et al., 2007), although at a lower level of significance. 
 
In keeping with initial findings in the Scottish 1 sample (Thomson et al., 2007), the region A 
SNP rs553950 was found to show nominally significant association in the schizophrenia 
group (uncorrected p = 0.013) and the combined case group (uncorrected p = 0.026) in the 
test of genotype significance, with this association remaining significant after correction for 
multiple testing in both groups (schizophrenia: corrected pst = 0.030; combined cases: 
corrected pst = 0.047). In both groups, genotypes containing the T allele were found to occur 
more frequently amongst the cases than the controls. Pair-wise comparisons between 
genotypic odds ratios (OR; table 2.7) suggest a recessive mode of inheritance as the TT 
genotype confers an increase in risk for both schizophrenia and the combined case group 
when compared to the GG genotype (schizophrenia: ORTT/GG = 6.90, 95% CI: 1.54-30.95, Z-
test p = 0.006; combined cases: ORTT/GG = 5.54, 95% CI = 1.28-23.94, Z-test p = 0.011), 
whilst the GT genotype does not pose an increased risk compared to the GG genotype 
(schizophrenia: ORGT/GG = 1.07, 95% CI: 0.81-1.41, Z-test p = 0.318; combined cases: 
ORGT/GG = 1.11, 95% CI: 0.88-1.41, Z-test p = 0.185). A recessive mode of inheritance is 
further corroborated by the finding that the strength of the association to the TT genotype in 




both the schizophrenia and the combined case groups is increased when tested under a 
recessive model (TT vs. GG+GT) using a χ
2
 test (schizophrenia: p = 0.004; combined cases: 
p = 0.011). 
 
Another region A SNP, rs327329, showed nominally significant association with 
schizophrenia at the genotype level (uncorrected p = 0.048); however, this association was 
no longer significant after correction for multiple testing (corrected pst = 0.129). In keeping 
with Thomson et al., (2007), homozygous CC and TT genotypes are more common amongst 
the cases than the controls (table 2.7). However, pair-wise comparison of ORs does not 
reveal an obvious mode of inheritance (table 2.7). 
 






















Sample SNP  Allele P-value  OR (95% CI) Genotype P-value 
(corrected 
p-value) 
OR (95% CI)  
 
OR p-value 
1 (%) 2 (%) 11 (%) 12 (%) 22 (%) 
 rs553950 G T  T/G GG GT TT  TT/GG GT/GG TT/GT TT/GG GT/GG TT/GT 








7 (1.8) 0.023 
 









11 (1.5) 0.009 N/A N/A N/A N/A N/A N/A 
Controls 841 
(92.6) 
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Table 2.7.  Odds ratio analysis for significant single markers and genotypes. See page 79 for legend. 




Sample SNP  Allele P-value  OR 95% CI) Genotype P-value 
(corrected 
p-value) 
OR (95% CI)  
 
OR p-value 
1 (%) 2 (%) 11 (%) 12 (%) 22 (%) 
 rs327329 C T  T/C CC CT TT  CC/TT TT/CT CC/CT CC/TT TT/CT CC/CT 

























































       
 rs6988339 A G  G/A AA AG GG  GG/AA AG/AA GG/AG GG/AA AG/AA GG/AG 



































































       
 
Table 2.7. Odds ratio analysis for significant single markers and genotypes (continued). See next page for legend. 
 




Table 2.7. Odds ratio analysis for nominally significant single markers and genotypes in the Merged 
Scottish sample, which comprised two Scottish case-control samples: the Scottish 1 sample, 
previously analysed by Thomson et al. (2007), and the Scottish 2 sample. Nominally significant 
associations in the allelic and genotypic tests of association (p ≤ 0.05) were subjected to permutation 
analysis to correct for multiple testing. P-values corrected at the single-test level are displayed in 
parentheses. Associations attaining nominal significance are highlighted in yellow, while those 
remaining significant after permutation analysis (carried out in the Merged Scottish sample only) are 
highlighted in green. Odds ratios (OR) were calculated relative to the non-risk allele or genotype and 
considered significant when the lower boundary of their 95% confidence interval (CI) was not less 
than one, and their Z-test p-value was less than or equal to p ≤ 0.05. The p-values for ORs satisfying 
these requirements are highlighted in blue and their corresponding ORs and 95% CIs are indicated in 
bold. Results from the analysis of the Scottish 1 sample are shown for comparison. N/A-not available 
(due to genotype count of 0 in control sample). 
 
 
2.4.3.1.3 Merged all case-control sample 
 
No individual SNP or genotype was found to be significantly associated with bipolar 
disorder, schizophrenia, or the combined case group in the Merged all case-control sample. 
 
2.4.3.2 Haplotype analysis 
 
Single-marker analysis is most useful when the aetiological variant has been genotyped. As 
SNPs in the current study were initially selected by Thomson et al. (2007) to tag blocks of 
LD, it is highly unlikely that they are aetiological variants. It is more probable that 
association to these SNPs indicates that the SNP is in LD with a disease risk variant. 
Haplotype analysis is likely, therefore, be more powerful than single-marker analysis as 
aetiological variants might be in stronger LD with the haplotype than with individual SNPs 
within the haplotype (Akey et al., 2001; Zaykin et al., 2002) or could be present on a specific 
genetic background (Cordell and Clayton, 2002). Moreover, haplotypes are more robust than 
single markers, as the LD between a haplotype and an aetiological variant is less likely to be 
affected by random drift and mutations at the marker locus (Akey et al., 2001). 
 
Haplotype frequencies were estimated, using the expectation-maximisation (EM) algorithm, 
and analysed in Cocaphase. Haplotypes were analysed separately for the region A and the 
region B SNPs, as these regions are separated by ~0.5Mb. All possible two- and three-
marker haplotypes formed by consecutive SNPs were assessed in each region in both global 
(pg) and individual (pi) tests of significance.  
 




Haplotype analysis yielded three nominally significant (p ≤ 0.05) haplotypes: two that 
replicate those identified in the Scottish 1 dataset, and one novel haplotype (table 2.8). 
Haplotypes attaining significance in the Scottish 1 dataset are shown for comparison. 
 








Region  A   B  
rs3757930 
     
SNP ID  rs1503491 rs553950 rs327329 rs2919390 rs6988339 
       Case frequency Control frequency Pi (corrected  Pi) Pg OR (95% CI) 
Block no. 2 3 3 9 9 10      
Scottish 1 
SCZ T T T    0.013 4.13x10-13 0.000320 0.00434 N/A 
SCZ    A G  0.401 0.321 0.00120 0.00545 1.42 (1.13-1.77) 
SCZ     G C 0.331 0.249 0.00140 0.0110 1.51  (1.20-1.91) 
SCZ    A G C 0.334 0.240 0.000100 0.00780 1.59 (1.23-2.05) 
BPD+SCZ    A G  0.392 0.321 0.000800 0.00502 1.36 (1.12-1.65) 
BPD+SCZ     G C 0.327 0.249 0.000400 0.00343 1.47 (1.20-1.80) 
BPD+SCZ    A G C 0.326 0.240 0.000100 0.00553 1.52 (1.22-1.89) 
German 





Merged Scottish     
SCZ T T T    0.010 0.00300 0.0280  
(st: 0.208,  
ew: 0.581) 
0.168 3.44 (1.16-10.3) 
SCZ     G C 0.329 0.273 0.00370 
(st: 0.0220,  
ew: 0.0720) 
0.0303 1.31 (1.10-1.56) 
BPD+SCZ     G C 0.320 0.273 0.008000 
(st: 0.0440,  
ew: 0.139) 
0.0287 1.24 (1.06-1.45) 
Merged All     
BPD+SCZ     G C 0.3004 0.270 0.0452 
(st: 0.139,  
ew: 0.427 
0.108 1.18 (1.05-1.34) 
 
Table 2.8. Haplotypes demonstrating nominally significant association to schizophrenia, bipolar disorder, or the combined case group. See next page for legend. 




Table 2.8. Nominally significant estimated haplotypes showing association to bipolar disorder (BPD), 
schizophrenia (SCZ), or the combined case group (BPD+SCZ). Haplotypes showing nominally 
significant association were identified in the Scottish 1, German, Merged Scottish (Scottish 1 and 
Scottish 2) and Merged All (Scottish 1, Scottish 2, and German) samples. Alleles forming the 
significant haplotype are indicated in the second and third columns. Block number indicates the LD 
block in which each SNP is located according to Thomson et al. (2007). For the German, Merged 
Scottish and Merged All samples, p-values attaining nominal significance (p ≤ 0.05) in the individual 
or global tests of significance are highlighted in bold. P-values attaining nominal significance in the 
individual test of significance were corrected by permutation analysis at the single-test (st) and 
experiment-wise (ew) levels. Corrected p-values are displayed in parentheses.  Alleles forming the 
novel haplotype identified in the German sample are indicated in italics. Haplotypes attaining nominal 
significance at the Nyholt-corrected significance threshold of p ≤ 0.0016 in the Scottish 1 sample 
(Thomson et al., 2007) are presented for comparison. Matching colours indicate corresponding 
haplotypes in the original Scottish 1 sample and current analysis.  
 
 
2.4.3.2.1 Scottish 2 and German case-control samples 
 
None of the haplotypes identified by Thomson et al. (2007) were found to be significant in 
either the Scottish 2 or the German case-control sample. A novel three-SNP region B 
haplotype (C-A-C) was identified as significant in bipolar disorder cases in the German 
sample at the individual (uncorrected pi = 0.020) but not global (uncorrected pg =0.353) 
level of significance. However, following correction by permutation analysis the individual 
p-value was not statistically significant (corrected pst= 0.128).  
 
2.4.3.2.2 Merged Scottish and Merged All case-control samples 
 
The three-SNP region A haplotype (T-T-T), which was nominally associated with 
schizophrenia in the Scottish 1 sample (Thomson et al., 2007), was significantly associated 
with schizophrenia in the Merged Scottish sample in the individual (uncorrected pi = 0.028) 
but not the global test (uncorrected pg = 0.168) of significance. However, this association did 
not survive multiple testing correction (corrected p = 0.208).  
In keeping with the Scottish 1 sample, the two-SNP region B haplotype involving SNPs 
rs6988339 and rs3757930 (G-C) was significantly associated with schizophrenia and the 
combined case group in the Merged Scottish sample in both the individual (schizophrenia: 
uncorrected pi = 0.0037; combined cases: uncorrected pi = 0.0080) and global 
(schizophrenia: uncorrected pg = 0.030; combined cases: uncorrected pg =0.029) haplotype 
tests. These associations remained significant after correction of individual p-values by 
permutation analysis (schizophrenia: corrected pst = 0.022; combined cases: corrected pst = 




0.044). This haplotype was more common in cases (schizophrenia: 32.9%, combined cases: 
32.0%) than controls (27.3%), conferring an increased disease risk (schizophrenia: OR = 1.3, 
95% CI: 1.1-1.6; combined cases: OR = 1.2, 95% CI: 1.1-1.5). This haplotype was also 
associated with the combined case group in the Merged All group in the individual 
(uncorrected pi = 0.045) but not the global (uncorrected pg = 0.108) test of significance. The 
association in the Merged All group did not remain significant after permutation analysis 
(corrected pst = 0.139).  
2.4.3.2.3 Imputation of the missing region B haplotype 
 
In an attempt to compensate for the genotyping failure of one of the region B SNPs 
(rs2919390) in the Scottish 2 sample, the ability of the two-SNP (rs6988339 and rs3757930) 
region B haplotype to predict the three-SNP region B haplotype was assessed in the Scottish 
1 sample. Genotype data was uploaded to Haploview v4.2 and r
2
 calculated as a measure of 
LD between the two- and three-SNP region B haplotypes. The two SNP G-C haplotype, 
which was significant in the Merged Scottish sample, was found to predict the three-SNP A-
G-C haplotype , which was significantly associated with schizophrenia and the combined 
case group in the Scottish 1 sample (Thomson et al., 2007), with an r
2
 of 0.97 (figure 2.5). It 
therefore seems likely that the same three-SNP haplotype would show significant association 








































Figure 2.5.  Prediction of the three-SNP region B haplotype from the two-SNP (rs6988339 and 
rs3757930) haplotype. The ability of the two-SNP region B haplotype (GC), which was 
significantly associated with schizophrenia and the combined case group in the Merged Scottish 
sample, to predict the three-SNP region B haplotype (AGC), which was significantly associated 
with schizophrenia and the combined case group, in the Scottish 1 sample (Thomson et al., 2007), 
was assessed. Genotype data from the Scottish 1 sample for the markers composing the two- and 
three-SNP region B haplotypes was uploaded to Haploview v4.2 and r
2
 between the GC and AGC 
haplotypes calculated as a measure of LD. All possible allele combinations (individual 
haplotypes) for the two-SNP haplotype (left-hand side) and the three-SNP haplotype (right-hand 
side) are displayed. The frequency of each individual haplotype is shown to the right of the 
haplotype. Lines connecting the two- and three- SNP haplotypes indicate the co-occurrence of 
these haplotypes in greater than (i) 0% (thin lines) or (ii) 20% (thick lines) of chromosomes. The 
two-SNP G-C haplotype was found to predict the three-SNP A-G-C haplotype with r
2
 = 0.97. 
 




2.5 Summary and discussion 
 
In this chapter, association analysis was carried out to assess the involvement of six 
haplotype-tagging SNPs in NRG1, a leading candidate gene for schizophrenia, in 
schizophrenia and bipolar disorder in two independent case-control samples from Scotland 
and Germany. These SNPs were previously found to be significantly associated with 
schizophrenia and a combined schizophrenia and bipolar disorder case group in a Scottish 
sample (Scottish 1; Thomson et al., 2007). In this sample, the SNPs were found to form two 
significantly associated three-SNP haplotypes, one located at the 5’ end of the gene (region 
A) and the other located at the 3’ end of the gene (region B). In addition to testing 
association in the two new case-control samples, two merged samples were assessed: the 
Merged Scottish sample comprised the Scottish 1 sample and the new Scottish sample 
(Scottish 2), and the Merged All sample comprised the two Scottish samples and the German 
sample. 
 
Individual analyses of the two novel case-control samples failed to replicate any of Thomson 
et al.’s (2007) previously reported associations. On combining the two Scottish samples, the 
two-SNP region B haplotype (rs6988339 and rs3757930) was found to be significantly 
associated with schizophrenia and the combined case group, with these associations 
withstanding correction for multiple testing by permutation analysis. Association was always 
to the G-C haplotype, consistent with Thomson et al.’s (2007) findings. No associations in 
the Merged All sample remained significant after permutation correction. 
 
Unfortunately, one of the region B SNPs (rs2919390) failed to genotype in the Scottish 2 
sample. Thus, only two haplotype-tagging SNPs in region B could be analysed in this 
sample. By considering the LD between the two- and three-SNP region B haplotypes in the 
Scottish 1 sample, the ability of the two-SNP haplotype to predict the three-SNP haplotype 
was assessed. This revealed a high level of predictability, with the two-SNP haplotype that 
showed significant association in both the Scottish 1 and the Merged Scottish samples 
predicting the three-SNP haplotype that was significantly associated in the Scottish 1 sample 
on 98.9% of occasions. It is therefore likely that very little information was lost by the 
failure to genotype the region B SNP, rs2919390, and it seems fair to conclude that had this 
SNP not failed to genotype, the three-SNP region B haplotype would have been likely to 




show significant association in the schizophrenia and combined case groups in the Merged 
Scottish sample. 
 
The interpretation of association findings in studies of psychiatric illness is complicated by 
both heterogeneity at the level of observable phenotypes and a lack of understanding of the 
underlying genetic architecture. Both issues call into question the rationale of performing 
association studies to detect genetic loci that contribute to disease susceptibility. This 
uncertainty opens both positive and negative association findings up to several equally 
plausible explanations, which can often only be differentiated between by further studies.  
 
A fundamental assumption behind the use of association analysis is that the genetic 
contribution to the disorder in question involves several common variants whose effects are 
detectable at the population level. This assumption essentially re-states the polygenic 
common disease common variant (CDCV) hypothesis of psychiatric illness, which describes 
a situation in which, within an individual, the combined effect of several common variants of 
modest effect size in different genes contributes to disease predisposition. To accommodate 
the fact that diagnostic status is a discrete variable, a liability threshold was invoked: 
although the underlying distribution of liability is continuous, only those individuals who 
pass a minimum burden of common variants actually get the disease (Falconer, 1989). 
Although the CDCV hypothesis is just one of many hypotheses of the potential genetic 
architecture of psychiatric disorders, is has, historically, been the most widely accepted. In 
recent years, however, the premises of this hypothesis have been called into question, and the 
plausibility of other hypotheses considered (Mitchell, 2012; Mitchell and Porteous, 2011). 
These authors have argued that epidemiological observations of schizophrenia and bipolar 
disorder are compatible with the effects of multiple rare mutations occurring in a large 
number of genes, with mutations in different genes contributing to disease pathogenesis in 
different individuals (i.e. genetic heterogeneity). It is suggested that whilst, within an 
individual, the presence of a certain rare mutation may be necessary for disease onset, the 
resultant phenotype will be dependent on the genetic background (Mitchell and Porteous, 
2010).  
 
In light of this uncertainty, the results presented in this chapter must be interpreted with 
caution. Assuming a CDCV model, it can be predicted that an increase in sample size would 
confer an increase in statistical power, and thus greater likelihood of detecting association to 




variants of small effect size. A corollary of this argument is that failure to replicate findings 
between samples is likely to be attributable to random sampling effects rendering (at least 
some of) the samples unrepresentative of the populations from which they were drawn, 
assuming, of course, that the samples are not drawn from genetically divergent populations. 
As such, the positive findings in the Scottish 1 sample (Thomson et al., 2007) may have been 
products of the “winner’s curse” (Trikalinos et al., 2004), the well-documented phenomenon 
whereby initial estimates of effect size are often inflated compared to subsequent estimates. 
The reduced effect sizes detected in the Merged Scottish sample would be likely to represent 
a more accurate depiction of effect size in the population; these effect sizes are in-line with 
results from genome wide association studies (Cichon et al., 2009). The absence of 
significant associations in the two new samples could reflect insufficient statistical power to 
detect effects of the magnitude estimated by the Merged Scottish sample. Under the CDCV 
model, the lack of significant associations in the Merged All sample is more difficult to 
interpret. One explanation is that the further increase in sample size following the addition of 
the German sample to the two Scottish samples resulted in an even more accurate estimate of 
effect size, and thus that variants in the NRG1 regions assessed do not confer susceptibility 
to schizophrenia and/or bipolar disorder in either of these populations. Alternatively, 
systematic differences may have existed between the Scottish and German cases, rendering 
invalid their combination in one sample.  
 
One potential source of systematic difference between the Scottish and German samples is 
LD structure. Differences in LD structure could result in a haplotype tagging a susceptibility 
variant in one sample but not another sample. This difference could either reflect a true 
difference in the LD structure of the populations that the samples are drawn from, or be the 
result of random sampling effects. Too few markers were genotyped in the present study to 
examine the LD structure of the different samples. However, previous comparison of LD 
structure between different European populations has found that whilst similar patterns of 
LD are found in different populations, there are some genomic regions where shifts in the 
bounds of LD blocks can be observed (Mueller et al., 2005). The authors concluded that 
“The observed population differences in haplotype frequencies and LD structure may affect 
the power to detect phenotype-genotype associations”. Whilst Mueller et al., (2005) did not 
include any samples drawn specifically from Scotland, or even the United Kingdom, in their 
analysis, their findings highlight the possibility of differences in the LD structure of the 
Scottish and German populations. 




The SNPs genotyped in the present study had previously been identified as haplotype-
tagging SNPs in the initial NRG1 association study in the Scottish 1 sample carried out by 
Thomson et al. (2007). As such, these SNPs were specifically selected to efficiently capture 
genetic variation within their haplotype blocks. Nevertheless, rare variants and haplotypes 
present in this region would not necessarily have been captured by the genotyped variants 
(when Thomson et al. (2007) defined the NRG1 haplotype structure, haplotype-tagging SNPs 
were selected from SNPs with MAF at least 10% to tag haplotypes of greater than 10% 
frequency). As such, it is possible that functional variants were not effectively captured by 
the current analyses. One approach to further investigating the genetic variation present at 
this locus would be to genotype a larger number of variants in a larger number of subjects 
(i.e. deep genotyping); however, this approach will always be limited by its inability to 
capture as-of-yet unknown sequence variants. Re-sequencing of the NRG1 locus, in contrast, 
would permit an unbiased assessment of the variants present in this region. 
 
It is possible that certain NRG1 variants only confer risk for psychiatric illness on a 
particular genetic background. As such, between-samples differences in genetic background 
might have influenced the power of each sample to detect risk variants in LD with the 
markers/haplotypes analysed. It is possible that any differences between samples reflect true 
population differences between the Scottish and German populations in genetic background. 
Such heterogeneity amongst different European populations has been demonstrated for 
another schizophrenia- and bipolar disorder-risk gene, DISC1 (Hennah et al., 2009).To 
investigate this heterogeneity, Hennah et al. (2009) used conditional association analysis and 
found a DISC1 variant that confers risk only on certain genetic backgrounds. It is already 
known that variants within NRG1 interact epistatically with each other and with variants in 
ERBB4, which encodes an NRG1 receptor, and the schizophrenia-risk gene AKT1 
(Nicodemus et al., 2009). Furthermore, a functional interaction has been detected between 
NRG1 and DISC1 that is mediated by ErbB2 and ErbB3 receptors and PI3/Akt signalling 
(Seshadri et al., 2010). Together, these findings suggest that genotype at many functionally 
relevant loci will ultimately determine the phenotypic effect of variants within NRG1. 
 
Phenotypic differences between the cases included in the Scottish and German samples 
represents a further potential confound. A potential source of between-samples variation is 
the difference in inclusion criteria for bipolar disorder used in the Scottish and German 
samples: the Scottish samples included individuals diagnosed with both bipolar disorder 1 




and bipolar disorder 2, whereas the German sample only included individuals with bipolar 
disorder 1. Furthermore, it is possible that systematic differences were introduced between 
the Scottish and German cases if the diagnoses made by the Scottish and German clinical 
teams were affected by different biases. In the study of conditions, such as psychiatric 
illnesses, where there is no established diagnostic marker, this latter concern is particularly 
pertinent. 
 
The issue of phenotypic heterogeneity is of serious concern when considering the validity of 
using association analysis to study psychiatric illnesses. The diagnostic categories of 
schizophrenia and bipolar disorder are broad (even when considering bipolar disorder 1 and 
2 separately) and can result in patients diagnosed with the same disorder sharing few 
symptoms. In light of this phenotypic heterogeneity there is no reason to assume that 
schizophrenia or bipolar disorder represent unitary conditions in terms of their underlying 
aetiology. As such, it is not surprising that association studies in which the only inclusion 
criterion for cases is diagnostic status often yield either no significant findings, or findings 
that are not replicable. Even if a CDCV model operates within specific disease subtypes, the 
pooling together of all cases with a given diagnosis will significantly diminish statistical 
power to detect associated variants.  
 
Phenotypic heterogeneity also has significant implications for the predicted genetic 
architecture of psychiatric illness. If conditions such as schizophrenia and bipolar disorder 
are no longer considered as unitary, then it follows that each condition may in fact consist of 
several genetically distinct conditions that happen to share varying degrees of phenotypic 
overlap. This possibility calls into question the dogma that these conditions are common, and 
thus the rationale of the CDCV model. A strong argument against the involvement of rare 
variants of large effect size in psychiatric illness is that such variants would have been 
detected with ease by genetic linkage and association studies. As both of these approaches 
have been limited in their success in identifying variants of large effect size, the CDCV 
model gained in favour. However, the results obtained from association analyses are also 
compatible with a scenario in which the case groups consist of several different sub-
conditions, each individually rare, caused by different rare mutations. When considered at 
the sample level, the estimated effect size of a rare mutation would be diluted compared with 
its effect within a particular sub-condition. Furthermore, it is possible that genotyped 
variants tag several rare variants of large effect size. Association to the genotyped variant 




may, therefore, represent different rare variants acting in different individuals. As such, a 
rare variant model could explain the pattern of positive and negative associations detected in 
the current study. 
 
There is evidence to suggest that phenotypic heterogeneity in schizophrenia and bipolar 
disorder can be related to particular NRG1 variants. Several studies have demonstrated 
association of NRG1 variants with particular aspects of psychiatric illness (Bramon et al., 
2008; Goes et al., 2009; Hall et al., 2006; Prata et al., 2009; Sei et al., 2007). The assessment 
of association in phenotypically homogenous samples selected for relevant endophenotypes 
may, therefore, represent an improvement over the study of cases selected solely on 
diagnostic status. The validity of this approach will, however, depend upon the rarity of the 
mutations involved and the specificity of the relationship between genotype and 
endophenotype. Nevertheless, such an approach has the potential to detect pathways whose 
disruption contributes to a given endophenotype, and thus has the potential to identify novel 
therapeutic targets. It is, however, important to note that even if genetic variants are detected 
that play a causal role in determining variation in an endophenotype, these variants may 
represent modifiers of disease-risk rather than causal variants per se. It has been suggested 
that endophenotypes of psychiatric illness, such as cognitive deficits, may be indicative of a 
brain that is less well-adapted for dealing with the effects of disease-causing rare mutations; 
thus, such endophenotypes may frequently co-occur with, but not play a directly causal role 




To conclude, this study found no evidence for association to region A and produced evidence 
consistent with, but not indubitably supportive of,  the presence of a risk variant for 
schizophrenia and/or bipolar disorder within, or in LD with, region B in an enlarged Scottish 
case-control sample. 
 
The observations of (i) failure to replicate Thomson et al.’s (2007) initial association of 
NRG1 region B haplotype with schizophrenia and/or bipolar disorder in the second Scottish 
sample and (ii) continued support, albeit with reduced effect size, for the involvement of a 
variant in this region in the Merged Scottish sample suggests two possible conclusions. 
Firstly, a variant in LD with region B haplotype might confer risk for schizophrenia and/or 




bipolar disorder in the Scottish population, with the increased sample size of the Merged 
Scottish sample permitting a more accurate assessment of the effect size of this variant. 
Alternatively, the initial association of the region B haplotype in the first Scottish sample 
(Thomson et al., 2007) may, due to random sampling error, not be representative of the 
involvement of this region in susceptibility to psychiatric illness in the Scottish population. It 
will only be possible to distinguish between these two interpretations with further studies, 
which should be designed so as to minimise the potential confounds of genetic and 
phenotypic heterogeneity. 
  
These findings should be interpreted in the context of a substantial body of genetic and 
functional evidence supporting the candidacy of NRG1 as a schizophrenia- and bipolar 
disorder-susceptibility gene. Failure to find evidence for association in the two new samples 
when analysed individually raises questions regarding the impact of allelic, genotypic, and 
phenotypic heterogeneity on the comparability and representativeness of different case-
control samples. These issues highlight limitations in our understanding of the genetic 
architecture of psychiatric illnesses and, therefore, the potential limitations of association 
analysis. Our lack of understanding of the genetic architecture of psychiatric illness makes it 
difficult to predict how the role of candidate risk genes, such as NRG1, would be most 
usefully assessed. Association analysis of more phenotypically homogenous samples may be 
more likely to identify risk variants; however, as discussed previously, the validity of this 
approach is subject to caveats. While deep genotyping may improve the validity of 
association analysis, if very rare variants within NRG1 do play a role in the pathogenesis of 
psychiatric illness, then they are only likely to be detected through the sequencing of large 
numbers of affected individuals. A recent study in which the regions ~3kb upstream of the 
transcription start sites of the NRG1 type I, type II/IV, and type III isoforms were 
resequenced in individuals with schizophrenia and control subjects found an increased load 
of rare novel variants in cases (Weickert et al., 2012), highlighting the potential of this 
approach to elucidate the contribution of variation in NRG1 to psychiatric illness. 
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Genetic and functional evidence highlight DISC1 as one of the leading candidate genes for 
psychiatric illness. Nevertheless, relatively little is known about how variation in the gene 
might confer risk for major mental illness. One potential mechanism is via the dysregulation 
of DISC1 expression. This chapter describes the first characterisation of the DISC1 promoter 
region. Improved understanding of the mechanisms governing wildtype DISC1 regulation 
will permit predictions to be made about the effects of variants. Some of the work presented 
in this chapter has previously been published (Walker et al., 2012). 
 
3.1.1 DISC1 expression and susceptibility to psychiatric illness 
 
3.1.1.1 Evidence for the role of altered DISC1 expression in conferring 
susceptibility to psychiatric illness 
 
DISC1 was first identified in a large Scottish family in which a balanced chromosomal 
translocation t(1;11) (q42.1;14.3) disrupting the DISC1 locus segregates with schizophrenia, 
bipolar disorder, and recurrent major depression (Millar et al., 2000b; St Clair et al., 1990). 
Lymphoblastoid cell lines derived from carriers of the t(1;11) translocation have been found 
to have a 50% reduction in the expression of DISC1 protein (Millar et al., 2005). The 
findings from subsequent studies investigating DISC1 expression in psychiatric illness have, 
however, been equivocal. Some studies (Maeda et al., 2006; Nakata et al., 2009; Olincy et 
al., 2012; Sawamura et al., 2005) have identified altered DISC1 expression in individuals 
diagnosed with psychiatric illnesses, whereas others (Dean et al., 2007; Rastogi et al., 2009) 
have not identified any such differences. One study (Lipska et al., 2006) reported no change 
in DISC1 mRNA expression in the dorsolateral prefrontal cortex or the hippocampus in 
patients with schizophrenia, but identified a significant increase of ~20% in hippocampal 
DISC1 protein expression in patients. Furthermore, this study reported a positive correlation 
between DISC1 mRNA and protein expression in the hippocampus.  
 
Several factors could underlie the lack of consistency between the above studies, including 
differences in the composition of the patient groups: dysregulated DISC1 expression might 
contribute to the pathogenesis of the disease only in some cases. Other factors such as 
differences in the brain regions assessed and differences in the DISC1 transcripts quantified 
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might also have contributed to the lack of consensus between these studies. Furthermore, it is 
important to note that the demonstration of altered mRNA expression does not necessarily 
indicate a change in protein expression. These factors are discussed further in section 3.5. 
 
Whilst not a direct assessment of gene expression, the presence of copy number variation in 
a region is at least suggestive of altered expression of the affected genes. Two studies have 
reported the presence of copy number variants (CNVs) involving the DISC1 locus in 
individuals diagnosed with autism spectrum disorders: Williams et al. (2009) reported the 
case of a boy with autism spectrum disorder who was found to have a deletion involving 
DISC1, DISC2, and TSNAX, and Crepel et al. (2010) identified a duplication involving seven 
genes, including DISC1, in two brothers with autism and mild mental retardation. In a 
genome-wide association analysis of CNVs with schizophrenia, Glessner et al. (2010) 
identified an association between large CNVs (≥100kb) affecting DISC1 and schizophrenia. 
The key question, however, when discussing CNVs in relation to gene expression is to what 
extent do changes at the DNA level resulting from CNVs result in altered gene expression? 
Assessment of the relationship between CNVs and gene expression in cell lines from 
individuals in the HapMap project revealed that CNVs could account for almost 18% of the 
variation in mRNA expression (Stranger et al., 2007). The relationship between CNVs and 
protein expression may, however, be less direct: a study in cancer cells revealed that in most 
cases there is no correspondence between gene copy number and the level of protein 
expression, although the protein expression of some oncogenes and tumour suppressor genes 
was found to be affected by gene copy number (Geiger et al., 2010). In light of these 
findings, it would be of interest to investigate the relationship between CNVs and gene 
expression in individuals diagnosed with psychiatric illnesses. 
 
3.1.1.2 Evidence for the role of sequence variation in the DISC1 upstream region 
in the regulation of DISC1 expression 
 
Studies examining the effect of polymorphisms in the upstream region of DISC1 on DISC1 
gene expression are somewhat limited: to date, only three studies have been carried out 
(Carless et al., 2011; Hayesmoore et al., 2008; Hennah and Porteous, 2009). Of these three 
studies, two looking at the effect of single nucleotide polymorphisms (SNPs; Hennah and 
Porteous, 2009; Carless et al., 2011) have identified SNPs in the DISC1 upstream region that 
are associated with DISC1 expression level.  
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Using data available from publicly available databases, Hennah and Porteous (2009) 
assessed 754 SNPs located in the region from 10kb upstream of TSNAX to 10kb downstream 
of DISC1 for association with DISC1 expression values drawn from 210 lymphoblastoid cell 
lines from the four HapMap cohorts (CEU: Utah residents with Northern and Western 
European ancestry from the CEPH collection; YRI: Yoruba in Ibadan, Nigeria; CHB: Han 
Chinese in Beijing, China ; and JPT: Japanese in Tokyo, Japan). Only one SNP, rs1765778, 
which is located 30kb upstream of DISC1 demonstrated association in all four populations, 
and a further five SNPs were found to be associated in three of the four populations, with the 
common exception being the Japanese population. In all cases, the minor allele (G), as 
defined by allele frequencies in the CEU population was found to be associated with 
decreased DISC1 expression. 
 
Many more SNPs were found to be significantly associated with DISC1 expression level in a 
study carried out by Carless et al. (2011). The greater number of associated SNPs could be 
attributable to the fact that this study was carried out in a larger sample (1232 individuals). 
Fifteen SNPs in the DISC1 promoter region (defined as the region ~2kb upstream of the 
gene) were identified as being associated with DISC1 expression level; of these fifteen 
SNPs, only one, rs3738398, which is located 221 bp upstream of the DISC1 transcription 
start site (TSS), overlapped with the SNPs identified by Hennah and Porteous (2009). The 
direction of effect for this SNP was consistent between the two studies. 
 
A different approach to the identification of SNPs involved in the cis-regulation of DISC1 
expression was taken by Hayesmoore et al. (2008). In this study individuals heterozygous for 
a SNP, rs3738401, located in DISC1 exon 2, were assessed for expression imbalance 
between the maternally and paternally inherited transcripts. One individual was found with 
such an expression imbalance. Sequencing of the region extending approximately 1kb 
upstream of the DISC1 TSS revealed a novel insertion polymorphism, a tandem duplication 
of the 22 nucleotides located -168 to -147 relative to the DISC1 TSS. The duplication 
affected a dinucleotide repeat region, such that chromosomes carrying the duplicated 
sequence carried one (TG)8 repeat and one (TG)10 repeat. Variation in the numbers of repeats 
in dinucleotide repeat regions has previously been associated with regulation of promoter 
activity (Borrmann et al., 2003; Wang et al., 2005). In the case of the DISC1 promoter, 
however, Hayesmoore et al. (2008) concluded that that the repeat was not per se functional, 
as individuals who did not show allelic expression imbalance were also heterozygous for the 
number of TG repeats in the repeat region.  




It is worth noting that cis-regulatory mechanisms involved in the control of DISC1 
expression will, to varying extents, operate in a tissue-specific and developmental period-
specific manner. This will, in part, reflect between-tissue and developmental variation in the 
expression of transcription factors. As such, the three studies carried out to date, which have 
been carried out in adult subjects and have investigated expression in lymphoblastoid cell 
lines (Hennah and Porteous, 2009), lymphocytes (Carless et al., 2011) and the post-mortem 
brain (Hayesmoore et al., 2008), are likely to have identified variants affecting the function 
of only a small number of the cis-regulatory modules present upstream of DISC1. In order to 
establish a more comprehensive understanding of the cis-regulatory control of DISC1 
expression the effect of sequence variants in the DISC1 putative promoter region should be 
studied in a range of tissues across development. Moreover, it will be of particular interest, 
in the context of psychiatric illness, to identify variants affecting region- and cell-specific 
expression of DISC1 in the brain. 
 
3.1.1.3 Evidence for the involvement of sequence variation in the DISC1 upstream 
region in conferring susceptibility to psychiatric illness 
 
A key question when relating the experiments carried out in this chapter to the field of 
psychiatric genetics is whether variation in, or in linkage disequilibrium with, the DISC1 
promoter region has been shown to be associated with the diagnosis of psychiatric illness or 
related endophenotypes. Perhaps one of the most obvious variants to consider in relation to 
this question is rs3738398, the SNP identified by both Hennah and Porteous (2009) and 
Carless et al. (2011) as being associated with DISC1 expression level. Hennah et al. (2003) 
identified the C allele of this SNP as participating in a haplotype that was understransmitted 
from parents to female offspring diagnosed with schizophrenia, and, in an initial study, 
Kockelkorn et al. (2004) identified the association of this variant with schizophrenia, with 
the G allele being more prevalent amongst cases (figure 3.1). However, upon analysis of a 
larger sample, Kockelhorn et al. (2004) found that the association was no longer significant. 
This latter result is in keeping with subsequent association studies that also found no 
evidence for association between this SNP and schizophrenia and mood disorders (Arai et 
al., 2007; Saetre et al., 2008; Schumacher et al., 2009). Similarly, Carless et al. (2011) found 
no association between this SNP and performance on several neurocognitive measures 
relevant to psychiatric illness. It is, of course, possible that this SNP only confers risk in the 
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context of other variants; association analysis conditioned on the presence of genotype at 
other variant(s) could be performed to assess this hypothesis. 






Figure 3.1. Schematic showing the genomic locations of variants and haplotypes in the DISC1 upstream region that have been associated with psychiatric illness. The genomic 
locations (UCSC human genome browser, hg19) of associated haplotypes and variants are indicated by black rectangles. Track names indicate the study in which significant 
association was detected. The locations of DISC1 (long variant) and the upstream gene TSNAX are shown for reference, and the transcription start site (TSS) of each gene is 
indicated by an arrow. Thomson et al. (2005) detected association between an eight-marker haplotype and bipolar disorder in males. Cannon et al. (2005) found a four-marker 
haplotype to be associated with schizophrenia. Schosser et al. (2010) identified a three-marker haplotype as being associated with both bipolar disorder and major depressive 
disorder (1) and a two-marker haplotype as being associated with bipolar disorder (2). Schumacher et al. (2011) identified an eight-marker haplotype as being associated with 
schizophrenia. Hennah et al. (2003) identified a three-marker haplotype as being under-transmitted to females with schizophrenia. Kockelkorn et al. (2004) found both the TG 
dinucleotide repeat polymorphism (1) and the SNP rs3738398 (2) to be associated with schizophrenia in an initial sample, but failed to replicate these associations in a larger 
sample. 




Several haplotypes spanning the DISC1 upstream region have been found to show significant 
association to psychiatric illnesses, supporting the notion that variation in this region might 
contribute to illness susceptibility (Cannon et al., 2005; Hennah et al., 2003; Schosser et al., 
2010; Schumacher et al., 2009; Thomson et al., 2005) (figure 3.1). One potential mechanism 
for this risk is via the disturbance of neural systems required for normal cognitive function: 
the four-marker haplotype identified by Cannon et al. (2005) as being associated with 
schizophrenia was also associated with visuospatial working memory, verbal learning and 
memory, and reaction time to visual targets, independent of diagnostic status. Identification 
of the functional variants responsible for these positive association and linkage findings is, 
however, necessary before speculating too much on the possible mechanisms of their action. 
It should also be noted that, to date, no GWAS study has identified variation in the DISC1 
promoter region as conferring risk for schizophrenia or bipolar disorder at the level of 
genome-wide significance. Nevertheless, as discussed in section (1.6.2.3), failure to identify 
association by GWAS does not negate the potential pathogenic contribution of variation in 
this region. 
 
The polymorphic TG dinucleotide repeat region located upstream of DISC1 investigated by 
Hayesmoore et al. (2008; discussed in section 3.1.1.2) occurs in tandem with a polymorphic 
CG dinucleotide repeat region. This region, which has the sequence (TG)8(CG)8 in the 
UCSC human genome browser  (chr1: 231762399-231762430, hg19), was assessed for 
association with schizophrenia by Kockelkorn et al. (2004; figure 3.1). In keeping with the 
findings for rs3738398, the number of TG repeats was found to be associated with 
schizophrenia in the initial sample, but not the larger sample. One explanation for these 
results is that the findings in the initial, smaller, sample were due to random variation 
resulting from the small sample size; alternatively, it is possible that the compositions of the 
two samples differed, and that variation in these repeats is associated with a phenotype that 
was more prevalent in the small sample. A lack of evidence for association between the 
length of the TG repeat region and schizophrenia and mood disorders was also reported by 
Devon et al. (2001) and Arai et al. (2007); however, it should be noted that the assay 
implemented by Devon et al. (2001) did not distinguish between the (TG)n polymorphism 








3.1.2 Sequence features of promoter regions 
 

















The eukaryotic core promoter comprises the genomic region extending approximately 35 bp 
upstream and downstream of the TSS. In this region, the basal transcription factors, the 
factors minimally essential for transcription, interact with the DNA sequence to mediate 
transcription. Initial studies of core promoter regions highlighted the TATA box as a key 
feature required for transcription (Breathnach and Chambon, 1981). The TATA box, which 
has the consensus sequence TATAWAAR, is present approximately 31 bp to 26 bp upstream 
of the TSS (figure 3.2) (Smale and Kadonaga, 2003). Transcription from TATA box-
containing promoters is initiated by the binding of the TATA box by TATA box binding 
protein (TBP), a component of the multiprotein complex, transcription factor IID (TFIID). 
Other basal transcription factors (TFIIA-H), including RNA polymerase II, then bind to form 
the preinitiation complex and transcription is initiated at a site approximately 30 bp 
downstream. However, as an increasing number of core promoter regions have been 
identified, it has become apparent that only a minority (10-20%) include a TATA box 
(Cooper et al., 2006; Gershenzon and Ioshikhes, 2005). Those genes transcribed from TATA 
 
Figure 3.2. Schematic of core promoter elements that can contribute to basal transcription. 
Motifs are depicted by filled rectangular boxes and their usual location relative to the 
transcription start site (where the transcription start size is +1) indicated above. The name and the 
consensus sequence of each core promoter element are given in the boxes below. Consensus 
sequences are denoted in IUPAC notation for degenerate nucleic acids (R= A or G; S = C or G; V 
= A or C or G; W = A or T; Y = C or T). The direction of transcription is indicated by the arrow 
above the Initiator. 
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box-containing promoters tend to encode proteins expressed only in specific tissues or 
contexts (Schug et al., 2005).  
 
The initiator (Inr) is a core promoter element, located -2 to +4 bp relative to the TSS, which 
can occur both in TATA box-containing and TATA-less promoters. The Inr consensus 
sequence, YYANWYY, comprises an adenosine at the +1 position, surrounded, 
predominantly, by pyrimidines (figure 3.2; Smale and Kadonaga, 2003). The Inr can bind 
TFIID via components known as TBP-associated factors (TAFs), and it does not appear to be 
essential for the TBP component to interact with DNA sequence in the -30 bp region in 
TATA-less promoters for transcription to occur (Martinez et al., 1995). Experiments in 
which the Inr has been deleted, or inserted into promoters that naturally do not contain an Inr 
have demonstrated that the presence of an Inr results in high levels of transcription from a 
specific start site (Smale and Kadonaga, 2003).  
 
The downstream promoter element (DPE) is a core promoter element located +28 to +32 bp 
relative to the TSS, usually found in promoters lacking a TATA box but containing an Inr 
(Smale and Kadonaga, 2003). The DPE is a TFIID recognition site with the consensus 
sequence RGWYV, which is additionally often associated with the presence of a guanine 
nucleotide at position +24 (figure 3.2). The Inr and the DPE appear to function as a unified 
core promoter element: the binding of TFIID binding and basal transcriptional activity is 
eliminated by mutation of either the Inr or the DPE (Burke and Kadonaga, 1996), and 
decreased by alteration of the spacing between the Inr and the DPE (Kutach and Kadonaga, 
2000). 
 
Another core promoter element located downstream of the TSS is the motif ten element 
(MTE) (Lim et al., 2004). This element has the consensus sequence CSARCSSAAC, is 
located at +18 to +27 bp relative to the TSS (figure 3.2), and, in common with the DPE, acts 
together with the Inr to bind TFIID (Lim et al., 2004).  
 
The transcription factor II B recognition element (BRE) is marked out by being one of the 
only core promoter elements not to recognise TFIID. The BRE is situated upstream of the 
TATA box, at approximately -37 to -32 bp relative to the TSS, and has the consensus 
sequence SSRCGCC (figure 3.2; Smale and Kadonaga, 2003). The function of the BRE 
remains to be fully understood: in archaeal promoters, the interaction of the BRE with 
transcription factor B serves to enhance the assembly of the preinitiation complex, and thus 
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transcription, whereas studies in humans suggest that binding of TFIIB to the BRE can 
sometimes exert a repressive effect on transcription (Smale and Kadonaga, 2003). 
 
3.1.2.2 Transcription factor binding sites 
 
The core promoter motifs described above are sufficient for the assembly of the preinitiation 
complex and can, therefore, support a basal level of transcription. To fine-tune this 
transcription additional gene-specific transcription factors (henceforth referred to as 
transcription factors) are required. The binding of these transcription factors to cis-regulatory 
sites can support or repress transcription from a promoter, thus permitting control over where 
and when a gene is expressed. Modulation of transcriptional activity by transcription factors 
is achieved via the recruitment of co-activators and co-repressors. Co-activators include 
histone modifying enzymes and chromatin remodelling enzymes that act to promote an open 
chromatin structure required for transcription (Spiegelman and Heinrich, 2004). Other co-
activators operate by recruiting RNA polymerase II and interacting with the basal 
transcription factors (Spiegelman and Heinrich, 2004). Co-repressors are frequently 
associated with histone deacetylase activity (Spiegelman and Heinrich, 2004), which 
promotes a closed chromatin structure (Cress and Seto, 2000). Co-repressors have also been 
identified that block transcription via direct interaction with basal transcription factors 
(Burke and Baniahmad, 2000). 
 
The identification of transcription factor binding sites (TFBSs) presents a challenge: TFBSs 
consist of short, degenerate sequences that occur frequently in the genome (Bulyk, 2003); as 
such, not all binding sites are functional (Whitington et al., 2009). In fact, between-promoter 
variability in the binding site for a given transcription factor, and thus variability in the 
affinity of the site for the transcription factor, is thought to be one mechanism by which 
diversity in gene expression levels can be generated (Stormo, 2000). Computational 
programs can, therefore, aim only to infer the binding potential of a site but cannot determine 
functionality (Cartharius et al., 2005). The computational identification of putative TFBSs 
has been greatly aided by the development of positional weight matrix (PWM) 
representations of known binding sites. PWMs represent the likelihood of finding a 
particular nucleotide at each location in a binding site, thus permitting assessment of the 
similarity between a given transcription factor binding site and a DNA sequence of interest 
(Cartharius et al., 2005; Stormo, 2000). Additional tools to identify functional TFBSs 
include inter-species comparison, on the basis that functional regulatory regions are more 
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likely to be conserved between species (see section 3.1.2.5 for further discussion of this 
issue), and the comparison of the upstream sequences of co-regulated genes within a species, 
as such genes are hypothesised to be under the regulatory control of shared pathways 
(Pennacchio and Rubin, 2001). 
 
The advent of high-throughput chromatin immunoprecipitation (ChIP) has made a 
significant contribution to the identification of TFBSs. In a standard ChIP experiment, 
transcription factors are cross-linked to their binding sites, the chromatin is sheared into 
short fragments, and the DNA fragments binding to a transcription factor of interest isolated 
by immunoprecipitation. The identity of these DNA fragments is then discerned using one of 
several possible techniques. One possibility is microarray hybridisation (ChIP-chip). The 
main limitation of microarrays is their poor spatial resolution; in this regard, high-throughput 
sequencing of the immunoprecipitated DNA fragments is superior (Ho et al., 2011). In 
comparison to purely computational approaches to TFBS identification, ChIP has the 
advantage of reflecting tissue-, or cell-, specific chromatin architecture. The study of ChIP-
ed regions of DNA is, therefore, a useful approach to narrowing down putative functional 
TFBSs. Further experimental assessment is, however, still required to determine both the 
functionality of a site and the effect of the binding of a transcription factor on promoter 
activity (i.e. whether it represses or promotes transcription) (Tijssen et al., 2011). The study 
of ChIP-identified binding sites is likely to offer particular advantages for the identification 
of TFBSs in promoters that are poorly conserved and/or that drive the expression of genes 
with few known co-expressed genes. In this regard, the use of ChIP data may be particularly 
beneficial for the identification of putative binding sites in the DISC1 promoter: The DISC1 
gene has been shown to have undergone a high level of divergence in recent evolutionary 
history (Bord et al., 2006). Although Bord et al. (2006) only examined the open reading 
frame, as evolutionary divergence was found to be particularly marked at the N-terminal of 
the gene, it seems plausible that a high level of divergence might also be evident in the 
region upstream of the TSS. 
 
3.1.2.3 CpG islands 
 
CpG islands are regions of DNA enriched for CpG dinucleotides. The CpG dinucleotide 
occurs relatively rarely: as it is a DNA methyltransferase substrate, methylation of the 
cytosine can result in deamination to form thymine, a mutation which is inefficiently 
repaired (Bird, 2002). The promoters of approximately 60% of human genes fall near a CpG 
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island (Venter et al., 2001). CpG island promoters are associated with genes that are 
constitutively activated, such as housekeeping genes, but are also found in tissue-specific 
genes (Gardiner-Garden and Frommer, 1987). Interestingly, CpG-rich promoters have been 
reported as being enriched in the brain (Gustincich et al., 2006). Investigation of the 
relationship between the presence of CpG islands and core promoter elements has revealed 
that TATA boxes, Inr and DPE elements are more common in promoters that do not contain 
CpG islands, whereas BREs are more common in CpG island-containing promoters (Blake et 
al., 1990; Gershenzon and Ioshikhes, 2005). A key difference between CpG island-
containing promoters and TATA-box containing promoters is that the former often have 
multiple TSSs whereas the latter usually only contain one TSS (Sandelin et al., 2007; Smale 
and Kadonaga, 2003). One mechanism by which CpG islands are thought to contribute to 
constitutive expression is by destabilising the chromatin structure (Ramirez-Carrozzi et al., 
2009), and thus making the DNA sequence accessible to transcription factors (see section 
3.1.2.3, below, for an introduction to the role of chromatin structure in transcription). 
 
3.1.2.4 Chromatin structure in the promoter region 
 
In order for transcription to take place the promoter region of a gene must be accessible. 
Chromatin structure plays a large part in determining the accessibility of DNA, with a lightly 
packed chromatin structure, euchromatin, promoting transcriptional activity. Initial studies of 
nucleosome occupancy in promoter regions revealed the region around the TSS to be 
depleted of nucleosomes, leading to the term “nucleosome free region” (NFR) (Ozsolak et 
al., 2007; Yuan et al., 2005). Subsequent studies have shown, however, that these NFRs do, 
in fact, contain nucleosomes that bind DNA unstably. This unstable binding of DNA was 
found to be due to the substitution of canonical histone proteins with variant histone proteins 
(Henikoff et al., 2009; Jin and Felsenfeld, 2007).  
 
Epigenetic modification of histones is another mechanism by which chromatin structure can 
be made accessible to the transcriptional machinery. Histone acetylation is a key mechanism 
for creating an open chromatin structure (Kadonaga, 1998). It has been suggested that 
acetylation reduces the ability of histones to bind DNA by neutralising positive charges at 
the lysine and arginine residues (Hong et al., 1993). In contrast to histone acetylation, the 
effects of histone methylation are more variable, with methylated histones marking areas of 
both active and repressed transcription: for example, the trimethylation of lysine 4 on histone 
H3 (H3K4me3) is frequently associated with actively transcribed genes (Barski et al., 2007; 
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Guenther et al., 2007), whereas the trimethylation of lysine 27 on histone H3 (H3K27me3) is 
generally a repressive histone modification (Cao et al., 2002; Kirmizis et al., 2004). The 
promoters of some genes have been found to carry both the activating H3K4me3 mark and 
the repressive H3K27me3 mark. These regions, termed “bivalent domains”, have been 
identified in embryonic stem cells and are thought to “poise” key developmental genes for 
lineage-specific activation or repression (Mikkelsen et al., 2007).  
 
In regions enriched for GC or TG repeats, the formation of left-handed Z-DNA, in contrast 
to the conventional right-handed B-DNA, may contribute to transcriptional activation (Liu et 
al., 2006). The Z-DNA conformation has been associated with transcriptional activity by the 
finding that transcription can induce Z-DNA formation and that Z-DNA formation near the 
promoter regions of genes can regulate their transcription in vivo (Liu et al., 2006; Liu et al., 
2001a; Wittig et al., 1992). Typically, Z-DNA is less stable than B-DNA; however, under 
certain conditions the Z-DNA conformation can be stabilised. One such condition is in 
reaction to the torsional stress created by negative superhelicity; Liu et al. (2006) propose 
that sequences rich in GC or TG repeats release negative superhelical torsion by converting 
to a Z-DNA formation. Superhelical torsion can result from the actions of ATP-utilising 
chromatin remodelling enzymes (Havas et al., 2000), and actively transcribing RNA 
polymerase (Liu and Wang, 1987; Wittig et al., 1992). It has been suggested that the zigzag 
structure of Z-DNA may promote the disruption, or even ejection, of the nucleosome (Liu et 
al., 2006), thus permitting the access of transcriptional machinery to the DNA sequence. 
 
3.1.2.5 Conservation of promoter elements 
 
As regions of functional DNA are likely to have undergone fewer substitutions than neutral 
DNA, the cross-species comparison of promoter regions can aid in the identification of 
regulatory motifs. Cross-species comparison has had mixed success in the identification of 
functional cis-regulatory elements: some studies have found a high percentage of the 
conserved non-coding regions assessed to have regulatory function in in vitro assays (Grice 
et al., 2005; Nobrega et al., 2003), while others have been less successful (Martin et al., 
2004). Key to the success of the identification of functional regulatory motifs by cross-
species comparison is the selection of the species to compare. When making this choice a 
trade-off must be made between the ability to detect functional promoter elements with high 
power and specificity, which is facilitated by the comparison of evolutionarily distant 
species, and the ability to detect the majority of functional promoter elements, facilitated by 
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the comparison of evolutionarily close species. To address this issue, Prabhakar et al. (2006) 
carried out a systematic assessment of the ability of cross-species comparison with various 
combinations of species to identify functional human cis-regulatory elements. Comparison 
with five eutherian mammals (mouse, rat, cat, cow, and pig) or six simians (human, baboon, 
colobus, squirrel monkey, owl monkey, marmoset, and dusky titi) resulted in the ability to 
detect cis-regulatory elements with a sensitivity of 53-80% and a true positive rate of 27-
67%. In contrast, comparison with more distant species failed to identify many empirically 
defined functional non-coding elements. 
 
The combination of conservation data with knowledge of functional regulatory motifs has 
been shown to be successful in identifying functional regulatory elements. ESPERR 
(evolutionary and sequence pattern extraction through reduced representation) is a 
computational approach to functional element prediction that implements this approach. 
ESPERR designates regulatory potential scores to conserved regions of the genome based on 
their similarity to known regulatory elements (Taylor et al., 2006). For the detection of cis-
regulatory modules, the use of regulatory potential scores has been shown to confer an 




The aims of this chapter were as follows: 
 
 To use bioinformatic analysis to assess the DISC1 upstream region for sequence 
features associated with promoter activity, and to use this information to select a 
series of DISC1 promoter fragments to assess experimentally for promoter activity. 
 To use dual luciferase reporter assays to assess the transcriptional activity of the 
DISC1 promoter constructs. 
 To use publicly available ChIP-seq data to identify transcription factors potentially 
involved in the regulation of DISC1 expression.  
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3.3 Materials and Methods 
 
3.3.1 In silico analysis of the DISC1 promoter region 
 
DISC1 has previously been shown by 5’ rapid amplification of cDNA ends (5’ RACE) to 
have one TSS (Nakata et al., 2009). This TSS, located at chr1: 231762561 (February 2009, 
GRCh build 37; http://genome.ucsc.edu/), was, therefore, considered as the DISC1 TSS for 
subsequent definition of the promoter region. An initial candidate promoter region extending 
from 1000bp upstream of the TSS to the translation start site (chr1: 231761561-231762613) 
was downloaded from the UCSC human genome browser (http://genome.ucsc.edu/). This 
region was used for subsequent analyses of promoter-related sequence features. 
 
3.3.1.1 Detection of canonical core promoter motifs 
 
The candidate DISC1 promoter region was assessed for canonical core promoter motifs 
using the eukaryotic core promoter predictor program YAPP, 
(http://www.bioinformatics.org/yapp/cgi-bin/yapp.cgi), which permits the user to search for 
core promoter elements, and synergistic combinations of these elements, in their expected 
location relative to a known TSS  (table 3.1). Following a previously described method 
(Cartharius et al., 2005), the test sequence was compared against positional weight matrix 
representations (table 3.2) of core promoter elements to calculate a matrix similarity score, 
which only reaches one when the test sequence corresponds to the most conserved nucleotide 
at every position of the matrix. Searches were carried out using similarity score thresholds of 
0.8, 0.7, and 0.6.  
 
CpG islands were identified using the “CpG Islands” track of the UCSC human genome 
browser. CpG islands represented by this track have been defined according to the following 
criteria: GC content of 50% or greater, length greater than 200 bp, and a ratio of greater than 
0.6 of the observed number of CG dinucleotides to the expected number of CG dinucleotides 


























Core promoter element Location searched (base pair relative to TSS) 
Start  Stop  
Transcription factor IIB recognition element -43 -31 
TATA box -35 -24 
Initiator  -3 -1 
Motif ten element > 16 > 18 
Downstream promoter element > 27 > 29 
 
Table 3.1. Core promoter elements searched for in the DISC1 putative promoter region. Core 
promoter elements were searched for using the YAPP Eukaryotic Core Promoter Predictor 
program (http://www.bioinformatics.org/yapp/cgi-bin/yapp.cgi). This program permits the user to 
specify the location of the transcription start site (TSS) and then searches for core promoter 
elements in their expected location relative to the TSS, as specified above. The inputted sequence 
is compared, using a sliding windows algorithm, to position weight matrix representations 
(supplementary table 1) of the core promoter elements and a matrix similarity score calculated. 
Core promoter elements are identified when the matrix similarity score exceeds a pre-defined 
threshold. The DISC1 candidate promoter region (chr1: 231761561-231762613) was searched 
using three thresholds: the default threshold of 0.8, and 0.7, and 0.6.  
 






































Core promoter element Position weight matrix 
Transcription factor IIB recognition element Pos A C G T 
1 0 68.9 31.1 0 
2 0 67.6 32.4 0 
3 35.1 0 64.9 0 
4 0 100 0 0 
5 0 0 100 0 
6 0 100 0 0 
7 0 100 0 0 
 
TATA box Pos A C G T 
1 17.7 21.1 29 32.2 
2 19.3 36.1 36.4 8.2 
3 6.6 14.8 6.8 71.8 
4 83.4 0 0 16.6 
5 0 0 0 100 
6 95 0 0 5 
7 72.3 0 0 27.7 
8 94.2 0 5.8 0 
9 53.3 0 20.1 26.6 
10 29.3 9 51.2 10.5 
11 17.7 32.5 37.7 12.1 
12 22.7 33 33.2 11.1 
 
Initiator Pos A C G T 
1 0 55.4 0 44.6 
2 0 75.0 0 25.0 
3 100 0 0 0 
4 23.2 28.6 26.8 21.4 
5 28.6 0 0 71.4 
6 16.1 42.8 0 41.1 
7 0 51.8 16.1 32.1 
 
Motif ten element Pos A C G T 
1 3.4 34.5 60.3 1.7 
2 24.1 41.4 31 3.4 
3 87.9 3.4 8.6 0 
4 8.6 5.2 74.1 12.1 
5 1.7 94.8 0 3.4 
6 1.7 41.4 53.4 3.4 
7 10.3 44.8 44.8 0 
8 43.1 0 56.9 0 
9 12.1 8.6 67.2 12.1 
10 5.2 86.2 3.4 5.2 
11 1.7 5.2 89.7 3.4 
12 17.2 34.5 46.6 1.7 
 
Downstream promoter element Pos A C G T 
1 51.7 0 48.3 0 
2 0 0 100 0 
3 58.8 0 0 41.2 
4 0 55.2 0 44.8 
5 21.5 30.5 48 0 
 
 
Table 3.2. Core promoter position weight matrix representations used by the YAPP Eukaryotic 
Core Promoter Predictor program to identify core promoter elements. See next page for legend. 
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Table 3.2. Core promoter position weight matrix representations used by the YAPP Eukaryotic Core 
Promoter Predictor program to identify core promoter elements. The inputted sequence is compared, 
using a sliding windows algorithm, to the core promoter element position weight matrix 
representations and conservation index and matrix similarity scores calculated, following the methods 
of Cartharius et al. (2005). For each nucleotide position of the core promoter element (Pos), the 
position weight matrix indicates the probability (in percentage terms) of observing an A, C, G, or T.  
 
 
3.3.1.2 Assessment of epigenetic modification  
 
Regions of the DISC1 candidate promoter region carrying epigenetic marks relevant to 
transcriptional activity were identified using the “ENCODE Regulation” super-track on the 
UCSC human genome browser (hg19) and the “GIS ChIP-PET” track on the UCSC human 
genome browser (hg18). The ENCODE Regulation super-track contains three sub-tracks 
detailing regions identified as being enriched for three histone marks: H3K4me1, H3K4me3, 
and H3K27ac. These regions were identified by chromatin immunoprecipitation followed by 
sequencing (ChIP-seq) in several human cell lines (table 3.3). The GIS ChIP-PET track 
displays regions enriched for H3K4me3 and H3K27me3 identified by ChIP followed by 




















Table 3.3. Cell lines assessed for epigenetic chromatin modifications for the ENCODE 
Regulation super-track on the UCSC human genome browser (hg18).  ChIP followed by 
sequencing (ChIP-seq) was used to assess the cell lines for three modifications: H3K4me1, which 
is often found near regulatory elements; H34me3, which is associated with the promoters of 
actively transcribed or poised genes; and H3K27ac, which is associated with active regulatory 
elements. The name of the cell line, a description of its origin, and the chromatin modifications 
assessed in each cell line (indicated by a tick) are shown. 
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3.3.1.3 Assessment of potential for Z-DNA formation 
 
The online program Zhunt (http://gac-web.cgrb.oregonstate.edu/zDNA/) (Ho et al., 1986) 
was used to assess the potential of the DISC1 candidate promoter region for Z-DNA 
formation. The potential for Z-DNA formation in response to negative superhelicity is 
calculated by consideration of the energy required to stabilise dinucleotides in the Z-DNA 
conformation compared to the B-DNA confirmation. These energy requirements were either 
determined empirically or predicted based on empirically defined values using an algorithm 
that took into account the following parameters: base identity (A, C, G, or T) and base 
conformation (syn or anti). As the base conformation cannot be defined from the input 
sequence, Zhunt implements an algorithm to maximise the alternation of syn and anti base 
pairs in the sequence, a pattern characteristic of Z-DNA. The Z-DNA forming potential of a 
sequence was then calculated using an algorithm that takes into account sequence effects on 
the energy required for Z-DNA stabilisation by including nearest neighbour interactions. The 
resultant score reflects the superhelical density required for the onset of Z-DNA formation. 
By comparison with the scores obtained for random nucleotide sequences, a Z-score is 
derived that reflects the number of random nucleotide bases that must be searched in order to 
find a sequence that is as likely or more likely to form Z-DNA than the sequence in question. 
A Z-score of above 700 is considered to identify regions likely to form Z-DNA.  
 
3.3.1.4 Identification of evolutionarily conserved regions with regulatory potential 
 
As mentioned previously (section 3.1.2.5), the identification of functional non-coding 
elements can be aided by the combination of conservation data with knowledge of the 
sequence characteristics of known regulatory elements. The ESPERR algorithm introduced 
in section 3.1.2.5 has been applied to the identification cis-regulatory elements and the 
results of this analysis are available in the “ESPERR Regulatory Potential (7 Species)” track 
of the UCSC human genome browser. This track was, therefore, chosen to detect regions 
with conserved regulatory potential in the DISC1 candidate promoter region. The track 
displays regulatory potential scores calculated from alignments of human, chimpanzee, 
macaque, mouse, rat, dog, and cow genetic sequences, thus striking a balance between the 
use of evolutionary convergent and divergent organisms, as suggested by Prabhakar et al. 
(2006). Aligned regions for which regulatory potential scores are calculated are defined as 
regions of the reference genome in which no region of more than 100 bases lacks alignment 
in at least three non-human species. For these regions, regulatory potential scores are 
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calculated based on the similarity of the sequence to the sequences of known regulatory 
elements versus regions of neutral DNA contained in a training set. Scores below 0 are 
deemed to reflect similarity with neutral DNA and scores above 0.1 to indicate very marked 
resemblance to alignment patterns typical of regulatory elements present in the training set. 
As sequence data for the macaque is missing in all but the most 5’ region of the DISC1 
candidate promoter region (macaque sequence is available for the region aligned to human 
chr1: 231761561-231761764), it is worth noting that for the majority of the DISC1 candidate 
promoter region the only non-human species assessed for alignment were chimpanzee, 
mouse, rat, dog, and cow. 
 
Regulatory potential scores for the candidate DISC1 promoter region were downloaded from 
the UCSC human genome browser, using the tables function, and evolutionarily conserved 
regions likely to be of regulatory importance identified by filtering regulatory potential 
scores using a threshold of ≥ 0.1. 
 
3.3.1.5 Identification of putative transcription factor binding loci 
 
Transcription factors potentially involved in the regulation of DISC1 expression were 
identified using the “Transcription Factor ChIP” track of the “ENCODE Regulation” super-
track of the UCSC human genome browser (hg18 and hg19). Genomic regions bound by a 
particular transcription factor were identified by ChIP-seq in several cell lines; however, not 
every transcription factor was assessed in every cell line.  
 
Potential FOXP2 binding sites were identified in the region upstream of DISC1 
corresponding to the long promoter fragment. This region (chr1: 231761579-231762608, 
hg19) was downloaded from the UCSC human genome browser and analysed using the 
DNA Pattern Find program of the Sequence Manipulation Suite (Stothard, 2000) at 
http://www.bioinformatics.org/sms2/dna_pattern.html. The region was searched for the 
consensus binding sites of the general FOX family of transcription factors, the FOXP family, 
and FOXP2, as well as sites differing from the consensus sequences by one base pair, as this 
level of deviation has previously been identified as being tolerated by FOXP2 (Vernes et al., 
2007). The FOX family bind to sites with the consequence sequence TRTTKRY (Overdier et 
al., 1994; where R = A or G, K = G or T, and Y = C or T). FOXP binds to sites with the 
consensus sequence TATTTRT (Wang et al., 2003), and FOXP2 binds to sites with the 
consensus sequence AATTTG or ATTTGT (Stroud et al., 2006; Wu et al., 2006), as well as 
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the core binding site, ATTT (Konopka et al., 2009). As experimental assessment of FOXP2 
binding has revealed that it can bind to the non-consensus sequence AAAGSAAA (S = G or 
C) (Vernes et al., 2011), this site was also searched for. 
 
3.3.2 Luciferase reporter vectors 
 
Three luciferase reporter vectors purchased from Promega were used in this study: the 
promoterless vector, pGL4.10, which encodes firefly luciferase reporter gene luc2; pGL4.13, 
which expresses luc2 under the control of an SV40 promoter; and pRL-TK, which expresses 
Renilla luciferase (Rluc) under the control of a thymidine kinase promoter.  
 
3.3.3 Cloning of DISC1 promoter fragments 
 
3.3.3.1 DNA isolation from a bacterial artificial chromosome 
 
A bacterial artificial chromosome (BAC), RP11-17H4, covering the region chr1: 
231,697,040- 231,766,242 (hg19), which includes the DISC1 putative promoter region, was 
obtained from the BACPAC Resources Centre as a stab culture. The stab culture was 
streaked out onto a lysogeny broth (LB) agar plate containing 20µg/ml chloramphenicol and 
left to grow overnight at 37°C. The following day, a single colony was picked and placed in 
3ml LB medium supplemented with 25µg/ml chloramphenicol and left to grow for 16 hours 
at 37°C in a shaking incubator. DNA was then isolated using the peqGOLD plasmid mini kit 
II (PEQLAB). The culture was centrifuged at 5000 x g for 10 minutes at room temperature, 
the supernatant discarded, and the pellet resuspended in 500µl solution I (resuspension 
buffer) containing RNase A (100µg/ml). The cell suspension was transferred to a 2ml 
microcentrifuge tube, and 500µl solution II (lysis buffer) added. The tube was inverted and 
then incubated at room temperature for five minutes to obtain a clear lysate. DNA was then 
precipitated by adding 700µl solution III (neutralisation buffer), inverting the tube, and 
centrifuging at 10000 x g for 10 minutes at room temperature. The supernatant (750µl) was 
then loaded onto a PerfectBind DNA column in a 2ml collection tube. The column was 
centrifuged at 10000 x g for 1 minute at room temperature, the flow-through discarded, and a 
further 750µl of supernatant loaded onto the column. The column was centrifuged again at 
10000 x g for 1 minute at room temperature and the flow-through discarded. These steps 
were repeated until all the supernatant had been processed. The column was then washed 
using 500µl PW buffer to remove protein contamination. PW buffer was added to the 
column, centrifuged at 10000 x g for 1 minute, and the flow-through discarded. A second 
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wash step was then carried out using 750µl DNA wash buffer, which removes salt residues 
from the membrane, the column was centrifuged at 10000 x g for 1 minute, and the flow-
through discarded. The second wash step was repeated before the column was dried to 
remove ethanol by centrifuging at 10000 x g for 2 minutes. DNA was then eluted by placing 
the column into a clean 1.5ml microcentrifuge tube, adding 75µl elution buffer and 
centrifuging at 5000 x g for 1 minute. Isolated DNA was stored at -20°C until required. 
 
3.3.3.2 Primer design 
 
Primers were designed using the online program Primer 3 (http://frodo.wi.mit.edu/) to 
amplify a series of four nested fragments covering different extents of the DISC1 candidate 
promoter region (figure 3.3). Each promoter fragment was amplified using a unique forward 
primer with a common reverse primer. Each primer contains a region of genomic sequence, a 
restriction site (NheI for the forward primers, HindIII for the reverse primer), and an 






















Figure 3.3.  Sequence details (5’-3’) of the primers used to amplify the four DISC1 promoter 
fragments. Each promoter fragment (long, medium, medium 1, and short) was amplified using a 
unique forward primer and a common reverse primer.  Each primer comprises a region of 
genomic target sequence, a restriction site (NheI for the forward primers, and HindIII for the 
reverse primer), and an additional 4bp of sequence to ensure efficient cutting by the restriction 
enzyme. 
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3.3.3.3 Polymerase chain reaction (PCR) amplification of DISC1 promoter 
fragments 
 
The four promoter fragments were PCR-amplified from a BAC (RP11-17H4) using the 
Expand High Fidelity Plus PCR System (Roche), which uses a thermostable DNA 
polymerase with proofreading ability. One microlitre (2.5ng) of template DNA was added to 
a reaction containing 10µl 5x Expand High Fidelity Plus buffer, 10mM dNTPS, 4µM 
forward and reverse primers,  0.5µl (2.5U) Expand High Fidelity Plus Enzyme Mix, and 
32.5µl double distilled water (ddH2O). Polymerase amplification was carried out using a 
thermal cycler (MJ Thermocycler) using the parameters detailed in figure 3.4 for touch-down 
PCR. The promoter fragments were then PCR purified to remove any contaminants that 
might interfere with subsequent stages using the QIAquick PCR Purification Kit (Qiagen), 
























Figure 3.4. Thermocycling parameters for touch-down PCR amplification of the long, medium, 
and short DISC1 promoter fragments. 




3.3.3.4 Restriction enzyme digest 
 
Enzymatic digestion of the inserts (DISC1 promoter fragments) and the pGL4.10 vector with 
the restriction enzymes NheI and HindIII (Roche). Digests were carried out sequentially for 
each enzyme. For the inserts, 28µl of each PCR product was digested using 0.5µl (5U) 
enzyme, 3.5µl 10x restriction enzyme buffer (NheI: Roche buffer M; HindIIII: Roche buffer 
B), and 3µl ddH2O. For the vector, 3µg pGL4.10 was digested using 0.5µl (5U) enzyme, 
10µl 10x restriction enzyme buffer, and 87.5µl ddH2O. Digests were carried out overnight at 
37°C.  
 
3.3.3.5 Product purification 
 
Digested products were purified using the QIAquick PCR Purification Kit according to the 
manufacturer’s instructions. Buffer PB, which binds small single- or double-stranded PCR 
products (~100 bp) and primers up to 40 nucleotides in length, was added to each sample in 
a 5:1 volumetric ratio and mixed. The sample was then applied to a QIAquick spin column, 
which was placed in a 2ml collection tube and centrifuged at 17900 x g for 1 minute. Flow-
through was discarded and the spin column replaced in the collection tube. The sample was 
then washed with 750µl buffer PE by centrifuging at 17900 x g for 1 minute, the flow-
through discarded, and the column centrifuged for a further 1 minute to remove residual 
ethanol. Purified DNA was then eluted by placing the spin column in a clean 1.5ml 
collection tube, adding 32µl elution buffer, resting for 1 minute, and then centrifuging at 
17900 x g for 1 minute. DNA was stored at -20°C until required. 
 
3.3.3.6 Spectrophotometric analysis of DNA using the NanoDrop 
 
The concentration and purity of DNA samples was measured using a Thermo Scientific 
NanoDrop 1000 spectrophotometer, a full-spectrum spectrophotometer. Accurate 
determination of sample concentration and purity can be made from as little as 1-2µl of 
sample, thus reducing the amount of sample required compared to traditional 
spectrophotometric methods. Samples are pipetted onto a pedestal onto the end of a fibre 
optic cable. An arm, containing a second fibre optic cable, is the lowered onto the sample, 
such that the liquid bridges the gap between the two fibre optic ends. A pulsed xenon flash 
lamp is used as the light source, and a CCD array is used to analyse the light after passing 
through the sample. 




Samples were measured by selecting the “nucleic acids” program on start-up and setting the 
measurement option to “DNA-50”. The machine was then “blanked” by taking a reading 
from a reference sample (the elution buffer used to re-suspend the purified DNA in section 
3.3.3.5). Each sample (1.5µl) was then pipetted onto the pedestal (which was cleaned 
between samples), and the absorption of the sample calculated by comparison of the 
intensity of light that transmitted through the sample compared to that which transmitted 
through the blank reference sample, using the equation: 
 
Absorbance = -log (Intensitysample/Intensityblank) 
 
Concentration was calculated from absorbance of light at 260nm using the Beer-Lambert 









), b is the path length in centimetres, and c is the analyte molarity 
(M). 
 
Sample purity was determined by calculation of the ratio of absorbance at 260nm and 280nm 
(260/280) and 260nm and 230nm (260/230). Pure DNA should have a 260/280 ratio of ~1.8. 
Lower ratios can indicate the presence of contaminating agents absorbing at around 280nm, 
such as protein or phenol. The 260/230 ratio should be in the range of 1.8-2.2. Lower ratios 
can be caused by contaminating salts, phenol, or protein.  
 
3.3.3.7 Treatment with shrimp alkaline phosphatase  
 
Digested pGL4.10 was treated with shrimp alkaline phosphatase (SAP) to remove 5’ 
phosphate groups in order to prevent re-ligation. One microgram of DNA was added to a 
reaction containing 1µl SAP and 7µl dilution buffer (USB) and left for 4 hours at 37°C 
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3.3.3.8 Ligation of DISC1 promoter fragments and the pGL4.10 promoterless 
vector 
 
The inserts were then ligated into the pGL4.10 vector upstream of the coding sequence of 
luc2. Ligations were carried out using a 5:1 molar ratio of insert to vector using the Rapid 
DNA Ligation Kit (Roche), according to the manufacturer’s instructions. Thirty-six 
femtomoles (fmoles) vector and 180 fmoles insert were added to 1x buffer 2 to make a total 
volume of 10µl. This mixture was added to 10µl 2x buffer 1 and 1µl T4 DNA ligase and left 
for 1 hour at room temperature.  
 
3.3.3.9 Endotoxin free purification of plasmid DNA 
 
 
Two microlitres of the ligated vector and insert were electroporated into 20µl ElectroMax 
DH10B electrocompetent cells (Invitrogen), using a MicroPulser (Bio-Rad). The 
electroporated cells were then suspended in 400µl SOC (Super Optimal Broth with 
Catabolite repression) medium (Invitrogen), and left to shake for 1 hour at 37°C, before 
being diluted 1/5 with SOC medium (20µl cell suspension and 80µl SOC medium). The 
diluted mixture was then applied to an LB-agar plate containing ampicillin (100µg/ml) and 
left to grow overnight at 37°C.  
 
A single colony was selected for each promoter construct and used to inoculate a starter 
culture of 2ml LB-broth with ampicillin (100µg/ml). The starter culture was left to grow for 
8 hours in a shaking incubator at 37°C. After 8 hours, the starter culture was poured into a 
flask containing 200ml LB-broth with ampicillin (100µg/ml) and grown for 16 hours in a 
shaking incubator at 37°C. The culture was then centrifuged at 6000 x g for 15 minutes at 
4°C in a Beckman centrifuge. DNA was purified using an EndoFree Plasmid Purification kit 
(Qiagen), according to the manufacturer’s instructions. An EndoFree kit was used to 
improve transfection efficiency. The supernatant was discarded and the cell pellet 
resuspended in 10ml buffer P1. The sample was then lysed by adding 10ml buffer P2, 
mixing, and incubating the sample for 5 minutes at room temperature. DNA was then 
precipitated by adding 10ml buffer P3 and mixing. The sample was then applied to a 
QIAfilter cartridge and incubated for 10 minutes at room temperature, in order to let a 
precipitate containing various contaminants, such as genomic DNA, protein, and detergent to 
form. Following the incubation, the sample was filtered through the cartridge, 2.5ml of the 
endotoxin removal buffer (buffer ER) added to the lysate, the sample mixed, and incubated 
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on ice for 30 minutes. A QIAGEN-tip 500 was equilibrated by adding 10ml buffer QBT. The 
sample was then added to the equilibrated QIAGEN-tip and allowed to enter the resin in the 
QIAGEN-tip by gravity flow. Contaminants were removed by washing the QIAGEN-tip 
twice with 30ml buffer QC, and the DNA eluted by placing the QIAGEN-tip into a 30ml 
collection tube and applying 15ml buffer QN. Precipitation of the DNA was carried out by 
adding 10.5ml isopropanol, mixing, and centrifuging at 15000 x g for 30 minutes at 4°C. 
After decanting the supernatant, the DNA pellet was washed with 5ml endotoxin-free 70% 
ethanol and centrifuged at 15000 x g for 10 minutes. The supernatant was removed, the 
pellet air-dried, and then re-suspended in 250µl endotoxin-free TE buffer. Purified DNA was 
stored at -20°C until required.  
 
3.3.3.10 Sequencing reaction 
 
Prior to use, the promoter constructs were sequenced to confirm integrity using the BigDye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). Each construct was sequenced 
using a forward primer and a reverse primer located in the multiple cloning site of pGL4.10, 
either side of where the DISC1 promoter fragment was inserted. The primer sequences used 
were as follows: forward: 5’-CTAGCAAAATAGGCTGTCCC-3’; reverse: 5’-
CCGTCTTCGAGTGGGTAGAA-3’. Reactions were carried out in 96-well plates. Two 
hundred nanograms of plasmid DNA was added to a sequencing reaction containing 1µl 
Terminator Ready Reaction Mix, 1µl BigDye Sequencing Buffer, 1µl 3.2 pmol primer, and 
3µl ddH2O. The reaction was carried using the following thermal cycling conditions: 96°C 
for 1 minute (initial denaturation), followed by 30 cycles of 96°C for 10 seconds 
(denaturation), 50°C for 5 seconds (annealing), and 60°C for 4 minutes (extension). 
 
3.3.3.11 Ethanol/EDTA precipitation of sequencing reaction 
 
The sequencing reactions were precipitated by adding 2.5µl 125mM 
Ethylenediaminetetraacetic acid (EDTA) and 30µl 100% EtOH to each well. The plate was 
then sealed and inverted four times to mix the reaction. Following a 15 minute incubation at 
room temperature, the plate was spun in a Jouan centrifuge at  2500 x g for 30 minutes. The 
plate was unsealed and inverted over a paper towel and spun briefly to remove the EtOH. 
Forty microlitres 70% EtOH was then added to each well, the plate resealed  and mixed by 
inverting 4 times. The plate was then centrifuged at 2500 x g for 15 minutes, the seal 
removed, the plate inverted over a paper towel again and centrifuged briefly to remove the 
Chapter 3: Characterisation of the DISC1 promoter 
122 
 
EtOH. Wells were air dried and the plate sealed with adhesive film before being sent to the 
Medical Research Council Human Genetic Unit to be sequenced by Agnes Gallacher. 
 
3.3.3.12 Assessment of the DNA conformation of the DISC1 promoter constructs 
 
As the conformation of plasmid DNA has been shown to affect the efficiency with which it 
is transfected (Cherng et al., 1999), the DISC1 promoter constructs were visually assessed 
for the proportion of DNA in the supercoiled form, which transfects most efficiently (Cherng 
et al., 1999), the open circle form, and the linear form. These three forms can be 
differentiated by gel electrophoresis as they migrate at different rates: The supercoiled form 
migrates fastest through the gel; the next fastest is the linear; and the open circle form 
migrates the slowest. One hundred nanograms of plasmid DNA was combined with 4 x 
Orange G loading buffer (1g Ficoll-400 (Sigma) and 0.2ml 50mM EDTA made up to a total 
volume of 10ml with ddH2O. Orange G added to colour) and made up to a total volume of 
8µl with ddH2O. Samples were electrophoresed on a 1% tris-borate-EDTA (TBE) gel 
containing 5µl SYBRSafe (Invitrogen). The gel was then visualised under ultraviolet 
illumination. 
 
3.3.4 Dual luciferase reporter assay 
 
3.3.4.1 Cell culture and transient transfection  
 
The neuroblastoma cell lines, SH-SY5Y and LAN-5, and the human embryonic kidney cell 
line, HEK293, were maintained in Dulbecco’s Minimal Essential Medium (DMEM; 
Invitrogen) supplemented with 10% foetal bovine serum (FBS) at 37°C in a humidified 5% 
CO2 atmosphere. Cells were grown to ~80% confluency in tissue culture flasks before being 
transfected using Nucleofector (Lonza Biologics), according to the manufacturer’s 
instructions. Cell culture medium was aspirated off, the cells were washed in PBS, and 
dissociated using TrypLE Express (Invitrogen). Cells were then counted and, for each 
promoter construct, 1 x 10
6
 cells were harvested by centrifuging at 90 x g for 10 minutes at 
room temperature. After removing the supernatant, the cell pellet was resuspended in 100µl 
Nucleofector Solution V. The 100µl cell suspension was then combined with a total of 2µg 
DNA, comprising (i) 1961ng of the appropriate reporter construct (promoterless pGL4.10 for 
the negative control, or pGL4.13 vector for the positive control, or pGL4.10-DISC1 
promoter construct (long, medium, medium 1, or short)), and (ii) 39ng of the transfection 
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efficiency control pRL-TK. The solution was transferred to a cuvette and inserted into the 
Nucleofector Cuvette Holder and transfected using the program A-023, which is 
recommended for transfecting SH-SY5Y and HEK293 cells with high viability (there is no 
established Nucleofector program recommended for LAN-5 cells). The solution was then 
mixed immediately with 500µl culture medium, and 31.25µl was pipetted into each of 6 
wells of a 96-well plate, which had previously been filled with 62.5µl culture medium and 
warmed to 37°C. These six wells were treated as technical replicates. The activity of each 
promoter construct was assessed in three experimental replicates. 
 
3.3.4.2 Measurement of luciferase activity 
 
Following transfection with the promoter constructs, cells were incubated at 37°C for 24 
hours, after which time the cells had reached approximately 80% confluency. At this point, 
the cell culture medium was removed and the cells washed with PBS. Lysis was achieved by 
adding 20µl 1 x Passive Lysis Buffer (Promega) to each well and shaking at room 
temperature for 1 hour. 
 
The dual luciferase reporter (DLR) assay was carried out using the Dual-Luciferase Reporter 
Assay System (Promega). Five microlitres of cell lysate was transferred from each well of 
the 96-well cell culture plate to a well of a 96-well half-well opaque white plate. An opaque 
plate was used to reduce cross-talk between adjacent wells. The plate was then inserted into 
an Omega FLUOstar luminometer (BMG Labtech). The first well was then injected with 
12.5µl luciferase assay reagent II (LARII), which activates firefly luciferase, and a reading 
of firefly luciferase activity taken over a period of 10 seconds following a 2 second post-
injection delay, during which time the plate was shaken at 550rpm. Once the firefly 
luciferase activity had been measured, the well was injected with 12.5µl Stop & Glo reagent, 
which quenches the firefly luciferase signal and activates the Renilla luciferase signal. 
Again, Renilla luciferase activity was measured over a period of 10 seconds following a 2 
second post-injection delay whilst the plate was shaken. This process was then repeated for 
the remaining wells on the plate. 
 
3.3.4.3 Calculation of normalised relative luciferase activity 
 
Assessment of the activity of each DISC1 promoter construct was carried out in three 
experimental replicates. Within each experimental replicate, six technical replicates were 
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performed. The stages involved in the calculation of the normalised relative luciferase values 
for each promoter construct are summarised in figure 3.5. Transfection efficiency was 
controlled for by normalising the firefly luciferase value for each well (obtained from the 
empty pGL4.10 vector, pGL4.10-DISC1 promoter construct, or pGL4.13) to the 
corresponding Renilla luciferase value. For each plate, subtraction of the mean normalised 
luciferase value for the empty pGL4.10 vector controlled for the contribution of background 
luminescence. The pGL4.13 vector, which expresses the firefly luciferase gene luc2 under 
























3.3.4.4 Statistical analysis of DLR assay data 
 
Statistical analysis was carried out using SPSS (Statistical Package for the Social Sciences) 
17.0 (Apache Software Foundation). Significant main effects were identified by one-way 
 
Figure 3.5. Schematic summarising the stages involved in obtaining normalised relative luciferase 
activity values for each of the DISC1 promoter constructs assessed using the dual luciferase 
reporter assay. Cells were co-transfected with a firefly luciferase (luc2) containing vector (either 
the promoterless vector pGL4.10 or pGL4.13, which expresses luc2 under the control of an SV40 
promoter), together with pRL-TK, which expresses Renilla luciferase under the control of a 
thymidine kinase promoter. Transfections were performed in six technical replicates (indicated by 
the six wells of the same colour on each 96-well plate) and repeated in three experimental 
replicates.(represented by the three 96-well plates). 
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analysis of variance (ANOVA) and post-hoc analysis was carried out using Tukey’s 
Honestly Significant Difference (HSD) test.  When analysing data with equal sample sizes, 
the F-test has been shown to be robust to deviations from the normality and homogeneity of 
variances assumptions (Boneau, 1960); therefore, formal assessment of these assumptions 
was not performed. 
  





3.4.1 In silico analysis of the DISC1 candidate promoter region 
 
3.4.1.1 Selection of a DISC1 candidate promoter region 
 
The region spanning from 1000 bp upstream of the DISC1 TSS to the translation start site 
(chr1: 231761561-231762613) was selected as the DISC1 candidate promoter region. This 
region was chosen based upon the findings of the ENCODE Pilot Project, which 
characterised 45 promoters and found that, on average, the sequence -300 bp to -50 bp 
relative to the TSS contributes positively to core promoter activity, whereas, in 55% of the 
promoters studied, the region further upstream, -1000 bp to -500 bp relative to the TSS, 
confers a repressive effect (Cooper et al., 2006) (figure 3.6). The region between the TSS 
and the translation start site was included as this region can influence promoter activity and 
sometimes contains canonical promoter motifs, such as the downstream promoter element 
(DPE) (Kadonaga, 2002). 
 







Figure 3.6. Schematic showing the information used from the UCSC human genome browser (hg18) in the design of the DISC1 promoter fragments. See next page for 
full legend.  
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Figure 3.6. Schematic showing the information used from the UCSC human genome browser (hg18) 
and other publicly available sources in the design of the DISC1 promoter fragments. The region 
designated as the DISC1 candidate promoter region (chr1: 229828184-229829236) is shown together 
with the promoter fragments to be assessed in the dual luciferase reporter assay (long, medium, and 
short). The track marked “DISC1” indicates the location of the DISC1 transcript. Regions previously 
identified as generally contributing positively or negatively to promoter activity in the promoters 
investigated as part of the ENCODE Pilot Project (Cooper et al., 2006) are indicated. A CpG island 
identified from the UCSC human genome browser CpG Island track is depicted together with the 
complex dinucleotide repeat region. Regions identified as carrying histone modifications associated 
with promoter activity are denoted by three sub-tracks of the ENCODE Regulation super-track and the 
GIS-ChIP-PET track. The ENCODE Regulation sub-tracks indicate regions identified by ChIP-chip 
as carrying three histone marks: H3K4me1, H3K4me3, and H3K27ac. Data from eight (H3K4me1 
and H3K27ac) or nine (H3K4me3) cell lines is presented in overlay format, such that each cell line is 
represented by a different colour and the height of the bars represents the extent of enrichment at each 
position in the genome. The GIS-ChIP-PET track shows regions identified by ChIP-PET as carrying 
the H3K4me3 modification and the repressive H3K27me3 modification in human embryonic stem 
cells (hES3). Regions enriched for a histone modification are indicated by two blocks, representing 
the ends of the di-tag pair, connected by a thin arrowed line. The direction of the arrows indicates the 
orientation of the ChIP-ed sequence and the colour of the line indicates the number of sequences 
identified overlapping that particular location (light grey: one or two sequences, dark grey: three 
sequences, and black: four or more sequences). The ESPERR Regulatory Potential (7 Species) track 
displays regulatory potential scores calculated from alignments of human, chimpanzee, macaque, 
mouse, rat, dog, and cow genetic sequences. Regulatory potential scores below 0 are deemed to reflect 
similarity with neutral DNA and scores above 0.1 to indicate very marked resemblance to alignment 
patterns typical of regulatory elements present in the training set. NB. The overlay format of the 
ENCODE Regulation sub-tracks is best viewed online (http://genome.ucsc.edu/); here the track 
displays in transparent overlay method rather than the solid overlay format available in the 
downloaded image. 
 




3.4.1.2 Detection of canonical promoter motifs 
 
Analysis of the DISC1 candidate promoter region using the eukaryotic core promoter 
prediction program, YAPP, revealed a lack of canonical core promoter elements, including 
the TATA box, Transcription factor IIB Recognition Element (BRE), Initiator, and DPE, in 
their expected location relative to the TSS when the default matrix similarity score threshold 
of 0.8 was used. To ensure that this threshold was not overly conservative, the analysis was 
repeated with the lower thresholds of 0.7 and 0.6. This still yielded no matches. The region 
does contain a CpG island (Chr1: 231762415-231763115), which is a common feature of 
constitutively active genes. Interestingly, at the 5’ end of the CpG island, there is a complex 
dinucleotide repeat region ((TG)4TATGTC(TG)8(CG)8).  
 
3.4.1.3 Identification of epigenetic modifications associated with transcriptional 
activity in the DISC1 candidate promoter region 
 
The “ENCODE Regulation” super-track on the UCSC human genome browser (hg19) and 
the “GIS ChIP-PET” track on the UCSC human genome browser (hg18), which indicate 
regions of ChIP-identified histone modification, were used to assess the DISC1 candidate 
promoter region for H3K4me3, H3K4me1, H3K27ac, and H3K27me3 modifications (figure 
3.5). H3K4me1 is often found near regulatory elements, H3K4me3 is associated with 
promoters that are actively transcribed or poised for transcription, and H3K27ac is associated 
with active regulatory elements. H3K27me3 is a repressive histone modification. 
 
H3K4me3, H3K4me1, and H3K27ac histone marks were found to be present in all the cell 
lines assessed by the ENCODE regulation track, although to different extents in each cell 
line. The H3K4me3 and H3K27ac modifications were most enriched nearest the DISC1 
transcription start site, whereas the H3K4me1 modification was present further upstream. 
The GIS ChiP-PET track identifies both the H3K4me3mark and the H3K27me3 mark in the 
DISC1 promoter region in embryonic stem cells, suggesting that DISC1 might fall into the 
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3.4.1.4 Assessment of the Z-DNA forming potential of the DISC1 candidate 
promoter region 
 
Assessment of the DISC1 candidate promoter region for its potential to form Z-DNA in 
response to negative superhelicity was assessed using the program Zhunt. A region of 56 
base pairs with the genomic coordinates chr1: 231762380-231762435 was identified as being 
highly likely to form Z-DNA with a Z-score of 31396934.60, compared to the threshold Z-
score for Z-DNA formation of 700 (Ho et al., 1986). This region spans the complex 
dinucleotide repeat region. 
 
3.4.1.5 Identification of evolutionarily conserved regions with regulatory potential in 
the DISC1 candidate promoter region 
 
Regions of the DISC1 candidate promoter region likely to contain conserved regulatory 
elements were identified using the “ESPERR Regulatory Potential (7 Species)” track of the 
UCSC human genome browser. As sequence data for the macaque is missing in all but the 
most 5’ region of the DISC1 candidate promoter region (macaque sequence is available for 
the region aligned to human chr1: 231761561-231761764), the majority of comparisons 
within this region were between human, chimp, cow, dog, rat, and mouse. Using a regulatory 
potential score of 0.1 as the threshold for the detection of putative regulatory importance, the 
identified loci visually clustered into four distinct regions (figure 3.6).  
 
3.4.2 A series of DISC1 promoter constructs for assessment in the dual 
luciferase reporter assay 
 
A series of three nested promoter constructs (pGL4.10-short, -medium, and -long) were 
designed to characterise the candidate promoter region (figure 3.6). The long construct 
extends from -982 bp to +47 bp relative to the TSS, and, therefore, extends almost to the 
translation start site, which is located at +52 bp relative to the TSS. This construct was 
designed to include the region from -1000 bp to -500 bp identified by Cooper et al. (2006) as 
typically repressing promoter activity in the 45 promoters studied as part of the ENCODE 
Pilot Project. In the DISC1 candidate promoter region, this typically repressive region 
coincides with the area showing the greatest enrichment for the repressive H3K27me3 
histone modification. Two regulatory potential peaks are included in this promoter fragment, 
possibly suggesting two clusters of regulatory motifs. 
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The medium construct, which spans the region from -300 bp to +47 bp relative to the TSS, 
was designed to correspond to the region identified by Cooper et al. (2006) as usually 
contributing positively to core promoter activity. This construct contains the complex 
dinucleotide repeat region, and an additional 124 bp upstream. Consistent with the 
possibility that this region might contribute positively to promoter activity, the medium 
fragment coincides with regions identified as showing the greatest enrichment for the 
H3K4me3 and the H3K27ac histone modifications, which are often associated with actively 
transcribed genes. Two regions of high regulatory potential are contained within the medium 
fragment. 
 
The short construct, which includes the region -129 bp to +47 bp relative to the TSS, was 
designed to assess the contribution of the sequence from the translation start site to the 3’ 
end of the complex dinucleotide repeat region. Like the medium fragment, the short 
fragment includes sequence identified as carrying the typically activating histone 
modifications, H3K4me3 and H3K27ac. The short construct contains only the more 3’ 
region of the two regions of high regulatory potential included in the medium fragment. 
 
3.4.3 Cloning of the DISC1 promoter constructs and confirmation of 
sequence 
 
The DISC1 promoter constructs were cloned upstream of the luciferase reporter gene, luc2, 
in the promoterless pGL4.10 vector (figure 3.7). The constructs were sequenced to confirm 
their integrity using primers located in the pGL4.10 multiple cloning region, either side of 
the DISC1 promoter fragment insert. All constructs were found to contain an insert with the 
correct sequence in the correct orientation. A sequencing trace for the DISC1 medium 
promoter construct is shown as an example (figure 3.8). 
  























Figure 3.7. Schematic showing the features of pGL4.10, the promoterless vector used to assess the 
promoter activity of the DISC1 promoter constructs. DISC1 promoter constructs were cloned 
between the Nhe1 (underlined in red) and HindIII (underlined in blue) restriction sites in the 
multiple cloning region, upstream of the firefly luciferase (luc2) gene. The vector additionally 
contains a synthetic poly(A) signal/transcriptional pause site to reduce background expression, an 
SV40 late poly(A) signal to enhance RNA stability and translation efficiency, a ColEI-derived 
origin of replication (ori), and an ampicillin resistance gene (Amp
r
). 




Figure 3.8. Sequencing trace showing the DISC1 medium promoter fragment cloned into the promoterless pGL4.10 vector. Insert sequence and orientation were 
assessed using a forward primer located upstream of the intended insert location in the pGL4.10 multiple cloning region. Restriction sites are indicated by 
underlining: the blue line indicates the NheI site and the green line indicates the HindIII site. The DISC1 medium promoter fragment is present as a 348 bp insert 
between the two restriction sites. 
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3.4.4 Assessment of DISC1 promoter constructs in the dual luciferase 
reporter assay 
 
3.4.4.1 Cell line selection 
 
Three cell lines were chosen for the assessment of the DISC1 promoter constructs: two 
neuroblastoma cells lines, SH-SY5Y and LAN-5, and the human embryonic kidney cell line, 
HEK293. The rationale for assessing the promoter constructs in multiple cell lines was that 
this would reveal the activity of the constructs in a range of cellular environments, thus 
reducing the likelihood that any findings would be cell line specific. All three cells lines 
express DISC1 endogenously (James et al., 2004; Murdoch et al., 2007). 
 
3.4.4.2 Assessment of DNA conformation 
 
Plasmid DNA can exist in supercoiled, open circle, and linear forms. As the supercoiled 
form has been shown to transfect with the greatest efficiency (Cherng et al., 1999), the 
proportion of supercoiled DNA in each of the DISC1 promoter construct preparations was 
assessed. Gel electrophoresis revealed the majority of DNA to be in supercoiled form and 
did not suggest any obvious differences in the proportions of supercoiled DNA between the 

















Figure 3.9. Assessment of plasmid DNA conformation. The conformation of the plasmid DNA 
preparations for the pGL4.10-short (S), -medium (M), and –long (L) DISC1 promoter constructs 
was assessed by gel electrophoresis. Two endo-free maxi-prep preparations of each construct were 
assessed for proportions of open circle (OC), linear (LC), and supercoiled (SC) DNA by 
electrophoresing 100ng of each preparation on a 1% tris-borate-EDTA gel.    
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3.4.4.3 Assessment of the short, medium, and long DISC1 promoter constructs 
using the dual luciferase reporter assay 
 
The short, medium, and long DISC1 promoter fragments were assessed for their ability to 
drive gene expression using the dual luciferase reporter (DLR) assay. SH-SY5Y, LAN-5, 
and HEK293 cells were co-transfected with (i) either a DISC1 promoter construct (pGL4.10-
long, -medium, or -short), the promoterless pGL4.10 vector, or pGL4.13, which expresses 
luc2 under the control of an SV40 promoter, and (ii) the transfection efficiency control, pRL-
TK. Transfections were performed in six technical replicates and the experiment repeated in 
three experimental replicates.  
 
As described in section 3.3.4.3, normalisation of the firefly luciferase values (arising from 
the pGL4.10 or pGL4.13 vectors) to the Renilla luciferase value of the co-transfected pRL-
TK vector provided a control for transfection efficiency. Promoterless pGL4.10 was assessed 
as an indicator of background luminescence. Within each experimental replicate, following 
normalisation for transfection efficiency, the mean value of the six pGL4.10 technical 
replicates was subtracted from the normalised luciferase values of the remaining wells on the 
plate. For each well, the resultant value was divided by the mean value of the six technical 
replicates for pGL4.13, which acted as an inter-plate (and thus inter-experimental replicate) 
calibrator.  
 
One-way ANOVA revealed significant differences between the promoter activity of the three 
DISC1 promoter constructs in both SH-SY5Y and HEK293 cells (SH-SY5Y: p ≤ 0.001, 
figure 3.10A; HEK293:  p = 0.006, figure 3.10B). In both cases, Tukey’s HSD post-hoc test 
revealed that the promoter activity of the medium construct was significantly greater than 
that of the long (SH-SY5Y: p ≤ 0.001; HEK293: p = 0.016), and the short (SH-SY5Y: p ≤ 
0.001; HEK293: p = 0.006) constructs. No significant difference was observed between the 
constructs in LAN-5 cells (p = 0.206; figure 3.10C); however, the trend for greater 
















Figure 3.10. Characterisation of the DISC1 candidate promoter region using the dual luciferase 
reporter assay. A., B., and C. Dual luciferase reporter assays comparing the promoter activity of 
the short, medium, and long DISC1 promoter constructs reveal that the medium construct yields 
the highest level of promoter activity in SH-SY5Y (A), HEK293 (B), and LAN-5 (C) cells (n = 
3). Statistical significance was assessed by one-way ANOVA followed by Tukey’s HSD post-hoc 
test. *p  ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Error bars represent standard error of the mean. This 
figure is adapted from a figure published previously in Walker et al. (2012) 
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3.4.4.4 Assessment of the role of the complex dinucleotide repeat region 
 
To assess whether the complex dinucleotide repeat region underlies the enhanced promoter 
activity of the medium construct a further construct (pGL4.10-medium-1) was designed. 
This construct spans the region -176 bp to +47 bp relative to the TSS, thus comprising the 
short construct plus the dinucleotide repeat region. This construct does not contain the 124 
bp 5’ of the dinucleotide repeat region included in the medium construct, thus permitting a 
more accurate assessment of the contribution of the dinucleotide repeat region (figure 
3.11A). Having established similar promoter activity profiles in all cell lines for the long, 
medium, and short constructs, assessment of the medium-1 construct was carried out only in 
SH-SY5Y cells. Tukey’s HSD revealed that the medium-1 construct had significantly lower 
promoter activity than the medium construct (p = 0.001) and did not differ significantly from 


























Figure 3.11. Assessment of the contribution of the dinucleotide repeat region to DISC1 promoter 
activity. A. Design of the pGL4.10-medium-1 (M1) construct to assess the contribution of the 
complex dinucleotide repeat region. The genomic locations of the primers used to amplify the 
M1 construct (forward: M1, and reverse: R), are shown in relation to the primers used to amplify 
the medium (forward: M) and short (forward: S) constructs, which were amplified using a 
common reverse primer (R). B. Dual luciferase reporter assays suggest that the complex 
dinucleotide repeat region does not underlie the enhanced promoter activity of the medium 
promoter construct (n = 3). Statistical significance was assessed by one-way ANOVA followed 
by Tukey’s HSD post-hoc test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Error bars represent standard 
error of the mean. This figure is adapted from a figure published in Walker et al. (2012). 
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3.4.5 Identification of transcription factors potentially involved in the 
regulation of DISC1 expression 
 
Having assessed the transcriptional activity of a series of DISC1 promoter fragments, it was 
of interest to identify transcription factors that might be involved in regulating DISC1 
promoter activity. As discussed previously (section 3.1.1.2), for the identification of putative 
TFBSs, there are several advantages to using databases of ChIP-identified transcription 
factor-bound DNA regions over a purely computational approach. Hence, the ENCODE 
Regulation super-track on the UCSC human genome browser (hg 18 and hg 19) was used to 
search the DISC1 candidate promoter region. Two questions were of interest: firstly, does the 
data within this track yield any clues to the mechanisms contributing to different levels of 
activity of the four DISC1 promoter fragments? Secondly, do any of the transcription factors 
identified as potentially regulating DISC1 link the dysregulation of DISC1 to any known risk 
factors/mechanisms for psychiatric illness?  
 
With regards to the first question, it was difficult to determine which transcription factors in 
the ENCODE Regulation track, if any, might contribute to the activating properties of the 
medium construct compared to the medium 1 construct and the short construct as the 
resolution of the ChIP-seq performed by ENCODE was such that no transcription factor was 
found to bind to a region of DNA unique to the medium construct (figure 3.11; table 3.4). 
Sequencing of the ChIP-ed fragments with additional primers to increase the spatial 
resolution of the data would be necessary to determine more precisely the regions of DNA 
required for transcription factor binding. Looking at the data from the hg18 assembly, there 
is one transcription factor, Max, predicted to bind in a region only contained within the long 
construct (figure 3.11A). Max is a basic/helix-loop-helix/leucine zipper transcription factor 
that either forms heterodimers or homodimers to exert an effect on transcription. Depending 
on the nature of the dimer formed and the DNA sequence bound, Max can exert either an 
activating effect, a repressive effect, or no effect on transcription (Solomon et al., 1993). As 
such, further investigation of the nature of Max binding in the DISC1 promoter region would 
be a worthwhile pursuit in investigating the mechanisms behind the low transcriptional 
activity of the long fragment relative to the medium fragment. 
 
Regarding the second question, the presence of a FOXP2-bound region immediately 
upstream of DISC1 in the hg18 assembly (figure 3.12A) was of particular interest. 
Moreover, the FOXP2-bound region was identified in a neuronal cell line, PFSK-1 (table 
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3.4), thus increasing the likelihood that this finding might be of relevance to psychiatric 
illness. It is important to note that FOXP2 was not amongst the transcription factors assessed 
for the hg19 version of the ENCODE Regulation track (i.e. its absence in this assembly does 
not indicate a negative result). Genetic variation in the FOXP2 gene has previously been 
implicated in speech and language function (Feuk et al., 2006; Lai et al., 2001; Lennon et al., 
2007; MacDermot et al., 2005; Shriberg et al., 2006; Tomblin et al., 2009; Zeesman et al., 
2006), and FOXP2 has been shown to regulate a network of genes involved in brain 
development and neurite outgrowth (Vernes et al., 2011). Furthermore, some of FOXP2’s 
transcriptional targets include genes previously implicated in autism (Mukamel et al., 2011; 
Vernes et al., 2008). Thus, a regulatory relationship between FOXP2 and DISC1 would 
represent a potential mechanism linking dysregulated DISC1 expression to 
neurodevelopmental disorders. It would, therefore, be of great interest to establish 
experimentally whether DISC1 is regulated by FOXP2. 
 
Other transcription factors identified as potentially playing in the regulation of DISC1 also 
have relevance to current understanding of psychiatric illness. Genetic variation inTCF4 
(also known as TCF7L2) has been associated with schizophrenia (Alkelai et al., 2012; 
Hansen et al., 2011). Furthermore, TCF4 is a member of the Wnt signaling pathway, 
dysfunction of which has been implicated in psychiatric illness (Okerlund and Cheyette, 
2011). HDAC2, a histone deacetylase, is one of the targets of histone deactylase inhibitors, 
which have attracted attention as potential drug therapies for psychiatric illness (Grayson et 
al., 2010). c-fos, FOSL2, c-jun, JunD and BATF are members of the activator protein 1 (AP-
1), family of transcription factors that modulate gene expression in response to cytokines, 
growth factors, stress, and bacterial and viral infections (Betz et al., 2010; Hess et al., 2004). 
NF-κB, IRF4, and PU.1 are also regulators of the immune response (Carotta et al., 2010; 
Hayden et al., 2006; Shaffer et al., 2009), which, as introduced in section 1.3, is believed to 
play an important role in the aetiology of schizophrenia. Furthermore, NF-κB and PU.1 have 
been found to show altered expression in schizophrenia (Song et al., 2009; Weigelt et al., 
2011). Taken together, the known functions of transcription factors identified by ChIP as 
potential regulators of DISC1 expression suggest that DISC1 might be involved in a 
regulatory network that when perturbed confers risk for psychiatric illness. 
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Figure 3.12. Schematic showing the location of regions of DNA identified by ChIP as being bound by 
a transcription factor. The DISC1 upstream region was assessed for putative transcription factor 
binding regions using the ENCODE Regulation super-track of the UCSC human genome browser, 
which contains ChIP data for several transcription factors in several cell lines. As the cell lines and 
transcription factors assessed differed between the hg18 and hg19 assemblies of the genome browser, 
findings for both assemblies are displayed (A: hg18; B: hg19). The genomic region assessed was 
identical for both assemblies and has the co-ordinates chr1:229828184-229828231 for hg18 and chr1: 
231761561-231762608 for hg19. For A and B, the location of the DISC1 transcription start site (TSS) 
is indicated by an arrow, and the locations of the four DISC1 promoter fragments assessed in the dual 
luciferase reporter assay are shown for reference. Regions identified as being bound by a transcription 
factor are indicated by a grey rectangular box, with the darkness of the box indicating the greatest 
observed level of enrichment for the transcription factor in any of the cell lines assayed (darker = 
greater enrichment). The identity of the transcription factor is indicated on the left-hand side of the 
image. At the right-hand side of each bar are letters representing the cell lines in which binding was 








Transcription factor Assembly Cell line(s)  
Max hg18 and hg19 Acute promyelocytic leukemia (NB4), lymphoblastoid 
(GM12878), and umbilical vein endothelial cells (HUVEC) 
NFKB hg18 and hg19 Lymphoblastoid (GM10847, GM12891, GM12892, 
GM15510, GM18951, GM19099, GM19193) 
IRF4 hg18 and hg19 Lymphoblastoid (GM12878) 
BATF hg18 and hg19 Lymphoblastoid (GM12878) 
FOSL2 hg18 and hg19 Hepatocellular carcinoma (HepG2) 
PU.1 hg18 and hg19 Lymphoblastoid (GM12878 and GM12891) and 
myelogenous leukemia (K562) 
USF-1 hg18 and hg19 Lymphoblastoid (GM12878), hepatocellular carcinoma 
(HepG2), and myelogenous leukemia (K562) 
c-Jun hg18 and hg19 Umbilical vein endothelial cells (HUVEC) 
c-Fos hg19 Umbilical vein endothelial cells (HUVEC) 
JunD hg18 and hg19 Hepatocellular carcinoma (HepG2), 
TCF4 hg19 Colorectal carcinoma (HCT-116), and hepatocellular 
carcinoma (HepG2) 
HDAC2 hg19 Hepatocellular carcinoma (HepG2) 
YY1 hg19 Lymphoblastoid (GM12878) 
Pol2-4H8 hg19 Colorectal carcinoma (HCT-116) 
NRSF hg18 Neuroectodermal (PFSK-1) 
Sin3Ak-20 hg18 Hepatocellular carcinoma (HepG2) 
p300 hg18 and hg19 Hepatocellular carcinoma (HepG2) and neuroblastoma 
cell line (SK-N-SH)  
c-Myc hg19 Human breast adenocarcinoma (MCF7) and acute 
promyelocytic leukemia (NB4) 
FOXA1 hg19 Hepatocellular carcinoma (HepG2) 
PAX5 hg19 Lymphoblastoid (GM12892)  
HNF4A hg18 Lymphoblastoid 
TAF1 hg18 and hg19 Hepatocellular carcinoma (HepG2) and embryonic stem 
cells (H1-hESC) 
HEY1 hg18 and hg19 Hepatocellular carcinoma (HepG2) 
ELF1 hg19 Hepatocellular carcinoma (HepG2) 
FOXP2 hg18 Neuroectodermal (PFSK-1) 
HA-E2F1 hg19 Human breast adenocarcinoma (MCF7) 
GABP hg19 Hepatocellular carcinoma (HepG2) 
Pol2 hg19 Fibroblast (ProgFib) and promyelocytic leukemia (NB4) 
 
Table 3.4.  Cell lines in which transcription factors have been ChIP-ed in the DISC1 candidate 
promoter region. See next page for legend. 
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Table 3.4. Cell lines in which transcription factors have been ChIP-ed in the DISC1 candidate 
promoter region. Transcription factors identified as potential regulators of DISC1 expression by ChIP 
are listed together with the assembly of the UCSC genome browser (hg18 or hg19) in which their 
interaction with the DISC1 candidate promoter region (chr1:229828184-229828231 for hg18 and 
chr1: 231761561-231762608 for hg19) is indicated. Cell line(s) in which the interaction was identified 




3.4.5.1 In silico identification of putative FOXP2 binding sites in the DISC1 
promoter 
 
As the putative role of FOXP2 in the regulation of DISC1 transcription was of particular 
interest, the DISC1 upstream region was searched for potential FOXP2 binding sites. 
Consensus binding sites of increasing levels of specificity have previously been identified 
for members of the general FOX family of transcription factors, the FOXP family, and 
FOXP2. The FOX family bind to sites with the consequence sequence TRTTKRY (where R 
= A or G, K = G or T, and Y = C or T) (Overdier et al., 1994). FOXP binds to sites with the 
consensus sequence TATTTRT (Wang et al., 2003), and FOXP2 binds to sites with the 
consensus sequence AATTTG or ATTTGT (Stroud et al., 2006; Wu et al., 2006), as well as 
the core binding site, ATTT (Konopka et al., 2009). Experimental assessment of FOXP2 
binding has revealed that it can bind to sites that deviate from the consensus binding site by 
one base pair (Vernes et al., 2007), or have the non-consensus sequence AAAGSAAA (S = 
G or C) (Vernes et al., 2011). 
 
Searching the region upstream of DISC1 that corresponds to the long promoter fragment 
(chr1: 231761579-231762608, hg19) for these sequences revealed 11 putative FOXP2 
binding sites. As can be seen in table 3.5, of these sites, eight were unique to the long 
construct, two were located in sequence common to the long and the medium constructs, and 
one was present in all three constructs.  
 
  





Table 3.5. In silico screening of the promoter region of the DISC1 gene (chr1: 231761579-
231762608) for the presence of putative FOXP2 binding sites. Sites corresponding to the 
consequence binding site of the general FOX family (TRTTKRY), the FOXP family 
(TATTTRT), FOXP2 (AATTTG/ATTTGT), and the core FOXP2 binding site (ATTT) were 
identified. In addition, sites deviating from the FOXP2 consensus binding site by one base pair 
and non-consensus (NC) sites previously demonstrated to bind FOXP2 (Vernes et al., 2007, 
2011) were searched for. 
a 
Deviations from the consensus binding site are indicated in red. Both 
of these sequences have previously been shown to bind FOXP2 (Vernes et al., 2007) 
b 
A plus 
sign (+) indicates the presence and a minus sign (−) indicates the absence of the indicated class 
of binding site. Where a putative binding site is compatible with more than one class of 
consensus binding site, the most specific class is indicated. 
c 
Position of the first nucleotide of 
the putative binding site relative to the transcription start site. 
d 
The number of times each 
putative binding site sequence is observed in each promoter construct is indicated. Where a 
sequence is present in a region of DNA common to more than one construct, only the shortest 
construct is indicated. 
 




3.5 Summary and discussion 
 
This chapter describes the characterisation of the promoter of DISC1, a leading candidate 
gene for schizophrenia and bipolar disorder, which has also been implicated in autism. The 
region was first analysed in silico to identify genomic features and epigenetic modifications 
commonly associated with promoter regions. These findings were used to inform the design 
of a series of constructs encoding nested fragments of the candidate DISC1 promoter region 
for assessment in the dual luciferase assay. 
 
The DISC1 candidate promoter region was found to be devoid of canonical core promoter 
elements in the expected location relative to the previously identified transcription start site 
(TSS) (Nakata et al., 2009). The region was found to contain a CpG island, a feature of many 
constitutively expressed genes, which is in keeping with DISC1’s ubiquitous pattern of 
expression (Millar et al., 2000b). Assessment of ChIP-identified epigenetic modifications in 
the cell lines depicted by the ENCODE Regulation track revealed a pattern of enrichment 
consistent with actively transcribed genes. The presence of both the activating histone 
modification, H3K4me3, and the repressive modification, H3K27me3, in human embryonic 
stem cells (as indicated by the GIS ChIP-PET track) suggests that the DISC1 promoter might 
fall into the bivalent class of promoters. The bivalent promoter is a hallmark of 
developmentally regulated stem cell genes (Johnson et al., 2011). Promoters carrying this 
modification are frequently transcriptionally silenced in embryonic stem cells but are ready 
to be activated upon differentiation (Bernstein et al., 2006). One putative mechanism for 
activation is the binding of RNA polymerase II in the bivalent state permitting swift 
transcriptional activation upon the loss of the H3K27me3 modification throughout 
development (Johnson et al., 2011).  
 
The H3K27me3 modification is particularly prevalent at CpG island promoters and, in a 
genome-wide scan of chromatin state, 22% of promoters with a high CpG content were 
identified as carrying both the H3K4me3 and H3K27me3 histone modifications in mouse 
embryonic stem cells (Mikkelsen et al., 2007). Such promoters were associated with reduced 
transcriptional activity. Upon differentiation to neural progenitor cells, the majority of these 
bivalent promoters were found to resolve to H3K4me3 alone and show an increase in 
expression (Mikkelsen et al., 2007).  
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In light of these findings, it is somewhat surprising that DISC1 has previously been reported 
to be expressed at a modest level in human embryonic stem cells and to show reduced 
expression upon neural differentiation (Sun et al., 2011), leading to the conclusion that 
DISC1 might play an important role in stem cells.  
 
Profiling of DISC1 mRNA expression in human post-mortem brain from a range of 
developmental stages has been carried out as part of the Human Brain Transcriptome project 
(http://hbatlas.org/; (Kang et al., 2011); figure 3.13). DISC1 mRNA expression was 
measured in six brain regions (neocortex, hippocampus, amygdala, striatum, mediodorsal 
nucleus of the thalamus and cerebellar cortex), with the neocortex being divided into eleven 
sub-regions for more detailed investigation. In the six brain regions, DISC1 mRNA 
expression was found to remain relatively constant across development, although some 
region-specific regulation was observed (figure 3.13A). While expression in the neocortex, 
striatum and mediodorsal nucleus peaks around during the neonatal/early infancy stage, 
cerebellar expression peaks during the late mid-foetal stage and hippocampal expression 
reaches its maximum during early foetal development and then remains fairly stable. In the 
11 neocortical sub-regions, DISC1 expression shows little between-region variability and 
remains reasonably constant throughout development (figure 3.13B). Although these 
findings indicate relatively limited variation in DISC1 mRNA expression across 
development and between-brain regions, it is important to note that the assessment of 
expression in each region at each developmental time point would have encompassed 
multiple cell types, thus diluting the contribution of individual cell types, which may have 
shown greater temporal and/or spatial regulation. Studies in which individual cell types are 
isolated using techniques such as laser capture microdissection would facilitate a more 
accurate understanding of the spatial and temporal regulation of DISC1 expression. 
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Figure 3.13. Developmental profiling of DISC1 mRNA expression in human post-mortem brain.  
Developmental profiling of DISC1 mRNA expression in human post-mortem brain samples was 
carried out by microarray as part of the Human Brain Transcriptome project (http://hbatlas.org/). A. 
DISC1 expression was measured in six brain regions (NCX = neocortex; HIP = hippocampus, AMY = 
amygdala, STR = striatum, MD = mediodorsal nucleus of the thalamus; CBC = cerebellar cortex) 
across 15 developmental periods. Birth is indicated by a red arrow. B. DISC1 expression was 
measured in eleven sub-regions of the neocortex (OFC = orbital prefrontal cortex; DFC = dorsolateral 
prefrontal cortex; VFC = ventrolateral prefrontal cortex; MFC = medial prefrontal cortex; M1C = 
primary motor cortex; S1C = primary somatosensory cortex; IPC = posterior inferior parietal cortex; 
A1C = primary auditory cortex; STC = superior temporal cortex; ITC = inferior temporal cortex; V1C 
= primary visual cortex) across 15 developmental periods. Birth is indicated by a red arrow. C. Table 
showing a description and range of ages for each of the 15 developmental periods assessed. 
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 In the mouse brain, Sun et al. (2011) showed Disc1 mRNA to be expressed at a very low 
level in the cortices of mice at E18 and P7 and in the whole brain in adult mice. These 
observations are somewhat at odds with a previous study that reports the detection of Disc1 
in the mouse cerebral cortex throughout development, with peaks in expression at E14, E16, 
and E18 (Austin et al., 2004). Furthermore, Disc1 has been found to show strong expression 
in the hippocampus at E18 (Meyer and Morris, 2008), and unpublished findings from our lab 
(Brown et al., manuscript in preparation) indicate that hippocampal expression of Disc1 
peaks at E18. As such, further studies assessing both the expression of Disc1 in embryonic 
stem cells and later in development, and the contribution of epigenetic histone modification 
to the observed developmental expression pattern are necessary. 
 
DISC1 transcription may also be regulated by disruption of the chromatin structure via the 
formation of Z-DNA. Computational assessment, using Zhunt, of the Z-DNA forming 
potential of the DISC1 promoter region suggests that this region is more likely than many 
genomic regions to undergo a transition to Z-DNA under conditions of negative 
superhelicity, which could be invoked by the actions of chromatin remodelling enzymes or 
RNA polymerase II (Havas et al., 2000; Liu and Wang, 1987; Wittig et al., 1992). The Z-
DNA forming region identified by Zhunt encompassed the complex dinucleotide repeat 
region. This region, with its composition of alternating purine and pyrimidine nucleotides 
matches the canonical Z-DNA forming sequence (Rich et al., 1983). In a previous study in 
which a region of DNA that acted as a transcriptional repressor was identified as having Z-
DNA forming potential with a Z-score similar to that of the DISC1 candidate promoter 
region, mutation of the dinucleotides to non-Z-DNA forming dinucleotides reduced the 
repressor activity of the region in some cell lines (Ray et al., 2010). Clearly, however, 
multiple factors are likely to contribute to the transition of B-DNA to Z-DNA and empirical 
assessment would be necessary to determine whether Z-DNA formation does contribute to 
the transcriptional activity of the DISC1 promoter. 
 
In the dual luciferase assay, the highest level of transcription was obtained from the medium 
promoter construct, which spans the region from -300 bp to +47 bp relative to the TSS, while 
a reduced level of transcription was obtained from the long construct, which comprises the 
sequence of -982 bp to +47 bp relative to the TSS. This pattern of results was evident in all 
three cell lines assessed, suggesting that the observed differences are not specific to a 
particular cell type. However, whilst statistically significant differences were observed in 
SH-SY5Y cells and HEK293 cells, the differences did not attain significance in LAN-5 cells. 
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As the magnitude of the differences between the mean expression levels obtained from each 
construct are fairly similar in all three cell lines and the same number of experimental 
replicates was performed for each cell line, a likely explanation for the lack of statistical 
significance in LAN-5 cells is the greater level of variability observed. One potential 
explanation for this variability is that LAN-5 cells showed greater cell death following 
transfection than the other two cell lines. This may be because the protocol used for the 
Nucleofection of LAN-5 cells had not been optimised. Nucleofector Kit V was used with the 
A-023 electroporation program as this kit is recommended for several other neuronal cell 
lines (e.g. NG108-15, SH-SY5Y and SK-N-SH), and the program is recommended for the 
high viability transfection of SH-SY5Y cells, amongst others. A study published after I 
completed this work has used the T-020 program to electroporate LAN-5 cells (Petroni et al., 
2011); however, as Lonza do not provide any details about the differences about the custom 
programs installed on the Nucleofector device, it is difficult to ascertain why T-020 might be 
more suitable than A-023. Nevertheless, although the results in LAN-5 cells were not 
statistically significant, the evidence does seem to support the conclusion that the medium 
promoter construct has greater transcriptional activity than either the short or the long 
constructs. The pattern of these findings is consistent with the ENCODE Pilot Project, which 
found that, in general, the region -300 bp to -50 bp relative to the TSS contributes positively 
to core promoter activity, whereas the region located-1000 bp to -500 bp relative to the TSS 
confers a repressive effect (Cooper et al., 2006). 
 
Before considering the factors that might contribute to the differing promoter activities of the 
three promoter constructs, it is necessary to acknowledge the limitations of this work. An 
obvious limitation is that the promoter activity of the DISC1 promoter fragments was 
assessed in isolation and the findings will, therefore, not necessarily reflect how the sequence 
contributes to promoter activity in the context of the genome. The effects of both structural 
properties influenced by the genomic context and interactions with regulatory elements 
outside of the region of interest would have been missed. Furthermore, as the promoter 
constructs were transfected transiently, the sequence of interest was assessed in a chromatin 
conformation different to that which occurs in the context of the genome; chromatin context 
is known to play an important role in transcriptional regulation (Smith and Hager, 1997). 
Results from the dual luciferase reporter assays performed here can, therefore, only be taken 
to indicate how a particular region might contribute to promoter activity. These findings can 
be used as a guide for the identification of regulatory elements and sequence variants that 
might be of interest; however, further experiments to assess cis-regions or trans-acting 
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factors of interest using approaches that take into account the genomic context of the 
promoter region should be performed. 
 
In addition to being limited by their inherently artificial nature, dual luciferase reporter 
assays are also subject to the influence of many potentially confounding extraneous 
variables. In an assessment of the factors affecting reporter assays, Karimi et al. (2009) 
identified several factors that affected the relative reporter activities of two constructs that 
differed by one SNP. A SNP would only be expected to have a relatively small effect on 
promoter activity; therefore, extraneous variables would be likely to exert a larger effect on 
the outcome of the experiment than in situations, such as this one, where constructs of 
markedly different promoter activity are compared. Nevertheless, it is worth considering the 
extraneous variables that might have affected the findings presented in this chapter. The 
confounding variables identified by Karimi et al. (2009) included the transfection method 
used, the concentration of the DNA transfected, DNA conformation, the growth history of 
the cells, and cell cycle phase.  
 
The transfection method used and the amount of DNA transfected were identical in all of the 
experiments performed in this chapter and, prior to use the long, medium, and short promoter 
constructs were assessed for DNA conformation and found to contain similar proportions of 
supercoiled, open circle, and linear DNA. It is possible, however, that between-experiment 
differences in the growth history of the cells and cell cycle phase may have contributed to 
between-experiment variability. Whilst in future experiments, it would be a good idea to 
attempt to control for these extraneous variables, the magnitude and the consistency of the 
differences between the promoter activities of the medium construct and the other two 
constructs suggests that extraneous variables did not exert a particularly large effect on the 
conclusions drawn from these experiments.  
 
Whilst cognisant of the potential limitations of the experiments performed in this chapter, it 
is of interest to consider the mechanisms that might underlie the differences in the activity of 
the three promoter constructs. The medium promoter construct, which gave the highest level 
of transcriptional activity, contains the complex dinucleotide repeat region. Dinucleotide 
repeats have previously been identified as contributing to the transcriptional activity of some 
promoters (Borrmann et al., 2003; Wang et al., 2005); however; in the case of the DISC1 
promoter, the complex dinucleotide repeat region did not appear to underlie the enhanced 
transcriptional activity of the medium construct. The promoter activity of the medium 1 
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construct, which lacked the 124 bp 5’ of the complex dinucleotide repeat region present in 
the medium construct, did not differ significantly from the short or the long constructs. It is, 
of course, the case that this analysis would not have detected any contribution of the 
complex dinucleotide repeat region that was dependent on the genomic context. The 
relatively small region of DNA considered in luciferase assays is a limitation of the 
technique. The involvement of distal regulatory elements in the control of gene transcription 
is well documented: regulatory elements located hundreds of kilobases away from the 
transcription start site have been reported previously (DiLeone et al., 2000; Spilianakis et al., 
2005). 
 
The results obtained in the present study can be compared with those of Hayesmoore et al. 
(2008). As mentioned in the introduction (section 3.1.1.2), Hayesmoore et al. (2008) 
concluded that the polymorphic TG repeat region, which forms part of the complex 
dinucleotide repeat region, does not influence DISC1 expression in the brain. Whilst this 
conclusion appears to fit with the present findings, limitations in Hayesmoore et al.’s (2008) 
approach render their findings compatible with several conclusions. Perhaps the most 
obvious limitation of Hayesmoore et al.’s (2008) approach was the lack of consideration of 
potential interaction effects between other sequence variants and the TG repeat 
polymorphism. The fact that some individuals heterozygous for polymorphisms affecting the 
number of TG repeats did not show allelic expression imbalance was interpreted to mean 
that the TG repeat polymorphism does not influence the expression of DISC in the brain. In 
fact, it is possible that the effect of the TG repeat polymorphism on DISC1 expression is 
modified by another sequence variant.  Furthermore, the contribution of TG repeat number to 
the allelic expression imbalance shown by the individual affected by the duplication of the 
TG repeat region was dismissed somewhat prematurely. The affected individual carried one 
(TG)8 and one (TG)10 on the chromosome affected by the duplication and a (TG)9 on the 
unaffected chromosome. Hayesmoore et al. (2008) concluded that, as (TG)9 is similar in size 
to both (TG)8 and (TG)10, TG repeat number was unlikely to play a part in the allelic 
expression imbalance. This conclusion appears unwarranted: the duplication results in a TG 
repeat region with the sequence (TG)8TATGTC(TG)10, as the two sets of TG repeats are in 
such close proximity to each other it seems feasible that they might have an additive or 
interactive effect.  
 
The assessment of the role of the complex dinucleotide region in DISC1 promoter activity 
carried out in this chapter together with Hayesmoore et al.’s (2008) assessment of the TG 
Chapter 3: Characterisation of the DISC1 promoter 
153 
 
repeat region represent only a preliminary investigation of the function of this region. Before 
any firm conclusions can be drawn, further characterisation is required. Assessment of the 
association between polymorphisms in this region and DISC1 expression in a large sample, 
including the consideration of interaction effects with other genetic variants, would be 
informative. Further in vitro assessment could be carried out using reporter assays to assess 
the promoter activity of constructs carrying varying numbers of repeats in the complex 
dinucleotide repeat region in the context of upstream sequence. Using such assays, the length 
of the dinucleotide repeat region and the genetic background could be varied systematically 
permitting a more direct assessment of the effect of dinucleotide repeat region length on 
promoter activity than is possible in a naturalistic study, such as that carried out by 
Hayesmoore et al. (2008). Furthermore, the cloning of a longer section of the DISC1 
upstream region than studied in this chapter would improve the validity of the in vitro 
assessment. 
 
ChIP data obtained as part of the ENCODE project was used to identify transcription factors 
that might be involved in the regulation of DISC1. Both the spatial resolution of ChIP-seq 
and the large number of transcription factors identified as binding the DISC1 candidate 
promoter region, made it impossible to draw any conclusions about any individual 
transcription factors that might contribute to the relatively high level of promoter activity 
obtained from the medium fragment. The observation that the medium promoter fragment 
contains a region of high regulatory potential, according to the ESPERR Regulatory 
Potential (7 Species) track, not included in the short fragment or the medium 1 fragment 
suggests that conserved regulatory elements might contribute to the activating effect of the 
124 bp unique to the medium fragment. As such, further investigation of the aligned 
sequences could yield clues to transcription factors that confer a positive effect on promoter 
activity. 
 
In contrast to the medium, medium 1 and short fragments, there was a paucity of 
transcription factors predicted to bind to the genomic region unique to the long fragment. As 
diminished gene expression was observed from this fragment compared to the medium 
fragment, repressive elements may be located in the region located -982 bp to -301 bp 
relative to the TSS. As such, it was interesting to find that the transcription factor Max, 
which under some circumstances can exert a repressive effect (Solomon et al., 1993), had 
been identified by ChIP as binding in the within this region. Experimental assessment of (i) 
the binding of Max to this region, perhaps using electromobility shift assays, and (ii) the 
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effect of Max on the transcriptional activity of the long construct, using the dual luciferase 
reporter assay, would help to establish whether the repressive effect of Max binding 
contributes to the low activity of the long fragment.  
 
Assessment of the ENCODE Regulation super-track for transcription factors identified by 
ChIP as binding in DISC1 upstream region assessed in this chapter revealed several 
transcription factors with links to psychiatric illness. These include FOXP2, TCF4 and 
transcription factors with links to immune function (NF-κB, IRF4, and members of the AP-1 
family).Variation in the FOXP2 gene has been linked to speech and language function (Feuk 
et al., 2006; Lai et al., 2001; Lennon et al., 2007; MacDermot et al., 2005; Shriberg et al., 
2006; Tomblin et al., 2009; Zeesman et al., 2006), and transcriptional targets of FOXP2 
include genes, such as CNTNAP2 and MET, implicated in autism (Mukamel et al., 2011; 
Vernes et al., 2008). TCF4 is a Wnt signalling responsive transcription factor. The Wnt 
signalling pathway is of great interest in the study of the pathogenesis of psychiatric illness 
due to its role in neurodevelopment and amenability to pharmacological targeting (Okerlund 
and Cheyette, 2011). As mentioned in the introduction (section 1.7.2.4.2), DISC1 has 
previously been implicated in Wnt signalling (De Rienzo et al., 2011; Mao et al., 2009); 
therefore, the regulation of DISC1 expression by a Wnt signalling responsive transcription 
factor might represent a feedback mechanism. The finding that DISC1 is potentially 
regulated by transcription factors implicated in immune function is interesting in the context 
of the growing evidence for abnormal immune function in psychiatric illness (see section 
1.3) and the evidence, albeit not unequivocal, for the therapeutic effect of adjunctive 
treatments that target the immune system (Mansur et al., 2012). The role of these 
transcription factors in regulating DISC1 warrants experimental assessment as the 
identification of regulatory links would assist in the synthesis of our understanding of the 
mechanisms involved in conferring risk for psychiatric illness.  
 
Given the evidence for the involvement of FOXP2 in neurodevelopmental disorders, its 
putative role in regulating DISC1 transcription was of particular interest. As such, the DISC1 
promoter fragments assessed in this chapter were assessed for potential FOXP2 binding sites. 
Eleven predicted FOXP2 binding sites were identified, the majority of which were unique to 
the long construct. As FOXP2 generally confers a repressive effect on transcription (Shu et 
al., 2001), the effects of FOXP2 may have contributed to the decreased promoter activity of 
the long construct relative to the medium construct; although, it should be noted that the 
ENCODE ChIP-seq assay did not detect FOXP2 binding in the sequence unique to the long 
Chapter 3: Characterisation of the DISC1 promoter 
155 
 
promoter fragment. As discussed previously (section 3.1.2.2), however, the computational 
prediction of TFBSs based on consensus sequences is plagued by false positives, and, 
therefore, the role of FOXP2 in regulating DISC1 must be assessed experimentally and the 
functionality of predicted binding sites determined using techniques such as electrophoretic 




To conclude, the DISC1 promoter region is devoid of canonical promoter motifs but does 
contain a CpG island, in common with many ubiquitously expressed genes. Histone 
modifications identified by ChIP by previous studies indicate that the DISC1 promoter may 
exist in a bivalent state in embryonic stem cells, although this possibility requires 
experimental assessment. Dual luciferase reporter assays suggested the presence of positive 
regulatory elements in the region unique to the medium promoter fragment (-300 bp to -177 
bp relative to the TSS) and repressive regulatory elements in the region unique to the long 
promoter fragment (-982 bp to -301 bp relative to the TSS). The presence of peaks in the 
ESPERR Regulatory Potential (7 Species) track in regions unique to both the medium and 
the long fragments suggest that certain features controlling the promoter activity of these 
fragments might show cross-species conservation. Several transcription factors identified by 
previous studies as potentially binding to the DISC1 promoter region are themselves linked 
to psychiatric illness. This finding suggests that further investigation of the mechanisms 
regulating DISC1 expression might help to integrate currently disparate strands of 
understanding regarding the pathogenesis of psychiatric illness. The assessment of the 
regulation of DISC1 by one of these transcription factors, FOXP2, is the subject of the next 
chapter. 
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Understanding how a gene is regulated, and, in turn, how it regulates other genes, permits the 
gene to be considered in the context of a regulatory network. Identifying the other members 
of this network can provide important clues to both normal gene function and the 
mechanisms that might be disturbed in a pathological state. Here, the role of one 
transcription factor, forkhead box P2 (FOXP2), in regulating DISC1 expression was 
assessed. In addition, a putative bi-directional regulatory relationship between DISC1 and 
FOXP2 expression was explored in a mouse model carrying an N-ethyl-N-nitrosourea 
(ENU)-induced point mutation, L100P, in the Disc1 gene. Some of the work presented in 




FOXP2 is a member of a large, evolutionarily conserved family of transcription factors, 
characterised by the presence of a forkhead box (FOX) DNA-binding domain (Benayoun et 
al., 2011). Members of the FOXP subfamily have, in addition to the FOX domain, a zinc 
finger domain and a leucine zipper motif, which permit regulation of their transcriptional 
activities by facilitating homo- and hetero-dimerisation (Takahashi et al., 2009). In addition 
to FOXP2, two other members of the FOXP subfamily, FOXP1 and FOXP4, are abundantly 
expressed in the brain (Takahashi et al., 2009).  
 
4.1.1.1 The FOXP2 gene 
 
The FOXP2 gene displays a complex pattern of splicing resulting in multiple isoforms. To 
date, 26 FOXP2 exons have been defined (Bruce and Margolis, 2002; MacDermot et al., 
2005; Schroeder and Myers, 2008) (figure 4.1), which, according to the UCSC genome 
browser, are arranged to form 14 distinct transcripts. The FOXP2 isoform, isoform 1, 
investigated in this chapter is the major protein-coding transcript: it comprises 17 exons, 
utilises a start codon in exon 2, and encodes a protein of 715 amino acids (Lai et al., 2001). 
The majority of FOXP2 isoforms contain the same functional domains: exons 5-6 encode a 
polyglutamine tract, exons 8-10 encode the zinc finger domain and the leucine zipper motif, 
exons 12-14 encode the FOX domain, and exon 17 encodes an acidic C-terminal tail. A 
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notable exception is isoform FOXP2.10+, an alternatively spliced isoform that includes an 
elongated version of exon 10 followed by a polyadenylation site, which lacks the FOX 















4.1.1.2 Mechanisms controlling the transcriptional regulation of FOXP2 
 
In an initial attempt to understand the regulation of FOXP2, Schroeder and Myers (2008) 
mapped the gene’s transcription start sites (TSSs). They identified four distinct TSSs located 
in exons S1, 1, 1b, and 2 (figure 4.1). The TSSs in exons S1 and 2 appeared to contribute to 
basal expression, whereas the TSSs in exons 1 and 1b appeared to be more cell line specific.  
Interestingly, the expression of the transcripts derived from the exon 1 and exon 1b TSSs 
was found to be highest in the brain, lung, and digestive tract, organs where the expression of 
FOXP2 is particularly important during development (Schroeder and Myers, 2008). 
Intriguingly, Schroeder and Myers (2008) failed to demonstrate transcriptional activity using 
putative promoter fragments derived from the sequence upstream of the exon 1 and exon 1b 
TSSs in transient transfection dual luciferase assays. Failure to detect activity is unlikely to 
be attributable to the choice of experimental cell line (PFSK-1), as endogenous expression of 
FOXP2 transcripts derived from these start sites was detected in PFSK-1 cells. This led to 
the suggestion that distal regulatory elements might be required to initiate transcription from 
these TSSs.  
 
 
Figure 4.1. Exon structure of FOXP (not to scale). Exons are represented by horizontal bars with 
the exon number indicated above. Red arrows indicate transcription start sites detected by 
Schroeder and Myers (2008). Asterisks indicate exons included in FOXP2 isoform 1, the major 
protein coding transcript. Exon 10+ (black and grey bars) is an elongated version of exon 10 
(black bar) formed by alternative splicing. Most FOXP2 isoforms include a poly-Q domain, a zinc 
finger domain (ZnF), a leucine zipper motif (LeuZ), a FOX domain, and an acidic C-terminal tail 
(Acidic). An exception is FOXP2.10+, an alternatively spliced isoform that includes an elongated 
version of exon 10 (10+) followed by a polyadenylation site. This transcript, therefore, lacks the 
FOX domain and the acidic C-terminal tail. Adapted from Schroeder and Myers (2008).  
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Analysis of the Encyclopaedia of DNA Elements (ENCODE) transcription factor binding 
site (TFBS) track on the UCSC genome browser reveals several binding sites in the FOXP2 
promoter regions predicted by chromatin immunoprecipitation (ChIP) (Rosenbloom et al., 
2010). The presence of two FOXP2-bound regions upstream of the exon S1 TSS and several 
FOXA1-bound regions upstream of both the exon S1 and exon 1 TSSs suggests that FOXP2 
may regulate itself. A putative TCF4 (TCF7L2) binding site present upstream of exon S1 is 
of particular interest as it links the regulation of FOXP2 with the Wnt signaling pathway, 
dysfunction of which is believed to be a risk factor for psychiatric illness (Okerlund and 
Cheyette, 2011). Members of the Wnt-activated LEF/TCF family can bind to a common 
binding site (Hallikas et al., 2006), therefore the ChIP-identified TCF4 site is consistent with 
a previous study that found FoxP2 to be regulated by Lef1 during zebrafish central nervous 
system (CNS) development (Bonkowsky et al., 2008). In the context of the known role of 
DISC1 in regulating the Wnt signalling pathway (section 1.7.4.2.4), these observations raise 
the question of whether DISC1 function might affect the transcriptional regulation of 
FOXP2. 
 
Whilst the bioinformatic prediction of TFBSs suffers from many limitations (section 
3.1.2.2), it is interesting that a search for TFBSs in the 5’ flanking region of exon S1 (-
1500bp to +100bp relative to the TSS) using a TFBS prediction program identified a putative 
cAMP response element-binding (CREB) binding site (Bruce and Margolis, 2002). As 
mentioned in section 1.7.4.2.4, PDE4B, an enzyme responsible for the hydrolysis of cAMP 
is a DISC1-interating protein, thus this finding identifies another potential link between 
DISC1 function and FOXP2 regulation. This study also identifies EGR1 as a potential 
regulator of FOXP2. EGR1 has been found to be downregulated in the prefrontal cortex in 
patients with schizophrenia (Yamada et al., 2007), and the closely related transcription 
factor, Egr4, has been identified as being disregulated in a genetic mouse model of 
schizophrenia, which carries a mutation in the Disc1 gene (section 4.1.2.1). Both EGR1 and 
EGR4 can bind to a common EGR consensus motif (Zipfel et al., 1997). Although 
preliminary, these observations suggest several potential links between the regulation of 
FOXP2 and genetic mechanisms with suspected involvement in the aetiology of 
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4.1.1.3 The pathogenic consequences of point mutations in the FOXP2 gene 
 
The FOXP2 gene was originally identified through mapping studies of a large multi-
generational family (the KE family) with a monogenic speech and language disorder (Fisher 
et al., 1998). All affected members of the family have a heterozygous non-synonymous 
FOXP2 mutation, yielding a subsitution (R553H) within the highly-conserved DNA-binding 
domain of the encoded protein (Lai et al., 2001). Affected individuals are profoundly 
impaired in the selection and sequencing of coordinated orofacial movements required for 
speech, resulting in the characterisation of their disorder as a developmental verbal dyspraxia 
(DVD) (Hurst et al., 1990; Vargha-Khadem et al., 1995; Vargha-Khadem et al., 1998; 
Watkins et al., 2002a). In addition, affected individuals display deficits in linguistic and 
grammatical processing, as well a decrease in IQ in both verbal and, to a lesser extent, non-
verbal domains (Vargha-Khadem et al., 1995; Watkins et al., 2002a). Following extensive 
behavioural testing, Vargha-Khadem et al. (1995) concluded that the core deficit in affected 
family members is orofacial dyspraxia; however, what remains unclear is whether the 
additional deficits are secondary to the orofacial dyspraxia or whether they represent 
additional core deficits. 
 
Another heterozygous FOXP2 point mutation, R328X, which results in a prematurely 
truncated protein lacking the DNA-binding domain, was identified in a second family 
segregating DVD (MacDermot et al., 2005). Functional characterisation has revealed that 
both mutations can disturb nuclear localisation of FOXP2, as well as interfere with its 
capacity to act as a transcription factor (Vernes et al., 2006). Moreover, chromosomal 
rearrangements (including translocations and deletions) that disrupt FOXP2 have been 
reported in other individuals and families with speech and language impairments (Feuk et al., 
2006; Lennon et al., 2007; Shriberg et al., 2006; Tomblin et al., 2009; Zeesman et al., 2006). 
 
4.1.1.4 Evidence for the involvement of FOXP2 in the transcriptional regulation of 
DISC1 
 
DISC1 was first suggested as a potential direct target of FOXP2 by ChIP followed by 
microarray (ChIP-chip) in human foetal basal ganglia (Spiteri et al., 2007). Subsequently, a 
second ChIP screen carried out as part of the ENCODE project identified FOXP2 binding in 
the DISC1 upstream region in the neuroectodermal cell line, PFSK-1 (Rosenbloom et al., 
2010) (figure 4.2). 
 



















The potential involvement of FOXP2 in the regulation of DISC1 was of great interest as 
several lines of evidence suggest overlap in the phenotypic consequences of variation in the 
two genes. FOXP2 has been shown to regulate genes involved in susceptibility to autism 
spectrum disorder (ASD) (Mukamel et al., 2011; Vernes et al., 2008), a condition associated 
with genetic variation in DISC1 (Crepel et al., 2010; Kilpinen et al., 2008; Williams et al., 
2009; Zheng et al., 2011). In addition, there is tentative evidence to suggest that variation in 
FOXP2 might be a risk factor for both schizophrenia and major depressive disorder: Li et al. 
(2012) identified association between a rare FOXP2 variant and both conditions in a sample 
drawn from the Chinese Han population and Sanjuán et al. (2006) found a SNP and a 
haplotype in FOXP2 to be associated with schizophrenia with auditory hallucinations. 
Association between gray matter concentration in patients with schizophrenia and a FOXP2 
variant has also been reported (Spaniel et al., 2011). One study has been published in which 
no association was identified between FOXP2 variants and schizophrenia (Sanjuan et al., 
2005); however, only two variants were assessed.  
 
Abnormalities in cognitive function represent an area of phenotypic overlap in conditions 
resulting from variation in FOXP2 and/or DISC1. The reductions in cognitive function 
observed in individuals carrying the R553H FOXP2 mutation were described in the previous 
section and, as mentioned in the introduction, deficits in cognitive function are a core feature 
Figure 4.2. Schematic showing the genomic location of putative FOXP2 binding sites identified 
by chromatin immunoprecipitation (ChIP) in the DISC1 upstream region. Potential FOXP2 
binding sites were identified by either ChIP followed by sequencing (ChIP-seq) in human foetal 
brain (Spiteri et al., 2007), or by ChIP followed by microarray (ChIP-chip) in the PFSK-1 
neuroectodermal cell line (“ENCODE Integrated Regulation” track on the UCSC human genome 
browser, Rosenbloom et al., 2010). The DISC1 transcription start site (TSS; chr1: 231762561, 
UCSC genome browser, February 2009, GRCh build 37; http://genome.ucsc.edu/) is shown for 
reference. 
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of the schizophrenia phenotype that have been associated with variation in DISC1 (section 
1.1). Of particular interest, given the putative FOXP2-DISC1 regulatory relationship, is the 
association of DISC1 variants with verbal working memory (Burdick et al., 2005). 
Characterisation of cognitive functioning in autism has resulted in less clear cut findings: 
some studies support the existence of an uneven pattern of cognitive functioning (Joseph et 
al., 2002; Kuschner et al., 2007); however, another has reported children with autism to have 
a wide range of cognitive abilities without the existence of a characteristic pattern of deficits 
(Siegel et al., 1996). It should, however, be noted that studies of cognitive function in autism 
have typically been limited to high-functioning individuals. Linguistic function is another 
area of apparent overlap in the conditions associated with variation in FOXP2 and/or DISC1. 
Impaired language function is a core symptom of autism (Groen et al., 2008), while 
linguistic abnormalities are a well-established finding in schizophrenia (Barrett et al., 2009; 
Bull and Venables, 1974; Condray et al., 2002; John et al., 2011). Variation in DISC1 has 
been associated with verbal fluency (Palo et al., 2007) and the fMRI-assessed activity of 
multiple brain regions, including the pre/post-central gyrus, inferior frontal gyrus, and the 
cuneus during a language task (Chakirova et al., 2011; Whalley et al., 2012). The effects of 
variants on brain activation do, however, appear to differ between control subjects and those 
diagnosed with, or at high genetic risk of, bipolar disorder or schizophrenia. Despite the 
evidence for schizophrenia- and DISC1-related effects on language function, it is important 
to note that the linguistic abnormalities displayed by individuals carrying the R553H and 
R328X FOXP2 mutations, and those diagnosed with autism or schizophrenia show only 
partial overlap. For example, the contribution of orofacial praxia to linguistic dysfunction 
appears to be predominantly a feature of the conditions arising from the R553H and R328X 
FOXP2 mutations. 
 
Consistent with the neurodevelopmental nature of the conditions associated with variation in 
FOXP2 and DISC1, both genes are known to play important roles in brain development: 
genome-wide ChIP-chip analysis has revealed FOXP2 to regulate genes involved in neurite 
outgrowth in the developing brain (Vernes et al., 2011) and the involvement of DISC1 in key 
neurodevelopmental processes, including neuronal migration, neurite outgrowth, axon 
myelination, and synaptic function has previously been mentioned in section 1.7.4.2.4. The 
available evidence suggests, therefore, that FOXP2 and DISC1 might contribute to partially 
overlapping neurodevelopmental pathways, the dysfunction of which contributes to the 
development of disorders that share some phenotypic similarities.  
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In this chapter, the ChIP-generated hypothesis that FOXP2 is involved in the regulation of 
DISC1 was tested, and the effect of the two pathogenic point mutations, R553H and R328X, 
assessed. 
 
4.1.2 The Disc1 L100P mutant mouse 
 
A line of mutant mice carrying an ENU-induced point mutation in Disc1 was developed by 
Clapcote et al. (2007). The mutation occurs in exon 2 of the gene and results in an amino 
acid substitution from leucine to proline at the 100
th
 amino acid residue. First generation 
carriers of the mutation were backcrossed for six generations to generate heterozygotes with 
a predominantly C57BL/6J (98.4%) genetic background. At this point, heterozygotes were 
intercrossed to generate homozygous and heterozygous carriers of the point mutation.  
 
Behavioural phenotyping of the Disc1 L100P mice revealed a “schizophrenia-like” 
phenotype (Clapcote et al., 2007). The mice show deficits in prepulse inhibition (PPI) and 
latent inhibition (LI), which were reversed by treatment with the antipsychotics haloperidol 
and clozapine, and the PDE4 inhibitor rolipram. PPI describes the neurobehavioural 
phenomenon whereby the presentation of a low-intensity stimulus prior to a high-intensity 
stimulus reduces the startle reaction to the high-intensity stimulus (Hoffman and Searle, 
1965). LI refers to the finding that pre-exposure to a non-reinforced stimulus decreases 
learning to the stimulus if it is subsequently rewarded (Lubow and Moore, 1959). Deficits in 
PPI and LI are found in individuals diagnosed with schizophrenia and are thought to reflect a 
deficit in the ability to filter out non-salient information, and thus in information processing 
(Braff and Geyer, 1990; Lubow and Gewirtz, 1995; Perry and Braff, 1994). The mice 
additionally demonstrated hyperactivity in the open field maze, which was reduced by 
clozapine, and impaired working memory, as assessed by the T maze. Deficits in working 
memory are frequently observed in individuals with schizophrenia (Barch, 2005).  
 
Subsequent studies have provided mixed support for the behavioural deficits observed by 
Clapcote et al. (2007): the PPI deficit has been observed by Lipina et al. (2010), and Walsh 
et al. (2012) found the Disc1 L100P mice to be hyperactive in the open field. In contrast, 
Shoji et al. (2012) failed to replicate Clapcote et al.’s (2007) findings of impaired PPI and 
working memory but did observe the Disc1 L100P mice to be hyperactive. Shoji et al. (2012) 
backcrossed the mice for a further two generations compared to Clapcote et al. (2007), so it 
is possible that their findings reflect the removal of additional ENU-induced mutations or 
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residual DBA/2J genetic material that remained in the genetic background of the mice 
assessed by Clapcote et al. (2007). Shoji et al. (2010) did, however, backcross their mice to 
C57BL/6JJcl mice rather than C57BL/6J mice, as used by Clapcote et al. (2007), so it is 
possible that their results have been influenced by between-substrain behavioural 
differences. It is also possible that differences in the experimental variables or the laboratory 
environment might have contributed to the differences between the two studies. Indeed, 
whilst Clapcote et al., (2007) assessed both male and female mice, Shoji et al. (2012) 
assessed only male mice. The gender of the mice cannot, however, fully explain the 
differences between these two studies, as Lipina et al. (2010) also only assessed male mice. 
Additional differences between the studies were the age at which the mice were assessed and 
their previous experience of behavioural tests: Clapcote et al. (2007) used experimentally 
naive mice aged between 12-16 weeks of age, while Shoji et al. (2012) used mice that were 
not experimentally naive and were aged between 16-19 weeks for assessment of PPI and 18-
22 weeks for the assessment of working memory. Further studies are required to investigate 
the reasons behind Shoji et al.’s (2012) failure to replicate the behavioural phenotype of the 
Disc1 L100P mice. Furthermore, in light of the neuroanatomical and neurochemical 
abnormalities identified in the L100P mice, which are described in the following paragraphs, 
it would be of interest to assess Shoji et al.’s (2012) mice at these levels. 
 
Neuroanatomical investigation of the Disc1 L100P mice has revealed a 13% reduction in 
adult brain volume (Clapcote et al., 2007), reduced neuron number, reduced neurogenesis, 
and altered neuronal distribution (Lee et al., 2011a). Neurons in the frontal cortex were 
found to have shorter dendrites and decreased surface area and spine density (Lee et al., 
2011a). These abnormalities correspond to some of the neuroanatomical abnormalities 
present in patients with schizophrenia (Akbarian et al., 1995; Lawrie and Abukmeil, 1998; 
Ross et al., 2006; Wright et al., 2000).  
 
A biochemical mechanism for at least some of the behavioural and neuroanatomical 
phenotypes displayed by the Disc1 L100P mice is suggested by the observation that the 
mutation reduces Disc1-Pde4b (Clapcote et al., 2007) and Disc1-Gsk3α and –Gsk3β binding 
(Lipina et al., 2011), which occur under normal circumstances in a region at the N-terminal 
of the gene. Binding by DISC1 serves to inhibit GSKβ activity (Mao et al., 2009); however, 
somewhat counterintuitively, no difference has been found in the kinase activities of either 
Gsk3α or β in the Disc1 L100P mice (Lipina et al., 2010). Similarly, the L100P mutation has 
been shown to have no effect on Pde4b activity (Clapcote et al., 2007). Nevertheless, genetic 
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and pharmacological inactivation of Gsk3 reverses the PPI and LI deficits and reduces the 
hyperactivity of the Disc1 L100P mice (Lipina et al., 2011).  Furthermore, inactivation of 
Gsk3α rescues the spine density phenotype (Lee et al., 2011b). A synergistic interaction 
between Gsk3 and Pde4b has been highlighted by the finding that combined treatment of the 
Disc1 L100P mice with a GSK3 inhibitor, TDZD-8, and the PDE4 inhibitor rolipram, using 
each drug at a sub-threshold dose, corrects the PPI deficit and reduces hyperactivity (Lipina 
et al., 2012). In light of the paradoxical nature of these observations further work is required 
to understand how the altered interactions between Disc1 and Gsk3 and Pde4b affect the 
functioning of these enzymes and thus contribute to the behavioural and anatomical 
phenotypes of the mice.  
 
Abnormalities in dopamine function have also been observed in the Disc1 L100P mouse: the 
mice are hypersensitive to the dopamine agonist amphetamine and show increased striatal 
expression of high-affinity D2 receptors (Lipina et al., 2010). Treatment with the dopamine 
antagonist haloperidol ameliorates the LI and PPI deficits, reduces hyperactivity and 
sensitivity to amphetamine (Lipina et al., 2010). Abnormalities in dopamine function may be 
a consequence of disrupted Pde4b function: the binding of Disc1 to Pde4b modulates cyclic 
adenosine monophosphate (cAMP) function, and thus dopamine synthesis (Nishi et al., 
2008; Yamashita et al., 1997). 
 
4.1.2.1 Altered gene expression in the Disc1 L100P mouse 
 
During her PhD, Sarah Brown (SB) carried out microarray analysis to identify genes that are 
differentially expressed in the Disc1 L100P mouse. A subset of the genes identified as being 
differentially expressed by the microarray was followed up using qRT-PCR to measure gene 
expression throughout development. In addition to assessing the expression of these genes, 
SB characterised the developmental profile of Disc1 in the Disc1 L100P mice and showed 
altered expression at E13 and P1 but not in the adult mouse, consistent with a previous report 
of Disc1 protein expression in the adult mouse (Clapcote et al., 2007). Developmental 
expression of Disc1 in the Disc1 L100P mouse appears to be shifted such that peak 
expression occurs later in the mutant mice than their wildtype counterparts. A similar shift in 
peak expression was observed for neurexins (NRXNs) 1 and 3 (Brown et al., 2011), and Pak3 
(Brown et al., manuscript in preparation). Altered developmental expression was also 
confirmed for Sort1, Cdh11, and Egr4. 
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In this chapter the effect of the Disc1 L100P mutation on the developmental expression of 
Foxp2 was assessed using qRT-PCR. The rationale for carrying out this analysis is that, as 
described in section 4.1.1.2, the expression of FOXP2 may be regulated by several pathways 
with a known link to DISC1 function (section 1.7.4.2.4), including Wnt signalling, and 
cAMP- and EGR-dependent transcription. The expression of Foxp2 in the Disc1 L100P mice 
has not been studied previously as expression of Foxp2 was not detectable above background 
on the microarray. 
 
4.1.3 Introduction to the quantitative real-time polymerase chain reaction 
(qRT-PCR) technique 
 
In this chapter, qRT-PCR is used twice: (i) to assess the effect of FOXP2 overexpression on 
DISC1 mRNA expression in HEK293 cells, and (ii) to characterise developmental Foxp2 
expression in mice carrying the Disc1 L100P mutation and their wildtype counterparts. qRT-
PCR is the most sensitive method for the accurate detection of low abundance mRNA 
(Bustin et al., 2000); however its validity depends on accurate normalisation of the 
expression values for the gene(s) of interest (GOI) to account for the amount of cDNA 
present in the reaction. The need for normalisation is borne from the fact that: (i) the 
efficiency of the reverse transcriptase reaction is variable, rendering the quantification of 
RNA insufficient as an estimate of cDNA quantity (Bustin and Nolan, 2004), and (ii) the 
quantification of cDNA by most methods (including nano-dropping) is not sufficiently 
accurate for direct normalisation to cDNA quantity. 
 
The normalisation of GOI  expression values to the expression values of internal control 
genes, “reference genes”,  measured in the same sample has become the most widely 
accepted approach to normalisation. The advantage of this approach is that the reference 
genes are exposed to the same conditions as the GOI at all stages of the experimental 
workflow, and therefore should normalise for variation introduced at any step. 
Unfortunately, no known gene meets the requirement for an “ideal reference gene”; that is, a 
gene is yet to be identified that shows invariant mRNA expression under all possible 
experimental conditions and at all developmental stages (Thellin et al., 1999; Vandesompele 
et al., 2002). The effect of variation in reference gene expression on study outcome has been 
explored by studies that have compared the results obtained when normalising gene-of-
interest data to different reference genes. These studies have revealed reference gene choice 
to have a large effect on the outcome of a study, sometimes changing a finding from being 
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statistically significant to non-significant (Dheda et al., 2005; Ferguson et al., 2010). 
Therefore, it is important to identify reference genes whose expression is affected the least 
by the variables present in a certain experiment. One way of improving the chances 
accurately quantifying cDNA is to use multiple reference genes that participate in diverse 
cellular processes, and are, therefore, unlikely to be co-regulated (Vandesompele et al., 
2002). This minimises the bias that any one non-ideal reference gene might introduce during 
normalisation.  
 
The identification of suitable reference genes is plagued by the circular problem of having to 
assess the expression stability of a candidate reference gene when there is no reliable method 
to normalise the candidate. Several computer programs have been developed to address this 
problem, each implementing a slightly different algorithm. In this chapter, two different 
programs are used: geNorm and NormFinder. The different approaches used by the two 




The geNorm software developed by Vandesompele et al. (2002) works on the assumption 
that the expression ratio of two genuine reference genes should be constant across samples. 
For each candidate reference gene, the program calculates the pairwise variation value of the 
gene with each other candidate reference gene and assigns a gene stability value (M value), 
which represents the average pairwise variation of the gene with all other tested genes. 
Through a stepwise process of excluding the worst performing reference genes, the software 
ranks the candidate reference genes in order of stability. Identification of the minimum 
number of reference genes for accurate normalisation is permitted through the calculation of 
“V”. V represents the variation in the sequential normalisation factors derived from the n and 
n+1 most stable genes. When Vn/n+1 ≤ 0.15, there is no benefit to using an additional gene 
to calculate the normalisation factor. Normalisation factors are calculated by taking the 
geometric mean of the n most stable reference genes. The geometric mean is favoured over 
the arithmetic mean as it is more robust to outlying values and differences in abundance 
between the candidate reference genes (Vandesompele et al., 2002). It is recommended that 
geNorm is used with eight candidate reference genes measured in ten samples; however, the 
minimum requirements are that it is run on three candidate reference genes measured in two 
samples. 
 





NormFinder employs a statistical model to assess the expression stability of candidate 
reference genes (Andersen et al., 2004). This model, which is based on a two-way ANOVA, 
assesses stability by comparing the expression of each candidate reference gene to a norm 
that is calculated by taking the mean of the expression values of all candidate reference 
genes for each sample. The program permits the user to indicate whether the samples belong 
to different groups (i.e. treated and control), and the most stable reference gene is then 
defined as the gene with the lowest inter- and intra-group variation. The most stable pair of 
reference genes is also calculated: this is the pair of reference genes that, when used in 
combination, result in the lowest combined standard deviation. An obvious assumption of 
this model is that the mean expression level of all the candidate genes does not differ 
between groups. Additionally, it is recommended that the model is used with a minimum of 
three candidate reference genes measured in a minimum of eight samples per a group 
(Andersen et al., 2004). 
 
4.1.3.3 A comparison of the geNorm and Normfinder approaches 
 
It has been shown that, in general, geNorm and NormFinder tend to agree on the most stable 
reference genes (Perez et al., 2008; Uddin et al., 2011); however, this is not always the case 
(Andersen et al., 2004). Furthermore, it has been demonstrated that the pairwise method used 
by geNorm has the tendency to rate co-regulated genes highly, independently of their 
expression stabilities; NormFinder is less susceptible to this confound (Andersen et al., 2004; 
Beekman et al., 2011). However, the NormFinder approach is limited by the assumption that 
the mean expression of the candidate reference genes does not vary between groups. This 
can be difficult both to predict and to assess, due to the circular problem of attempting to 
quantify reference genes. An advantage of NormFinder over geNorm is the ability to directly 
assess the inter-group variation of a gene. One advantage of geNorm over NormFinder is that 
it calculates the optimum number of reference genes to use. In contrast, NormFinder 
identifies the best pair of reference genes.  
 
As there are different advantages and disadvantages associated with the use of both 
NormFinder and geNorm, both approaches were used in this chapter to identify the best 
reference genes. It was hoped that the use of two programs would (i) maximise the chance of 
identifying the most stable reference genes, and (ii) permit a comparison between the results 
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obtained using the reference genes identified by the two approaches, thus increasing the 




The aims of this chapter were as follows: 
 
 To assess the role of FOXP2 in regulating DISC1 expression 
 To establish whether the pathogenic FOXP2 point mutations, R553H and R328X, 
alter any regulatory relationship observed 
 To assess Foxp2 expression in the Disc1 L100P mouse, as a preliminary step in 
assessing whether DISC1 might be involved in the regulation of FOXP2 expression 
  
Chapter 4: Assessment of the DISC1-FOXP2 Regulatory Relationship 
170 
 
4.3 Materials and Methods 
 
4.3.1 Expression constructs 
 
4.3.1.1 FOXP2 expression constructs 
 
The three FOXP2 constructs used in this study, pcDNA4/HisMax-FOXP2, 
pcDNA4/HisMax-FOXP2.R553H, and pcDNA4/HisMax-FOXP2.R328X were kind gifts 
from Dr. Simon Fisher at the University of Oxford.  
 
4.3.1.2 DISC1 promoter expression constructs 
 
The generation of these constructs has been described in section 3.3.3. 
 
4.3.2 Cell culture and transfection 
 
The neuroblastoma cell line, SH-SY5Y, and the human embryonic kidney cell line, 
HEK293, were maintained in Dulbecco’s Minimal Essential Medium (DMEM; Invitrogen) 
supplemented with 10% foetal bovine serum (FBS) at 37°C in a humidified 5% CO2 
atmosphere. Cells were grown to ~80% confluency in T175 tissue culture flasks (Greiner) 
before seeding onto either 96-well plates (Sigma Aldrich) at 5 x 10
4
 cells per well (dual 
luciferase reporter assays), or 6-well plates (Sigma Aldrich) at 5 x 10
5
 cells per well (western 
blots and qRT-PCR), in order to reach ~80% confluency following overnight incubation. 
Transient transfections were carried out using either Fugene HD (Roche) or X-tremeGENE 
HP (Roche) according to the manufacturer’s instructions. Transfections for the dual 
luciferase reporter assays and western blots were carried out using Fugene HD, while 
transfections performed for qRT-PCR were carried out using X-tremeGENE HP. The change 
from Fugene HD to X-tremeGENE HP was made because Fugene HD was discontinued by 
Roche. Both Fugene HD and X-tremeGENE HP are non-liposomal transfection reagents 
recommended for the transfection of high-density cells. Fugene HD was used at a ratio of 4:1 
(transfection reagent to DNA), a ratio found by Elise Malavasi to result in optimal 
transfection efficiency of HEK293 cells with luciferase constructs (data not shown). As the 
ratio of X-tremeGENE HP to DNA had not previously been optimised it was used at two 
different ratios, 3:1 and 4:1, in all of the experiments presented in this chapter. These ratios 
were selected based on information from Roche who advised that X-tremeGENE HP 
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operated very similarly to Fugene HD (and could, therefore, probably be directly substituted) 
but that assessing a lower ratio of transfection reagent to DNA would be advisable in case of 
toxicity. 
 
4.3.3 Western blotting 
 
Western blotting was used to assess the effect of (i) the pcDNA3.1/HA (the control plasmid) 
and (ii) full-length FOXP2 on DISC1 protein expression.  
 
4.3.3.1 Antibody selection 
 
DISC1 protein expression was detected using a C-terminal antibody kindly supplied by Dr. 
Tetsu Akiyama from the University of Tokyo. The generation and validation of the antibody 
has been described previously (Ogawa et al., 2005). This antibody has been reported to 
detect the 100 kDa full-length isoform of DISC1 by immunoblotting (Murdoch et al., 2007; 
Ogawa et al., 2005). 
 
FOXP2 protein expression was detected using a commercially available rabbit polyclonal 
antibody from Abcam (ab16046). This antibody binds to the C-terminal of FOXP2 and 
detects an 80 kDa product by immunoblotting (manufacturer’s datasheet; 
http://www.abcam.com/FOXP2-antibody-ab16046.html) (Fatemi et al., 2008a; Hu et al., 
2009). This antibody has been validated in PFSK-1 cells, a human neuroectodermal cell line, 
by ENCODE (http://www.epigenomebrowser.org/ENCODE/antibodies.html), who used it to 
perform the ChIP-seq experiment that identified DISC1 as a putative target of FOXP2 
(Rosenbloom et al., 2010).  
 
The reference genes α-tubulin, β-actin, and GAPDH were detected using the following 
commercially available antibodies: α-tubulin (Abcam, ab18251); β-actin (Sigma), and 
GAPDH (Milipore, MAB374).  
 
4.3.3.2 Transfection and protein extraction 
 
For the assessment of the effect of the control plasmid on DISC1 expression level, cells were 
transfected with either 2µg of the control plasmid (pcDNA3.1/HA) or exposed to the 
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transfection reagent alone (mock transfection). Each condition was performed in three 
experimental replicates.  
 
To assess the effect of FOXP2 on DISC1 expression level, cells were transfected with either 
2µg of pcDNA4/HisMax-FOXP2, or 2µg of the control plasmid. Each condition was 
performed in five experimental replicates. 
 
Twenty-four hours post-transfection each well was supplemented with 2000µl fresh DMEM 
with 10% FBS. Forty-eight hours post-transfection, cells were rinsed with PBS and lysed 
with 400µl PBS-1% Triton-X 100-10% glycerol protein extraction buffer, containing 
Complete Protease Inhibitor Cocktail (Roche). Protein lysates were gently mixed for 30 
minutes at 4˚C, before being centrifuged at 16 060 x g for 20 minutes at 4˚C to remove cell 
debris.   
 
4.3.3.3 Quantification of protein concentration 
 
Protein concentrations were determined using the colorimetric Bio-Rad DC Protein Assay 
(Bio-Rad Laboratories). This assay is a modified version of the Lowry protein assay, which 
exploits the formation of copper-protein complexes under alkaline conditions. On the 
addition of Folin reagent an unstable product is formed, which is reduced, producing a blue 
colour. 
 
 A set of eleven standards of known protein concentration (0.0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 
1.4, 1.6, 1.8, and 2.0 mg/ml) were prepared by diluting bovine serum albumin in dH20. Five 
microlitres of each standard was pipetted onto a 96-well plate in duplicate. Experimental 
samples were diluted two-fold in dH20 and 5µl of each sample was loaded onto the 96-well 
plate in triplicate. To each well was added a total volume of 25µl of Reagent A (alkaline 
copper tartrate solution) and Reagent S (surfactant solution), combined in a 50:1 ratio, and 
200µl Reagent B (Folin reagent). 
 
Following an incubation of fifteen minutes, the absorbance of each sample at 750nm was 
read using a Synergy HT plate reader (Bio Tek). A protein concentration-absorbance curve 
was plotted for the standards and the protein concentration of the experimental samples 
interpolated from this curve. 
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4.3.3.4 Protein samples from the L100P Disc1 mice 
 
EG provided protein samples from the L100P Disc1 mice and wildtype controls. Whole-
brain protein was available from embryonic mice at embryonic days (E) 12.5, 15.5, and 17.5. 
Brain region-specific protein samples were available from postnatal mice at postnatal days 
(P) 1, 7, 21, and 90. Wildtype controls were littermates of the L100P mice at P21 and P90; 
for the other developmental stages non-littermate controls (cousins) were used. 
 
4.3.3.5 Gel electrophoresis of protein samples  
 
Immediately before electrophoresis, protein samples (10ug brain lysates, or 40ug cell 
lysates) were mixed with 5x loading buffer (final concentration 0.16M Tris-chloride (pH 
6.8), 5% sodium dodecyl sulphate (SDS), 25% glycerol, 6% β-mercaptoethanol, 0.02% 
Bromophenol blue) and heated at 100˚C for 2 minutes. Protein samples and the Precision 
Plus Protein All Blue Standards molecular weight marker (Bio-Rad Laboratories) were 
fractionated on a 7% SDS-polyacrylamide-tris-acetate gel (Invitrogen) and 
electrophoretically transferred onto a polyvinyl difluoride (PVDF) membrane (Invitrogen). 
Gel electrophoresis and transfer efficiency were assessed by Ponceau S staining. 
 
4.3.3.6 Immunolabelling of PVDF membrane and chemiluminescent detection of 
immunoreactive bands 
 
The membrane was immersed in blocking buffer (phosphate buffered saline (PBS) 
containing 0.2% Tween (PBS-T) and 5% non-fat milk) for one hour, followed by incubation 
(overnight at 4˚C followed by four hours at room temperature) with the primary antibody 
(DISC1, 1:1000; FOXP2, 1:500; GAPDH, 1:100,000; Millipore) in blocking buffer. 
Membranes were then washed in PBS-T, and incubated with a horseradish peroxidase 
(HRP)-conjugated secondary antibody (For both DISC1 and FOXP2: swine-anti-rabbit, 
1:2000, Dako; for GAPDH:  goat-anti-mouse, 1:1000, Dako), in blocking buffer for one 
hour. Membranes were washed in PBS-T as before. Immunoreactive bands were visualised 
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4.3.3.7 Quantification and statistical analysis of immunoreactive bands 
 
Immunoreactive bands were quantified by optical densitometry OD using GeneTools image 
analysis software (Syngene). Gene tools permits the user to manually quantify bands by 
drawing a rectangular box around each band of interest and selecting either automatic or 
manual background correction. Manual background correction was used for the experiments 
described in this chapter. A corrected optical density (OD) value is then returned for each 
band. For each sample lane on a given blot, the optical density value for the GOI 
immunoreactive band was normalised to the optical density value for a reference gene 
immunoreactive band.  
 
Statistical analysis of normalised OD values was carried out using Statistical Package for the 
Social Sciences (SPSS) version 17.0. Between-genotype differences were assessed using the 
independent samples two-tailed Student’s t-test and differences were deemed to be 
statistically significant when p ≤ 0.05.  
 
4.3.4 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
 
RT-PCR was carried out to assess the endogenous expression of FOXP2 by HEK293 and 
SH-SY5Y cells. One of the SH-SY5Y samples had previously been extracted and reverse 
transcribed into cDNA by SA. Niamh Ryan (NR) carried out the polymerase amplification 
and the gel electrophoresis of samples. I carried out all the other steps. 
 
4.3.4.1 Primer design 
 
RT-PCR primers were designed using the online program Primer 3 (http://frodo.wi.mit.edu/) 
to amplify a region within the first exon of FOXP2. According to the UCSC genome browser 
(hg19), this region is common to all eight FOXP2 RefSeq transcripts and is included in four 
non-RefSeq transcripts (identified by the “UCSC Genes” track of the UCSC genome 
browser). Two predicted short transcripts, which have not been validated by RefSeq, do not 
contain the amplified region. Primers were designed to comply with the following 
requirements: melting temperatures in the range of 50-63°C and a maximum difference in 
melting temperature of 10°C, a GC content of 40-60%, and length of around 20 nucleotides. 
The sequences of the designed primers are: forward: 5’-
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AGGAATCTGCGACAGAGACAA-3’; and reverse: 5’-GTTGCAGATGCAGCAGTTCT-
3’.  
 
4.3.4.2 mRNA extraction  
 
HEK293 and SH-SY5Y cells were grown to ~80% confluency in six-well tissue culture 
plates before being washed with PBS and dissociated by incubation in TrypLE
TM
 Express 
(500µl/well), a trypsin substitute, for five minutes at room temperature. A cell pellet was 
formed by centrifuging the lysates for five minutes at 300 x g. The supernatant was removed 
and the cell pellet washed in PBS.  
 
Total RNA was then extracted using an RNeasy Mini Kit (Qiagen), according to the 
manufacturer’s instructions. Briefly, cell pellets were lysed and homogenised in 600µl buffer 
RLT, which inactivates RNases. The lysates were then added to a Qiashredder column and 
centrifuged for 2 minutes at 17,000 x g and the supernatant transferred to a fresh 
microcentrifuge tube. Following the addition of 70% ethanol (600µl), 600µl of each lysate 
was applied to an RNeasy Mini spin column. RNeasy spin columns contain a silica 
membrane that binds RNA molecules longer than 200 nucleotides. After centrifuging for 15 
seconds at 9,500 x g, the flow-through was discarded and the remaining 600µl of each lysate 
was added to the spin column and centrifuged for 15 seconds at 9,500 x g. The column was 
then washed to remove contaminants, such as carbohydrates, proteins, and fatty acids, by 
adding 350µl wash buffer, RW1, and centrifuging for 15 seconds at 9,500 x g. An on-
column DNase digest was then performed: for each sample, 10µl DNase 1 was added to 70µl 
buffer RDD, the mixture was then pipetted directly onto the spin column silica membrane 
and incubated for 15 minutes at room temperature. The column was then washed by adding 
350µl buffer RW1 and centrifuging for 15 seconds at 9,500 x g, before being transferred to a 
new collection tube. A second wash buffer, RPE (500µl), was then applied to the column, 
which was centrifuged for 15 seconds at 9,500 x g. The flow-through was discarded and 
another 500µl buffer RPE added to the column. This time the column was centrifuged for 
two minutes at 9,500 x g to dry the silica membrane. To eliminate carryover of buffer RPE, 
the column was transferred to a fresh collection tube and centrifuged for a further 1 minute at 
9,500 x g. RNA was then eluted by placing the column in a fresh collection tube, adding 
50µl RNase-free water, and centrifuging for one minute at 9,500 x g. To obtain the optimum 
RNA yield, a further 30µl RNase-free H2O was applied to the column, which was 
centrifuged again for one minute at 9,500 x g.  




The concentration and purity of total RNA samples was determined using the Thermo 
Scientific NanoDrop 1000 spectrophotometer (see section 4.2.4.3) and RNA was stored at -
80°C until required for cDNA synthesis. 
 
4.3.4.3 Spectrophotometric analysis of RNA using the NanoDrop 
 
The concentration and purity of RNA samples was measured using a Thermo Scientific 
NanoDrop 1000 spectrophotometer (see section 3.3.3.6). Samples were measured by 
selecting the “nucleic acids” program on start-up and setting the measurement option to 
“RNA-40”. The machine was then blanked by taking a reading from a reference sample 
(RNase-free H2O). Each sample (1.5µl) was then pipetted onto the pedestal (which was 
cleaned between samples), and the absorption of the sample calculated as described in 
section 3.3.3.6. 
 
Sample purity was determined by calculation of the ratio of absorbance at 260nm and 280nm 
(260/280) and 260nm and 230nm (260/230). Pure RNA should have a 260/280 ratio of ~2.0. 
Lower ratios can indicate the presence of contaminating agents absorbing at around 280nm, 
such as protein or phenol. The 260/230 ratio should be in the range of 1.8-2.2. Lower ratios 
can be caused by contaminating salts, phenol, or protein.  
 
4.3.4.4 cDNA synthesis 
 
cDNA was synthesised from DNase-treated RNA using the Transcriptor First Strand cDNA 
Synthesis kit (Roche). Two microlitres of random hexamer primer was added to 1µg RNA 
diluted to a total volume of 11.5µl with RNase-free H2O. The RNA was denatured in a 
thermal cycler (Peltier Thermal Cycler 225, MJ Research) using the following program: 
65°C, 10 minutes; 4°C, 5 minutes. The denatured RNA was then added to a reaction 
containing 5X Transcriptor Reverse Transcriptase reaction buffer (8µl), 10nM dNTP mix 
(4µl), RNase inhibitor (1µl), and Transcriptor Reverse Transcriptase enzyme (1µl). The 
reaction was incubated in a thermal cycler at 25°C for 10 minutes (primer annealing), 
followed by 50°C for 60 minutes (cDNA synthesis), and 85°C for 5 minutes (enzyme 
inactivation). Single-stranded DNA was stored at -20°C until required for PCR 
amplification. 
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4.3.4.5 PCR reaction and cycling conditions  
 
One microlitre of cDNA was added to an PCR reaction comprising 2µl 10x PCR buffer 
(Qiagen), 4µl Q solution (Qiagen), 0.8µl dNTPs (5mM), 1µl combined forward and reverse 
primers (10µM), 0.1µl HotStarTaq DNA Polymerase (Qiagen), and 11.1µl RNase-free H2O. 
 
Polymerase amplification was carried out using a thermal cycler (Peltier Thermal Cycler 
225, MJ Thermocycler) using the following parameters for touch-down PCR: 95°C for 5 
minutes (initial Taq activation), followed by 10 touch-down cycles of 94°C for 30 seconds, 
68°C for 30 seconds (-1°C each cycle), and 72°C for 1 minute, and then 30 cycles of 94°C 
for 30 seconds, 58°C for 30 seconds, and 72°C for 1 minute, followed by a final extension 
step of 72°C for 10 minutes. 
 
4.3.4.6 Agarose gel electrophoresis 
 
Agarose gels were prepared by adding 0.7-1.4g UltraPure
TM
 agarose (Invitrogen) to 70ml 
tris-borate-EDTA (TBE) in a flask and heating until a clear solution was formed. The 
solution was allowed to cool for a few minutes before adding 7µl of the DNA gel stain 
SYBR Safe (Invitrogen). Once the SYBR safe had been mixed into the solution by swirling 
the flask, the solution was poured into a gel casting tray, gel combs inserted and the gel left 
to set. Once the gel had set, the combs were removed and the gel placed into an 
electrophoresis chamber containing TBE buffer.  
 
Prior to loading, samples were mixed with 4 x Orange G loading buffer (1g Ficoll-400 
(Sigma) and 0.2ml 50mM EDTA made up to a total volume of 10ml with ddH2O. Orange G 
added to colour). A 1 kb or 1 kb Plus DNA ladder (Invitrogen) and the samples were then 
pipetted into the wells of the gel and electrophoresed at 100V until the samples were 
sufficiently fractionated. Samples were then visualised under UV light in a UVIdoc gel 
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4.3.5 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
 
4.3.5.1 Selection of gene-of-interest (GOI) assays 
 
Assays for human DISC1 and mouse Foxp2 were ordered from Applied Biosystems. Criteria 
for probe selection were: i) that the probe covered as many isoforms of the gene as possible, 
thus permitting a representative depiction of gene expression; and ii) that the probe was 
intron spanning, thus minimising the effect of gDNA contamination. Details of these assays 
are available in table 4.1. 
  








Table 4.1. Details of Applied Biosystems TaqMan gene expression assays used to measure genes 
of interest in this chapter. See next page for legend. 













Human Hs00962133_m1 140 tatgataaagctg
agacgttacaac 
NM_001164546.1 3 4 
NM_001012959.1 3 4 
NM_001164538.1 3 4 
NM_001164539.1 3 4 
NM_001012957.1 3 4 
NM_001164540.1 3 4 
NM_001164541.1 3 4 
NM_001164542.1 3 4 
NM_001164544.1 3 4 
NM_001164545.1 3 4 
NM_001164547.1 3 4 
NM_001164548.1 3 4 
NM_001164549.1 3 4 
NM_001164551.1 3 4 
NM_018662.2 3 4 
NR_028393.1 7 8 
NR_028394.1 8 9 
NR_028395.1 8 9 
NR_028396.1 7 8 
NR_028397.1 7 8 
NR_028398.1 5 6 
DISC1  Human Hs00962131_m1 119 accgcgcaggcag
ccgggattgctt 
NM_001012957.1 1 2 
NM_001012958.1 1 2 
NM_001012959.1 1 2 
NM_001164537.1 1 2 
NM_001164538.1 1 2 
NM_001164539.1 1 2 
NM_001164540.1 1 2 
NM_001164541.1 1 2 
NM_001164542.1 1 2 
NM_001164544.1 1 2 
NM_001164545.1 1 2 
NM_001164546.1 1 2 
NM_001164547.1 1 2 
NM_001164548.1 1 2 
NM_001164549.1 1 2 
NM_001164550.1 1 2 
NM_001164551.1 1 2 
NM_001164552.1 1 2 
NM_001164553.1 1 2 
NM_001164554.1 1 2 
NM_001164555.1 1 2 
NM_018662.2 1 2 
Foxp2 Mouse Mm00475030_m1 85 ctgcctcaagctgg
cttaagtcctg 
NM_053242.4  8 9 
NM_212435.1 6 7 
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Table 4.1.  Details of Applied Biosystems TaqMan gene expression assays used in this chapter. The 
table shows the target of the TaqMan assay, the species, the assay ID, the length of the PCR amplicon 
generated by the assay, the probe context sequence, the accession number of each transcript detected 
by each assay, and the location of the forward (F) and reverse (R) primers (denoted by exon number 
for each targeted transcript). 
a 
The m1suffix at the end of each assay ID indicates that the probe spans 
an exon junction and the assay will not detect any genomic DNA.  
b
 The probe context sequence is a 
25 bp sequence that contains the probe sequence, which is usually 15-18 nucleotides long. 
 
 
4.3.5.2 Selection of reference gene assays 
 
4.3.5.2.1 Reference gene assays for the normalisation of DISC1 expression 
 
Reference gene assays were ordered from PrimerDesign as part of their geNorm reference 
gene kits. Assays were ordered to target four reference genes: glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), succinate dehydrogenase complex, subunit A (SDHA), splicing 
factor 3 subunit 1 (SF3A1), and ubiquitin C (UBC). All four assays are intron-spanning. 














4.3.5.2.2 Reference gene assays for the normalisation of Foxp2 expression 
 
An assay for the reference gene hypoxanthine phosphoribosyltransferase 1 (Hprt1) was 
ordered from Applied Biosystems (Mm01318743_m1). To permit comparison with previous 
gene expression profiling experiments carried on the Disc1 L100P RNA samples by Sarah 
Brown (SB) during her PhD, the same Hprt1 TaqMan assay (Applied Biosystems) was used. 
Target Species Sequence 
accession 
Primer location (exon) Probe location 
(exon) Forward Reverse 
GAPDH Human NM_002046 8 9 8 
SDHA Human NM_004168 7 8 7 
SF3A1 Human NM_001005409.1 11 12 11 
NM_005877.4 11 12 11 
UBC Human NM_021009 1 2 1-2 
 
Table 4.2. Details of the PerfectProbe (PrimerDesign) reference gene assays used for the 
normalisation of DISC1 expression. Shown are the name of the probe target, the species the probe 
is designed to work in, the accession number of the target, the location of the forward and reverse 
primers and the probe (denoted by exon number for each targeted transcript).  
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This assay spans an intron (between exons 3 and 4) and has been designated an “m1” suffix 
by Applied Biosystems, indicating that it has been shown to not detect a product in gDNA.   
 
4.3.5.2.3 Use of geNorm and NormFinder reference gene selection algorithms 
 
geNorm was used within the Biogazelle qbase
PLUS
 qRT-PCR software. When using geNorm, 
the optimum number of reference genes suggested by geNorm (as described in section 
4.1.3.1) was used to normalise the GOI. 
 
NormFinder was used within the GenEx qRT-PCR analysis software. On the basis that the 
use of more than one reference gene is likely to increase the likelihood of the reference genes 
giving an accurate depiction of cDNA quantity, the most stable pair of reference genes, as 
chosen by NormFinder, was used for normalisation of the GOI (section 4.1.3.2).  
 
4.3.5.3 Sample preparation 
 
4.3.5.3.1 Disc1 L100P mice 
 
cDNA was synthesised from the brains of mice carrying the L100P Disc1 mutation, and their 
wildtype littermates by SB during her PhD and by Helen Torrance (HT). SB and HT 
synthesised cDNA from mice at embryonic days (E) 13, 15, and 18, postnatal days (P) 1, 7, 
and 20, and adult mice (12-13 weeks of age).  
 
4.3.5.3.2 HEK293 cells 
 
Cells were transfected with either 2µg of i) pcDNA4/HisMax-FOXP2, or ii) the control 
plasmid pcDNA3.1/HA, or exposed to the transfection reagent alone (mock transfection), or 
left untransfected. Transfections with pcDNA4/HisMax-FOXP2 and the control plasmid 
were performed in four biological replicates. The mock and untransfected conditions were 
performed in three biological replicates. Twenty-four hours post-transfection each well was 
supplemented with 2000µl fresh DMEM with 10%FBS. Forty-eight hours post-transfection, 
the cells were washed with PBS and dissociated by incubation in TrypLE
TM
 Express 
(500µl/well) for five minutes at room temperature. A cell pellet was formed by centrifuging 
the lysates for five minutes at 300 x g. The supernatant was removed and the cell pellet 
washed in PBS. 




Extraction of mRNA was carried as described in section 4.2.4.2, quantified as described in 
section 4.2.4.3, and cDNA synthesised as described in section 4.2.4.4. 
 
4.3.5.4 Assessment of cDNA samples for gDNA contamination 
 
cDNA samples were assessed for contamination by carrying out RT-PCR using primers that 
















One microlitre of cDNA was added to an RT-PCR reaction comprising 2µl 10x PCR buffer 
(Applied Biosystems), 0.6µl dNTPs (5mM), 0.5µl combined forward and reverse primers 
(20µM), 0.3µl Taq DNA Polymerase (made in house), and 14.4µl RNase-free H2O. 
 
The reaction was carried out using a thermal cycler (Peltier Thermal Cycler 225, MJ 
Research) using cycling conditions for touch-down PCR: 93°C for 1 minute (initial 
denaturation), followed by 10 touch-down cycles of 93°C for 20 seconds, 65°C for 30 
seconds (-1°C each cycle), and 72°C for 1 minute, and then 30 cycles of 93°C for 20 
seconds, 55°C for 30 seconds, and 72°C for 1 minute, followed by a final extension step of 
72°C for 10 minutes. PCR amplimers were fractionated by agarose gel electrophoresis, as 
described in section 4.3.5.4, and gDNA contamination assessed. 
 
Tissue/cell type Target 
gene 
Primer sequences Expected product size (bp) 
cDNA gDNA 
HEK293 cells WDR1 F: cttgctggggttgtttctgt 
R: ccacgacggtgggattta 
238 590 




Table 4.3. Details of the primers used in the RT-PCR carried out to detect gDNA contamination 
in cDNAs synthesised from mRNA extracted from either mouse brain or HEK293 cells. The 
sequences of the forward (F) and reverse (R) primers are given, together with the expected 
product size, in base pairs (bp), if the primers were to amplify their target from either cDNA or 
gDNA. 
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4.3.5.5 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) analysis of 
mRNA expression 
 
qRT-PCR was carried out using an Applied Biosystems 7900HT Fast Real-Time PCR 
System at the Wellcome Trust Clinical Research Facility (WTCRF), at the Western General 
Hospital, Edinburgh. A hydrolysis probe-based chemistry was chosen over the use of an 
intercalating dye, as hydrolysis probes permit greater target recognition specificity. 
Hydrolysis probes are fluorescently labeled DNA oligonucleotides that are designed to bind 
downstream of one of the primers. The 5’ end of the probe is labeled with a fluorescent 
reporter molecule and at the 3’ end of the probe there is a quencher molecule. When the 
probe is intact, the quencher suppresses fluorescence from the 5’ end of the probe; however, 
during the PCR reaction, the probe is degraded by the polymerase enzyme, the quencher is 
physically separated from the fluorescent reporter molecule, and fluorescence is emitted. It is 
only possible for a probe to fluoresce if it has bound to the correct target; in contrast, the 
intercalating dye approach relies on the primers amplifying the correct target, as the dye will 
intercalate with any double-stranded DNA molecule that is formed during the reaction. Two 
different types of probe-based assay were used in this chapter: TaqMan assays (Applied 
Biosystems) and PerfectProbes assays (Primer Design). The main difference between these 
assays is the chemistry of probes: TaqMan probes are linear, whereas PerfectProbes create a 
stem-loop secondary structure (figure 4.3). The stem-loop structure brings the fluorescent 
reporter molecule and the quencher into greater spatial proximity, reducing background 
fluorescence and thus the number of qRT-PCR cycles required for target detection.  
  
 
Figure 4.3. Schematic depicting the chemistries of TaqMan probes and Perfect Probes. Before 
amplification, TaqMan probes are linear while PerfectProbes form a stem-loop structure. The 
stem-loop structure brings the fluorescent reporter molecule (blue) into greater spatial proximity 
with the quencher molecule (green), resulting in less background fluorescence than linear TaqMan 
probes. Both probes types anneal to the DNA during the hybridisation step and are then cleaved 
by the 5’-3’ exonuclease activity of the polymerase (beige), thus separating the fluorescent 
reporter molecule from the quencher and permitting fluorescence. Figure adapted from 
http://www.primerdesign.co.uk. 




Samples were assayed for a GOI (either DISC1 or Foxp2), together with either six (DISC1) 
or three (Foxp2) reference genes. Each sample was measured in three technical replicates. 
Reactions were carried out in 384-well plates, with samples arranged according to the 
sample maximisation approach recommended by Hellemans et al. (2007). This approach 
ensures that if the number of wells required for all sample and gene combinations exceeds 
one plate, as many samples as possible are analysed on the same plate and different genes are 
analysed on different plates, thus minimising the impact of between-sample technical 
variation. In addition, each plate contained a standard curve and a calibrator for each gene 
assayed. The standard curve comprised a set of four 1/10 serial dilutions (1/10, 1/100, 1/1000 
and 1/10,000) of whole brain cDNA (human or mouse, as appropriate). The standard curve 
was used to quantify cDNA using the relative standard curve method (described in section 
4.2.6.5). Whole brain cDNA (1/200 dilution) was also used as the calibrator. Inclusion of a 
calibrator permitted correction for between-plate differences and thus the comparison and 
combination of results across plates. 
 
qRT-PCR was carried out using TaqMan Fast Universal PCR Master Mix (2x), no 
AmpErase UNG. Reactions were carried out in a total volume of 10µl, comprising 5µl 
mastermix, 0.5µl of the appropriate probe and 4.5µl cDNA. Plates were sealed with a plastic 
sheet using a heat sealer and centrifuged for 30 seconds before being placed in the Applied 
Biosystems 7900HT Fast Real-Time PCR machine. Thermal cycling conditions differed for 
the TaqMan assays and the PerfectProbe assays, due to their different chemistries. 
Conditions for each probe type are described below:  
 
TaqMan assays: 95°C for 10 minutes (enzyme activation), followed by 40 cycles of 95°C for 
15 seconds (denaturation) and 60°C for 1 minute (annealing/extension).  
 
PerfectProbes assays: 95°C for 10 minutes (enzyme activation), followed by 50 cycles of 
95°C for 15 seconds (denaturation) and 50°C for 30 seconds (annealing), and 72°C for 15 
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4.3.5.6 Quality control and statistical analysis of qRT-PCR data  
 
qRT-PCR produces a cycle threshold (Ct) value for each sample. The Ct value indicates how 
many PCR cycles were required before the quantity of a given sample reached the detection 
threshold. 
 
Data were initially analysed using the Sequence Detection Systems (SDS) software version 
2.3 (Applied Biosystems) for the 7900HT Fast Real-Time PCR System. First, the Ct values 
for each triplicate of technical replicates were checked for outliers: if any sample had a Ct 
value that differed by more than one from either of the other two samples in the triplicate, it 
was discarded. Then, the standard curves were checked to assess the reaction efficiency and 
the accuracy of each assay. If the PCR reaction works with 100% efficiency (i.e. the amount 
of product has doubled with every cycle) the slope of the standard curve will be -3.32. If the 
slope deviated from this value, Ct values were inspected. Sometimes it was clear that the 
assay did not work efficiently for the most dilute samples in the standard curve. In this case, 
these samples were excluded. The correlation of the curve reflects the accuracy of the 
reaction, with 100% accuracy denoted by R
2
 = 1. Correlations of R
2
 ≥ 0.98 were considered 
acceptable. 
 
Ct values for experimental samples were translated into quantity values using the relative 
standard curve method. This method requires a set of relative standards formed by serial 
dilution of a cDNA, RNA, or DNA sample known to express the appropriate target, and a 
calibrator sample, also expressing the appropriate target, to be run for each probe used on 
each plate. Preparation of the relative standards and calibrator sample used in this thesis has 
been described in section 4.2.6.4.I. Quantity values for experimental samples were 
determined by interpolating from the standard curve. At this point, the data were exported to 
Microsoft Excel for further analyses.   
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1. Calculation of a normalisation factor (NF). 
For each sample, k, a NF was calculated based on the geometric mean of the quantity values 
(QVs) of the reference genes, p: 
 
    √∏    
 




For Foxp2, two or three reference genes were used, and for DISC1, the required number of 
reference genes was calculated using the geNorm algorithm described by Vandesompele et 
al. (2002).  
 
2. Calculation of the normalised experimental sample QVs (NQVs). 
NQVs were calculated by for each gene, j, measured in sample, k: 
 
       
    
   
 
 
3. Calculation of the calibrator normalisation factor (CF). 
For each gene, j, in each run, l, a CF was calculated: 
 
     √∏      
 




4. Calculation of calibrated NVQs (CNVQs). 
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For gene, j, measured in sample, k, a CNVQ was calculated: 
 
        
      
    
 
 
Following CNVQ calculation, outlying samples within each condition were identified using 
the inter-quartile range method, whereby the CNVQ for a sample x must abide by the 
following restrictions, where Q1 is the first quartile and Q3 is the third quartile: 
 
(         )        (          ) 
 
Samples with a CNVQ value violating these conditions were deemed to be outliers and were 
excluded from further analyses. 
 
The mean, standard deviation, and standard error of the mean (SEM) were then calculated 
for each condition using the statistical functions of Microsoft Excel. Comparisons between 
genotypes were carried out using SPSS. Comparisons were performed separately for each 
developmental stage using two-tailed independent samples Student’s t-tests, where data met 
the assumption of normality and homogeneity of variances. When analysing data with equal 
sample sizes, the t-test has been shown to be relatively robust to deviations from these 
assumptions (Boneau, 1960). However, as sample sizes in this analysis varied, compliance 
with the assumptions of normality and homogeneity of variances was formally assessed. 
Normality was assessed using the Shapiro-Wilk test and homogeneity of variances was 
assessed using Levene’s test. If data were found to violate the assumption of normality, 
homogeneity of variances was assessed using a non-parametric Levene’s test (Nordstokke 
and Zumbo, 2010). Deviations from these assumptions were deemed to have occurred when 
p ≤ 0.05. None of the samples were found to violate the assumption of normality; however, 
deviations from the assumption of homogeneity of variance were corrected by carrying out a 
Welch’s t-test in which the degrees of freedom are reduced according to the Welch-
Satterthwaite method. Between-group differences were deemed to be statistically significant 
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4.3.6 Dual Luciferase Reporter (DLR) assay 
 
4.3.6.1 Cell transfection and lysis 
 
For the assessment of the effect of FOXP2 and the mutated forms of FOXP2, FOXP2.R553H 
and FOXP2.R328X, on DISC1 promoter activity, HEK293 cells were co-transfected with 
three constructs: (i) 163.7µg of the appropriate reporter construct (promoterless pGL4.10 or 
pGL4.10-DISC1 promoter construct (long, medium, or short)), (ii) 3.3µg of the transfection 
efficiency control pRL-TK, and (iii) 166.7µg of a FOXP2 expression construct 
(pcDNA4/HisMax-FOXP2/-FOXP2.R553H/-FOXP2.R328X), or the control plasmid, 
pcDNA3.1/HA (Invitrogen). Transfections were performed in triplicate and repeated in three 
experimental replicates. Twenty-four hours post-transfection, each well was supplemented 
with 100µl fresh DMEM with 10%FBS. Forty-eight hours post-transfection, cells were 
rinsed with phosphate buffered saline (PBS) and lysed with 20µl Passive Lysis Buffer (PLB; 
Promega). 
 
4.3.6.2 Measurement of luciferase activity 
 
The measurement of luciferase activity using the Dual-Luciferase Reporter Assay System 
(Promega) has been described previously in section 3.3.4.2. 
 
4.3.6.3 Calculation of relative luciferase activity 
 
The calculation of relative luciferase values was performed using a similar method to that 
described in section 3.3.4.3. The main differences were that (i) for the data presented in this 
chapter, only three technical replicates were performed for each of the three experimental 
replicates and (ii) the pGL4.13 (SV40/luc2) was not used as a positive control, as the SV40 
promoter contains function FOXP2 binding sites and, therefore, the expression of this 
construct is regulated by FOXP2 (Vernes et al., 2006). Moreover, little between-plate 
variation was observed in the experiments described in chapter 3 and, therefore, an inter-
plate calibrator was not considered necessary. 
 
As described in section 3.3.4.3, for each technical replicate, firefly luciferase values were 
divided by Renilla luciferase values to obtain relative luciferase values. Background 
luciferase activity (the mean relative luciferase value obtained from the three technical 
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replicates transfected with the promoterless vector pGL4.10), was subtracted from each 
relative luciferase value.  
 
Statistical analysis of the relative luciferase values was performed using SPSS version 17.0. 
Dual luciferase reporter assay data was assessed using either one-way or two-way analysis of 
variance (ANOVA), followed by Tukey’s HSD post-hoc test. Significant interaction terms 
were investigated by splitting the data file by each independent variable and performing 
either two-tailed independent samples Student’s t-tests or one-way ANOVAs followed by 
Tukey’s HSD post-hoc test.  
  





4.4.1 Assessment of the effect of FOXP2 on DISC1 expression 
 
4.4.1.1 Cell line selection and antibody characterisation 
 
In order to assess the effects of the transient overexpression of FOXP2 on DISC1 protein 
expression and promoter activity in an appropriate cellular context, a cell line that 
endogenously expresses FOXP2 was required. Endogenous expression of FOXP2 has 
previously been demonstrated in HEK293 and HEK293T cells (Abcam datasheet for 
ab16046) (Vernes et al., 2006), but was not detected in SH-SY5Y cells (Vernes et al., 2006). 
The expression of endogenous FOXP2 in HEK293 cells was confirmed by western blotting 
(figure 4.4.A). Overexpressed and endogenous FOXP2 were detected by western blotting as 
a band of 80 kDa, consistent with the manufacturer’s data sheet. SH-SY5Y cell lysates were 
probed for FOXP2 expression as a negative control; however, a band at 80 kDa was 
detected. This band was detected in two independent SH-SY5Y cell lysates (data not shown). 
In order to assess further whether this band represented FOXP2, FOXP2 mRNA expression 
was measured by RT-PCR. Expression was detected as a product of 152bp in SH-SY5Y 
cDNA (figure 4.4.B). HEK293 cDNA was assayed for FOXP2 expression at the same time 
as a positive control. It was, therefore, concluded that SH-SY5Y cells do endogenously 
express FOXP2.   
 
Due to time constraints, the assessment of the effect of FOXP2 activity on DISC1 promoter 
activity could only be carried out in one cell line. Thus, despite the evidence for the 
expression of FOXP2 in SH-SY5Y cells, it was decided that HEK293 cells would be used 
for future experiments, as this would permit comparison with previous studies in which the 
transcriptional effects of FOXP2 and the R553H and R328X mutant forms of FOXP2 have 




































The DISC1 antibody used in this chapter has been previously shown to detect endogenous  
full-length 100 kDa DISC1 expression in SH-SY5Y cells (Murdoch et al., 2007; Ogawa et 
al., 2005), but there are no reports of its use in HEK293 cells. Therefore, its ability to detect 
DISC1 expression in HEK293 cells, which have previously been demonstrated to express 
DISC1 (James et al., 2004), was assessed by western blotting. Consistent with findings in 
SH-SY5Y cells, endogenous DISC1 was detected as a single 100 kDa immunoreactive band 
(figure 4.5.A). The expression of DISC1 by HEK293 cells was further confirmed by qRT-
PCR (figure 4.4.B). qRT-PCR was carried out using the DISC1 TaqMan probe 
Hs009962131_m1 described in table 4.1. This probe detects 22 of the 23 RefSeq transcripts 
for DISC1, including the full-length transcript. 
 
Figure 4.4. Detection of endogenous and over-expressed FOXP2. A. FOXP2 is detected as an 
80kDa immunoreactive band by western blotting. Endogenous expression was detected in both 
SH-SY5Y and HEK293 cells, after a one minute exposure. Detection of over-expressed FOXP2 
as an 80kDa band (30 second and 1 minute exposures) in HEK293 cells transfected with 2µg 
pcDNA4/HisMax-FOXP2 supported the identification of the 80kDa band as FOXP2. Blots were 
probed for GAPDH as an indicator of protein loading. The location and molecular weight (in 
kDa) of relevant bands from the Precision Plus Protein All Blue Standards molecular weight 
marker are indicated to the left of the image and expected product sizes are indicated to the right 
of the image. B. Gel electrophoresis of RT-PCR amplimers showing a 152bp product indicative 
of endogenous expression of FOXP2 in HEK293 and SH-SY5Y cells. Assessment of FOXP2 
expression in SH-SY5Y cells was carried out in two independent replicates, due to the prior 
evidence suggesting that this cell line does not endogenously express FOXP2 (Vernes et al., 
2006). No product was observed in the no template control (NTC) negative control reaction. The 
sizes of relevant bands from the 1 kb ladder (in bp) are indicated to the left of the image and the 
expected product sizes are indicated to the right of the image. 
 






















4.4.1.2 Selection of a control vector for the transfection of FOXP2 
 
To assess the effect of FOXP2 on DISC1 RNA and protein expression and promoter activity, 
the empty vector, pcDNA3.1/HA (Invitrogen) was used as control for the effect of 
transfecting cells with foreign DNA. This vector was used in place of pcDNA4/HisMax, the 
vector into which the FOXP2 constructs were cloned, which would have been the ideal 
control vector, as this vector was not available in the laboratory at the time of carrying out 
these experiments. pcDNA3.1/HA was selected as an alternative as it is highly similar in size 
to pcDNA4/HisMax (pcDNA3.1/HA: 5.4kb; pcDNA4/HisMax: 5.3kb), and therefore 
provides a control for the molar quantity of foreign DNA transfected into the cell. 





Figure 4.5. Detection of endogenous DISC1 expression in HEK293 cells. A. The ability of the C-
terminal DISC1 antibody (Ogawa et al., 2005) to detect DISC1 endogenous expression in HEK293 
cells was assessed by western blotting. DISC1 was detected as a 100 kDa immunoreactive band, 
consistent with previous reports in SH-SY5Y cells (Ogawa et al., 2005; Murdoch et al., 2007). The 
location and molecular weight (in kDa) of relevant bands from the Precision Plus Protein All Blue 
Standards molecular weight marker are indicated to the left of the image and the expected product 
size is indicated to the right of the image. B. The presence of endogenous DISC1 in HEK293 cells 
was confirmed by qRT-PCR. DISC1 mRNA expression was detected in HEK293 cDNA but not in 
a no template control (NTC) negative control reaction.  
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4.4.1.3 Selection of a ratio of transfection reagent to DNA for transfections using X-
tremeGENE HP 
 
As described in section 4.3.2, a novel transfection reagent (X-tremeGENE HP) was used to 
transfect HEK293 cells for the qRT-PCR assays carried out in this chapter. As this 
transfection reagent operates in a similar manner to Fugene HD, the transfection reagent 
used for all other transfections presented in this chapter, it was used at the same ratio of 
transfection reagent to DNA as Fugene HD (4:1). In case this ratio resulted in excess 
toxicity, all transfections were additionally performed using a lower ratio of transfection 
reagent to DNA (3:1). Although cell death was not formally quantified, visual inspection did 
not reveal any obvious differences in toxicity between the two conditions and, therefore, 
gene expression was assayed in both conditions. 
 
4.4.1.4 Assessment of gDNA contamination in HEK293 cDNA samples 
 
Prior to using the HEK293 cDNA samples in the experiments presented in this chapter, the 
samples were assessed by Helen Torrance (HT) for contamination with gDNA. Each sample 
was PCR-amplified using intron-spanning primers targeting a region of the WDR1 gene and 
the resulting amplimers fractionated on an agarose gel (figure 4.6). Control reactions were 
performed for both the reverse transcription reaction and the PCR. Samples were reverse 
transcribed in two batches, such that half the experimental replicates (replicates 1 and 2) 
were reverse transcribed in batch 1 and the other half (replicates 3 and 4) were reverse 
transcribed in batch 2. None of the HEK293 cDNA samples were found to be contaminated 
with gDNA. 
 
For each batch of samples, two negative control reactions were carried out, one without any 
RNA (no RNA) and the other without the reverse transcriptase enzyme (-RT). Both the no 
RNA reactions were free from contamination; however, a band of 238 bp, indicating cDNA, 
was evident in the –RT reaction for Batch 1. Positive controls were carried out to assess 
whether the primers amplified products of the expected size in cDNA from the brain, where 
WDR1 is known to be expressed, and gDNA. These reactions produced products of the 
expected sizes. A negative control PCR reaction (no template control) did not produce a 









Figure 4.6. Assessment of gDNA contamination in HEK293 cDNA. HEK293 cDNAs were 
assessed for contamination with gDNA by performing PCR using a set of primers that amplify a 
region of WDR1 to yield a product of 590bp from a gDNA template and 238bp from a cDNA 
template. cDNAs were assessed from cells that had been transfected with FOXP2, the 
pcDNA.31/HA control plasmid (CP), or mock transfected (Mock). Transfections were carried out 
using two different ratios of transfection reagent to DNA, 4:1 and 3:1. For each condition, cDNAs 
were made from cells transfected in four experimental replicates (1-4). The reverse transcription 
reactions were carried out in two batches: experimental replicates 1 and 2 were reverse 
transcribed in batch 1 and experimental replicates 3 and 4 were reverse transcribed in batch 2. For 
each batch, two negative control reactions for the reverse transcription reaction were carried out: 
no RNA and no reverse transcriptase (-RT; 1 = Batch 1, 2 = Batch 2). Positive control PCR 
reactions were carried out using (i) gDNA as the template (PCR performed in duplicate) and (ii) 
cDNA from the brain, where WDR1 is known to be expressed, as the template. A PCR negative 
control (PCR -ve) was carried out in which no template was included. Samples were run with a 1 
kb DNA ladder. The sizes of relevant bands from the 1 kb ladder (in bp) are indicated to the left 
of the image and the expected sizes of the products detected in cDNA and gDNA are indicated to 
the right of the image. 
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Regarding the 238 bp band observed in the –RT reaction for batch 1, the absence of 
contamination in the no RNA reactions indicates that the reverse transcription reagents were 
free from DNA or RNA contamination. The band in this sample could, therefore, indicate 
either (i) contamination of the RNA sample with cDNA contamination or (ii) contamination 
of the reverse transcription reagents with reverse transcriptase. The latter explanation seems 
unlikely as the same reagents were subsequently used for the second batch of reverse 
transcription reactions, for which the –RT reaction was free from DNA contamination. 
Another possibility is that the reverse transcriptase enzyme was accidently added to the –RT 
reaction. To differentiate between these possibilities, the sample used for the batch 1 –RT 
reaction was reverse transcribed again and another –RT reaction performed. As a control, the 
sample used for the –RT reaction for batch 2, which did not show evidence of contamination, 
was reverse transcribed as well, and another –RT reaction performed for this sample. PCR 
amplification of the products from these reactions using the same WDR1 primers as used 
previously revealed the two reverse transcription reactions to contain a single band of 238 
bp, indicative of cDNA free from gDNA contamination. A low level of cDNA contamination 
was evident in the –RT reactions for both batches 1 and 2; however, a similar level of cDNA 
contamination was present in the PCR negative control reaction (no template control). It, 
therefore, seems likely that the 238 bp bands indicative of cDNA in the –RT reactions are 
due to cDNA contamination of the PCR reagents. Importantly, the intensity of the band 
present in the –RT reaction for batch 1 is much lower than that observed initially (figure 
4.7), suggesting, perhaps, that the reverse transcriptase enzyme was accidently added to the 
initial reaction. As such, these cDNA samples were deemed to be unlikely to be unduly 






































4.4.1.5 Identification of suitable reference genes for qRT-PCR assays 
 
Stably expressed reference genes were required for the normalisation of qRT-PCR assays 
carried out to compare DISC1 expression in HEK293 cells under the following conditions: 
(i) transfection with the control plasmid vs. mock transfection, and (ii) transfection with full-
length FOXP2 (pcDNA4/HisMax-FOXP2) vs. transfection with the control plasmid. For 
both the above comparisons four reference genes were selected to be assessed for the 
stability of their expression. These genes were chosen as they fulfilled the criteria of (i) not 
having any ChIP-identified potential FOXP2 binding sites in their upstream region, 
according to the “ENCODE Integrated Regulation” track on the UCSC human genome 
browser (hg18 and hg19), and (ii) being targeted by an intron-spanning assay available from 
PrimerDesign in their hydrolysis probe (PerfectProbe) “geNorm kits”. The selected genes 
 
Figure 4.7. Assessment of the reverse transcriptase negative controls for DNA contamination. 
To clarify the source of a band indicative of cDNA contamination previously observed in the 
reverse transcriptase negative (-RT) control carried out for batch 1 of the reverse transcription 
reactions (-RT 1; figure 4.5), the reverse transcription (RT) and –RT reactions were repeated for 
this sample. As a control, RT and –RT reactions were repeated for the sample used in the –RT 
reaction for batch 2 of the reverse transcription reactions (-RT2), which previously showed no 
evidence of DNA contamination. Samples were PCR amplified using a set of primers that 
amplify a region of WDR1 to yield a product of 590bp from a gDNA template and 238bp from a 
cDNA template. A PCR negative control (PCR –ve), which contained no cDNA template was 
performed together with two positive control PCR reactions in which (i) gDNA was used as the 
template and (ii) cDNA from the brain, where WDR1 is known to be expressed, was used as the 
template. Samples were run with a 1 kb Plus DNA ladder. The size (in bp) of relevant ladder 
bands are shown to the left of the image and the expected sizes of the products detected in cDNA 
and gDNA are indicated to the right of the image. 
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were: glyceraldehyde 3-phosphate dehydrogenase (GAPDH), succinate dehydrogenase 
complex, subunit A (SDHA), splicing factor 3 subunit 1 (SF3A1), and ubiquitin C (UBC). 
 
As discussed previously (section 4.1.3.1-4.1.3.3), there are several algorithms available for 
the assessment of the stability of candidate reference genes. Here, two algorithms, geNorm, 
and NormFinder were implemented. As described in sections 4.1.3.1 and 4.1.3.2, geNorm 
identifies the n most stable reference genes required for the variation in sequential 
normalisation factors to fall below a pre-determined threshold, while NormFinder identifies 
the most stably expressed pair of reference genes. The results of these two algorithms are 
















4.4.1.6 Assessment of the effect of pcDNA3.1/HA on DISC1 expression 
 
Before using the control plasmid, it was important to establish whether it had any effect on 
DISC1 expression. The effect of the control plasmid on DISC1 expression was assessed in 
HEK293 cells by western blotting and qRT-PCR using the DISC1 TaqMan probe 
Hs00962131_m1 (table 4.1). For the assessment at the RNA level, HT extracted the RNA, 




Ratio Comparison geNorm NormFinder 
3:1 CP vs. Mock SDHA and UBC SDHA and UBC 
FOXP2 vs. CP SDHA and UBC GAPDH and UBC 
4:1 CP vs. Mock SDHA and UBC SDHA and UBC 
FOXP2 vs. CP SDHA and GAPDH SDHA and SF3A1 
 
Table 4.4. Reference genes selected for the normalisation of DISC1 qRT-PCR data. The 
expression values of the gene of interest, DISC1, and four reference genes, GAPDH, SDHA,  
SF3A1, and UBC, were determined by qRT-PCR in HEK293 cells transfected with the control 
plasmid (CP), full-length FOXP2 or mock transfected using two different ratios of transfection 
reagent to DNA (3:1 and 4:1). Two programs, geNorm and NormFinder, were used to select the 
most stably expressed reference genes to permit the comparison of DISC1expression values under 
the following conditions: (i) CP vs. Mock and (ii) FOXP2 vs. CP. 
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4.4.1.6.1 Assessment of the effect of pcDNA3.1/HA on DISC1 protein expression 
 
To assess the effect of pcDNA3.1/HA, the control plasmid, on DISC1 protein expression, 
HEK293 cells were transfected with either 2µg of the control plasmid or mock untransfected. 
Comparison of DISC1 protein expression in the control plasmid-transfected cells with 
expression in the mock transfected cells was carried out using a two-tailed independent 
samples t-test. This revealed no significant difference between the two conditions when 




















4.4.1.6.2 Assessment of the effect of pcDNA3.1/HA on DISC1 mRNA expression 
 
DISC1 expression was assessed by qRT-PCR in HEK293 cells transfected with either 2µg of 
the control plasmid, pcDNA3.1/HA, or mock transfected using two ratios of transfection 
reagent to DNA (3:1 and 4:1). For both ratios, the two reference gene selection programs, 
geNorm and NormFinder, identified the same two reference genes for calculation of the 
normalisation factor, SDHA and UBC (table 4.4). DISC1 expression was assayed using two 
TaqMan qRT-PCR assays, Hs00962131_m1 and Hs00962133_m1 (table 4.1). No significant 
 
Figure 4.8.  Assessment of the effect of the control plasmid, pcDNA3.1/HA on DISC1 protein 
expression. HEK293 cells were transiently transfected with either the control plasmid or 
subjected to mock transfection. A. DISC1 expression, together with the expression of the 
reference gene, GAPDH, was assayed 48 hours post-transfection by western blot. B. 
Immunoreactive bands were quantified by optical densitometry (OD) and the OD values for 
DISC1 normalised to the OD values for GAPDH. Statistical significance was assessed using a 
two-tailed independent samples Student’s t-test; no statistically significant differences were 
detected. The experiment was performed in experimental triplicate. 
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differences in normalised DISC1 expression values were identified between cells transfected 
with the control plasmid and mock transfected cells (all p ≥ 0.319, two-tailed independent 
samples t-tests; figure 4.9). 
 
  
Figure 4.9. Assessment of the effect of the control plasmid, pcDNA3.1/HA on DISC1 mRNA 
expression. HEK293 cells were transfected with either 2µg of the control plasmid 
(pcDNA3.1/HA) or mock transfected using two different ratios of transfection reagent to DNA 
(3:1 and 4:1). Forty-eight hours post-transfection mRNA was extracted, cDNA synthesised and 
gene expression measured by qRT-PCR. Two different TaqMan gene expression assays were used 
to measure DISC1 expression, Hs00962131_m1 and Hs00962133_m1. Two algorithms, geNorm 
and NormFinder, were used to identify stably expressed reference genes. For both ratios of DNA 
to transfection reagent, the two algorithms identified SDHA and UBC as the most stable reference 
genes. DISC1 expression values were normalised to the geometric mean of the expression values 
of SDHA and UBC. Shown are normalised DISC1 mRNA expression values obtained under the 
following conditions (DISC1 gene expression assay, transfection ratio): A. Hs00962131, 3:1, B. 
Hs00962133, 3:1, C. Hs00962131, 4:1, D. Hs00862133, 4:1. Comparison of normalised DISC1 
mRNA expression values was carried out using two-tailed independent samples Student’s t-tests; 
no statistically significant differences were detected. Experiments were performed in experimental 
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To conclude, the available evidence suggests that the transfection of HEK293 cells with the 
control plasmid does not alter DISC1 expression at the protein or mRNA level.  
 
4.4.1.7 Assessment of the effect of FOXP2 on DISC1 protein expression 
 
The effect of FOXP2 on endogenous DISC1 protein expression was assessed by western 
blotting (figure 4.10A). For two of the five experimental replicates, Alice Newman (AN), a 
student under my supervision, performed the transfections, protein extraction and western 
blotting; I performed the data analysis.  
 
HEK293 cells were transfected with 2µg of either the pcDNA4/HisMax vector containing 
full-length FOXP2 or the control plasmid. HEK293 cells transfected with the FOXP2-
expressing construct showed a mean decrease in the expression of the 100 kDa full-length 
isoform of DISC1 of 35.3% (corresponding to a fold change of -1.54), which was 






















 Figure 4.10. DISC1 protein expression is regulated by wild-type FOXP2. A.  Representative 
image of western blot analysis of DISC1, FOXP2, and GAPDH protein expression in HEK293 
cells transfected with either pcDNA4/HisMax-FOXP2 or the control plasmid (pcDNA3.1/HA). B. 
Quantification of DISC1 protein expression normalised to GAPDH. DISC1 expression was 
reduced in cells transfected with the FOXP2-expressing construct compared to the control 
plasmid, (n = 5). Statistical significance was assessed by a two-tailed independent samples 
Student’s t-test, **p ≤ 0.01, error bars represent standard error of the mean (S.E.M.). Figure 
adapted from Walker et al. (2012). 
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4.4.1.8 Assessment of the effect of FOXP2 on DISC1 mRNA expression 
 
The effect of FOXP2 on endogenous DISC1 mRNA expression was assessed using qRT-
PCR. For this analysis, HT extracted the RNA, synthesised the cDNA and performed the 
qRT-PCR; I performed the transfections and the data analysis. 
 
HEK293 cells were transfected with 2µg of either pcDNA4/HisMax-FOXP2 or the control 
plasmid, pcDNA3.1/HA, using two ratios of transfection reagent to DNA (3:1 and 4:1). As 
described in section 4.4.1.5, two algorithms, geNorm and NormFinder, were used to select 
the optimal reference genes for normalisation of DISC1 expression values. The genes 
selected by these algorithms are listed in table 4.4. DISC1 expression was measured using 
two DISC1 gene expression assays, Hs00962131_m1 and Hs00962133_m1 (table 4.1). 
Comparison of normalised DISC1 mRNA expression values between the FOXP2- and 
control plasmid-transfected cells revealed significant differences when DISC1 was measured 
using the Hs00962133_m1 assay in three of four combinations of reference gene selection 
algorithm and transfection reagent to DNA ratio assessed (table 4.5, figure 4.11). In all three 
cases, the direction of the change was such that DISC1 expression was decreased in the cells 
transfected with FOXP2. Consistent with these findings, a decrease in DISC1 expression was 
also observed in the fourth comparison for this probe; however the p-value fell just short of 
the threshold for statistical significance. When DISC1 was measured with the 
Hs00962131_m1 assay, no significant changes in DISC1 expression were observed. 
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p-value CP FOXP2 CP FOXP2 
geNorm 3:1 Hs00962131  0.533 0.605 0.003 0.032 1.13  0.117 
Hs00962133  0.967 0.693 0.113 0.050 -1.40  0.068 
4:1 Hs00962131  0.318 0.264 0.025 0.008 -1.21  0.081 
Hs00962133  0.314 0.233 0.019 0.026 -1.35  0.047 
NormFinder 3:1 Hs00962131 0.394  0.394 0.053 0.018 -1.00  0.994 
Hs00962133 0.689 0.449 0.088 0.023 -1.23  0.023 
4:1 Hs00962131 0.356 0.378 0.039 0.041 1.06  0.728 
Hs00962133 0.348 0.307 0.007 0.002 -1.13  0.006 
 
Table 4.5.  Assessment of the effect of FOXP2 on DISC1 mRNA expression. Summary of the 
data presented in figure 4.10. For each combination of reference gene selection algorithm 
(geNorm or NormFinder), ratio of transfection reagent to DNA (3:1 or 4:1), and DISC1 
expression assay (Hs00962131, highlighted in yellow, or Hs00962133, highlighted in blue), mean 
DISC1 mRNA expression levels together with the standard error of the mean (S.E.M.) are shown 
for HEK293 cells transfected with either the control plasmid (CP; pcDNA3.1/HA) or full-length 
FOXP2 (pcDNA4/HisMax-FOXP2). For each comparison between control plasmid- and FOXP2-
transfected cells the fold change in DISC1 expression, calculated relative to the control plasmid-
transfected cells, is shown together with an arrow indicating the direction of change. Statistical 
significance was assessed using a two-tailed independent samples Student’s t-test with the 
threshold for significance defined as p ≤ 0.05. P-values meeting the significance threshold are 
indicated in bold.  















Figure 4.11. Assessment of the effect of FOXP2 on DISC1 mRNA expression. See next page for 
legend. 
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Figure 4.11. Assessment of the effect of FOXP2 on DISC1 mRNA expression. HEK293 cells were 
transfected with 2µg of either the control plasmid (CP; pcDNA3.1/HA) or full-length FOXP2 
(pcDNA4/HisMax-FOXP2) using two different ratios of transfection reagent to DNA (3:1 and 4:1). 
Forty-eight hours post-transfection mRNA was extracted, cDNA synthesised and gene expression 
measured by qRT-PCR. Two different TaqMan gene expression assays were used to measure DISC1 
expression, Hs00962131 and Hs00962133. Two algorithms, geNorm and NormFinder, were used to 
identify stably expressed reference genes for normalisation of the DISC1 mRNA expression values 
(table 4.4). Shown are normalised DISC1 mRNA expression values obtained under the following 
conditions (reference gene selection algorithm, DISC1 gene expression assay, transfection ratio): A. 
geNorm, Hs00962131, 3:1, B. geNorm, Hs00962133, 3:1, C. geNorm, Hs00962131, 4:1, D. geNorm, 
Hs00862133, 4:1., E. NormFinder, Hs00962131, 3:1, F. NormFinder, Hs00962133, 3:1, G. 
NormFinder, Hs00962131, 4:1, H. NormFinder, Hs00862133, 4:1. Experiments were performed in 
experimental quadruplicate. Error bars represent standard error of the mean (SEM). Comparison of 
normalised DISC1 mRNA expression values was carried out using two-tailed independent samples 
Student’s t-tests. *p ≤ 0.05 and **p ≤ 0.01. 
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4.4.1.9 Assessment of the effect of FOXP2 on DISC1 promoter activity 
 
4.4.1.9.1 Assessment of the effect of wildtype full-length FOXP2 on DISC1 
promoter activity 
 
To determine whether the decrease in DISC1 protein expression observed in cells 
overexpressing FOXP2 could be attributed to repression of transcriptional activity, dual 
luciferase reporter assays were carried out. The region of the DISC1 promoter identified by 
ChIP-seq as being bound by FOXP2 (see section 4.1.1.4) overlaps with the short, medium 
and long DISC1 promoter constructs; therefore, the effect of transient overexpression of 
FOXP2 on all three was assessed. HEK293 cells were co-transfected with: (i) a DISC1 
promoter construct (pGL4.10-long, -medium, or –short, described in the previous chapter); 
(ii) either a FOXP2-containing vector (pcDNA4/HisMax-FOXP2) or the control plasmid; 
(iii) and the transfection efficiency control, pRL-TK (figure 4.12).  
 
Two-way ANOVA with the independent variables “FOXP2 condition” (control plasmid or 
wildtype FOXP2) and “promoter construct” (long, medium, or short) revealed a significant 
reduction in DISC1 promoter activity in cells transfected with the FOXP2-expressing 
construct compared to the control plasmid (p ≤ 0.001). As reported in chapter three (figure 
3.9), the effect of promoter construct was also significant (p ≤ 0.001), and, in addition, the 
interaction between promoter construct and FOXP2 condition was also significant (p = 
0.00388).  
 
To investigate the interaction between promoter construct and FOXP2 condition, simple 
main effects were analysed. This was achieved by performing a series of one-way ANOVAs 
followed by Tukey’s Honestly Significant Difference (HSD) post-hoc tests. Firstly, the effect 
of FOXP2 on promoter activity was assessed independently for each promoter construct. 
Tukey’s HSD revealed a decrease in promoter activity for all constructs in FOXP2-
transfected cells compared to control plasmid-transfected cells, with this decrease attaining 
statistical significance for both the long (p = 0.0101) and the medium (p = 0.00923) 
constructs, but not the short (p = 0.114) construct. Secondly, the effect of promoter construct 
was assessed independently for each FOXP2 condition. In keeping with our initial 
characterisation of the long, medium, and short promoter constructs, Tukey’s HSD revealed 
that in both FOXP2-transfected and control plasmid-transfected cells, the activity of the 
medium construct was significantly greater than the activity of the short (control plasmid: p 
≤ 0.001; FOXP2: p ≤ 0.001) and the long (control plasmid: p = 0.00369; FOXP2: p =0.0173) 
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constructs. Additionally, in cells transfected with FOXP2, the activity of the long construct 
was significantly greater than the activity of the short construct (p = 0.0310), whilst in the 
control plasmid-transfected cells the same pattern of activity was observed but only 






















4.4.1.9.2 Assessment of the effect of FOXP2 mutations implicated in speech and 
language disorder on FOXP2-mediated transcriptional repression of 
DISC1 
 
Two FOXP2-expressing constructs each containing one of the rare coding mutations, R553H 
or R328X, which are found only in individuals affected with developmental verbal dyspraxia 
(DVD) (Lai et al., 2001; MacDermot et al., 2005) were assessed for their ability to repress 
transcription of DISC1 using the dual luciferase reporter assay. HEK293 cells were co-
transfected with: (i) a DISC1 promoter construct (pGL4.10-long, -medium, or -short); (ii) 
either a FOXP2-containing vector (pcDNA4/HisMax-FOXP2, -FOXP2.R553H, or-
Figure 4.12. DISC1 promoter activity is regulated by wild-type FOXP2. Dual luciferase reporter 
assays show down-regulation of DISC1 promoter activity in cells transfected with the FOXP2-
expressing construct compared to the control plasmid. The significant main effect of FOXP2 
(***p ≤ 0.001; indicated by a red bracket), determined by two-way ANOVA, and the significant 
effect of FOXP2 on the long (*p ≤ 0.05) and the medium (**p ≤ 0.01) constructs (indicated by 
black brackets), determined by two-tailed independent samples Student’s t-tests are indicated on 
the graph (n = 3). Error bars represent standard error of the mean (S.E.M.). Figure adapted from 
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FOXP2.R328X) or the control plasmid; (iii) and the transfection efficiency control, pRL-TK 
(figure 4.13).  
 
Separate two-way ANOVAs were carried out for the two FOXP2 mutations with the 
independent variables “FOXP2 condition” (control plasmid, wildtype FOXP2, and 
FOXP2.R553H or FOXP2.R328X) and “promoter construct” (long, medium, and short). For 
both mutations ANOVA revealed significant main effects of FOXP2 condition and promoter 
construct (p ≤ 0.001 for all comparisons). The interaction between FOXP2 condition and 
promoter construct was also significant for both FOXP2 mutations (R553H: p = 0.00202; 



























Figure 4.13. FOXP2-mediated inhibition of DISC1 promoter activity is altered by the pathogenic 
point mutations R553H and R328X. A and B. Dual luciferase reporter assays reveal that both the 
R553H (pcDNA4/HisMax-FOXP2.R553H; A) and R328X (pcDNA4/HisMax-FOXP2.R328X; B) 
point mutations reduce the ability of FOXP2 to inhibit DISC1 promoter activity. Both point 
mutations resulted in a significant reduction in the ability of FOXP2 to down-regulate the 
promoter activity of all three DISC1 promoter constructs (n = 3). Statistical significance was 
assessed by two-tailed independent samples Student’s t-tests. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
Error bars represent standard error of the mean (S.E.M.). This figure has been published 
previously in Walker et al. (2012). 
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In order to understand the significant interactions, the effect of the two FOXP2 point 
mutations, R553H and R328X, on the ability of FOXP2 to repress DISC1 promoter activity 
was assessed for each promoter construct individually using two-tailed independent samples 
t-tests. A reduction in the ability of FOXP2 to repress DISC1 promoter activity was observed 
for both mutations, with this effect attaining significance across all constructs (p ≤ 0.0251 for 
all comparisons). The effect of promoter construct was then assessed individually for each 
FOXP2 condition. Consistent with previous observations, Tukey’s HSD revealed that under 
both conditions the medium promoter construct displayed significantly greater promoter 
activity than either the short (R553H: p ≤ 0.001; R328X: p ≤ 0.001) or long (R553H: p ≤ 
0.001; R328X: p = 0.00639) constructs.  As observed for cells transfected with FOXP2, the 
activity of the long construct was significantly greater than that of the short construct in cells 
transfected with FOXP2.R553H (p = 0.006). A trend in the same direction was observed in 
cells transfected with FOXP2.R328X; however this difference did not attain statistical 
significance (p = 0.0932). 
 
4.4.2 Assessment of Foxp2 expression in mice carrying the L100P Disc1 
point mutation 
 
In the introduction to this chapter (section 4.1.1.2), it was suggested that a bi-directional 
regulatory relationship might exist between FOXP2 and DISC1 expression. This hypothesis 
was based on the observation that pathways involved in transcriptional regulation (Wnt 
signalling, cAMP signalling, and EGR-mediated transcription), which have been linked to 
DISC1 function, are implicated in the regulation of FOXP2. 
 
As a preliminary step in the investigation of this putative bi-directional regulatory 
relationship, Foxp2 expression was characterised in mice carrying an ENU-induced point 
mutation, resulting in an L100P amino acid substitution, in the Disc1 gene (Clapcote et al., 
2007). As described in the introduction to this chapter (section 4.1.2), the Disc1 L100P 
mouse displays a “schizophrenia-like” phenotype, which may arise, in part, from the aberrant 
expression of several genes, including Disc1. 
 
Foxp2 mRNA expression was assessed by qRT-PCR in a panel of samples representing 
different developmental stages collected by SB during her PhD, which has been described 
fully in Brown et al. (2011). Whole brain cDNA was available for embryonic (E) stages E13, 
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E15, and E18, and hippocampal cDNA was available for the postnatal (P) stages P1, P7, 
P20, and adult.  
 
4.4.2.1 Assessment of Foxp2 mRNA expression in the Disc1 L100P mouse by 
qRT-PCR  
 
4.4.2.1.1 Detection of gDNA contamination 
 
cDNA samples synthesised by SB had previously been found to be free from gDNA 
contamination. As there was insufficient cDNA for some samples (P1 wildtypes, P7 Disc1 
L100P mice and wildtypes, and P20 wildtypes), RNA for these samples were reverse 
transcribed by HT and checked, by HT, for gDNA contamination by PCR amplification 
using intron-spanning primers. Evidence for gDNA contamination was observed in all of the 
samples from the wildtype mice at P1, P7 and P20. Unfortunately, no more RNA was 
available from these mice to repeat the cDNA synthesis, so it was decided to proceed with 
the qRT-PCR using only intron-spanning assays known not to amplify gDNA. 
 
4.4.2.1.2 Selection of reference genes normalisation of qRT-PCR data 
 
As there was only very limited cDNA available for the embryonic samples, and no more 
RNA available to synthesise additional cDNA, only three reference genes could be 
measured. To permit comparison with the gene expression profiles obtained from these mice 
by SB, it was decided that the two reference gene assays used by SB, Hprt1 and Gapdh, 
should be used in addition to an assay measuring Actb.  
 
After measuring the expression of these three reference genes by qRT-PCR, it was found that 
both the Gapdh and Actb assays were single-exon assays, which, therefore, would amplify 
gDNA. As evidence for gDNA contamination had been detected in the wildtype mice at P1, 
P7 and P20, these assays cannot be considered to provide valid reference gene expression 
data for normalisation. As such, the sections below report Foxp2 expression values 
normalised to Hprt1expression, which was measured using an intron-spanning assay, 
previously shown (by Applied Biosystems) not to amplify gDNA.  
As an aside, it is worth noting that prior to realising that both the Gapdh and Actb assays 
would be affected by the gDNA contamination present in some samples, Foxp2 expression 
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values were normalised to the geometric mean of Hprt1, Gapdh and Actb. The results of this 
analysis were highly similar to those obtained when normalising to Hprt1 alone. 
4.4.2.1.3 qRT-PCR analysis 
 
Comparison of the developmental expression of Foxp2 in mice carrying the L100P point 
mutation with their wild-type counterparts revealed significant differences at E15, E18, P1, 
P7 and in the adult mice (figure 4.14 and table 4.6). As the uneven numbers of mice in each 
group may render the Student’s t-test less robust to violations of the assumptions of 
normality and homogeneity of variances (Boneau, 1960), compliance with these assumptions 
was assessed. Normality was assessed using the Shapiro-Wilk test and homogeneity of 
variances using Levene’s test. The data were found to comply with the assumption of 
normality (all p ≥ 0.170); however, deviation from the homogeneity of variances assumption 
was detected at P1 (p = 0.00678) and P7 (p = 0.048). At these developmental stages 























Figure 4.14. Developmental profile of Foxp2 mRNA expression in the L100P mouse obtained by 
the normalisation of Foxp2 expression values to the expression values of the reference gene 
Hprt1. Gene expression was measured in whole-brain cDNA at embryonic days (E) 13, 15, and 
18, and hippocampal cDNA at postnatal days (P) 1, 7, 20, and in adulthood. Normalised Foxp2 
expression values are represented in a bar chart (A) and a line graph (B). Each data point 
represents the mean of normalised expression values from a minimum of three mice. Error bars 
represent standard error of the mean (S.E.M.). Significance was assessed using the two-tailed 
independent samples Student’s t-test for all developmental stages except from P1 and P7. As the 
homogeneity of variances assumption was violated at these stages, significance was determined 
using Welch’s t-test. * p ≤ 0.05, **p ≤ 0.01, **** p ≤ 0.0001.  
























4.4.2.2 Comparison of Foxp2 and Disc1 developmental expression profiles 
 
During her PhD, SB measured Disc1 expression in the same developmental panel of mRNA 
samples used here for the measurement of Foxp2. To permit comparison between the 
developmental pattern of Disc1 and Foxp2 mRNA expression, the Disc1 expression data was 
re-analysed, this time normalising only to Hprt1. This revealed significant differences in 
Disc1 expression between the Disc1 L100P mice and the wildtype mice at E15, P1, P7 and 
P20 (figure 4.15; table 4.7). As there were unequal numbers of mice in several of the groups, 
the data were assessed for normality and homogeneity of variances. Normality was assessed 
using the Shapiro-Wilk test and homogeneity of variances using Levene’s test. The 
distribution of the data for the wildtype mice at P20 was found to significantly differ from 
the normal distribution (p = 0.0292) and violation of the homogeneity of variances 
assumption was detected at P7 (p = 0.00338) and in the adult mice (p = 0.00467). As such, 
Table 4.6. Assessment of Foxp2 expression in Disc1 L100P mice (L100P) and wildtype (WT) 
controls throughout development. Normalised Foxp2 mRNA expression values were ascertained 
by qRT-PCR followed by normalisation to the reference gene Hprt1. Gene expression was 
measured in whole-brain cDNA at embryonic days (E) 13, 15, and 18, and hippocampal cDNA at 
postnatal days (P) 1, 7, 20, and in adulthood. Shown for each group are the number (N) of mice 
assessed, the mean normalised Foxp2 mRNA expression value and the standard error of the mean 
(S.E.M.). The fold change in Foxp2 expression was calculated relative to the wildtype control 
group. The direction of each change is indicated by an arrow (red upwards arrow = increase, green 
downwards arrow = decrease). P-values are displayed for the two-tailed independent samples 
Student’s t-test. P-values meeting the significance threshold are indicated in bold. †As the 
homogeneity of variances assumption was violated for the P1 and P7 comparisons, significance 









 WT L100P WT L100P WT L100P 
E13 5 6 14.5 14.8 0.34 0.89 1.02  0.729 
E15 6 5 9.31 15.4 1.65 1.03 1.65  0.0156 
E18 5 6 11.6 7.58 0.23 0.36 -1.53  8.84 x 10-6 
P1 5 6 0.792 7.28 0.069 1.31 9.20  0.00427† 
P7 6 4 0.408 1.96 0.132 0.429 4.81  0.0307† 
P20 3 6 0.196 0.147 0.0208 0.0328 -1.34  0.358 
Adult 5 3 0.0245 0.0556 0.00643 0.00408 2.27  0.0141 
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the comparison at P20 was carried out using a Mann-Whitney U test and the comparisons at 






















Figure 4.15. Developmental profile of Disc1 mRNA expression in the L100P mouse obtained by 
the normalisation of Disc1 expression values to the expression values of the reference gene Hprt1. 
Gene expression was measured in whole-brain cDNA at embryonic days (E) 13, 15, and 18, and 
hippocampal cDNA at postnatal days (P) 1, 7, 20, and in adulthood. Normalised Disc1 expression 
values are represented in a bar chart (A) and a line graph (B). Each data point represents the mean 
of normalised expression values from a minimum of three mice. Error bars represent standard error 
of the mean (S.E.M.). Significance was assessed using the two-tailed independent samples 
Student’s t-test for all developmental stages except from P1, P7 and P20.  At P20 the assumption 
of normality was violated, so significance was assessed using a Mann-Whitney U test. At P1 and 
P7 the homogeneity of variances assumption was violated, so significance was determined using 
Welch’s t-test.  * p ≤ 0.05, **p ≤ 0.01. 







Table 4.7. Assessment of Foxp2 expression in Disc1 L100P mice (L100P) and wildtype (WT) 
controls throughout development. Normalised Foxp2 mRNA expression values were ascertained 
by qRT-PCR followed by normalisation to the reference gene Hprt1. Gene expression was 
measured in whole-brain cDNA at embryonic days (E) 13, 15, and 18, and hippocampal cDNA at 
postnatal days (P) 1, 7, 20, and in adulthood. Shown for each group are the number (N) of mice 
assessed, the mean normalised Foxp2 mRNA expression value and the standard error of the mean 
(S.E.M.). The fold change in Foxp2 expression was calculated relative to the wildtype control 
group. The direction of each change is indicated by an arrow (red upwards arrow = increase, green 
downwards arrow = decrease). P-values are displayed for the two-tailed independent samples 
Student’s t-test. P-values meeting the significance threshold are indicated in bold. †As the 
homogeneity of variances assumption was violated for the P1 and P7 comparisons, significance 
was determined using Welch’s t-test. 
‡
As the assumption of normality was violated at P20, 









 WT L100P WT L100P WT L100P 
E13 5 5 3.99 3.07 0.207 0.777 -1.30  0.288 
E15 6 3 0.953 2.27 0.136 0.272 2.38  0.00170 
E18 4 6 4.95 4.61 0.138 0.275 -1.08  0.363 
P1 5 5 0.281 7.49 0.0578 0.982 26.6  0.00255† 
P7 5 4 0.476 1.40 0.0401 0.106 2.93  0.00250† 
P20 3 5 0.243 0.568 0.0330 0.112 2.34  0.0360‡ 
Adult 4 6 0.608 1.14 0.128 0.404 1.88  0.254 
 
Chapter 4: Assessment of the DISC1-FOXP2 Regulatory Relationship 
214 
 
Comparison of the Disc1 and Foxp2 developmental expression profiles reveals some 
intriguing similarities between the expression patterns of the two genes in wild-type mice 
(figure 4.15). Interestingly, the relationship between Disc1 and Foxp2 expression is altered 
in the L100P mice.  
 
In the wildtype mice (figure 4.16 A and 4.16 B), both Disc1 and Foxp2 show a decrease in 
expression between E13 and E15, before increasing between E15 and E18. The expression of 
both in the postnatal mice is low, although there is a slight increase in the expression of 
Disc1, but not Foxp2, in the adult hippocampus between P20 and adulthood. 
 
The expression of both genes and the relationship between their expression levels is altered 
in mice carrying the Disc1 L100P mutation (figure 4.16 C and figure 4.15 D). In the 
embryonic stages, Disc1 and Foxp2 show almost inverse patterns of expression in the L100P 
mice, in contrast to the parallel patterns of expression found in the wildtype mice. In 
common with the wildtype mice, the expression of Disc1, but not Foxp2, increases from P20 
to adulthood.  
  




























Figure 4.16. Comparison of Foxp2 and Disc1 mRNA developmental expression profiles in the 
Disc1 L100P mice and wildtype (WT) controls. Gene expression was measured in whole-brain 
cDNA at embryonic days (E) 13, 15, and 18, and hippocampal cDNA at postnatal days (P) 1, 7, 
20, and in adulthood. Disc1 and Foxp2expression values were normalised to expression values for 
the reference gene Hprt1. A. Foxp2 mRNA expression in the WT mice, B. Disc1 mRNA 
expression in the WT mice, C. Foxp2 mRNA expression in the Disc1 L100P mice, and D. Disc1 
mRNA expression in the Disc1 L100P mice. Measurements were carried out in at least three 
biological replicates. Error bars represent standard error of the mean (S.E.M.). 
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4.4.2.3 Assessment of Foxp2 protein expression in the Disc1 L100P mouse by 
western blotting 
 
In addition to assessing Foxp2 mRNA expression in the Disc1 L100P mice, Foxp2 protein 
expression was measured. Expression was assessed in whole brain lysates from embryonic 
mice at embryonic days (E) 12.5, 15.5, and 17.5, and in region-specific lysates (cortex, 
hippocampus, striatum, and cerebellum) from postnatal mice at postnatal days (P) 1, 7, 21, 
and 90. Protein samples were extracted by EG, who also pooled the samples, such that the 
embryonic samples comprised the brains of approximately six littermates, and the postnatal 
samples comprised tissue from at least three mice. As protein samples were limited, it was 
only possible to assess Foxp2 expression in one experimental replicate. As such, these 
findings must be considered preliminary and in need of independent replication. 
 
4.4.2.3.1 Embryonic stages 
 
Foxp2 expression was measured in whole brain lysates from pooled litters of embryonic 
mice at E12.5, E15.5, and E17.5. The expression levels of three reference genes, α-tubulin, 
β-actin, and Gapdh were also measured to permit normalisation for between-lane differences 
in protein loading.  
 
Foxp2 was identified as a single band of 80 kDa, consistent with the manufacturer’s 
datasheet. Inspection of the immunoreactive bands (figure 4.17 A) revealed an apparent 
decrease in Foxp2 signal intensity in the Disc1 L100P mice at each developmental stage. The 
signal intensities of the α-tubulin and β-actin immunoreactive bands was fairly even between 
the Disc1 L100P and the wildtype mice at each developmental stage, with the exception of 
β-actin at E12.5: in the Disc1 L100P mice, the β-actin E12.5 band was disrupted by an air 
bubble, thus preventing comparison. Developmental regulation of β-actin is suggested by an 
increase in signal intensity with age. In contrast, inspection of the Gapdh immunoreactive 
bands revealed an alternating pattern of signal intensity, most obvious at E15.5 and E17.5, 
such that the signal intensity of Gapdh was decreased in mice carrying the Disc1 L100P 
mutation. 
 
The signal intensities of each band were quantified by optical densitometry, and normalised 
Foxp2 expression values obtained by dividing the Foxp2 optical density (OD) values by the 
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corresponding OD values for each reference gene. In light of the lack of consistency between 
the signal intensities of the different reference genes, it was decided that Foxp2 should be 
normalised to each gene separately in order to permit an unbiased depiction of Foxp2 
expression. Normalising to both α-tubulin and β-actin suggested a decrease in Foxp2 
expression across all the embryonic stages assessed in the Disc1 L100P mice compared to 
the wildtypes (figures 4.17 B and 4.17 C). In contrast, normalisation to Gapdh revealed the 
Disc1 L100P mice to have a slight decrease in Foxp2 expression at E12.5, but increased 
























The decrease in Gapdh signal intensity in the Disc1 L100P compared to the wildtype mice 
was unexpected given (i) the lack of a comparable difference in the signal intensities of α-
tubulin and β-actin, and (ii) the fact that equal loading of the samples was attempted. 
Unfortunately, it was not possible to obtain whole brain lysates from independent mice to 
 
Figure 4.17. Foxp2 protein expression in embryonic mice carrying the Disc1 L100P mutation at 
embryonic days (E) 12.5, 15.5, and 17.5. A. The expression of Foxp2, together with three 
reference genes, α-tubulin, β-actin, and Gapdh, was assessed in whole brain lysates pooled from 
a litter of either Disc1 L100P (M) or wildtype (WT) embryos by western blotting. Densitometric 
analysis was performed and the acquired optical density values for the Foxp2 immunoreactive 
bands were normalised to the corresponding optical density values for each of α-tubulin (B), β-
actin (C), and Gapdh (D). 
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attempt independent replication of these results; however, to assess the contribution of 
technical variation to the present results, a second western blot of the same samples was 
probed as a technical replicate. EG performed the western blotting and probed the blot for β-
actin and Gapdh, I probed the blot for Foxp2, and Susan Anderson (SA) probed the blot for 
α-tubulin. 
 
Visual inspection of the technical replicate revealed some unexpected results (figure 4.17 A): 
whereas an apparent decrease in the signal intensity of the FOXP2 immunoreactive bands 
was again evident in the L100P mice, the pattern of the reference gene immunoreactive 
bands differed from the first technical replicate. At E12.5, for both the wildtype and the 
L100P mice, the expression of α-tubulin was undetectable (previously, this was highest at 
E12.5 and decreased with age). β-actin expression showed a similar pattern in the two 
replicates, while the expression of Gapdh appeared more equal between the wildtype and 
mutant mice at each developmental stage in the second technical replicate.  
 
Normalisation of the Foxp2 OD values to the OD values of the reference genes (figure 4.18 
B-D) revealed a trend for decreased Foxp2 expression in the L100P mice at every 
developmental stage. For normalisation to α-tubulin (figure 4.18 B) and β-actin (figure 4.18 
C), the direction of the between-genotype expression changes were consistent between the 
two technical replicates, although, the relative expression levels of Foxp2 between the two 
genotypes, and the pattern of expression throughout development differed. Normalising to 
Gapdh produced results that contradicted the first Gapdh technical replicate: the L100P mice, 
instead of showing increased Foxp2 expression at E15.5 and E17.5, showed a decrease in 
Foxp2 expression at all embryonic stages.  
 
Assessment of the fold changes in Foxp2 expression calculated using normalised Foxp2 
values obtained from each of the three reference genes provides suggests a decrease in 
Foxp2 expression in embryonic Disc1 L100P mice (table 4.8). When considering both 
technical replicates and all three reference genes, the normalised Foxp2 expression values 
determined by normalising to Gapdh in the first technical replicate appear anomalous. 
Nevertheless, further technical and experimental replicates, which were unfortunately not 
possible due to limited protein samples, are required before any firm conclusions can be 
drawn. 
 

































Figure 4.18.  Technical replicate of the assessment of Foxp2 expression in embryonic mice 
carrying the Disc1 L100P mutation at embryonic days (E) 12.5, 15.5, and 17.5. A. The expression 
of Foxp2, together with three reference genes, α-tubulin, β-actin, and Gapdh, was assessed in 
whole brain lysates pooled from a litter of either Disc1 L100P (M) or wildtype (WT) embryos by 
western blotting. Densitometric analysis was performed and the acquired optical density values 
for the Foxp2 immunoreactive bands were normalised to the corresponding optical density values 




Fold change (replicate 1) Fold change (replicate 2) 
α-tubulin β-actin Gapdh α-tubulin β-actin Gapdh 
E12.5 -2.30 -2.01 1.30 N/A* -77.0 -40.9 
E15.5 -1.71 -1.16 12.7 -10.6 -6.96 -7.29 
E17.5 -1.89 -3.58 6.04 -1.58 -1.88 -2.17 
 
Table 4.8. Fold changes in Foxp2 protein expression in embryonic Disc1 L100P mice. Fold 
changes for normalised Foxp2 protein expression values (determined by normalisation to either α-
tubulin, β-actin, or Gapdh) in the Disc1 L100P mice were calculated relative to the wildtype 
control mice: a positive fold change indicates increased expression in the Disc1 L100P mice, 
while a negative fold change indicates decreased expression in the Disc1 L100P mice. Expression 
was assessed at embryonic (E) days 12.5, 15.5, and 17.5, in two technical replicates. Arrows 
indicating the direction of the fold change are included for clarity. *This value could not be 
calculated as the signal intensity of the α-tubulin immunoreactive bands was too low to quantify. 
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4.4.2.3.2 Postnatal stages 
 
Foxp2 protein expression was measured in the striatum, cerebellum, cortex, and 
hippocampus at P1, P7, P21, and P90. The striatum, cerebellum, and cortex were assessed as 
these regions have previously been shown to express Foxp2 throughout development, with 
expression in the striatum being particularly strong (Ferland et al., 2003; Lai et al., 2003). In 
contrast, there is a lack of consensus regarding the expression of Foxp2 in the hippocampus: 
some studies have failed to detect hippocampal expression of Foxp2 at the mRNA (Ferland 
et al., 2003; Takahashi et al., 2003) or protein level (Ferland et al., 2003), whereas another 
reports weak Foxp2 immunoreactivity in the hippocampus (Fujita et al., 2008). In humans, 
FOXP2 expression has been detected in the hippocampus (Wilcke et al., 2012). As qRT-PCR 
assessment of Foxp2 mRNA expression in the Disc1 L100P mice revealed hippocampal 
expression (section 4.3.7.1.2), the hippocampus was also assessed for Foxp2 protein 
expression. As for the embryonic stages, the expression of α-tubulin, β-actin and Gaodh 
were measured to permit normalisation of Foxp2 expression values. 
 
In all four brain regions an 80 kDa product indicative of Foxp2 expression was detected 
(figure 4.19). An additional, fainter, band, of a slightly lower molecular weight was also 
present in all four regions. Generally, this band was most evident at the earliest postnatal 
stages, disappearing by adulthood; it is, however, visible at P90 in the striatum (although 
only in the first technical replicate, STM (1)). As this band was not predicted by the 
manufacturer’s datasheet, only the 80 kDa band was quantified. 
 
As for the embryonic samples, normalisation of Foxp2 expression values was carried out for 
each reference gene individually rather than to the geometric mean of all three reference 
genes. This decision was made as (i) inconsistencies were evident between the relative 
expression levels of the three reference genes between the Disc1 L100P and the wildtype 
conditions for a given comparison and (ii) sometimes the signal intensity of one or more of 
the reference genes for a given sample was too low to quantify, perhaps due to a technical 
artefact. An example of the first issue is the relationship between the expression levels of the 
three reference genes in the hippocampus (HPC (1)). Here, at P1 and P7 the signal intensity 
of Gapdh is lower in the Disc1 L100P mice than the wildtype mice; a similar change is not, 
however, observed in the signal intensities of α-tubulin or β-actin. Unfortunately, Gapdh ran 
off the end of the gel during electrophoresis of the second technical replicate, so further 
assessment of the cause of this discrepancy was precluded. Regarding the second issue, there 
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are some incidences where it appears likely that a technical artefact, such as the presence of 
an air bubble during the transfer stage, resulted in a poorly formed band. One example of this 
is the band obtained for β-actin in the Disc1 L100P hippocampal sample (HPC (2)) at P1. In 
other cases, the expression levels of one or two of the reference genes were too low to 
quantify, while the expression of the other reference genes was clearly evident. This 
occurred in the cerebellum at P21 and P90: here, the expression of α-tubulin and β-actin was 
unquantifiable in the wildtype mice, while Gapdh was clearly expressed. When the band for 
a reference gene was only partially formed, or unquantifiable, normalisation to that reference 
gene was not performed. 
 
Comparison of the normalised Foxp2 values between the Disc1 L100P mice and the 
wildtype controls (figure 4.19 and table 4.9), suggests that Foxp2 expression may be altered 
in the Disc1 L100P mice at several developmental stages across multiple brain regions. 
Consistent with findings at the mRNA level, increased Foxp2 expression was observed in the 
Disc1 L100P mice at P1 in the hippocampus. This increase was evident in both technical 
replicates for all reference genes. Slight increases in Foxp2 expression at P1 were also 
observed in the striatum (although only for the first technical replicate) and cortex. A 
consistent decrease in Foxp2 expression in the Disc1 L100P mice at P7 was observed for all 
four brain regions when normalising to every reference gene. The findings at P20 and P90 
were less clear-cut, in part because the lower level of Foxp2 immunoreactivity detected at 
these stages limited the number of comparisons that could be made. Nevertheless, the 
available evidence suggests decreased Foxp2 expression at both these developmental stages 
in the Disc1 L100P mice, the exception being in the striatum, where normalisation to 
different reference genes yielded conflicting results. 
 
Considering each brain region separately, a consistent downregulation in Foxp2 expression 
in the cerebellum was observed for the Disc1 L100P mice at every developmental stage. In 
both the hippocampus and the cortex, the available evidence suggests an upregulation of 
Foxp2 expression in the Disc1 L100P mice at P1 and a downregulation at subsequent 
developmental stages. The pattern of expression in the striatum is less clear due to 
inconsistencies between reference genes and technical replicates. 

























Figure 4.19. Foxp2 protein expression in postnatal mice carrying the Disc1 L100P mutation at postnatal days (P) 1, 7, 20, and 90. See next page for full 
legend. 
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Figure 4.19. Foxp2 protein expression in postnatal mice carrying the Disc1 L100P mutation at 
postnatal days (P) 1, 7, 20, and 90. A. The expression of Foxp2, together with three reference genes, 
α-tubulin, β-actin, and Gapdh, was assessed in the hippocampus (HPC), striatum (STM), cortex 
(CTX) and cerebellum (CBM) in Disc1 L100P (M) mice and wildtype mice (WT) by western blotting. 
Densitometric analysis was performed and the acquired optical density values for the Foxp2 
immunoreactive bands were normalised to the corresponding optical density values for each of α-
tubulin (B), β-actin (C), and Gapdh (D). Western blotting of hippocampal and striatal lysates were 
performed in two technical replicates, indicated in parentheses; expression in the cortex and the 
cerebellum was assessed in one replicate.  Assessment of Gapdh expression in the second technical 
replicates of the hippocampus and the striatum was precluded as proteins of this molecular weight had 
run off the end of the gel during electrophoresis. 




















 HPC STM CTX CBM 
Replicate 1 Replicate 2 Replicate 1 Replicate 2 
AT BT G AT BT G AT BT G AT BT G AT BT G AT BT G 
P1 2.92 3.23 4.32 1.86 N/A N/A 1.22 1.11 1.27 -1.36 -2.41 N/A 1.14 1.26 1.00 -1.05 -3.43 -2.06 
P7 -3.73 -2.54 -1.45 N/A N/A N/A -84.8 -124 -82.6 -18.2 -46.2 N/A -5.92 -5.80 -6.34 -2.62 -4.49 -3.06 
P20 -1.09 -1.40 -1.93 N/A N/A N/A 1.25 1.66 -6.36 N/A N/A N/A -1.81 -2.28 -1.10 -1.60 N/A -1.32 
P90 N/A -17.3 -2.65 N/A N/A N/A 2.00 -1.79 1.37 N/A N/A N/A -3.17 -20.4 -2.45 -4.72 N/A -1.94 
 
Table 4.9. Fold changes in Foxp2 protein expression in postnatal Disc1 L100P mice. Fold changes for normalised Foxp2 protein expression values (determined by 
normalisation to either α-tubulin (AT), β-actin (BA), or Gapdh (G)) in the Disc1 L100P mice were calculated relative to the wildtype control mice: a positive fold change 
indicates increased expression in the Disc1 L100P mice, while a negative fold change indicates decreased expression in the Disc1 L100P mice. Expression was assessed at 
postnatal (P) days 1, 7, 20, and 90 in the hippocampus (HPC), striatum (STM), cortex (CTX) and cerebellum (CBM). Assessment of protein expression in the hippocampus 
and the striatum was carried out in two technical replicates, while expression levels in the cortex and the cerebellum were both assessed in one replicate. Arrows indicating the 
direction of the fold change are included for clarity. N/A indicates values that could not be calculated due to the signal intensity of Foxp2 and/or the reference gene being too 
low to quantify. 
 
Chapter 4: Assessment of the DISC1-FOXP2 Regulatory Relationship 
225 
 
4.5 Summary and discussion 
 
The work described in this chapter has explored the FOXP2-DISC1 regulatory relationship. 
A summary and discussion of each part of this work is presented below. 
 
4.5.1 The role of FOXP2 in the regulation of DISC1 expression and promoter 
activity 
 
The role of FOXP2 in regulating the expression of DISC1 was assessed by western blotting 
and qRT-PCR and the effect of FOXP2 on DISC1 promoter activity was assessed using the 
dual luciferase reporter (DLR) assay. All experiments were carried out in HEK293 cells, 
which were shown to express both FOXP2 and DISC1 endogenously.  
 
Western blotting revealed a significant decrease in the expression of endogenous DISC1 in 
HEK293 cells transfected with a vector encoding full-length FOXP2 compared to the control 
plasmid. This finding was partially supported by findings at the RNA level. Significant 
decreases in DISC1 mRNA expression were observed in cells transfected with FOXP2 when 
DISC1 expression was measured with one TaqMan gene expression assay but not with 
another. Dual luciferase reporter (DLR) assays demonstrated a significant reduction in the 
activity of the long and medium DISC1 promoter constructs in cells transfected with FOXP2, 
with the activity of the short construct showing the same trend. Failure to detect a significant 
effect of FOXP2 on the short promoter construct appears to be due to the relatively high 
variance associated with the measurement of activity from this construct, as the percentage 
decrease in mean luciferase activity in the FOXP2 condition compared to the control plasmid 
condition was similar to that observed for the long and medium constructs. The observation 
of decreased activity from all three DISC1 promoter constructs (albeit non-significant for the 
short construct) is compatible with the findings of chromatin immunoprecipitation (ChIP) 
screens in this region (Rosenbloom et al., 2010; Spiteri et al., 2007): both ChIP studies 
identified FOXP2-bound regions that span all three promoter constructs. 
 
Taken together with the ChIP data (Rosenbloom et al., 2010; Spiteri et al., 2007), the most 
parsimonious interpretation of the data presented in this chapter is that FOXP2 is a 
transcriptional repressor of DISC1, which, when overexpressed, results in reduced DISC1 
mRNA and protein expression.  
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The main caveat to this interpretation is the discrepancy between the results obtained using 
the two gene expression assays. The assay, Hs00962133, which detected reduced DISC1 
expression following FOXP2 transfection detects six RefSeq transcripts formed from the 
intergenic splicing of DISC1 and the upstream gene TSNAX (Millar et al., 2000a; Nakata et 
al., 2009), in addition to fifteen RefSeq DISC1 transcripts. The assay Hs00962131, which 
did not detect any difference in expression, detects 22 DISC1 transcripts, including the 15 
detected by Hs00962133. Of the seven transcripts detected by Hs00962131 but not 
Hs00962133, six encode short DISC1 isoforms. The FOXP2-mediated decrease in DISC1 
protein expression was detected using a C-terminal antibody, which only detects transcripts 
containing exons 10-13. This antibody would not, therefore, detect protein products 
produced from six of the seven DISC1 transcripts detected uniquely by Hs00962131. Before 
discussing possible explanations for the discrepant qRT-PCR results, it is worth noting that it 
would be useful to repeat this experiment using another pan-DISC1gene expression assay to 
determine whether the discrepancy might result from a technical issue affecting one of the 
assays (although, both assays had been validated by Applied Biosystems).  
 
If both assays are assumed to have functioned correctly, one explanation for their 
contradictory findings is that the FOXP2-mediated decrease in expression detected by the 
Hs00962133 assay was attributable to altered expression of the TSNAX-DISC1 transcripts. 
This possibility could be tested by performing gel electrophoresis of the qRT-PCR reaction 
products, followed by sequencing to confirm their identity. While this possibility should be 
formally assessed, an observation that implicates a FOXP2-mediated effect on DISC1 
expression rather than TSNAX-DISC1 expression is that FOXP2 has not been identified as 
binding in the region proximal (1 kb upstream or downstream) to the TSNAX transcription 
start site according to either the ENCODE Transcription Factor ChIP track on the UCSC 
human genome browser or genome-wide FOXP2/Foxp2 ChIP-chip studies (Spiteri et al., 
2007; Vernes et al., 2011; Vernes et al., 2007). Furthermore, altered TSNAX-DISC1 
expression cannot account for the change in expression observed at the protein level. Only 
one protein product of 100 kDa, known to correspond to full-length DISC1, was detected by 
western blotting. Moreover, according to RefSeq, all DISC1-TSNAX transcripts are 
predicted to be non-coding and to undergo nonsense mediated decay. As such, if a FOXP2 
mediated decrease in the expression of the TSNAX-DISC1 transcripts accounts for the 
discrepant qRT-PCR findings, then separate mechanisms would be required to explain both 
FOXP2’s effect on DISC1 protein expression and its effect on DISC1 promoter activity.  
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Another possible explanation for the disagreement between the two qRT-PCR assays is that 
additional DISC1 transcription start sites (TSSs) exist that remain to be characterised. As 
such, it would be possible for some DISC1 transcripts but not others to be regulated by 
FOXP2. Thus, DISC1 transcripts derived from different TSSs could have contributed 
differentially to the signal measured by each assay. This hypothesis could be assessed by gel 
electrophoresis followed by sequencing of the qRT-PCR products. If there is evidence 
suggestive of the use of alternative TSSs, then 5’ rapid amplification of cDNA ends (RACE) 
could be carried out to assess their existence.  
 
The existence of two additional DISC1 TSSs was suggested by the previous release of the 
UCSC human genome browser (hg18). Here, two DISC1 transcripts, one utilising a TSS in a 
putative exon between DISC1 exons 1 and 2 (exon 1b) and the other derived from a TSS in 
exon 2 were identified as non-RefSeq transcripts. However, following a series of 5’ RACE 
experiments carried out by Nakata et al. (2009), which identified only one DISC1 TSS (the 
exon 1 TSS used by all RefSeq transcripts), these two transcripts were excluded from the 
most recent release of the UCSC human genome browser (hg19). As Nakata et al. (2009) 
only assessed human foetal brain, it is possible that alternative DISC1 TSSs are used at other 
developmental stages, or that transcripts from alternative TSSs are expressed in a cell-type-
specific or region-specific manner not detectable when analysing whole-brain cDNA. 
 
4.5.1.1 FOXP2 as a transcriptional repressor of DISC1 expression 
 
The data presented in this chapter identify FOXP2 as a transcriptional repressor of DISC1. 
This adds DISC1 to a list of experimentally validated transcriptional targets of FOXP2 that 
includes CNTNAP2 (Vernes et al., 2008), SRPX2/uPAR (Roll et al., 2010) and MET 
(Mukamel et al., 2011). All three of these transcriptional targets have been implicated in 
neurodevelopmental conditions. Genetic variation in CNTNAP2 has been associated with 
several conditions including specific language impairment (Vernes et al., 2008), autism 
spectrum disorder (ASD) (Penagarikano and Geschwind, 2012), severe intellectual disability 
(Gregor et al., 2011), schizophrenia (Friedman et al., 2008; ISC, 2008; Wang et al., 2010), 
and bipolar disorder (Wang et al., 2010). Mutations in the SPRX2 gene have been found to 
cause speech dysfunction resulting from epilepsy of the rolandic speech areas, 
developmental verbal dyspraxia and bilateral perisylvian polymicrogyria (Roll et al., 2006). 
Bilateral perisylvian polymicrogyria is a clinical syndrome that manifests as mild mental 
retardation, epilepsy and pseudobulbar palsy, a lesion of the upper motor neuron that causes 
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slurred speech as well as difficulties in chewing and swallowing (Verrotti et al., 2010). 
Genetic variation in MET has been associated with ASD in several independent studies 
(Judson et al., 2011). The nature of the impairments resulting from genetic variation in these 
genes suggests FOXP2 to play an important role in neurodevelopment. This assertion is 
supported by the findings of genome-wide ChIP studies: FOXP2’s ChIP-identified targets 
are enriched for genes involved in synaptic plasticity and in neurite outgrowth, processes 
essential for normal brain development (Spiteri et al., 2007; Vernes et al., 2011; Vernes et 
al., 2007).  
 
Several lines of evidence implicate FOXP2 as being particularly important for the 
development and function of the corticostriatal and olivocerebellar circuits, which are 
involved in motor control. During development, FOXP2 is expressed in several brain 
regions, including the basal ganglia, thalamus, cerebellum, cortical plate and inferior olives 
(Lai et al., 2003). In the developing mouse brain, Foxp2 expression is highest in the basal 
ganglia (Ferland et al., 2003). These sites of expression coincide with regions shown to 
function abnormally in affected members of the KE family who suffer from a severe speech 
and language disorder resulting from an amino acid substitution in FOXP2 (R553H). MRI 
and PET analyses of carriers of the R553H mutation have revealed structural and functional 
abnormalities in the caudate nucleus of the basal ganglia (Vargha-Khadem et al., 1998; 
Watkins et al., 2002b). Mice carrying a “humanised” version of Foxp2, in which the two 
amino acid changes that have occurred in human FOXP2 but not in chimpanzee FOXP2 
have been knocked-in, show an increase in dendritic length in the striatum, cerebral cortex, 
and thalamus and an increase in long term depression in the medium spiny neurons of the 
striatum (Enard et al., 2009; Reimers-Kipping et al., 2011). Moreover, mice carrying an 
R552H Foxp2 amino acid substitution, which is equivalent to the human R553H mutation, 
show deficits in motor learning and abnormal synaptic plasticity in striatal and cerebellar 
circuits (Groszer et al., 2008). These findings have led to the idea that FOXP2 and its 
regulatory targets play a key role in sensorimotor learning, and that the speech and language 
deficits evident in individuals carrying point mutations in the gene arise from a core deficit 
in learning, planning and executing complex motor sequences (Fisher and Scharff, 2009; 
Vargha-Khadem et al., 1998; Watkins et al., 2002a).  
 
In light of this evidence, a key question to address, having identified FOXP2 as a 
transcriptional repressor of DISC1, is can any of the phenotypes associated with disturbed 
DISC1 function be explained by abnormal function of the basal ganglia circuitry? A review 
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of the literature revealed few studies explicitly investigating the expression or the role of 
DISC1 in the basal ganglia. In the mouse, Disc1 is expressed pre- and post-synaptically in 
striatal synapses (Ramsey et al., 2011) and mice carrying the Disc1 L100P amino acid 
substitution show an increase in striatal dopamine (D2) receptors (Lipina et al., 2010), 
although whether this is a direct effect of altered striatal Disc1 function is not known. An 
association between genetic variation in DISC1 and striatal volume has been suggested by 
one study; however, the association did not survive a stringent correction for multiple testing 
(Chakravarty et al., 2012). The observation of disturbed prepulse inhibition and/or latent 
inhibition in some Disc1 mouse models (Clapcote et al., 2007; Hikida et al., 2007) suggests 
that certain alterations to Disc1 function can disrupt sensorimotor gating, a process that 
depends, in part, on striatal function (Baldan Ramsey et al., 2011; Swerdlow and Geyer, 
1998). The evidence, therefore, suggests that DISC1 may play a role in basal ganglia 
function; however, it is clear that further studies are required before any conclusions can be 
drawn. Given the repressive regulatory relationship that exists between FOXP2 and DISC1 
and the high level of FOXP2 expression in the basal ganglia, it may be that the maintenance 
of DISC1 expression at a low level in the basal ganglia is important for normal function. 
This possibility should be formally assessed by characterising the developmental relationship 
between FOXP2 and DISC1 expression in the basal ganglia. If the basal ganglia appear to be 
characterised by a low level of DISC1 expression, then the effects of basal ganglia-specific 
overexpression of Disc1 could be assessed in a mouse model. 
  
An inverse relationship between the expression of FOXP2 and the expression of its 
regulatory targets that it represses might be expected. Such a pattern of expression is 
observed between FOXP2 and one of its transcriptional targets, MET (Mukamel et al., 
2011); however, it is likely that, when considering expression in the context of the entire 
brain, a neat inverse pattern of expression will not exist between FOXP2 and all of its 
regulatory targets. To some extent, there is evidence of an inverse pattern of expression 
between DISC1 and FOXP2: in the cortex, the expression of Foxp2 is restricted to layer VI 
(Ferland et al., 2003), whereas Disc1 expression is highest in layers II/III and IV/V (Schurov 
et al., 2004). Disc1 is expressed prominently in the hippocampus (Schurov et al., 2004), 
whereas, as mentioned previously (section 4.4.8.3.2), the evidence for Foxp2 expression in 
the hippocampus is mixed (Ferland et al., 2003; Fujita et al., 2008) but, when taken in the 
context of the results presented in this chapter, suggestive of a low level of expression in this 
region. The basal ganglia are characterised by a particularly high level of Foxp2 expression 
throughout development (Ferland et al., 2003). As mentioned above, little is known about 
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Disc1 expression in the basal ganglia relative to other brain regions; however, Disc1 
expression has been detected in synaptic fractions from striatal preparations (Ramsey et al., 
2011). In contrast, in the cerebellum, the expression of both Foxp2 and Disc1 is 
predominantly localised to Purkinje neurons (Ferland et al., 2003; Schurov et al., 2004). 
Further investigation of the cellular and subcellular expression patterns of Foxp2 and Disc1 
throughout development and in adulthood would be useful in furthering understanding of the 
relationship between the two genes. 
 
4.5.2 Assessment of the effect of two FOXP2 coding mutations on the ability 
of FOXP2 to regulate DISC1 expression 
 
The R553H and R328X FOXP2 point mutations, which have previously been implicated in 
developmental verbal dyspraxia (DVD) (Lai et al., 2001; MacDermot et al., 2005), were both 
found to reduce the ability of FOXP2 to exert transcriptional repression on DISC1 promoter 
activity. Both mutations significantly reduced FOXP2-mediated repression of all three 
DISC1 promoter constructs. These findings identify a regulatory link between genes 
implicated in disorders that have traditionally been considered as diagnostically distinct, thus 
furthering support for the view that clinically separate neuropsychiatric disorders might share 
overlapping aetiologies (Carroll and Owen, 2009; Mitchell and Porteous, 2011).  
 
The possibility of shared aetiologies was initially suggested by the partially overlapping 
behavioural characteristics and cognitive deficits observed in schizophrenia, bipolar disorder, 
and autism (Carroll and Owen, 2009). Further support came from the finding of overlap in 
the genetic variants that predispose to these disorders, suggesting that variation in certain 
genes alters neurological processes whose abnormal functioning results in phenotypes 
common to multiple conditions (Mitchell and Porteous, 2011). 
 
That there is overlap between the genetic aetiologies of clinically distinct 
neurodevelopmental disorders is not surprising: these conditions are phenotypically 
complex, essentially comprising a collection of co-occurring symptoms. It is plausible that a 
genetic variant predisposing to a particular symptom in one condition might predispose to 
the same symptom in another condition. Although, it should be noted that a strict 
relationship between genetic variation and observable phenotypes should not be expected as 
the relationship between the two will be modified by other genetic, epigenetic, and 
environmental factors. 




With this caveat in mind, it is interesting to consider the areas of phenotypic overlap between 
the condition resulting from the R328X and R553H FOXP2 point mutations (Lai et al., 2001; 
MacDermot et al., 2005) and those conditions, such as schizophrenia, bipolar disorder, and 
autism, associated with variation in the DISC1 (Bradshaw and Porteous, 2012; Chubb et al., 
2008). The phenotype arising from the FOXP2 point mutations has been described in section 
4.1.1.3. Briefly, the core phenotype associated with point mutations in the FOXP2 gene is 
speech and language dysfunction. Additionally, members of the KE family affected by the 
R553H mutation show lowering of non-verbal IQ, although the effects on verbal cognition 
appear more severe and wide-ranging. To varying extents, cognitive dysfunction and 
abnormalities in some aspects of language function are observed in autism, schizophrenia, 
and bipolar disorder (Barch and Ceaser, 2012; Barrett et al., 2009; Carroll and Owen, 2009; 
Mefford et al., 2012; Owen et al., 2011). Further studies are required to assess whether 
overlap in the observable phenotypes of these conditions is attributable to the shared 
disruption of components of the FOXP2 regulatory network. Assessment of DISC1 
expression in carriers of the R553H or the R328X point mutations would be useful in 
determining whether altered DISC1 expression is likely to contribute to the phenotype 
displayed by individuals carrying these mutations. 
 
Some of the overlap in phenotypes arising from genetic variation in FOXP2 and DISC1 
might be attributable to the fact that both genes play an important role at the synapse 
(Brandon and Sawa, 2011; Fisher and Scharff, 2009). Cognition relies on normal synaptic 
function (Grant, 2003), and synaptic dysfunction has been identified in schizophrenia 
(Harrison and Weinberger, 2005; Owen et al., 2005), autism (van Spronsen and Hoogenraad, 
2010) and bipolar disorder (Martinowich et al., 2009). Both DISC1 and FOXP2 have been 
implicated in regulating members of the neurexin (NRXN) family (Brown et al., 2011; 
Vernes et al., 2008). NRXNs are cell adhesion molecules that connect pre- and post-synaptic 
terminals and regulate synaptic transmission (Sudhof, 2008). FOXP2 has been shown to 
repress transcription of the NRXN family member CNTNAP2, which encodes CASPR2 
(Vernes et al., 2008). As discussed in section 4.5.1.1, polymorphisms in CNTNAP2 have 
been associated with specific language impairment, autistic spectrum disorder, schizophrenia 
and bipolar disorder. Recently, our group identified a role for DISC1 in the regulation of 
NRXN expression: disturbed developmental expression of Nrxn1 and Nrxn3 was observed in 
the Disc1 L100P mouse model of schizophrenia (Brown et al., 2011). Genetic variation in 
NRXN1 (Feng et al., 2006; Kim et al., 2008; Marshall et al., 2008; Szatmari et al., 2007; 
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Wisniowiecka-Kowalnik et al., 2011; Yan et al., 2008), and NRXN2 (Gauthier et al., 2011), 
has been implicated in autism, and variation in NRXN1 has been linked to schizophrenia 
(Gauthier et al., 2011; Kirov et al., 2008; Rujescu et al., 2009; Yue et al., 2011). Moreover, a 
ChIP-chip study has identified NRXN3 as a putative transcriptional target of FOXP2 (Vernes 
et al., 2007). 
 
Taken together, the findings presented in this chapter and the published literature suggest 
that FOXP2, DISC1, and the NRXN family are linked in a molecular network that, when 
altered confers risk for neurodevelopmental conditions in which various aspects of linguistic 
and cognitive function are disturbed, possibly due to aberrant synaptic function.  As 
discussed in section 4.5.1.1, the evidence implicating the FOXP2 regulatory network in basal 
ganglia function suggests this region to be worthy of investigation in the context of these 
conditions. Future studies should (i) further characterise the relationship between these 
genes, for example by determining the regional and temporal specificity of regulatory 
relationships, and (ii) aim to refine understanding of the phenotypes arising from the altered 
function of these genes. 
 
4.5.3 Assessment of the expression of Foxp2 in mice carrying the Disc1 
L100P point mutation 
 
The expression of Foxp2 in mice carrying the Disc1 L100P point mutation was assessed as 
an initial step in testing the hypothesis that Disc1 is involved in the regulation of Foxp2 
expression. This hypothesis was based on the observations that the expression of FOXP2 
may be regulated by pathways linked to DISC1 function, including Wnt signalling, and 
cAMP- and EGR-dependent transcription (section 4.1.1.2). Although the experiments carried 
out here were preliminary due to limitations in the availability of mRNA and protein 
samples, several significant differences were detected between the L100P mice and their 
wildtype counterparts at the mRNA level and investigation of Foxp2 protein expression 
suggested that differences in expression might occur at this level too. 
 
At the mRNA level, significant differences in expression were observed at E15, E18, P1, P7, 
and in the adult mice. At all stages except E18, Foxp2 expression was increased in the Disc1 
L100P mice. The decrease in mRNA expression at E18 and the increase in mRNA 
expression at P1 were supported by consistent changes in protein expression at these stages. 
At other developmental stages, the mRNA and protein data were less consistent; however, it 
Chapter 4: Assessment of the DISC1-FOXP2 Regulatory Relationship 
233 
 
is important to note that as the qRT-PCR analysis was carried out using only one reference 
gene and protein expression assessed in only one technical replicate, the results presented in 
this chapter must be replicated before any firm conclusions are drawn. Ferland et al. (2003) 
have previously measured Foxp2 mRNA and protein expression in the developing mouse 
brain and shown changes in protein expression to sometimes lag behind changes in mRNA 
expression, as might be expected. It is not immediately obvious that this explanation can 
explain the discrepancies in mRNA and protein expression observed in this chapter; 
however, it is a possibility that should be considered if further replicates are obtained.  
 
Consistency between mRNA and protein expression should not necessarily be expected: in a 
comparison of the mRNA and protein expression profiles of 1066 genes measured in 23 
human cell lines, Gry et al. (2009) found the mean correlation between mRNA and protein 
expression to be 0.25 or 0.20 depending on whether mRNA expression was measured using 
an cDNA- or oligo-based microarray. Moreover, the correlation coefficients between 
mRNAs and their corresponding protein products varied widely.  
 
Notwithstanding the need for replication, it seems reasonable to suggest that when consistent 
changes are observed in Foxp2 protein expression, either in terms of developmental stage or 
brain region, confidence in the validity of the results is increased. Foxp2 expression at P7 
was reduced in all four brain regions assessed (hippocampus, striatum, cortex, and 
cerebellum), and in the cerebellum expression was reduced at every postnatal stage assessed 
(P1, P7, P20, and P90). The functional consequences of these changes in expression require 
further investigation; however, by considering the processes occurring at a given 
developmental stage and/or in a given region, some insight can be gained into their likely 
effects. At E18, transcriptomic analysis of the mouse brain has revealed an up-regulation of 
genes involved in synapse development, neurogenesis, and cell survival and growth (Han et 
al., 2009; Matsuki et al., 2005). P1 is also a time of synaptogenesis (Matsuki et al., 2005; 
Mody et al., 2001). Comparison of the transcriptome at E18 and P7 has revealed a decrease 
in the expression of genes related to neurogenesis and an increase in the expression of genes 
involved in synaptogenesis (Han et al., 2009). Genes encoding cell signalling molecules, 
such as adenylate cyclase 1, were also up-regulated at P7 compared to E18. The pattern of 
changes in the expression of genes encoding neurotransmitter receptors is more complex, 
although there was a general increase in expression at P7 compared to E18. The Disc1 
L100P mice have been reported to have a decrease in neural proliferation and in the density 
of dendritic spines, the postsynaptic target of synaptic transmission (Lee et al., 2011). It can 
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be speculated that altered Foxp2 expression at these developmental stages might contribute 
to these abnormalities; however, this theory clearly requires experimental validation and 
refinement. It would also be useful to carry out electrophysiological assessment of the Disc1 
L100P mice to assess synaptic function. 
 
As Foxp2 generally confers a repressive effect on its regulatory targets (Shu et al., 2001), the 
decrease in Foxp2 expression in the cerebellum detected at all postnatal stages might result 
in a more permissive transcriptional environment. Given the evidence for the involvement of 
Foxp2 in regulating neurite outgrowth and synaptogenesis, decreased Foxp2 expression 
might result in over-connectivity or aberrant connectivity in this region; however, this 
hypothesis clearly requires experimental assessment. There are currently no reports of 
cerebellar morphology or function in the Disc1 L100P mice; however, in light of the current 
results, such studies would be warranted. As the cerebellum is involved in both motor and 
cognitive functions (Middleton and Strick, 2000), the abnormal function of this region could 
have wide-spread consequences. 
 
Comparison of the Foxp2 and Disc1 mRNA expression profiles between the Disc1 L100P 
and wildtype mice revealed an interesting similarity in the shape of the expression profiles of 
the two genes in wildtype mice but not in Disc1 L100P mice. Having demonstrated that 
Foxp2 negatively regulates the transcription and protein expression of Disc1, this result 
might appear surprising; however, it is, of course, the case that several factors will be 
involved in the regulation of Disc1 expression, and perhaps, therefore, a direct inverse 
correlation with Foxp2 expression should not be expected. It is also the case that, as it is 
Foxp2 protein that regulates the transcription of the Disc1 gene, evidence for a negative 
correlation between Foxp2 and Disc1 expression might be more obvious when considering 
Foxp2 protein expression and Disc1 mRNA expression. Intriguingly, in the Disc1 L100P 
mice, the developmental expression patterns of Foxp2 and Disc1 show almost inverse 
patterns of expression between developmental stages E13 and P1. Future studies should aim 
to establish whether it is the Disc1 L100P mutation per se or whether it is the dysregulation 
of Disc1 expression that the L100P mutation entails (Brown et al., unpublished) that results 
in the aberrant expression of Foxp2 in these mice. These possibilities could be distinguished 
in vitro by overexpressing wildtype and L100P Disc1 in a cell culture system and assessing 
Foxp2 expression.  
 
 





A significant caveat of the experiments discussed in this section is that as limited amounts of 
mRNA and protein were available from the mice, mRNA expression could only be 
normalised to one reference gene and western blotting was only carried out in one 
experimental replicate. As such, the results presented here require replication.  
 
Comparison of the Foxp2 mRNA developmental expression profile observed in the wildtype 
animals in this study with a previous study reveals only partial agreement. Here, the highest 
level of Foxp2 expression was observed at E13. Expression then decreased between E13 and 
E15, before increasing again between E15 and E18 and decreasing throughout postnatal 
development. In contrast, Lai et al. (2003) found an increase in the expression of Foxp2 in 
the mouse brain at E16.5 compared to E11.5, E15.5 and newborn animals. Differences in 
these findings might be attributable to differences in the method used (qRT-PCR vs. in situ 
hybridisation) or strain differences in the mice studied. It is also possible that as only one 
reference gene, which had not been assessed for the stability of its expression, was used to 
normalise Foxp2 expression values that the developmental profile of Foxp2 expression was 
influenced by a poor choice of reference gene. Future studies should measure the expression 
of a large number of reference genes in the Disc1 L100P mice and wildtype controls to 
determine a stably expressed subset (as recommended by Vandesompele et al., 2002) that 
can be used for future qRT-PCR experiments.  
 
The second immunoreactive band that was sometimes evident on western blots probed for 
Foxp2 expression was not expected given the information available on the manufacturer’s 
datasheet. A review of the literature identified only a few studies in which Foxp2 had been 
detected in mice by western blotting. Of these studies, one contains an image of a western 
blot (of cerebellar lysates) in which a second band similar to that observed here is visible 
(Fatemi et al., 2008a). Interestingly, this study used the same C-terminal Foxp2 antibody as 
used here. Foxp2 has also previously been detected as a double band in the striatum, 
nidopallium and area X of the zebra finch brain (Miller et al., 2008). The manufacturer’s 
datasheet for the Foxp2 antibody used here (http://www.abcam.com/FOXP2-antibody-
ab16046.htmlP) states that additional bands have been identified at 56 kDa and 70 kDa but 
that the identity of these bands is not known. One possibility is that the second band 
represents an alternatively spliced Foxp2 isoform. Using a different C-terminal Foxp2 
antibody to that used here, Tanabe et al. (2012) identified two Foxp2 isoforms of 80 kDa and 
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68 kDa in western blots of mouse cerebellum at P0 and P10. Similar to observations in this 
chapter, the lower molecular weight band decreased in signal intensity with development and 
was no longer evident at P15. Both bands disappeared when the Foxp2 antibody was pre-
absorbed with a specific peptide. A Foxp2 band of approximately 68 kDa corresponding to 
Foxp2 isoform III has been observed previously (Vernes et al., 2006). This isoform lacks the 
N-terminal domain, which is consistent with the fact that Tanabe et al. (2012) did not detect 
the 68 kDa band using an N-terminal antibody. As members of the Foxp family share a high 
level of homology at the amino acid level (Lu et al., 2002; Teufel et al., 2003), another 
possibility is that the second band might result from cross-reactivity with Foxp1, which is 
detected as a protein of 75 kDa, or Foxp4, which is detected as a protein of 73 kDa. Further 
experiments, are required to confirm the identity of the second band. It would be useful to 
pre-absorb the antibody with a blocking peptide to determine whether the lower molecular 
weight band corresponds to Foxp2. Additionally, it would be useful to determine whether 
this antibody detects products in samples where Foxp2 has been knocked down. 
 
The western blotting performed in this chapter was clearly affected by certain technical 
issues, as indicated by the partially contradictory results produced by technical replicates of 
the hippocampal and striatal blots. Disagreement between technical replicates could be 
caused by several factors. For example, it is possible that the compositions of the samples 
loaded onto the two gels differed. The samples were mixed prior to loading on the gel but it 
is possible that more mixing would have reduced the variation between replicates. Other 
factors that may have contributed include the temperature at which the antibody was used, 
differences between individual gels and between polyvinylidene fluoride (PVDF) 
membranes, differences in electrophoresis conditions, transfer and/or developing conditions, 
and the interval between performing the western blot and assessing protein expression. 
Attempts were made to standardise all of these variables; however, evidently, there were 
between-replicate differences. This variability highlights the need for further replicates to be 
performed. 
 
Another issue affecting the western blots carried out here was the inconsistency between the 
expression levels of the three reference genes measured. Initially, it was intended that Foxp2 
optical density values would be normalised to the geometric mean of the optical density 
values for the reference genes, a technique recommended for the normalisation of qRT-PCR 
results (Vandesompele et al., 2002). However, the clear inconsistencies between the 
expression levels of the reference genes, which in some incidences were so extreme that 
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certain reference genes were unquantifiable, meant that normalising to each reference gene 
separately was considered a more informative approach. This issue highlights the importance 
of (i) selecting reference genes unlikely to be affected by the experimental condition and (ii) 
confirming western blot data using multiple reference genes (or, complimentary approaches). 
 
In the first technical replicates of the western blots of the embryonic samples and the 
postnatal hippocampal samples, relative to the expression of α-tubulin and β-actin, the 
expression of Gapdh appeared to be reduced in the Disc1 L100P mice. As this pattern was 
not observed in the second technical replicate of the embryonic samples, and in the absence 
of experimental replicates, it is difficult to know to what extent this effect was caused by 
technical factors. Clearly, further experiments, perhaps using qRT-PCR or ELISA, are 
required to assess Gapdh expression in the Disc1 L100P mice.  
 
It is important to note that western blotting is a semi-quantitative technique. Even in a well-
controlled experiment, many variables can affect the signal intensities of the observed 
immunoreactive bands. As such, where accurate protein quantification is required, a more 
quantitative technique, such as ELISA or mass spectrometry, should be employed. 
 
A final caveat, affecting both the qRT-PCR and western blotting performed in this chapter, is 
the cellular heterogeneity of the samples assessed. Measurement of gene expression in 
embryonic animals was carried out using RNA or protein extracted from the whole brain, 
while gene expression in postnatal animals was carried out in the hippocampus. Thus, at 
each developmental stage, recorded gene expression levels represent the combined effects of 
multiple different cell types. It is, therefore, impossible to determine whether the observed 
changes in gene expression (i) are representative of the entire population of cells sampled or 
(ii) represent an averaging of changes of gene expression of different magnitudes and, 
potentially, directions occurring in different cell types. Moreover, implicit in the comparison 
of gene expression changes across the whole brain or hippocampus between genotypes is the 
assumption that the cellular composition of these gross anatomical structures is identical 
between genotypes at each developmental stage. This assumption may not be justified: Disc1 
L100P mice have been found to demonstrate reduced cortical neuronal proliferation at E12 
and E15 and a reduction in neocortical neuron number in adulthood (Lee et al., 2011). In 
order to obtain a more informative depiction of the expression of genes of interest in the 
Disc1 L100P mice, methods that enable the study of discrete populations of cells, such as 
laser-capture microdissection, should be employed. Measurements of gene expression in the 
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adult hippocampus are affected by the additional potential problem of variability in the 
accuracy of hippocampal dissection. Particularly at the early postnatal stages, it is possible 
that inaccuracies in hippocampal dissection, and, thus, the cellular composition of the 
samples, might result in spurious differences in gene expression. Again, the study of isolated 




To conclude, DISC1 protein expression and transcriptional activity appear to be negatively 
regulated by FOXP2. The findings for the assessment of the effect of FOXP2 on DISC1 
mRNA expression were less clear cut; however, they suggest that the overexpression of 
FOXP2 results in a reduction in the expression of at least some DISC1 transcripts. Further 
experiments are required to clarify the effect of FOXP2 on DISC1 mRNA expression. The 
discovery that two FOXP2 point mutations known to cause developmental verbal dyspraxia 
reduce FOXP2-mediated repression of DISC1 promoter activity expands the list of 
neurodevelopmental disorders in which dysregulated DISC1 expression may play a part. 
Profiling of DISC1 expression in individuals carrying these mutations would now be of great 
interest. Assessment of Foxp2 expression in the Disc1 L100P mice provided preliminary 
evidence for dysregulated expression at the mRNA and protein levels, although further 
experiments are required both to confirm these findings and to investigate whether any 
changes are the result of altered Disc1 expression or of the L100P mutation. Taken together, 
the results presented in this chapter link DISC1 and FOXP2, two genes known to play 
important roles in neurodevelopment, in a regulatory network, which when disturbed confers 
risk for a range of disorders that share varying degrees of phenotypic overlap. Future studies 
should aim to (i) elucidate the molecular and cellular consequences of the altered expression 
of these genes and (ii) characterise their expression in well-phenotyped samples, in order to 
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Chapter 5: Discussion 
 
The aim of the work presented in this thesis was to investigate putative genetic risk loci for 
psychiatric illness, thought to harbour variants potentially exerting a pathogenic effect via 
altered regulation of gene expression. This work was predicated on the growing evidence for 
the role of abnormal gene expression in the aetiology of psychiatric illness. Altered gene 
expression has received support as a candidate mechanism from several lines of evidence, 
including the frequent implication of variants in non-coding regions of the genome by 
association studies, evidence for altered gene expression in affected individuals, and the 
observed changes in the function of regulatory mechanisms, such as epigenetic modification 
and miRNA-mediated regulation, in patients. The focus of this thesis has been on NRG1 and 
DISC1, two of the leading candidate genes for schizophrenia, which have also been 
implicated in bipolar disorder. Here, the findings presented in the previous chapters will be 
summarised, their potential limitations considered and suggestions made for future 
experiments. The relevance of the work presented in this thesis to the wider field will then be 
considered. 
 
5.1.1 Chapter 2: Association analysis of NRG1 
 
5.1.2 Summary of findings 
 
In Chapter 2 association analysis was carried out to assess the involvement of two 
haplotypes in the NRG1 gene in schizophrenia and bipolar disorder. These two haplotypes 
had previously been found to be associated with schizophrenia and/or bipolar disorder in a 
sample from the Scottish population (Thomson et al., 2007). One haplotype, the region A 
haplotype, located at the 5’ end of the gene, comprised three intronic SNPs and the 
associated region, defined by linkage disequilibrium (LD), overlapped with the putative 
promoter region and extended into the first intron. The second haplotype, the region B 
haplotype also comprised three intronic SNPs and spanned a largely intronic region at the 3’ 
end of the gene, although it did also encompass the coding region of the SMDF NRG1 
isoform and 3’ exons of all other isoforms. 
 
Here, a two-SNP haplotype in region B showed significant association with both 
schizophrenia and a combined schizophrenia and bipolar disorder case group in a sample 
formed from combining Thomson et al.’s (2007) Scottish sample (Scottish 1) with a second 
Scottish sample (Scottish 2). This combined sample comprised 765 control subjects, 682 
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schizophrenic patients and 601 bipolar disorder patients. Assessment of association to the 
three-SNP region B haplotype was precluded by the failure of one of the SNPs in this region 
to genotype in the Scottish 2 sample; however, assessment of LD in the Scottish 1 sample 
suggested that little information was lost by the absence of the third SNP. 
 
Association analysis of the Scottish 2 sample (n = 307 control subjects, 303 schizophrenic 
patients, and 239 bipolar disorder patients) independent of the Scottish 1 sample did not 
yield any significant associations. Likewise, association analysis of the three region B SNPs 
in a German sample (n = 397 control subjects, 396 schizophrenic patients, and 400 bipolar 
disorder patients), in which association was assessed with schizophrenia, bipolar disorder, 
and the combined schizophrenia and bipolar disorder case group, did not identify any 
significant associations following correction for multiple testing.  
 
Finally, no significant associations were detected in a combined sample that comprised the 
Scottish 1 sample, the Scottish 2 sample and the German sample. 
 
5.1.3 Caveats  
 
The main caveats of the association analyses carried out in this chapter are the lack of 
certainty over the underlying genetic architecture of schizophrenia and bipolar disorder and 
the issue of phenotypic heterogeneity. These issues make the suitability of association 
analysis as a method for detecting the variants involved in psychiatric disorders unclear.  
 
Until the relative contributions of common vs. rare variants to the aetiology of psychiatric 
illness are known, the possibility that association analysis might not be the most suitable 
method for the detection of causal variants must be considered when interpreting the findings 
of association studies. Thus, failure to detect association must not be treated as evidence for 
the absence of causative variants. Likewise, the meaning of significant associations is 
difficult to ascertain as several possible explanations for their occurrence exist: such findings 
might reflect the existence of a variant(s) that confers increased risk for the disorder of 
interest at the population level; they might indicate the presence of a variant(s) that confers 
increased risk but only in a few individuals, which was, therefore, only detected in a 
particular sample due to random sampling bias; or they might have arisen entirely due to 
chance. Replication of association findings can assist in determining whether random 
sampling error is likely to have affected an initial finding; it cannot, however, rule out the 
possibility that there are causal variants in a given region.  
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Integrating association data with functional information can aid in identifying variants likely 
to play a causal role. Such variants can then be prioritised for further assessment. Recent 
years have seen significant advances in the functional annotation of the genome, particularly 
by the ENCODE Project (Bernstein et al., 2012), this information will permit variants 
implicated by association studies, including variants in LD with the associated variants, to be 
assessed for their functional potential. Genome-wide annotation of features such as 
chromatin states, transcription factor bound regions, and areas of DNase hypersensitivity will 
greatly aid in the identification of potential aetiological variants in non-coding regions. The 
potential for the study of DNase1 hypersensitivity sites (DHS) to yield insights into the 
functional effects of associated variants, and those implicated by LD, was recently 
demonstrated by Maurano et al. (2012). Here, Maurano et al. (2012) showed that variants 
located in DHSs may exert their phenotype via an effect on distant regulatory targets and are 
frequently predicted to alter transcription factor binding and chromatin state. 
 
Several tools are available online for the assessment of the functional potential of variants. 
One such tool, HaploReg, permits the user to search a set of haplotype-tagging variants for 
various features, including their chromatin state in nine cell lines, conservation across 
mammals and predicted effect on regulatory motifs (Ward and Kellis, 2012). The assignment 
of predicted functions to associated variants can, to some extent, mitigate some of the issues 
affecting association studies. For example: should multiple variants in a given gene showing 
inconsistent association between studies be predicted to affect the same function (e.g. 
splicing or transcription factor binding), then, despite the lack of direct between-study 
replication, insight can be gained into likely pathogenic mechanisms. 
 
If phenotypic heterogeneity reflects heterogeneity in aetiology, it is likely to represent a 
major limiting factor for analyses of schizophrenia and bipolar disorder carried out using 
diagnostic category as the sole method of case selection. As such, the lack of significant 
associations in the Scottish 2 sample and the German sample might have reflected 
differences in the composition of the case groups. The selection of cases using 
endophenotypes is a popular approach to limiting the extent of phenotypic heterogeneity. 
However, while the use of endophenotypes in the field of psychiatric genetics has received 
increasing attention in recent years, there is a lack of consensus regarding how best to define 
an endophenotype (Kendler and Neale, 2010). One definition states that endophenotypes 
should be heritable, co-segregate with the illness, be present in the absence of the disease and 
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be observed in family members at a higher rate than in the population (Gottesman and 
Gould, 2003). Various other criteria have been suggested, including the requirement that the 
endophenotype should be a causal factor for the disease (Lavori et al., 2002) or should be 
involved in a biologically plausible mechanism (Castellanos and Tannock, 2002; Tsuang et 
al., 1993). In a review of the subject, Kendler and Neale (2010) suggest that interest in the 
study of endophenotypes arises from two factors: (i) endophenotypes appear aetiologically 
simpler than diagnostic categories and (ii) endophenotypes appear to be “closer” to changes 
at the DNA level. Both of these factors suggest that endophenotypes will be more genetically 
tractable than their related diagnostic categories. In practice, however, association studies of 
psychiatric endophenotypes have rarely yielded effect sizes any larger than when assessing 
association to the diagnostic category itself (Flint and Munafo, 2007).  
 
GWASs have identified association to variants associated with several endophenotypes 
relevant to psychiatric illness, including resting state electroencephalogram activity 
(Hodgkinson et al., 2010), hippocampal volume (Bis et al., 2012; Stein et al., 2012), and 
neurocognitive function (LeBlanc et al., 2012); although an earlier study failed to identify 
any variants showing genome-wide significant association to neurocognitive function (Need 
et al., 2009). Stein et al.’s (2012) meta-analysis of GWASs of hippocampal volume 
identified one variant, significant at the genome-wide level, which, when analysed under 
several different models, explained no more than 0.458% of the variance in hippocampal 
volume. A meta-analysis of three GWASs assessing association to speed of information 
processing failed to identify any variants attaining genome-wide significance, although 
several nominally significant variants were detected (Luciano et al., 2011).  
 
These findings of these studies, while not representing an exhaustive discussion of the 
literature, are consistent with those of Flint and Munafò, (2007) and suggest that the study of 
endophenotypes will not necessarily circumvent the problems associated with the analysis of 
diagnostic categories. This might be, in part, because many of the endophenotypes studied 
are, in fact, no simpler in terms of their genetic architecture than their related diagnostic 
categories. Flint and Munafò (2007) suggest that the use of simpler endophenotypes, such as 
gene expression levels, may yield the desired advantages in genetic tractability. The potential 
of this approach to uncover genetic loci harbouring variants involved in the aetiology of 
schizophrenia has been demonstrated by Bray et al. (2008). By performing genome-wide 
linkage analysis on the expression level of DTNBP1, a schizophrenia susceptibility gene 
previously found to show dysregulated expression in patients, Bray et al. (2008) identified 
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evidence for loci involved in cis- and trans-regulation. Identifying the variants underlying 
the observed linkage peaks will lead to the identification of schizophrenia candidate genes 
for further assessment. Moreover, Richards et al.’s (2012) demonstration that schizophrenia 
susceptibility alleles are enriched for variants known to affect gene expression in the adult 
brain supports the use of gene expression as a schizophrenia endophenotype. 
 
5.1.4 Suggestions for future work 
 
The lack of clarity surrounding the validity, and therefore the interpretation, of association 
studies for psychiatric illness suggests the sequencing of regulatory and coding regions of the 
NRG1 locus might be a worthwhile pursuit in determining the existence and the nature of 
risk variants at this locus. The recent functional annotation of the genome by the ENCODE 
project (Bernstein et al., 2012) and Maurano et al.’s (2012) characterisation of DHSs are 
likely to facilitate understanding of associated variants in non-coding regions of the genome. 
 
5.2 Chapters 3: Characterisation of the DISC1 promoter region 
 
5.2.1 Summary of findings 
 
Chapter 3 described work carried out to identify and characterise the previously unstudied 
DISC1 promoter region. Here, the DISC1 candidate promoter region was initially defined as 
the region extending 1 kb upstream of the DISC1 transcription start site (TSS) to the 
translation start site. Bioinformatic analysis of this region revealed it to be devoid of 
canonical promoter motifs, but to contain a CpG island and a complex dinucleotide repeat 
region. Assessment of the potential for the region to form Z-DNA, a more open DNA 
conformation associated with transcriptional activity, revealed the DISC1 candidate 
promoter region to have high Z-DNA forming potential.  
 
An initial series of three nested DISC1 promoter fragments (short, medium and long) was 
designed for assessment for regulatory potential using dual luciferase reporter assay. These 
fragments were selected to taking into account sequence features of the DISC1 candidate 
promoter region (i.e. the CpG island and the dinucleotide repeat region), conserved regions 
of high regulatory potential identified by the ESPERR 7 x regulatory potential track of the 
UCSC human genome browser, and epigenetic modifications identified by ChIP studies. The 
findings of a study carried out as part of the ENCODE project in which the promoter regions 
of a large number of genes were characterised were also considered. This study found that 
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the region located -300 to -50 bp relative to the TSS usually contributes positively to 
promoter activity, while the region located -1000 bp to -500 bp relative to the TSS often 
confers a repressive effect (Cooper et al., 2006).  
 
Assessment of the promoter activity of the three DISC1 promoter constructs revealed the 
medium construct to have the highest level promoter activity in all cell lines assessed. This 
region corresponds with the region identified by the ENCODE project as usually 
contributing positively to promoter activity (Cooper et al., 2006). The observation that the 
long promoter construct, which extends approximately 1kb upstream of the DISC1 TSS,  
resulted in a reduced level of reporter gene expression compared to the medium construct 
was, again, consistent with the findings of ENCODE (Cooper et al., 2006), and suggested the 
existence of repressive elements in this region. The assessment of a fourth promoter 
construct designed to assess the contribution of the complex dinucleotide repeat region to the 
activity of the medium promoter construct suggested that this region did not underlie the 
high activity level of this construct; although, the caveat that the method employed here 
would not have identified any effects dependent on the genomic context should be noted. 
Assessment of publicly available ChIP-seq (Rosenbloom et al., 2010) data to identify 
transcription factors identified as potentially binding sites within the DISC1 candidate 
promoter region identified several interesting candidates for experimental follow-up. These 
included FOXP2, TCF4 (TCF7L2), NF-ΚB and PU.1. The potential role of FOXP2 in the 
regulation of DISC1 expression was considered particularly interesting in light of FOXP2’s 
involvement in speech and language function (Fisher and Scharff, 2009), suggested role in 
neurodevelopment (Vernes et al., 2011) and link, via its regulatory targets, with autism 
(Mukamel et al., 2011; Vernes et al., 2008). As such, the region was searched for known 




A key limitation work presented in this chapter is the artificial nature of performing dual 
luciferase reporter assays to assess the activity of transiently transfected reporter constructs. 
By studying a regulatory region outside of its genomic context, some regulatory effects are 
likely to remain unidentified, and those that are observed might be an artefact of the method. 
Furthermore, transient transfection of the reporter construct results in hundreds or even 
thousands of copies of the construct being present in a cell. As such, a shortage of 
transcription factors relative to constructs might result in some constructs being regulated by 
only a subset of the transcription factors that should regulate them (Carey and Smale, 2000). 
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Regarding the experiments performed in this chapter, the observation of replicable results 
between technical and experimental replicates, and in different cell lines, suggests that 
random effects resulting from the scarcity of transcription factors relative to reporter 
constructs are unlikely to have exerted a large effect on the observed results. Nevertheless, 
confirmation of results obtained using dual luciferase reporter assays using other, 
complimentary, methods should be sought. 
 
An alternative approach to the assessment of reporter constructs that overcomes some 
problems of transient transfection has been described by Karimi et al. (2007). This approach 
uses the FLP-FRT recombinase system to generate cell lines in which the reporter construct 
has been integrated at the same genomic locus, in the same orientation in all of the cells in a 
given culture. As each cell only expresses one copy of the reporter construct, there is no need 
to normalise for transfection efficiency, thus avoiding one potential source of random 
variation. A further advantage of this method is that the reporter construct is assessed in the 
context of chromatin. Chromatin-dependent events, which would have been missed using 
transient transfection, are, therefore, potentially observable. A caveat of this approach is that 
the observed effects may be dependent on the specific chromatin environment at the site of 
integration and, therefore, it is recommended that assessments are carried out using multiple 
cell lines with FRT sites in different genomic locations (Karimi et al., 2007).  
 
The used of immortalised cell lines represents an additional limitation. These cell lines often 
have an abnormal karyotype: HEK293 cells, for example carry three copies of the X 
chromosome and a modal number of 64 chromosomes per cell (European Collection of Cell 
Cultures datasheet: 
http://www.hpacultures.org.uk/products/celllines/generalcell/detail.jsp?refId=85120602&col
lection=ecacc_gc), while SH-SY5Y cells are affected by several chromosomal 
rearrangements including a complex duplication of the long arm of one chromosome 1 
(Spengler et al., 2002). Clearly, karyotypic abnormalities detract from the physiological 
validity of a cell-based assay; however, while not representing an ideal solution, replication 
of findings using multiple cell lines with different karyotype aberrations is likely to lend 
credence to the results. As such, it would appear fair to conclude that, having observed the 
same relative pattern of luciferase activity from the short, medium and long DISC1 promoter 
constructs in three different cell lines (albeit with non-significant results in the LAN-5 cells), 
it is likely that the observed pattern of results was not unduly influenced by any particular 
karyotype, or, more generally, cellular environment.  
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5.2.3 Suggestions for future work 
 
The work presented in this chapter represents only a preliminary characterisation of the 
mechanisms involved in regulating the expression of DISC1 and there are many further 
experiments that could be carried out to further understanding of this process. In light of the 
fact that the repeat length of the dinucleotide repeat region is known to be polymorphic 
(Hayesmoore et al., 2008), it would be usefully to further characterise its role. This could be 
achieved by generating a series of reporter constructs in which the number of dinucleotide 
repeats is varied. To negate the potential confounds associated with transient transfection, 
these reporter constructs could be assessed using the FLP-FRT site-specific integration 
system described above (Karimi et al., 2007).  Assessment of the association between 
dinucleotide repeat length and DISC1 expression level in humans would provide a further 
assessment of the role of this region. It would also be of interest to assess the effect of the 
duplication of this region identified by Hayesmoore et al. (2008) on the transcriptional 
activity of the DISC1 promoter region in reporter assays. Additionally, as a growing number 
of whole-genome sequencing projects are performed, the assessment of the effect of DISC1 
promoter sequence variants, including those implicated in psychiatric disorders, on the 
transcriptional activity of the promoter constructs would be informative.  
 
Analysis of the findings of ChIP studies suggested several interesting factors for 
experimental follow-up. Of particular interest is the transcription factor TCF4 (TCF7L2), a 
member of the Wnt-responsive family of transcription factors, which has been implicated in 
schizophrenia (Alkelai et al., 2012; Hansen et al., 2011). Thus, it would be of great interest 
to (i) experimentally validate the role of TCF4 in regulating DISC1 transcription and to 
assess the nature of any regulatory relationship, (ii) characterise the effects of Wnt-signalling 
through TCF4 on DISC1 expression and (iii) assess the effects of drugs, such as lithium, 
known to affect components of the Wnt-signalling pathway. 
 
In more general terms, it would be useful to characterise other mechanisms involved in 
determining the level at which the DISC1 protein is ultimately expressed. For example, the 
growing evidence for the role of miRNAs in schizophrenia and bipolar disorder (Beveridge 
and Cairns, 2012; Forero et al., 2010) highlights the identification miRNAs involved in the 
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5.3 Chapter 4: Assessment of the FOXP2-DISC1 Regulatory relationship 
 
5.3.1 Summary of findings 
 
In Chapter 4 the regulatory relationship between DISC1 and FOXP2 was explored: the 
potential role of FOXP2 in regulating transcription from the DISC1 promoter was 
investigated and preliminary assessment of a putative role for DISC1 in the regulation of 
FOXP2 was carried out. 
 
Transient overexpression of FOXP2 in HEK293 cells resulted in reduced DISC1 protein 
expression. A decrease in DISC1 mRNA expression was also detected when using one 
TaqMan gene expression assay but not another. Assessment of the promoter activity of the 
short, medium, and long DISC1 promoter constructs in response to the transient 
overexpression of FOXP2 revealed a decrease in the activity of all three constructs (although 
this decrease failed to attain statistical significance for the short construct). FOXP2 
constructs carrying non-synonymous point mutations identified in individuals affected by 
developmental verbal dyspraxia showed a reduced ability to repress transcription from the 
DISC1 promoter compared to wildtype FOXP2.  
 
The Disc1 L100P mouse, a mouse model of schizophrenia (Clapcote et al., 2007), was used 
to carry out a preliminary assessment of the putative bi-directional relationship between 
FOXP2 and DISC1 expression. Assessment of Disc1 mRNA and protein expression revealed 
evidence suggestive of altered expression. The strongest evidence for consistent changes in 
Disc1 mRNA and protein expression was observed at P7, P1, and at E18/E17.5 (mRNA 
expression was measured at E18, protein expression was measured at E17). At P1 and P7, 
expression was increased in the Disc1 L100P mouse, while at E18/E17.5, the evidence 
suggested a decrease in expression. Significant changes in mRNA expression were also 
observed at E15 and in the adult mouse, when expression was increased in the Disc1 L100P 
mouse; however, the nature of these changes at the protein level was unclear, either due to 
inconsistency between the results obtained when normalising to different reference genes, 
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5.3.2 Caveats  
 
The caveats of the work performed in Chapter 3 (section 5.2.2) also apply to the dual 
luciferase reporter assays performed in this chapter. Similarly, the limitations associated with 
the use of transient transfection discussed previously with respect to the dual luciferase 
reporter assays also apply to the assessments of FOXP2 overexpression on DISC1 mRNA 
and protein expression performed in this chapter. The transient overexpression of FOXP2 
would have resulted in FOXP2 being expressed at a level far exceeding that which occurs 
under normal physiological circumstances. As such, it is the fact that FOXP2 was shown to 
down-regulate DISC1 expression and promoter activity, rather than the extent of this down-
regulation, which is of interest. While each of the methods employed in assessing the effect 
of FOXP2 on DISC1 expression suffers from some limitations, the fact that the different 
approaches yielded compatible results (with the exception of DISC1 expression measured 
using one TaqMan assay) suggests that a true effect was observed.  
 
The work carried out in the Disc1 L100P mice to assess the putative role of Disc1 in the 
regulation of Foxp2 expression was affected by several limitations that mean the work must 
be considered preliminary in nature and in need of replication. Perhaps the most significant 
problem affecting these experiments was the limited nature of the samples available from the 
Disc1 L100P mice. Unfortunately, as I did not have access to these mice, the only RNA and 
cDNA samples available were those that had been collected by a previous PhD student 
(Sarah Brown). Protein samples were donated by Ellen Grünewald but, as she required 
protein for her own experiments, she could only spare limited amounts. The scarcity of the 
RNA and cDNA samples meant that only one reference gene could be used to normalise the 
qRT-PCR results obtained from these mice. Valid normalisation of qRT-PCR data is best 
performed by normalising to the geometric mean of multiple reference genes, which have, 
ideally been selected on the basis of their stability under the experimental conditions from a 
larger pool of reference genes (Vandesompele et al., 2002). As such, before pursuing the 
qRT-PCR results obtained in this chapter, the experiment should be repeated using additional 
reference genes. As assessment at the protein level was only carried out in one experimental 
replicate, further replicates should be performed. Additionally, a more quantitative technique 
for protein measure should be sought, particularly in light of the inconsistencies observed 
between the intensities of the immunoreactive bands for different reference genes. The 
interpretation of the findings arising from these experiments is also limited by the fact that 
altered gene expression in the Disc1 L100P mice could either result from the L100P 
mutation, or the change in Disc1 expression that it confers (Brown et al., unpublished). As 
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such, it is imperative that, should the findings presented here be replicated, future 
experiments identify the mechanism underlying the altered expression of Foxp2. Finally, as 
Foxp2 expression profiling was carried out using RNA or protein derived from either the 
whole brain or the hippocampus, it is impossible to determine whether the change in 
expression is localised to any particular cell type(s). Moreover, it is possible that between-
genotype differences in the cellular composition of samples might have confounded the 
results observed in this chapter. These limitations highlight the need for cell-type specific 
assessment of Foxp2 expression in the Disc1 L100P mice, using a technique such as laser-
capture microdissection. 
 
5.3.3 Suggestions for future work 
 
The observation that the transient overexpression of FOXP2 resulted in the downregulation 
of DISC1 mRNA expression when measured with one TaqMan gene expression assay but 
not another warrants further investigation. Examining the qRT-PCR products by gel 
electrophoresis and sequencing would be an informative next step in determining the reason 
behind these apparently conflicting results. If these analyses yield results suggestive of the 
use of alternative transcription start sites, it would be useful to perform 5’ RACE in an 
attempt to identify any additional transcription start sites. As HEK293 cells, the cells used 
for the qRT-PCR analysis, have an unusual karyotype, repeating the experiment in other cell 
lines, including more neuronal-like cell lines, would aid in determining whether the 
apparently conflicting results are cell-line dependent. When assessing the existence of 
alternative transcription start sites, it would be useful to assess tissue from multiple brain 
regions from several developmental stages, as Nakata et al. (2009) have shown the 
expression of DISC1 isoforms to be developmentally regulated. An additional approach to 
assessing the role of FOXP2 in regulating DISC1 expression would be to measure DISC1 
expression in cells following siRNA- or shRNA-mediated knockdown of FOXP2. This 
would offer a complimentary approach to the overexpression experiments performed here.  
 
Assessment of Disc1 expression in genetic mouse models in which Foxp2 expression is 
either decreased or increased would represent a useful addition to the experiments performed 
for this thesis. This approach would negate the issues associated with the artificial nature of 
in vitro assays discussed above; however, it would be significantly more time-consuming 
and costly. A further advantage to this approach is the opportunity to carry out assessments 
at the behavioural level; however, particularly when studying phenotypically complex 
conditions, such as psychiatric disorders, extrapolation from mouse behaviour to human 
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phenotypes must, clearly, be carried out with caution. More generally, any results obtained in 
mice come with the caveat that the extent to which they can be generalised to humans is 
uncertain. This caveat may be of particular relevance to psychiatric genetics: there is 
evidence that many candidate genes for schizophrenia have been subject to recent selective 
sweeps (Crespi et al., 2007). Thus, the potential limitations associated with the use of mouse 
models highlight the need to carry out research into psychiatric disorders using multiple, 
complimentary methods, including bioinformatic, in vitro, and in vivo approaches, as well as 
studies of the post-mortem human brain. 
 
The measurement of DISC1 expression in individuals known to carry either of the two 
FOXP2 point mutations, R553H and R328X, shown to reduce FOXP2’s ability to regulate 
DISC1 expression would provide an indication of whether these mutations exert an effect on 
DISC1 expression in a physiological context. This would provide an indication of whether 
altered DISC1 expression is likely to contribute to the phenotype observed in individuals 
carrying either of these mutations. Moreover, the developmental nature of the phenotypes 
resulting from these two mutations suggests that, ideally, DISC1 expression should be 
measured in these individuals at various stages throughout development.  
 
As mentioned previously, the experiments carried out to assess the role of DISC1 in the 
regulation of FOXP2 were very preliminary. In addition to the replication of the experiments 
performed in this thesis recommended previously, it would be useful to attempt to delineate 
the effects of the L100P mutation from the change in Disc1 expression it confers (Brown et 
al., unpublished). To address the question of whether DISC1 is involved in the regulation of 
FOXP2 expression in a more direct fashion, overexpression and knockdown of DISC1 could 
be performed in vitro and the effects on FOXP2 mRNA and protein expression assessed. 
Additionally, to obtain a better understanding of the relationship between Foxp2 and Disc1 
expression in a physiological context, Foxp2 expression could be assessed in mouse models 
in which the expression of wildtype Disc1 has been manipulated. Inducible and region- or 
cell-type-specific manipulation of Disc1 expression would be particularly valuable in 
assessing the effects of developmental stage, developmental history, and brain region on any 
observed regulatory relationship. 
 
More generally, in light of the strong evidence for the regulatory link between FOXP2 and 
DISC1, future studies should focus on: (i) identifying and experimentally validating other 
members of this regulatory network, (ii) characterising the expression of the genes involved 
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in the network in individuals with psychiatric disorders, (iii) investigating the role of DISC1 
in physiological functions suggested by its identification as a transcriptional target of 
FOXP2, and (iv) determining how drugs commonly used in the treatment of these conditions 
affect the absolute and relative expression levels of network members. 
 
5.4 Relevance of this thesis to the wider field 
 
The work presented in this thesis sought to aid understanding of the role of aberrant gene 
regulation in the pathogenesis of psychiatric illness. This aim was inspired by the growing 
evidence for the role of altered gene expression in both schizophrenia and bipolar disorder. 
Transcriptional profiling of the brains of schizophrenic patients has revealed consistent 
changes in the expression of genes involved in several functions including myelination and 
oligodendrocyte function, GABA and glutamate transmission, synaptic plasticity, 
mitochondrial function, and immune- and stress-response (Sequeira et al., 2012). Using a 
polygenic score approach first described by Purcell et al. (2009), Richards et al. (2012) 
demonstrated that variants conferring a risk of schizophrenia are enriched amongst those 
affecting gene expression. Altered gene expression has also been reported in patients with 
bipolar disorder, with affected functions including myelination, mitochondrial function and 
immune function (Konradi et al., 2012). In keeping with the observed overlaps between risk 
variants for the two disorders, common changes in gene expression have been identified 
(Shao and Vawter, 2008). 
 
The likely involvement of altered gene expression in the pathogenesis of schizophrenia and 
bipolar disorder highlights the investigation of mechanisms involved in the regulation of 
candidate genes as a useful endeavour in understanding the genetic bases of these conditions. 
The work carried out in this thesis highlights the important insights that can be gained from 
studying mechanisms involved in gene regulation. Consideration of candidate genes in the 
context of their regulatory networks is more informative than considering a gene in isolation. 
Knowing how a gene is regulated and what it regulates allows (i) predictions to be made 
about pathogenic mechanisms, (ii) the identification of plausible candidate genes and 
interesting gene x gene interactions for further assessment, and (iii) the identification of 
potential drug targets that can either prevent or rectify the pathogenic consequences of a 
given mutation. For example, one hypothesis that could be derived from the work presented 
here is that some phenotypes resulting from DISC1 variants and/or changes in DISC1 
expression levels will be due to altered basal ganglia function. This hypothesis is based on 
the fact that the FOXP2 network plays a key role in synaptic plasticity at cortico-basal 
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ganglia synapses, a process necessary for sensory-guided motor learning (Scharff and Petri, 
2011). Taken together with the observations of altered sensorimotor gating in the Disc1 
L100P mouse (Clapcote et al., 2007; Lipina et al., 2010), the investigation of the role of 
DISC1 in basal ganglia function appears to warrant further investigation. Moreover, greater 
understanding of a gene’s regulation will facilitate the prediction of the consequences of 
pathogenic variants, and thus aid the selection of variants identified by re-sequencing 
projects for experimental follow-up. 
 
The linking together of FOXP2 and DISC1 in a regulatory network supports the notion that 
diagnostically distinct psychiatric conditions are likely to share some genetic risk factors 
(Carroll and Owen, 2009; Owen et al., 2007). This notion is supported by the recent findings 
of Maurano et al. (2012). Here, it was shown that non-coding SNPs that have attained 
genome-wide significant association with at least one neuropsychiatric condition 
(schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD), panic 
disorder, conduct disorder, or depression) are repeatedly located in predicted transcription 
factor binding sites for a network of interacting transcription factors. Interestingly, this 
network included four members of the FOX family, binding sites for which were predicted to 
be affected by variants associated with schizophrenia, bipolar disorder, and ADHD.  
 
The likely aetiological overlap between neuropsychiatric conditions prompts the question of 
whether reliance on diagnostic categories defined by the DSM-IV actually limits the power 
of a study to detect genotype-phenotype relationships. The proposed use of 
psychopathological dimensions in the DSM-V (American Psychiatric Association DSM-V 
Development, http://www.dsm5.org/Pages/Default.aspx) may result in diagnoses being 
better grounded in the underlying genetic aetiology; however, the benefits of this approach 
will depend on the validity of the selected psychopathological dimensions. Given the 
inconclusive evidence regarding the usefulness of endophenotypes in genetic research (Flint 
and Munafo, 2007), it would be naive to assume that the study of individuals selected on 
psychopathological dimensions will necessarily result in greater genetic tractability. 
Moreover, the success of any method of determining diagnosis will ultimately be tested by 
its usefulness in a clinical setting. 
 
5.5 Recent developments  
 
Recent developments in the field are likely to greatly enhance future studies exploring the 
role of gene expression in psychiatric disorders. As alluded to previously, of particular note 
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is the publication of the ENCODE project’s “Integrated encyclopaedia of DNA elements in 
the human genome” (Bernstein et al., 2012), a genome-wide annotation of functional 
elements. According to ENCODE, a functional element is defined as “a discrete genome 
segment that encodes a defined product (for example, protein or non-coding RNA) or 
displays a reproducible biochemical signature (for example, protein binding, or a specific 
chromatin structure)”. The ENCODE project have characterised a comprehensive range of 
functional elements, including transcription start sites, protein-bound DNA regions, regions 
of histone modification, and long-range chromosome interactions in over 100 different cell 
types. This information will facilitate the generation of hypotheses both about the regulation 
of individual genes of interest but also about commonalities that may unite sets of genes 
thought to be implicated in a given disorder or biological process.  
 
Another development which is likely to be particularly beneficial to the study of neurological 
conditions is the possibility of studying human induced pluripotent stem cells (hIPSCs). The 
difficulties associated with acquiring live neurons from the human brain represents a key 
limitation in the study of psychiatric disorders; however, recent studies have demonstrated 
the possibility of reprogramming fibroblasts derived from schizophrenic patients into human 
induced pluripotent stem cells (hIPSCs) and then differentiating these hIPSCs into neurons 
(Brennand et al., 2011; Chiang et al., 2011). Although the application of hIPSCs to the study 
of psychiatric disorders is in its infancy, early findings appear to support many observations 
made previously using other approaches, including post-mortem studies, animal models, 
genetic association studies and gene expression profiling (Brennand et al., 2011). Compared 
to hIPSCs derived from control subjects, Brennand et al. (2011) found hIPSCs from 
schizophrenic patients to show reduced neuronal connectivity, reduced neurite outgrowth 
and wide-spread alterations in gene expression, including reduced expression of key synaptic 
proteins, such as PSD-95 and certain glutamate receptors. Furthermore, genes showing 
altered expression included members of the Wnt, cAMP, and glutamate signalling pathways, 
all of which, as discussed in Chapter 1, are believed to be relevant to pathogenesis of 
schizophrenia and bipolar disorder. Thus the study of hIPSCs is likely to yield important 
insights into the role of altered gene expression in psychiatric illness. Future studies should 
focus on identifying the genetic determinants of altered gene expression in hIPSCs derived 
from patients with schizophrenia and bipolar disorder, as well as the impact of altered 
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5.6 Concluding remarks 
 
The findings presented in this thesis (i) suggest that further investigation of the contribution 
of variation in the NRG1 gene, particularly at the 3’ end of the gene, to the aetiology of 
schizophrenia and bipolar disorder by re-sequencing is warranted and (ii) link DISC1 and 
FOXP2 in a regulatory network implicated in a range of psychiatric disorders that share 
varying degrees of phenotypic overlap. This latter finding suggests that the consideration of 
candidate genes in the context of their regulatory networks can provide valuable information 
about the genetic bases of the shared and distinct aspects of psychiatric conditions.  
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